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THE EFFECTS OF GENDER, PREGNANCY AND DIET UPON RAT TISSUE 
FATTY ACID COMPOSITION AND IMMUNE FUNCTION 
 
by Caroline Elizabeth Childs 
 
This thesis uses a rat model to investigate the effects of gender, pregnancy and 
maternal dietary fatty acids during pregnancy on adult and fetal tissue fatty acid 
composition, particularly upon longer chain (LC) omega 3 (n 3) polyunsaturated fatty 
acids (PUFA).  The effects of pregnancy and of diet during pregnancy upon immune 
function are also investigated.  
Gender differences in fatty acid composition were apparent in the rat with 
females having higher LC n 3 PUFA contents in plasma, liver and adipose tissue lipids.  
These differences appeared to result from gender differences in the activities of 
desaturase and elongase enzymes which generate LC n 3 PUFA rather than from 
differences in expression of these genes.  Increased  6 desaturase mRNA expression 
was observed during pregnancy and correlated to plasma progesterone status.     
The immune adaptations of rat pregnancy differed from those reported in human 
and murine studies.  The rat did not demonstrate a reduced Th1:Th2 cytokine ratio 
during pregnancy, but had reduced expression of CD161 upon the cell surface of 
maternal blood and spleen NK cells. 
Maternal dietary fatty acids during pregnancy significantly affected the fatty 
acid composition of maternal and fetal tissues, with tissue specific incorporation of LC 
n 3 PUFA into fetal tissues.  Maternal diets rich in n 3 PUFA exerted significant effects 
upon maternal and fetal immune function, including changes in the expression of CD3 
and CD8 upon both maternal and fetal cytotoxic T cells and in the number of CD161
+ 
cells (putative NK cells) in the fetal thymus.  The maternal diet during pregnancy 
therefore has the capacity to alter both maternal and fetal immune function, which may 
have significant effects upon maternal and fetal resistance to infection, and may exert 
longer term effects upon offspring health.   3 
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22:0  behenic acid  docosanoic acid 
     
16:1n 7  palmitoleic acid  cis 9 hexadecenoic acid 
18:1n 9  oleic acid (OA)  cis 9 octadecanoic acid 
20:1n 9  gondoic acid  eicosenoic acid 
24:1n 9  nervonic acid  tetracosenoic acid 
     
18:2n 6  linoleic acid (LA)  cis 9,cis 12 octadecadienoic acid 
18:3n 6  γ linolenic acid (GLA)  all cis 6,9,12 octadecatrienoic acid 
20:2n 6  eicosadienoic acid  cis 11, cis 14 eicosadienoic acid 
20:3n 6  di homo γ linolenic acid (DGLA)  all cis 8,11,14 eicosatrienoic acid 
20:4n 6  arachidonic acid (AA)  all cis 5,8,14,17 eicoastetraenoic acid 
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Chapter 1:  Introduction and literature 
review   11 
1.1 Introduction 
The studies described in this thesis use a rat model to investigate the effects of gender, 
pregnancy and maternal dietary fatty acids during pregnancy upon both adult and fetal 
tissue fatty acid composition, particularly in relation to omega 3 (n 3) fatty acids.  The 
effects of pregnancy and maternal dietary fatty acids during pregnancy upon immune 
function are also investigated.   
 
This literature review will therefore provide relevant information on fatty acids, the 
immune system and the programming hypothesis.  The available data on the effects of 
gender and pregnancy upon tissue fatty acid composition will be reviewed.  Literature in 
support of potential programming of the immune system by maternal diet will also be 
covered.  
1.2 Fatty acids 
This section is intended to give a broad overview of fatty acids, including their 
structure, nomenclature, dietary intakes, endogenous synthesis and physiological 
functions in order that their interaction with the immune system can later be discussed 
in detail.  Further information upon fatty acids is available elsewhere(1 3). 
1.2.1 Structure and nomenclature 
Fatty acids are hydrocarbon chains with a carboxyl ( COOH) group at one end and a 
methyl ( CH3) group at the other.  Biological fatty acids are typically unbranched chains 
with even numbers of carbon atoms (2 30 or more), with fatty acids in the human diet 
typically between 8 and 24 carbon atoms in length.   
 
Fatty acids can be named using their trivial or common names, systematic names or 
shorthand notation.  Details of the nomenclature of some common biological fatty acids 
are found in the definitions section (see page 9).  Trivial names are often based on the 
origins of the fatty acid (e.g. palmitic acid is found in high levels in palm oil).  
Systematic names are determined by the structural properties of the fatty acid (e.g. the 
systematic name for palmitic acid is hexadecanoic acid as this fatty acid contains 16 
carbons).  However, this method of naming becomes complicated when naming 
complex fatty acids with double bonds and various cis vs. trans configurations.  
Shorthand notation can therefore be used to indicate the number of carbons, the number 
of double bonds, and their position in the fatty acid (counting from methyl terminus to   12 
the position of the first double bond).  For example, the shorthand notation for palmitic 
acid is 16:0 (16 carbons, no double bonds).  Shorthand notation for linoleic acid (LA) is 
18:2n 6 (18 carbons, 2 double bonds with the first one 6 carbons from the methyl 
terminus). 
Fatty acids without any double bonds in the hydrocarbon chain are termed saturated 
fatty acids (e.g. stearic acid, 18:0).  Fatty acids with double bonds in the hydrocarbon 
chain are termed unsaturated fatty acids.  The number of double bonds in commonly 
encountered unsaturated fatty acids is between 1 and 6.  Unsaturated fatty acids can 
therefore be further classified into monounsaturated fatty acids (MUFA) with one 
double bond (e.g. oleic acid, 18:1n 9) or polyunsaturated fatty acids (PUFA) with two 
or more double bonds (e.g. LA, 18:2n 6; ALNA, α linolenic acid, 18:3n 3).  PUFA can 
be further classified into omega 3 (n 3), omega 6 (n 6) and omega 9 fatty acids (n 9) 
based upon the location of their first double bond relative to the methyl terminus.  
Subsequent cis configuration double bonds in PUFA are separated from one another by 
a single methylene ( CH2 ) group.  The structure of some common fatty acids is 
illustrated in figure 1.1.   
Figure 1.1: Structure of some common biological fatty acids 
 
 
 
 
 
 
 
Double bonds in a fatty acid change the shape of the fatty acid, and so can result in 
different biological properties and functions.  The effect of a double bond upon the 
function of a fatty acid will depend on the number, position and configuration of the 
double bonds present.  Double bonds in biological fatty acids are usually in the cis 
configuration (see figure 1.2).  Trans configuration double bonds are found in 
hydrogenated vegetable oils, ruminant fats, plant lipids and seed oils.  For example, 
H3C 
COOH 
COOH 
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H3C 
H3C   13 
conjugated LA (cis 9, trans 11 18:2) is formed in the rumen and mammary glands of 
cattle, and so is found in dairy products.   
 
Figure 1.2: Cis and trans isomers of carbon carbon double bonds 
 
 
 
 
Fatty acids are hydrophobic, and so within biological fluids and tissues are packaged 
into complex lipid molecules which include, but are not limited to, phospholipids, 
triacylglycerols (sometimes called triglycerides; TAG) and cholesteryl esters (CE).  
Free fatty acids are termed non esterified fatty acids (NEFA), and circulate in the 
plasma associated non covalently with albumin.  The incorporation of fatty acids into 
lipid structures is not random, with esterification controlled by enzymes which are 
specific to the position of the fatty acid.  The carboxyl group on fatty acids readily 
reacts with molecules containing alcohol groups to form ester bonds by condensation 
(see figure 1.3).  For example, fatty acids can form ester bonds with glycerol or 
cholesterol to form TAG and phospholipids or CE, respectively.  The breaking of an 
ester bond is known as saponification or hydrolysis.   
 
Cell membranes are composed of a phospholipid bilayer.  Phospholipids are a glycerol 
backbone to which two fatty acids and a phosphate head group are attached.  
Phospholipids contain both hydrophobic regions (e.g. fatty acids) and hydrophilic 
regions (e.g. phosphate head groups) which allow their interaction with aqueous cellular 
compartments.  The phosphate head group is used to classify the species of 
phospholipids with common head groups including choline, ethanolamine, serine and 
inositol.   The basic structure of phospholipids can be seen in figure 1.4.   
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Figure 1.3: Formation of an ester bond between a fatty acid and glycerol 
 
 
 
 
Figure 1.4: Phospholipid structure 
 
 
Phosphatidylcholine (PC, also known as lecithin) is the major class of phospholipid 
found within plasma lipoproteins.  PC typically has a saturated fatty acid such as 
palmitic or stearic acid at the sn 1 position and an unsaturated fatty acid such as oleic 
(OA), linoleic (LA), ALNA or arachidonic acid (AA, 20:4n 6) at sn 2.  The cellular 
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location of phospholipids is often specific to particular phospholipid classes.  For 
example, PC is found in plasma membranes localised on the outer leaflet, and 
phosphatidylethanolamine (PE) on the inner leaflet.   
 
Acidic phospholipids such as phosphatidylserine (PS), phophatidylinositol (PI) and 
phosphatidic acid (PA) tend to be found on the inner leaflet of the plasma membrane of 
cells, and their presence in the outer leaflet triggers apoptosis of the cell.  PI makes up 
around 5% of cell membrane phospholipids and has a sugar (inositol) as its head group.  
The fatty acids within this phospholipid are almost exclusively stearic acid (18:0) at the 
sn 1 position with AA at the sn 2 position. 
   
CE and TAG do not contribute to cellular membranes but instead are incorporated into 
intracellular and circulating lipid particles.  CE hydrolase enzymes within cells liberate 
cholesterol and free fatty acids as required for membrane and lipoprotein formation, and 
also provide cholesterol for hormone synthesis in adrenal cells.  Free cholesterol within 
cell membranes decreases membrane fluidity.   
1.2.2 Dietary fat intake 
Most (90 95%) dietary fat is in the form of TAG, a lipid which contains three fatty acids 
esterified to glycerol.  Other forms of dietary fats include phospholipids, glycolipids and 
cholesterol.   
 
Over last 40 years total fat intake has decreased and the types of fats consumed have 
changed in Western populations, with declining consumption of saturated fatty acids 
and increasing intakes of PUFA.  For example, table 1.1 shows daily dietary fat and 
fatty acid intakes among UK adults over time. 
Table 1.1: Dietary fat intake among UK adults over the last 50 years (g/day)(3;4) 
Year  Total fat  Saturates  MUFA  PUFA 
1959  110  53  43  9.2 
1969  120  56.7  46.5  11.0 
1979  106  47.9  39.7  10.7 
1989  90  36.9  33.1  13.6 
2003 ♂  86.5  32.5  29.1  15.17 
(n 6 = 12.9; n 3 = 2.27) 
2003 ♀  61.4  23.3  20.2  11.11 
(n 6 = 9.4; n 3 = 1.71) 
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The 2003 National Diet and Nutrition Survey(4) reported that the average daily fat 
intake provided approximately 35% of total food energy in both sexes, although there 
were variations between age groups, with young women most likely to exceed 
recommendations.  Table 1.2 provides a summary of the fats consumed expressed as a 
percentage of total food energy and also shows the UK dietary reference values (DRV). 
Table 1.2: UK dietary fat intake as % of total food energy in comparison with the UK 
dietary reference values (DRV) (4;5) 
  Men  Women  DRV 
Total fat intake  35.8  34.9  < 35 
Saturated fats  13.4  13.2  <10 
Trans fatty acids  1.2  1.2  < 2 
Monounsaturated  12.1  11.5  12 
n 3 PUFA  1  1 
n 6 PUFA  5.4  5.3 
6 10 
 
 
The increasing intake of PUFA in the Western diet is largely the result of increased 
consumption of vegetable based margarine and cooking oils and decreased use of 
animal products such as lard and butter.  The most common dietary PUFA consumed 
are the essential fatty acids (EFA) LA (18:2n 6) and ALNA.  LA is a fatty acid found in 
corn, sunflower, safflower and soybean oils.  Some nuts and rapeseed and soybean oils 
are good sources of ALNA, and the richest source of ALNA is linseed oil.   
 
Oily fish are a rich source of the longer chain (LC) n 3 PUFA eicosapentaenoic acid 
(EPA, 20:5n 3), docosapentaenoic acid (DPA, 22:5n 3) and docosahexaenoic acid 
(DHA, 22:6n 3).  The LC n 3 PUFA content of fish varies a great deal between species.  
For example, salmon is a rich source, containing approximately 2.2 g EPA + DPA + 
DHA per 100 g portion, while white fish such as cod contains around 300 mg of these 
fatty acids per 120 g portion(6).  Though average adult intakes of LC n 3 PUFA in the 
UK are thought to be approximately 200 mg/day, this average represents a highly 
skewed distribution as it is estimated that only 27% of UK adults habitually eat oily 
fish(7).  LC n 3 PUFA therefore only make up a small proportion of total n 3 fatty acid 
intake for the majority of people.  The dietary intake of LC n 6 PUFA is also much 
lower than that of LA, with intake of AA from sources such as meat and eggs estimated 
to be 50 300 mg/day(8). 
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The increasing consumption of the n 6 PUFA LA in Western diets is thought to have 
contributed to decreases in CHD mortality because LA lowers blood cholesterol 
concentrations, but has been noted to coincide with increased prevalence of asthma.  For 
example, figure 1.5 illustrates the changes in the LA content of adipose tissue over time 
which is believed to reflect changes in dietary intake.  Shortly after the observed 
increases in LA content of adipose tissue are corresponding reductions in CHD 
mortality, but increasing prevalence of childhood asthma(9 11). 
 
Figure 1.5: Diagram to illustrate the relationship between the LA content of adipose 
tissue, reduced rates of CHD mortality and the increased prevalence of asthma.  
Adapted from (9 11). 
 
 
 
1.2.3 Endogenous synthesis of fatty acids 
In addition to dietary consumption, fatty acids can be synthesised endogenously de 
novo.  Endogenous synthesis of saturated fatty acids occurs by the addition of 2 carbon 
units (in the form of acetyl coA) to a growing fatty acid chain.  This process occurs in 
the liver, mammary gland and adipose tissue, with the lipids synthesised derived from 
dietary carbohydrates.  The main fatty acid product of endogenous synthesis is palmitic 
acid (16:0).  Further elongation of endogenously synthesised or dietary fatty acids can 
also generate very long chain saturated fatty acids such as lignoceric acid (24:0).   
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Fatty acids can also be altered by desaturation or elongation reactions, which mainly 
occur in the liver.  In the endoplasmic reticulum (ER) double bonds are introduced into 
fatty acids by desaturase enzymes.  For example stearic acid (18:0) can be converted to 
oleic acid (OA, 18:1n 9) by the insertion of a cis double bond between carbons 9 and 
10.  The enzyme involved in this process is  9 desaturase, with  9 indicating the 
position of the double bond inserted relative to the carboxyl terminus of the 
hydrocarbon chain. 
Mammalian cells contain ∆5, ∆6 and  9 desaturases.  Mammals do not have  12 and 
 15 desaturases, and therefore cannot insert double bonds into the n 6 or n 3 position, 
which means that LA and ALNA are fatty acids which can only be obtained via 
consumption in the diet.  Mammals are also unable to interconvert between LA and 
ALNA.  The clinical features of EFA deficiency are reduced brain and body weight, 
dermatitis, infertility, loss of muscle tone, degenerative changes in the kidney, lung and 
liver, and increased susceptibility to infection and behavioural changes, but deficiency 
is rare in humans(12). 
LC PUFA (both n 6 and n 3) can be endogenously synthesised via the action of 
desaturation and elongation enzymes upon their precursor EFA(13) (see figure 1.6).  
The elongation and desaturation reactions occur in the ER, and the final β oxidation 
step occurs in peroxisomes.  This activity of these enzymes is highest in the liver in both 
humans and rats(14), with desaturase activity also detectable in the adrenal glands, 
testes and subcutaneous adipose tissue(15).   6 desaturase expression has also been 
identified at a high level in the human brain and lung, and at lower levels in the kidney, 
pancreas, spleen and skeletal muscle(16).  Rat studies have demonstrated that  5 and 
 6 desaturase activities are detectable within the fetal liver at days 19 and 22 of 
gestation, but are not detectable within the placenta(17).  Synthesis of LC PUFA has 
been demonstrated in the human neonate(18).     19 
Figure 1.6: Metabolic pathway of the generation of LC PUFA from their EFA 
precursors 
Linoleic acid (18:2n 6)    α α α α Linolenic acid (18:3n 3) 
￿ ￿ ￿ ￿         6 desaturase  ￿ ￿ ￿ ￿ 
γ Linolenic acid (18:3n 6)    Stearidonic acid (18:4n 3) 
￿ ￿ ￿ ￿  elongase  ￿ ￿ ￿ ￿ 
Di homo γ linolenic acid (20:3n 6)    Eicosatetraenoic acid (20:4n 3) 
￿ ￿ ￿ ￿         5 desaturase  ￿ ￿ ￿ ￿ 
Arachidonic acid (20:4n 6)    Eicosapentaenoic acid (20:5n 3) 
￿ ￿ ￿ ￿  elongase  ￿ ￿ ￿ ￿ 
Adrenic acid (22:4n 6)    Docosapentaenoic acid (22:5n 3) 
￿ ￿ ￿ ￿  elongase  ￿ ￿ ￿ ￿ 
Tetracosatetraenoic acid (24:4n 6)    Tetracosapentaenoic acid (24:5n 3) 
￿ ￿ ￿ ￿         6 desaturase  ￿ ￿ ￿ ￿ 
Tetracosapentaenoic acid (24:5n 6)    Testracosahexaenoic acid (24:6n 3) 
￿ ￿ ￿ ￿  β β β β oxidation  ￿ ￿ ￿ ￿ 
Docosapentaenoic acid (22:5n 6)    Docosahexaenoic acid (22:6n 3) 
 
 6 desaturase is the rate limiting step in this series of reactions, with ALNA the 
preferred substrate of  6 desaturase(19).  The use of this series of enzymes for both LC 
n 6 and n 3 PUFA synthesis results in competition between LA and ALNA for 
metabolism.  However, much more LA is consumed than ALNA in the UK diet, with 
intake in males identified as 10.5 g/day LA and 1.4 g/day ALNA(4), which suggests 
that metabolism of the former will predominate.  In situations of EFA deficiency the 
same sequence of enzymes can also act upon OA (18:1n 9) to form mead acid (20:3n 
9).  There are therefore numerous substrates which compete for the action of ∆6 and ∆5 
desaturases, as illustrated in figure 1.7.  The competition for  6 desaturase is greater 
due to the involvement of this enzyme in two steps of the synthesis of LC PUFA from 
EFA(20).     20 
Figure 1.7: Substrates and products of the ∆6 and ∆5 desaturase enzymes 
 
 
 
 
 
 
 
 
 
The activity of this series of desaturase and elongase enzymes has been demonstrated to 
be influenced by hormonal, genetic and dietary variables.  A review is available which 
describes the role of hormones in the regulation of  5 and  6 desaturase activity(14).  
In brief,  6 desaturase activity is depressed in rat models of diabetes, and restored by 
the administration of insulin, with corresponding effects upon the LC PUFA content of 
rat liver lipids.  Other hormones which have demonstrated effects upon desaturase 
activity include glucagon, adrenaline, adrenocorticotrophic hormone, prolactin and 
steroids which decrease desaturase activity.  These effects of hormones were associated 
with changes in the abundance of  6 desaturase mRNA expression.   
 
There are seven different elongase subtypes which have been identified in the mouse, 
human and rat genomes which vary in their substrate specificity and tissue expression, 
but are expressed at comparable levels within the liver of all three species.  The most 
abundant elongase subtype in the liver is Elovl 5(21).  As was the case for desaturase 
enzymes, elongase activity is under the influence of hormones, transcription factors and 
nutrients(22). 
 
Recent studies have identified that there is a significant effect of genotype upon the 
activity of enzymes involved in the synthesis of LC PUFA in humans.  Significant 
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correlations have been identified between serum phospholipid fatty acids and the 
haplotype of  5 and  6 desaturase genes, with haplotype demonstrating significant 
correlations to the AA content of both serum phospholipids(23) and erythrocyte 
membranes(24).  A deletion in the promoter of the  6 desaturase gene has also been 
demonstrated to associate with significantly lower γ linolenic acid (GLA, 18:3n 6), 
EPA and AA contents of subcutaneous adipose tissue and higher 20:2n 6 and 20:3n 3 
contents (elongase products of EFA)(25).   
 
The effect of diet upon desaturase and elongase activity was demonstrated in a study 
where rats received an ALNA deficient diet over a 15 week period.  Those on the 
deficient diet were found to have significantly higher mRNA expression and activities 
(assessed using radiolabelled fatty acids in vitro) of  5,  6 desaturase and elongase 
(elovl 5) enzymes in the liver(26).  
1.2.4 Physiological roles of fatty acids 
Fatty acids have numerous physiological roles (see figure 1.8).  Fatty acids are 
substrates for energy generation by β oxidation and are stored in adipose tissue in 
situations where energy intake exceeds expenditure.  Fatty acids can acylate membrane 
bound proteins, modulate membrane fluidity(27), interact with intracellular signalling 
pathways and transcription factors(28;29), and act as substrates for production of 
signalling molecules(30 35).  Unsaturated fatty acids are vulnerable to lipid 
peroxidation, with susceptibility increasing with the degree of unsaturation(36).   
Fatty acids and energy generation 
Fatty acid oxidation, also known as β oxidation, enables the use of fatty acids for 
energy production.  It should be noted that this β oxidation for energy production takes 
place in the mitochondria, whereas the β oxidation step involved in formation of LC 
PUFA occurs in peroxisomes.  Fatty acids in the form of fatty acyl CoA cross the 
mitochondrial membrane in a carnitine dependent process.  Fatty acid oxidation 
involves the progressive removal of 2 carbon units (in the form of acetyl coA) from the 
carboxyl end of fatty acids.  The acetyl CoA produced is then oxidised in the Krebs 
Cycle for energy production.    22 
Figure 1.8: Diagram to illustrate the physiological roles of fatty acids
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Fatty acids and energy storage 
Adipose tissue is a large physiological store of lipids, with fatty acids stored as 
intracellular TAG.  The release of fatty acids from adipose tissue occurs under the 
influence of hormones such as adrenaline, noradrenaline, glucagon and insulin upon 
hormone sensitive lipase.  Incorporation of fatty acids into adipose tissue occurs under 
the action of lipoprotein lipase on the surface of adipose epithelial cells which liberates 
NEFA from circulating lipoproteins, which are then esterified into TAG within adipose 
tissue.  The composition of adipose tissue TAG is influenced by past dietary intake and 
the selective mobilisation of specific fatty acids from adipose tissue.  For example, in 
vitro studies have identified that ALNA, EPA and AA are preferentially mobilised from 
adipose tissue compared to other fatty acids(37).   
Fatty acylation of proteins 
Fatty acids can covalently bind to proteins resulting in changes to protein protein 
interactions, membrane binding affinity and cellular signal transduction.  Fatty acylation 
enables proteins to be anchored to the plasma membrane and plays an important role in 
signal transduction by enabling relevant signalling components to be localised in close 
proximity to each other(38).  The type of fatty acid involved in acylation confers 
different effects onto the protein. 
Myristic acid (14:0) can form amide linkages to N terminal glycine residues and is a co 
translational modification with a long half life.  Myristoylation enables protein protein 
interactions in cytosolic proteins and stabilises protein conformation.  Myristoyl switch 
mechanisms function to control the location of cellular proteins, with the availability of 
myristic acid for membrane binding under the influence of the conformational shape of 
the protein.  Demyristylase enzymes can remove the myristic acid from proteins, freeing 
them from cell membranes(38). 
 
Palmitic acid (16:0) can attach to cysteine residues in proteins by thioester bonds.  This 
is a post translational modification of proteins, and palmitoylated proteins are 
exclusively membrane bound as palmitic acid has a much higher affinity for membrane 
binding than myristic acid(38).  
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Fatty acids and membrane fluidity 
The composition of cell membranes can be affected by the availability of dietary fatty 
acid substrates, though this is not the only determinant of membrane composition.  For 
example, when dietary EFA are consumed, this can also significantly affect the 
concentrations of downstream LC PUFA which are synthesised from that EFA.  For 
example, provision of dietary ALNA increases the amount of both ALNA and the LC n 
3 PUFA EPA within cell phospholipids(39).  The structural characteristics of fatty acids 
(e.g. saturates vs. PUFA) affect how closely the membrane phospholipids can pack 
together.  For example, the six double bonds within DHA result in the fatty acid having 
a ‘helical’ conformation which allows a high degree of membrane fluidity.  This in turn 
affects protein movement, and therefore has the potential to impact upon cell functions 
such as the activity of receptors or adhesion molecules.   
 
Membrane fatty acid composition also affects lipid rafts within cell membranes.  Lipid 
rafts are areas of membrane which are rich in sphingolipids and cholesterol and have PC 
fractions rich in saturated fatty acids.  These membrane areas contain high 
concentrations of acylated proteins(40).  Lipid rafts are associated with trans membrane 
proteins, and allows a range of proteins involved in signal transduction to be in close 
interaction with each other(41).  
 
Fatty acids and intracellular signalling pathways 
 
Fatty acids play several roles in cell signalling mechanisms, including the production of 
eicosanoids and the inositol lipid cycle.  The production of eicosanoids is a key 
interaction between fatty acids and the immune system, and will be discussed in detail 
in later sections. 
The inositol lipid cycle is a signalling cascade which generates diacylglycerol (DAG) 
and inositol trisphosphate (IP3), two important intracellular messengers.  The process is 
initiated when phosphatidylinositol (PI) in the cell membrane is phosphorylated to 
phosphatidylinositol 4,5 bisphosphate (PIP2).  PIP2 is positively charged, and attracts 
phospholipase C (a membrane bound enzyme) which generates DAG and IP3 by 
hydrolysis of PIP2.  DAG functions to activate protein kinase C in a calcium dependent   25 
manner.  IP3 increases levels of intracellular calcium by activating the release of 
calcium ions from the ER. 
Fatty acids and gene expression 
Fatty acids have the capacity to directly affect gene transcription by binding to 
transcription factors.  Transcription factors bind to areas of genes and act to promote or 
inhibit transcription.  Transcription factors that PUFA have been demonstrated to 
interact with include: hepatic nuclear factor 4α, liver X receptors (both α and β), 
peroxisomal proliferators activated receptors (PPAR) α,  β/δ and  γ(29;42;43) and 
sterol regulatory element binding proteins (SREBP) 1 and 2.  By these mechanisms 
PUFA increase the expression of genes involved in hepatic and skeletal muscle fatty 
acid β oxidation, while repressing genes involved in glycolytic, lipogenic and 
cholesterogenic activities.  These gene interactions have the net result of decreasing 
lipid synthesis and increasing lipid oxidation. 
Fatty acids and lipid peroxidation 
The incorporation of PUFA into cell membranes increases susceptibility of the cell 
membrane to lipid peroxidation, as it is the double bonds of fatty acids which are 
susceptible to oxidation.  Lipid peroxidation is induced by hydroxyl radicals, such as 
those generated from superoxide anions during immune activation.  n 3 PUFA are more 
susceptible to peroxidation than n 6 PUFA as they contain more double bonds.  Lipid 
peroxides are toxic to cells as they have the potential to damage cells by oxidation 
reactions, including effects on DNA which may cause mutations.  The susceptibility of 
cell membranes to lipid peroxidation can be reduced by the presence of free radical 
scavengers including α tocopherol (vitamin E), ascorbic acid (vitamin C) and selenium 
(essential for activity of catalase).  The incorporation of peroxidation susceptible PUFA 
into membranes may therefore increase the requirements for anti oxidant nutrients, and 
should be considered when increasing the dietary intake of PUFA.   
1.2.5 n-3 fatty acids and human health 
n 3 fatty acids have been studied extensively with regards to their potential benefits 
upon human health(3;6;44).  Benefits identified in adults to date include effects upon 
cardiovascular disease, inflammatory diseases, and cognitive function, while among 
infants benefits upon vision and cognitive function have been identified.   26 
Comprehensive reviews of epidemiological studies and human intervention trials of 
dietary LC n 3 PUFA and cardiovascular disease are available(45 47).  There are 
substantial epidemiological and case control study data which demonstrate that the risk 
of cardiovascular disease is lowest among those with the highest fish or LC n 3 PUFA 
intake or LC n 3 PUFA status.  Supplements containing LC n 3 PUFA have been 
demonstrated to be beneficial in secondary prevention of cardiovascular disease, 
reducing the risk of mortality related to cardiovascular events in subjects who had 
previously suffered a myocardial infarction(48).   
The clinical applications of LC n 3 PUFA in relation to chronic inflammatory disease, 
atopic disease and the systemic inflammatory response to surgery and injury have been 
reviewed(34;49).  There is strong evidence from randomized, placebo controlled trials 
that dietary fish oil supplements are beneficial for patients with the chronic 
inflammatory disease rheumatoid arthritis(50;51).  Benefits to other inflammatory 
disorders have not been conclusively demonstrated.  Evidence for the role of LC n 3 
PUFA supplementation in patients receiving enteral formula feeds after surgery in an 
attempt to reduce sepsis is complicated by the simultaneous provision of other nutrients 
such as certain amino acids and antioxidant vitamins(49;52).   
Meta analyses have identified statistically significant benefits of supplementation with 
LC n 3 PUFA among adults with uni polar and bi polar depression(53;54) though these 
benefits are only apparent in populations with an established clinical diagnosis of 
depressive illness.  Epidemiological and post mortem evidence has generated interest in 
the potential benefits that LC n 3 PUFA may have in the prevention or treatment of 
disorders of cognitive function in later life such as dementia and Alzheimer’s disease, 
with further investigation from intervention studies required(44).  Research has been 
conducted to evaluate the potential benefits that LC n 3 PUFA may confer in children 
with neurodevelopmental disorders such as attention deficit/hyperactivity disorder 
(ADHD)(55).
.  Studies which evaluated parent/teacher reported changes in behaviour of 
children with ADHD have identified benefits of LC n 3 PUFA supplementation, though 
these studies have used various combinations of EPA and DHA and it is not yet clear 
which is the most important fatty acid in this setting.   
The observation that DHA is found in high concentrations in the retina and accumulates 
in the brain during early life (from 3 months gestation to 18 months after delivery in 
humans) suggests that an adequate supply of n 3 PUFA is required for the development   27 
and function of the central nervous system(56;57).  Animal studies which have used n 3 
PUFA deficient diets identified that this causes visual and cognitive abnormalities.  
Studies undertaken in pre term infants have demonstrated that formulas which contain 
DHA improve visual function early in infancy(58).    
1.3 The immune system 
This section is intended to give a broad overview of the immune system, including the 
cell types and immune organs, innate and acquired immune function and how immune 
function is regulated by production of signalling molecules such as cytokines.  Further 
detailed information upon the complex and numerous functions of the immune system 
can be found elsewhere(59;60).  When functioning normally, the immune system 
enables the body to defend itself against potential damage induced by bacteria, 
parasites, toxins, viruses, foreign tissues and malignant and auto reactive cells.  Immune 
dysfunction is involved in auto immune and atopic disease.   
1.3.1 Cells of the immune system 
Cells of the immune system are leukocytes (also known as white blood cells).  All 
immune cells originate from the bone marrow, as do red blood cells and platelets.  The 
stem cells which give rise to all blood cells are known as pluripotent hematopoietic 
cells.  These stem cells undergo a complex process of maturation and differentiation to 
generate diverse cell populations.  Leukocytes have three main physiological functions: 
phagocytosis, cytotoxicity and generation of inflammation.  The two principal cell 
populations of circulating leukocytes are lymphocytes and phagocytes.  These 
populations can be further classified into cell subsets, each with their own characteristic 
properties and functions.  The cell types relevant to this thesis which will be discussed 
in this section are detailed in figure 1.9.  There are numerous other important cell types 
within the immune system such as dendritic cells, which will not be discussed in detail.   28 
Figure 1.9: Lineage of cells types of the immune system and their relative contribution 
to the circulating leukocyte pool 
 
 
 
 
 
 
 
 
 
 
Granulocytes 
Granulocytes include neutrophils, eosinophils and basophils.  These cells have roles in 
phagocytosis, inflammation and antigen presentation.  Neutrophils are involved in the 
acute inflammatory response, adhering to the vessel endothelium, migrating from the 
bloodstream to sites of infection and phagocytosing foreign particles.  Activated 
neutrophils release granules containing elastase, collagenase, myeloperoxidase and 
lysozyme, which enable movement through the tissues to the site of inflammation, and 
produce superoxide radicals, the metabolites of which are important in destroying the 
invading organism.  Eosinophils are abundant at sites of hypersensitivity reactions and 
contribute to tissue injury and inflammation.  They are capable of phagocytosis, but 
their primary role is in the elimination of multicellular parasitic infections by non 
phagocytic mechanisms such as cytotoxic actions.  These cytotoxic actions are also 
involved in the pathophysiology of asthma.  Basophils are circulating cells which cause 
a short lived inflammatory reaction at sites of infection.  Mast cells are similar to 
basophils, but remain localised within connective tissues, rather than circulating in the 
bloodstream. 
Leukocytes (white blood cells) 
Phagocytes  Lymphocytes 
(25 35%) 
Granulocytes  Monocytes 
(4 6%) 
Macrophages 
Neutrophils 
(50 70%) 
Basophils 
(0.4 1.0%) 
Eosinophils 
(1 3%) 
T lymphocytes  B lymphocytes  Natural killer 
cells (NK cells) 
(<1%) 
T helper cells 
(CD4 on surface) 
Cytotoxic T cells 
(CD8 on surface)   29 
Monocytes and macrophages 
Monocytes are phagocytic cells which circulate in the bloodstream and are able to 
migrate to sites of infection, where they develop into resident tissue macrophages, large 
cells with a long half life.  The movement of cells from the bloodstream to the tissues is 
known as extravasation, and requires the cell to adhere to the endothelial surface.  This 
occurs via interactions with adhesion molecules such as vascular cell adhesion molecule 
(VCAM) and intracellular adhesion molecule (ICAM).  Metalloproteinases are released 
enabling monocytes to move through tissues to reach the site of infection where they 
phagocytose infectious agents, and present antigen from pathogens to other immune 
cells. 
T lymphocytes 
T cells are lymphocytes which have matured within the thymus, enabling them to 
distinguish ‘self’ antigens from ‘non self’.  A failure of T cells to successfully 
differentiate between self and non self results in auto immune disease.  Mature T cells 
in the circulation interact with antigen presenting cells (APC) to initiate and regulate 
antigen specific immune responses.  Leukocytes are commonly classified based upon 
their surface membrane proteins, known as clusters of differentiation (CD).  For 
example, a cell surface marker which is unique to T cells is CD3, which is part of the T 
cell receptor complex.  Mature T cells can be further classified into T helper cells (Th 
cells) or cytotoxic T cells based upon their expression of CD4 or CD8, respectively, 
though these subsets cannot be distinguished morphologically.  Th cells and cytotoxic T 
cells are the two principal T cell subsets which will be discussed in this thesis, though 
other T cells subsets have been identified, such as T regulatory cells(61;62). 
The interaction between T cells and virally infected cells or APC (including 
macrophages, B cells and phagocytic cells) is mediated by an interaction between the T 
cell receptor (TCR) and MHC molecules (major histocompatibility complex, also 
sometimes referred to as human leukocyte antigens, HLA).  MHC I glycoproteins are 
present on the cell surface of almost every nucleated cell, with exceptions including 
fetal trophoblasts, hepatocytes and cells of the central nervous system.  All proteins 
within cells are regularly turned over and broken down and fragments of these broken 
down proteins (typically 6 8 amino acid residues in length) are cycled to the cell 
membrane on MHC I molecules, enabling the detection of any ‘non self’ intracellular   30 
proteins (e.g. of viral origin) by cytotoxic T cells (CD8
+).  If such proteins are detected 
the cell is destroyed.  MHC II is expressed on a limited range of cell types and is 
constitutively expressed on B cells, monocytes, macrophages and dendritic cells.  MHC 
II binds peptide fragments which originate from phagocytosed pathogens and presents 
antigen to Th cells (CD4
+ cells).  The Th cell will subsequently activate cellular 
responses that aim to eliminate the pathogen whose antigen was detected. 
 
In addition to the MHC complexes, there are other cell surface markers upon APC 
which function to present antigen to T cells.  While MHC I and II present peptide 
antigens to T cells, CD1 is a cell surface marker which presents lipids and glycolipids, 
such as those within the cell membranes of mycobacteria to cytotoxic T cells(63).  A 
potential role of CD1 in self antigen presentation has also been identified when PE (a 
phospholipid usually localised within intracellular membranes) is presented via CD1 to 
T cells.  This may suggest a role of CD1 in autoimmune dysfunction(64).  
Once T cells have been presented with antigen, they undergo morphological changes, 
known as blastic formation, when cell diameter more than doubles.  T cells function to 
regulate the intensity and duration of the acquired immune response by both cell to cell 
interactions and the production of specific soluble mediators such as cytokines.  The 
acquired immune response and cell specific profiles of cytokine production will be 
described in detail in later sections.   
B lymphocytes 
B lymphocytes are classified based upon their ability to produce and secrete 
immunoglobulins (Ig).  The B cell receptor is a membrane bound immunoglobulin (Ig).  
Ig specific to an antigen are known as antibodies.  The structure of membrane bound Ig 
and antibodies differ only in that Ig expressed on B cell surfaces have an additional 
hydrophobic sequence at the carboxyl terminus which spans the cell membrane.  B cells 
can be activated by Th cells, or directly stimulated by antigen alone, with the latter 
known as thymus independent B cell activation.   
 
Activated B cells are called plasma cells and function to synthesise and secrete large 
amounts of antibody.  Plasma cells have a half life of just a few days, but the antibody 
they secrete has a half life of some months.  Some activated B cells will develop into   31 
memory cells, which are morphologically identical to naïve B cells but express antibody 
on their surface that is already antigen specific.  While the MHC induces T cell 
responses to peptide fragments of antigens, Ig molecules on B cells respond to intact 
antigens, such as whole native proteins.   
 
There are five classes of Ig: IgM, IgD, IgG, IgA and IgE.  Each antibody class has a 
characteristic function and structure.  Naïve B cells have IgM or IgD on their cell 
surface, and after activation may undergo ‘class switching’ to produce other Ig isotypes.  
IgM is produced in the primary response to antigen.  IgM can be membrane bound or 
secreted into blood and lymph, where it forms an unstable pentamer structure of five Ig 
complexes.  IgD is always membrane bound, and is involved in B cell activation.  IgG is 
produced in the secondary response to antigen, persisting in the serum long after initial 
infection, is the most abundant of the Ig isoforms, and is able to cross the placenta.  IgA 
is a dimerised antibody found within mucous secretions.  IgE is involved in allergic 
reactions and in the response to parasitic infections.   
 
Secreted antibodies function to neutralise pathogens and activate the complement 
cascade.  The complement cascade is an aspect of ‘innate’ immune function which will 
be discussed in more detail in a later section.  Antibodies neutralise viruses, intracellular 
bacteria and bacterial toxins by binding to them and preventing their spread from cell to 
cell.  Antibodies with bound antigen are recognised by phagocytic cells, inducing 
phagocytosis and destruction of the organism.  IgE can bind to mast cells, basophils and 
eosinophils without having bound antigen.  This results in mast cells being ‘primed’ for 
an allergic response.   
NK cells 
Natural killer (NK) cells are large granular lymphocytes that provide innate cytotoxic 
immune responses against virally infected cells.  NK cells recognise changes on virally 
infected cells and destroy them, either by releasing perforin or by binding to the infected 
cell and destroying it by direct contact.  Human NK cells express the surface markers 
CD16 and CD56.  NK cell receptor protein 1 (NKR P1, also known as CD161) is a 
receptor expressed upon all rodent NK cells which activates cytotoxic mechanisms(65).   32 
1.3.2 Organs of the immune system 
Circulating immune cells represent only a small proportion of the whole body immune 
cell pool in humans (< 1%), with the majority of immune cells localised within tissues 
(e.g. resident tissue macrophages) or within organs of the immune system.  The major 
organs of the immune system include the thymus and bone marrow (primary lymphoid 
organs), spleen and lymph nodes (secondary lymphoid organs) and the mucosal 
associated lymphoid tissue.  Primary lymphoid organs are the site of immune cell 
generation and maturation.  Immune cells within the primary lymphoid organs have not 
been exposed to antigens.  In secondary lymphoid organs lymphocytes come into 
contact with APC (e.g. dendritic cells).  In this section the features of the thymus, spleen 
and lymph nodes will be outlined.  The roles of other immune organs such as the bone 
marrow and gut associated lymphoid tissue will not be described. 
Thymus 
The thymus is located in the thorax, overlying the heart and major blood vessels.  The 
two lobes of the thymus are organised into lobules, and the lobules separated by 
connective tissue.  Each lobule contains lymphoid cells (also known as thymocytes), 
which are arranged into an outer cortex and an inner medulla.  The cortex contains 
immature cells and the medulla contains the more mature cells.  The thymus has a rich 
vascular supply and a series of lymphatic vessels that drain into the mediastinal lymph 
nodes.  T cells originate in the bone marrow and migrate to the thymus, a site of rapid 
proliferation and extensive apoptosis.  Thymocyte progenitors are ‘triple negative’, not 
expressing CD3, CD4 or CD8.  Within the thymus these cells undergo maturation to 
become ‘double positive’, expressing CD3, and both CD4 and CD8.   
 
Within the cortex of the thymus the TCR on immature thymocytes interacts with MHC 
self peptide complexes.  It is important that receptors do not become activated in 
response to ‘self’ antigens.  In order to prevent this, a process of clonal selection, where 
self reactive lymphocytes are removed, occurs at the cortico medullary junction.  
Lymphocytes which are specific for self antigen are deleted, either by cytotoxic 
mechanisms or by being made anergic (functionally disabled) at an early stage of 
lymphoid development.  If the interaction between the TCR and self antigen is of low 
affinity, the lymphocytes go on to become mature T cells.     33 
Spleen 
The spleen in located in the upper left quadrant of the abdomen, behind the stomach and 
close to the diaphragm.  It is surrounded by a collagenous capsule containing smooth 
muscle that supports the cells within the spleen.  There are two main tissue types within 
the spleen, the red pulp and the white pulp.  The macrophages of the red pulp are 
involved in the destruction of old erythrocytes.  The white pulp contains the lymphoid 
tissues of the spleen.  Unlike other secondary lymphoid organs, the spleen is only 
supplied by blood vessels and not the lymphatic system and therefore reacts to antigens 
within the bloodstream.  The lymphoid tissue of the spleen is arranged around a central 
arteriole, and this structure is known as the periarteriolar lymphoid sheath (PALS).  The 
PALS has T and B cell areas, with T cells immediately around the central arteriole and 
B cells organised into follicles.  These B cell follicles can be classified as either primary 
(where B cells have not yet been stimulated by antigen exposure) or secondary (where B 
cells have been stimulated).  Lymphocytes are able to enter and leave the spleen via 
capillaries leading to the PALS.   
Lymph nodes 
The role of the lymphatic system is to drain fluid from the tissues past the lymph nodes, 
screening for antigens.  There are approximately 600 lymph nodes located along 
lymphatic vessels with lymph nodes organised into clusters, such as those found in the 
axilla and neck.  Lymph nodes are surrounded by a capsule and have both T cell and B 
cell areas.  The B cell areas are known as the cortex or follicular areas, and the T cell 
areas as the paracortex or parafollicular area.   Lymph nodes have a blood supply that 
allows the exchange of immune cells with the circulation.  This interaction with 
circulating blood maximises the chance of memory cells recognising an antigen upon 
secondary exposure. 
1.3.3 Innate and acquired immunity 
The actions of the immune system can be classified as either innate (also known as 
‘natural’ or ‘non specific’) or acquired (also known as ‘adaptive’ or ‘specific’).  Both 
systems involve cellular and humoral responses.   34 
Innate immunity 
Innate immunity is the first line of defence against pathogens and involves the 
prevention of entry of infectious agents by physical and biochemical barriers, 
inflammation, cytotoxic and phagocytosis mechanisms, and activation of the 
complement cascade.  Cells involved in innate immunity have general “antigen” 
receptors but cannot distinguish between different types of pathogen.  Innate immunity 
evokes similar responses amongst normal individuals, and provides a very rapid but 
inflexible response to pathogens.  Innate immunity forms the early phases of defence for 
the initial 3 5 days of infection, covering the time required for activation of acquired 
immunity.  Innate immunity is present before exposure to pathogens, and is not 
enhanced by previous exposure to pathogens.   
 
Physical and biochemical barriers 
Physical barriers to pathogens include the skin, mucus, the cilia lining the trachea and 
the acid pH of the stomach.  Biochemical barriers to pathogens include sebaceous gland 
secretions such as lysozyme, which is secreted by macrophages and acts to degrade 
bacteria in the interstitial spaces between cells, acting upon petidoglycans in bacterial 
cell walls.  Commensal bacteria within the gut are considered to be a component of 
innate immunity.  Commensal bacteria are tolerated by the body and compete with 
potential pathogens, effectively providing a physical barrier against pathogen 
colonisation.   
Inflammation 
The inflammatory process involves immune cells, adhesion molecules and cytokines 
and is typified by redness, swelling, heat and pain.  These symptoms of inflammation 
are a result of increased blood flow and increased permeability across blood capillaries, 
mediated by the release of inflammatory mediators from immune cells close to the site 
of injury.  For example, degranulation of mast cells releases the vaso active compound 
histamine.  Increased permeability of the endothelium enables leukocytes such as 
neutrophils and monocytes to undergo extravasation – migration from the capillary 
lumen into the tissues.   
Cytotoxic and phagocytic innate responses 
The innate response to viral infection includes cytotoxic targeting of infected cells by 
NK cells.  NK cells act upon virally infected cells by secreting perforin which causes   35 
the target cell to die by apoptosis or membrane damage.  Phagocytic cells such as 
neutrophils (within the circulation) and macrophages (resident in tissues) will be 
encountered if a pathogen penetrates epithelial surfaces.  Phagocytes attach to 
pathogens, extending pseudopodia to engulf them.  The pathogen is then internalised 
into a phagosome, to which lysosomes fuse, releasing toxic chemicals (such as 
superoxide radicals and hydrogen peroxide) and resulting in destruction of the 
pathogen.  
The complement cascade 
The complement cascade involves serum proteins, which when activated propagate a 
cascade of signal amplification by activating other complement proteins.  The classical 
pathway of complement activation is mediated by complement proteins binding to 
antibodies (produced as part of the acquired immune response), but can also be 
activated directly in response to toxins produced by pathogens.  Activated complement 
proteins act as chemoattractants and induce inflammatory responses.  Complement 
proteins also bind to pathogen membranes and can form a membrane attack complex, a 
pore in the pathogen cell membrane which induces cell lysis and targeting of the 
pathogen by phagocytic cells. 
 
An additional function of complement activation is the clearance of antigen antibody 
complexes from the blood.  Antigen antibody complexes are very large and can be very 
damaging, particularly in organs such as the kidneys and so it is important that they are 
cleared from the circulation quickly.  Complement proteins associated with antigen 
antibody complexes bind to receptors on red blood cell membranes and enable 
phagocytic cells (either those in the circulation or resident in tissues such as the spleen 
and liver) to target these large complexes.   
Acquired immunity 
Acquired immunity provides highly specific reactions to particular infectious agents in 
order to eradicate them.  Acquired immunity has a component of memory, allowing the 
infectious agent to be recognised and eliminated rapidly upon secondary exposure.  
Acquired immunity can be classified into cell mediated immunity and humoral 
immunity.  Acquired humoral immunity involves B cell proliferation and maturation 
into antigen specific antibody producing cells (also known as plasma cells), and will not 
be discussed in detail in this section.   
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Cell mediated acquired immunity involves lymphocyte proliferation and differentiation.  
T and B cells have cell surface receptors specific to a single antigen, often with many 
copies of this antigen specific receptor on the cell membrane.  A given antigen can 
stimulate more than one specific lymphocyte, as different fragments of the antigen may 
be recognised by different lymphocytes.  Variation in T and B cell receptor specificity 
between immune cells is a result of the random assortment and joining of mini gene 
sequences when assembling the T or B cell receptor.   
 
The total number of lymphocytes specific for any particular antigen is low, but when an 
antigen binds with high affinity binding to a lymphocyte receptor this stimulates the 
lymphocyte to proliferate.  Lymphocyte proliferation is also referred to as lymphocyte 
expansion or clonal expansion.   This proliferation results in the genes which enabled 
specific antigen binding to be passed on to a population of daughter cells.  Proliferation 
responses typically involve thousands of specific lymphocytes generated over 3 5 days, 
and it is this process of proliferation which is responsible for the lymph node swelling 
observed with infection.  Somatic mutations which occur during the proliferation of 
lymphocytes may cause minor changes in receptor specificity.  If these mutations cause 
the receptor to interact more strongly with the antigen then these cells will proliferate 
more effectively and therefore be selected over the other clones generated, increasing 
the receptor specificity to antigen.  As lymphocytes proliferate, a small number will 
differentiate into memory cells, which are long lived lymphocytes.  These memory cells 
ensure that when a given antigen is encountered for the second time the immune 
response generated is stronger and faster than the initial response.   
1.3.4 Immune signalling molecules 
The diverse cells and tissues involved in the immune system require a series of effective 
signalling molecules in order to initiate, regulate, and resolve immune responses 
appropriately during infection.  The principal signalling molecules of the immune 
system are cytokine and eicosanoids.   
 
Cytokines 
Cytokines are low molecular weight, highly soluble, stable proteins that regulate the 
activity of immune cells as well as many other cells and tissues.  Cytokine molecules 
induce their effects by binding to receptors on cell surfaces, causing rapid tyrosine 
phosphorylation of signal transducers and activators of transcription (STAT).    37 
Phosphorylated STAT dimerise and travel to the cell nucleus, resulting in changes in 
gene transcription and cell function, resulting in changes in growth, development or 
activity of the target cell. 
 
Cytokines are important mediators of both innate and acquired immunity and form an 
important link between these two branches of the immune response.  Cytokines can be 
produced by diverse cell types including non immune cells, such as the placenta.  
Cytokines are able to act upon many cell types, and are therefore said to be pleiotropic.  
Cytokines differ from hormones in that they are produced by dispersed cells rather than 
specific organs.  Various immune cell subsets produce characteristic profiles of 
cytokines, allowing some immune cells to be classified based upon the range of 
cytokines they produce, as is the case for T helper cells, which can be characterised as 
Th1 or Th2 on the basis of their cytokine production profiles. 
 
Th1 and Th2 responses 
Th1 and Th2 lymphocytes represent the most polarised subsets of cytokine production 
among Th cells.  Other T cell classes will not be discussed in detail but include Th0 
(which express cytokines characteristic of both Th1 and Th2 cells, and may be a 
precursor cell) and T regulatory cells (also known as Th3(66)) which produce high 
levels of the cytokine transforming growth factor β (TGF β).  The cytokines produced 
by Th1 and Th2 cells promote differentiation towards their own phenotype and inhibit 
differentiation towards the alternative phenotype.  This results in self amplification and 
antagonism between the Th1 and Th2 phenotypes.  Changes to the Th1/Th2 balance 
during early life may therefore effect long term change in the immune response.   
Activated Th1 cells produce the cytokines interleukin 2 (IL 2), interferon γ (IFN γ) and 
tumour necrosis factor β (TNF β).  Production of IFN γ is commonly used to identify 
Th1 cells, as its production is rarely observed by Th2 cells.  Th1 cytokines induce 
activation of macrophages, NK cells and cytotoxic T lymphocytes, and therefore lead to 
an inflammatory response.  Th1 activity is stimulated by interactions with antigens 
generated from bacteria, fungi and viruses and results in the elimination of these types 
of organisms.  Several autoimmune diseases are associated with inappropriate Th1 
responses.  Examples of autoimmune diseases (also known as chronic inflammatory 
diseases) include haemolytic anaemia, type I insulin dependent diabetes, Crohn’s 
disease, rheumatoid arthritis and multiple sclerosis.     38 
 
Activated Th2 cells produce the cytokines IL 4, IL 5, IL 6, IL 10 and IL 13.  IL 4 
production is used to identify Th2 cells as its production is rarely observed by Th1 cells.  
The cytokines generated by Th2 cells induce the differentiation, activation and survival 
of eosinophils (IL 5 mediated), promote IgE production by B cells (IL 4 and IL 13 
mediated) and stimulate the growth of mast cells and basophils.  The Th2 response is 
associated with parasitic infections, and is also generated in individuals with atopic 
responses in response to common environmental stimuli.  Some of the clinical features 
of atopic disease can be accounted for by an inappropriate Th2 immune response.  For 
example, excessive infiltration of eosinophils into lung tissues is a classic feature of 
asthma, as are high levels of circulating IgE.  Figure 1.10 provides an overview of the 
interactions between Th1 and Th2 responses, and the down stream effects they 
generate.  
 
Atopic responses involve immune cells becoming hypersensitive to food (such as egg 
protein) or other normal environmental factors (such as pollen).  These atopic responses 
can involve a range of organs and tissues, such as the airways, skin and eyes.  Atopic 
responses to specific stimuli originating from foodstuffs, the environment or animals are 
commonly referred to as allergies.  Atopic responses can result in disease states such as 
allergic rhinitis, asthma and systemic anaphylaxis.  The onset of atopic disease is 
typically during infancy or early childhood, and so any potential preventative treatments 
will need to be initiated during early life. 
Reviews are available upon the role of the Th1/Th2 balance in atopic disease(67 72), 
with excessive Th2 responses characteristic features of atopy.  Rates of atopic diseases 
have been increasing in Western populations(72) but vary between subpopulations, 
indicating that an environmental factor is involved in their development.  
Environmental factors thought to have a role in the increased rates of allergic diseases 
include changes in hygiene practices(73), rates of infections(74), levels of air 
pollution(75), living conditions(76) and dietary changes(9;77).  These environmental 
factors could influence the development of allergy both before and after birth.     39 
Figure 1.10: Overview of Th1 and Th2 cytokine profiles and their downstream effects 
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Eicosanoids 
Eicosanoids are mediators produced by cells including neutrophils, monocytes, 
macrophages, mast cells and platelets from the PUFA AA, di homo γ linolenic acid 
(DGLA, 20:3n 6) or EPA within cell membranes.  The involvement of fatty acids as a 
substrate for eicosanoid production means that this aspect of immune function has the 
capacity to be directly altered by the dietary availability of these fatty acids or their EFA 
precursors. 
 
Some of the enzymes involved in eicosanoid production, such as cyclooxygenase 1 
(COX1), are constitutively expressed, enabling eicosanoids to be synthesised within 
minutes of immune cell activation, while COX2 is induced by proinflammatory or 
mitogenic agents.  PUFA in immune cell membranes are released under the action of 
the enzyme phospholipase A2 (PLA2) in response to a stimulus.  PLA2 responds to Ca
2+ 
signalling, translocating from the cytosol to the ER or nuclear membrane where it acts 
to release fatty acids from the intracellular membranes.  The COX and lipoxygenase 
(LOX) enzymes which are also localised to these intracellular membranes then generate 
eicosanoid mediators from the fatty acid substrate, which include prostaglandins (PG), 
leukotrienes and hydroperoxy derivatives (see figure 1.11).  This thesis will investigate 
the effect of pregnancy and diet upon PGE2 production, and so the functional effects of 
leukotrienes and hydroperoxy derivatives will not be discussed in detail in this section.   
 
It should be noted that eicosanoids are not the only immune modulating signalling 
molecules which derived from fatty acids.  Resolvins, docosatrienes and protectins are 
other molecules which have been demonstrated to be formed during acute inflammation.  
These molecules are derived from EPA and DHA and exert inflammation resolving 
effects(33;78).  There is also a pathway of AA metabolism by cytochrome P450 
enzymes which produces epoxyeicosatrienoic acids (EETs) which are involved in the 
inflammatory and cardiovascular systems(79;80).  Figure 1.11 is therefore a very 
simplified scheme of the immune mediators produced from AA.   41 
Figure 1.11: Synthesis pathway for prostaglandin, leukotriene and hydroperoxy 
derivative production from the fatty acid AA 
 
 
 
 
 
 
 
 
Figure 1.12 shows the PGE isoforms generated from various fatty acids.  The 
differences in their structures affect their potency and immunological signalling 
properties.  Though DGLA, AA and EPA are the most extensively studied 
prostaglandin substrates, recent studies have identified that there are other fatty acid 
substrates such as adrenic acid (22:4n 6) which was demonstrated to be a substrate for 
the formation of di homo prostaglandins(81). 
Figure 1.12: Illustration of the prostaglandin isoforms which can be generated from 
fatty acid substrates 
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The complex, integrated and interactive way in which the immune system functions 
means that there is no single marker which can be used to draw conclusions about the 
function of the entire immune system, with the exception of clinical outcomes such as 
infection.  Assessment of immune function therefore requires the measurement of 
several markers of immune function, ideally a range of in vivo and ex vivo markers.  The 
markers of immune function which can be feasibly assessed in human trials are detailed 
elsewhere(82).  Markers of immune function which have been rated as being highly 
useful include vaccination responses and production of mucosal immunoglobulins 
(IgA), as these can be inferred to represent an in vivo co ordinated immune response to 
an intervention.  Those which scored as being of ‘medium’ usefulness include ex vivo 
assessments of oxidative burst, NK activity, cytokine production by APC or 
lymphocytes and lymphocyte proliferation. 
1.4 Fatty acids and the immune system 
There is now a large body of evidence to suggest that dietary fatty acids can exert 
effects upon immune function, such as the finding that dietary fish oil supplementation 
is beneficial to patients with the auto immune disease rheumatoid arthritis(50;51).  
There have also been observed associations between changes in dietary fat consumption 
(particularly increasing LA intake) and changes in the prevalence of atopic disease such 
as asthma(9).  The potential of dietary fatty acids to modulate immune function 
indicates that changes to dietary intake, or supplementation with specific fatty acids, 
may provide an effective and minimally invasive intervention tool in the prevention or 
management of diseases of immune dysfunction. 
 
The two main mechanisms by which dietary fatty acids may interact with the immune 
system are via effects upon membrane composition and therefore fluidity, and their role 
as substrates for eicosanoid synthesis.  The potential for PUFA to affect T cell 
signalling via their effects upon membrane organisation and MHC presentation has been 
studied in vitro and in vivo, and detailed reviews are available(83;84).  It is possible that 
there are other mechanisms which link dietary fatty acids to the function of the immune 
system, including the roles of fatty acids in protein acylation and gene expression, but 
these have not been fully characterised to date.     43 
1.4.1 Dietary fatty acids and immune cell fatty acid composition 
Immune system activation requires increased cell membrane synthesis to meet the 
demands of increased cell size (e.g. blast formation upon T cell activation), generation 
of new cells during lymphocyte proliferation and the turnover of membrane 
phospholipids in phagocytosis.  Changes to the fatty acid composition of cell 
membranes may have effects upon the fluidity of the membrane, affecting membrane 
bound protein function, and may also influence the formation of lipid rafts, areas of the 
membrane which serve to co localise protein components of signalling cascades.  There 
are human and animal model studies which have demonstrated that the fatty acid 
composition of immune cell membranes can be significantly altered by manipulation of 
dietary fatty acid intake. 
 
Human studies have demonstrated that dietary fatty acids have the capacity to 
significantly alter the fatty acid composition of immune cell membranes.  One study 
provided male volunteers for 12 weeks with up to 9 g/day of tuna oil (LC n 3 PUFA 
rich) or a placebo (palm oil and soybean oil) or a single dose of linseed oil (ALNA 
rich), and identified that this could significantly affect the fatty acid composition of 
neutrophils(85).  This study found that the EPA and DHA content of neutrophils 
increased, and AA content decreased, among those taking capsules which were at least 
25% tuna oil, with this change occurring in a dose dependent fashion, with maximal 
effects observed after four weeks of supplementation.  It was also observed that there 
were decreased levels of AA in neutrophils among those taking the ALNA rich linseed 
oil supplements.  It is possible that provision of ALNA increases competition for the 
action of desaturase and elongase enzymes involved in LC PUFA synthesis, and 
therefore competitively inhibited the formation of AA from LA.  While this study 
identified significant effects upon immune cell composition, no significant functional 
effects of supplementation were observed, though only superoxide production and 
chemotaxis were investigated. 
 
Dietary fatty acids have the potential to alter the fatty acid composition of a wide range 
of other immune cells.  A human study which provided 10 15 g/day fish oil (rich in LC 
n 3 PUFA) was demonstrated to significantly increase the amount of EPA within 
platelets, neutrophils, monocytes, T lymphocytes and B lymphocytes phospholipids 
within two weeks of supplementation(86).  This effect upon a wide range of cell types   44 
provides information upon how dietary fatty acids are incorporated into immune cells.  
Cells with a short half life (monocytes, 3 days; platelets 8 11 days; neutrophils, 6 hours) 
may have incorporated these fatty acids into cell membranes during cell formation, or 
by phospholipid exchange between mature cells and plasma lipoproteins.  T and B 
lymphocytes have a much longer half life (months to years) and are likely to have 
predominantly accumulated new fatty acids by exchange with plasma 
phospholipids(86).  
 
Studies have identified that feeding mice various high fat diets (10% w/w) for four 
weeks caused significant alterations in macrophage fatty acid composition(87).  Mice 
fed on a fish oil diet had higher levels of EPA, DPA and DHA in macrophage 
phospholipids compared to other groups, while mice fed on a borage oil or a safflower 
oil diet (rich in LA acid) had the highest levels of AA in macrophage phospholipids.  
This indicates that both n 3 and n 6 fatty acid rich diets have the potential to 
significantly alter immune cell fatty acid composition.  
 
The changes in membrane composition observed as a result of dietary manipulation 
have the potential to exert effects upon the function of immune cells, via effects on 
membrane protein function.  The interaction between the TCR upon T cells and MHC 
upon APC has been described as the formation of an immunological synapse.  This 
process requires cytoskeletal rearrangements to maintain a sustained, stable interaction.  
Both EPA and AA have been demonstrated in vitro to inhibit immunological synapse 
formation by affecting cytoskeleton relocalisation within T cells, and may therefore 
diminish signalling between T cells and APC(88).  Effects of AA and DHA have also 
been identified upon the expression of MHC I molecules upon APC in vitro, with both 
PUFA reducing expression of this cell surface marker upon B lymphocytes(83).  These 
in vitro findings are supported by in vivo dietary studies.  For example, a study which 
provided high fat (HF; 20% w/w) fish oil rich diets to rats demonstrated that MHC II 
expression upon dendritic cells was significantly lower than seen in HF safflower oil fed 
or low fat (2.5% w/w) corn oil fed groups(89). 
1.4.2 Fatty acids and prostaglandin synthesis 
AA is the fatty acid substrate metabolised by COX to generate PGE2.  It was detailed in 
earlier sections how alternative fatty acid substrates will generate different PGE 
isoforms (see figure 1.12), with EPA giving rise to PGE3, and DGLA giving rise to   45 
PGE1.  Since dietary fatty acid manipulation can affect the membrane composition of 
immune cells, this will change the availability of fatty acid eicosanoid substrates, which 
may have significant effects upon immune function due to competitive inhibition of 
COX activity or differences in potency of the isoforms generated.  For example, PGE2 
has been demonstrated to be more proinflammatory, and exerts a stronger positive 
feedback upon COX2 expression than PGE3(90).  
 
The pro inflammatory effects of PGE2 include fever, erythema, increased vascular 
permeability, vasodilation, pain, and oedema.  However, the action of PGE2 is not 
limited to the induction of inflammation.  PGE2 has also been demonstrated to exert 
effects upon the Th1/Th2 balance of cytokine production, and so may have an important 
role in diseases of immune dysfunction such as atopic disease.  In vitro, PGE2 enhances 
the effects of the Th2 cytokine IL 4 upon IgE synthesis by increasing the number of IgE 
secreting cells, and promotes class switching of B cells expressing IgM to produce 
IgE(91).  PGE2 suppresses of T  and B lymphocyte proliferation and activation, NK cell 
activity and inhibits the production of the Th1 cytokines IL 2 and IFN γ(92;93).  These 
effects of PGE2 therefore promote Th2 responses and suppress Th1 responses, and may 
be involved in the dysregulated Th2 responses which are characteristic of atopic 
disease. 
 
The n 6 PUFA substrate AA which is used to generate PGE2 is only consumed at very 
low levels in the diet, so the majority of AA within cell membranes will be derived from 
endogenous synthesis of LC PUFA from the EFA precursor LA.  This therefore 
provides a plausible mechanism by which increasing consumption of vegetable oils and 
margarines, which are rich in LA, may have contributed to increasing prevalence of 
asthma(9).  There is epidemiological evidence which supports this hypothesis, with an 
Australian study(94) attributing 17% of recent cases of childhood asthma to a high 
PUFA (predominantly n 6) intake.  Additional risk factors identified for childhood 
asthma were having a parent with a history of asthma and serious respiratory infection 
in the first two years of life.  Factors identified as providing protection against asthma 
include breastfeeding and having at least three older siblings.  This demonstrates clearly 
that while it is not diet alone that determines the risk of development of atopic disease, 
dietary fat intake and breastfeeding are two important risk factors with the potential to 
be modified by behavioural or dietary interventions.   46 
There is an indication from epidemiological studies that regular consumption of fresh 
oily fish (containing LC n 3 PUFA), but not canned or processed fish, is associated with 
a reduced risk of current asthma during among children aged 8 – 11 years(95).  Human 
supplementation studies support this hypothesis of a protective effect of n 3 fatty acids, 
as when healthy male volunteers were provided with supplements containing EPA (1.35 
  4.05 g/day for 12 weeks), inverse correlations were demonstrated between the EPA 
content of mononuclear cells and PGE2 production(96). 
1.4.3 Dietary fatty acids and immune responses in animal models 
Animal studies have clearly demonstrated that dietary fatty acids have the capacity to 
significantly affect immune function. 
 
A long term feeding study of mice (diets provided for 5 months, including two breeding 
cycles) identified that those upon high fat (10% w/w) n 3 PUFA rich diets (linseed oil, 
fish oil) had reduced NK cell activity, which was inversely proportional to the n 3 
PUFA content of the diet.  Both resting and stimulated superoxide production of 
macrophages were affected by diet, with those on the n 6 PUFA rich diet having the 
highest resting production and lowest stimulated production, and those on the fish oil 
diet demonstrating the opposite relationship.  CD8
+ cells were lowest among the n 3 
PUFA diet groups(97).  This demonstrates that dietary fatty acids can significantly 
affect the proportion of immune cell types and markers of their function.  This study 
also identified significant effects of diet upon the number of successful pregnancies 
(fish oil > linseed oil > safflower oil > olive oil), an indication that the n 6 PUFA rich 
diet was growth promoting (though dietary intake was not controlled and may have 
varied between groups), and significant effects of diet upon brain, spleen and thymus 
weight. 
 
A study which provided diets to mice that were either low in fat (2.5% w/w) or high in 
fat (20% w/w) and containing coconut oil (rich in saturated fat), safflower oil (rich in n 
6 PUFA) or fish oil (rich in n 3 PUFA) over six weeks looked specifically at the effect 
of diet upon spleen lymphocytes.  The fatty acid composition of spleen lymphocytes 
was significantly affected by the diet.  Proliferation and IL 2 production were greatest 
for lymphocytes from mice fed coconut oil.  IFN γ production was lowest among the 
safflower oil and fish oil groups, but no associated effect was seen on IL 4 production.  
The authors therefore suggested that Th1 cytokines are more sensitive to changes in   47 
dietary fatty acid content than Th2 cytokines(98).  This observation is supported by a 
murine study which provided diets rich (5% w/w) in corn oil or fish oil for two weeks, 
and then isolated and cultured CD4
+ splenocytes.  This study identified that fish oil 
suppresses in vitro Th1 development and production of IFN γ, and the authors 
speculated that this is responsible for the anti inflammatory effects of fish oil 
supplementation(99). 
1.4.4 Dietary fatty acids and immune responses among healthy adult 
humans 
In addition to the immune effects which are observed as a result of dietary 
supplementation with specific fatty acids, it has been identified that variations in both n 
3 and n 6 fatty acid composition of immune cells among free living healthy adults are a 
significant predictor of markers of immune function.  A study of free living human 
subjects found that the fatty acid composition of peripheral blood mononuclear cells 
(PBMC) demonstrated statistically significant correlations to several markers of 
immune function(100).  The proportion of ALNA within PBMC was positively 
correlated to markers of phagocytosis and the production of both Th1 and Th2 cytokines 
(IFN γ and IL 4), and DHA content was positively correlated to markers of 
phagocytosis and IFN γ production.  In contrast, the LC n 6 PUFA AA content was 
positively correlated to IL 6 production, a cytokine associated with inflammation.   
Interest in the specific interactions between n 3 PUFA and the immune system has 
resulted in a wide range of available data from in vitro studies, ex vivo studies and in 
vivo studies, and detailed reviews can be found elsewhere(35;101).  Briefly, in vitro 
studies have demonstrated that LC n 3 PUFA inhibit lymphocyte proliferation, decrease 
IL 2 production, decrease cytotoxic T cell degranulation and inhibit antigen 
presentation.  Ex vivo animal and some human studies have supported these findings 
with LC n 3 PUFA found to inhibit lymphocyte proliferation, decrease NK cell activity, 
decrease cytotoxic T cell activity and decrease antigen presentation.  
1.4.5 Dietary fatty acids and diseases of immune dysfunction 
 
While in vitro and ex vivo studies can provide useful information upon the potential 
mechanisms by which fatty acids and the immune system interact, it is of more 
relevance to human health to investigate the in vivo immune responses to dietary fatty   48 
acids, particularly in relation to development or severity of diseases of immune 
dysfunction.  Difficulties in gaining detailed and clear information upon the effect of n 
3 PUFA upon immune function in humans are often attributed to the numerous 
confounding factors which affect immune function, including age, sex, BMI, physical 
exercise, smoking, stress and vaccination history, factors which can be controlled by the 
use of animal models.   
 
Clinical trials which have been undertaken in patients with chronic inflammatory 
diseases have been reviewed elsewhere(101) and have identified robust benefits of LC 
n 3 PUFA supplementation in rheumatoid arthritis.  The results from studies of other 
autoimmune diseases such as Crohn’s disease, ulcerative colitis and psoriasis are mixed, 
with some studies reporting benefits, and others finding no effect of LC n 3 PUFA 
supplementation.  The effect of n 6 and n 3 PUFA supplementation upon atopic disease 
has also been reviewed(102).  This review identified the modest benefits of DGLA 
supplementation upon atopic skin, and the mixed and dose dependent effects of LC n 3 
PUFA supplementation of asthmatics.  It was suggested in this review that the timing of 
potential dietary interventions may be important, with intervention before or during the 
allergic sensitisation phase hypothesised to be of more benefit that supplementation 
after the onset of established disease. 
1.5 Programming 
 
Programming is term used to describe the process by which the environment 
experienced before birth or during early life exerts long term effects upon health that 
are expressed throughout adult life.  This process is also known as developmental 
plasticity(103), the thrifty phenotype hypothesis or developmental origins of adult 
health and disease(104).  Evidence for programming has been identified in both animal 
and human studies.  This section sets out to describe the theoretical basis of 
programming, evidence from human studies which supports the programming 
hypothesis, and the potential mechanisms responsible for programming. 
1.5.1 Theoretical basis of programming 
The two concepts which are fundamental to the programming hypothesis are functional 
capacity, and the importance of the timing of the environmental insult or stimulus to 
programming. 
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Functional capacity 
The principal that every organ or tissue has a maximum potential functional capacity 
which is determined by the type and number of cells or functional structures that are 
present, and a threshold capacity, under which normal tissue function cannot be 
maintained, is key to the programming hypothesis.  A graphical representation of the 
concept of functional capacity is illustrated in figure 1.13.   
 
As a large proportion of human tissue development occurs in utero, it is suggested that a 
high percentage of functional capacity is established during fetal life.  Once a tissue has 
matured and reached its maximal functional capacity a period of stability follows, 
before declining in response to stressors such as environmental insults or aging.  This 
decline in functional capacity will eventually reach a threshold under which normal 
tissue function can no longer be maintained, which may result in the onset of disease 
symptoms.  It has been suggested that programming may modify the maximal 
functional capacity achieved by a tissue or organ.  If programming is beneficial, this 
may delay or altogether avoid the deterioration of tissue function to a level at which 
normal functioning is lost.  If programming adversely affects tissue development, the 
maximal functional capacity achieved may be significantly lower, and the threshold of 
normal tissue function reached earlier or more rapidly in response to environmental 
stressors.   
 
Figure 1.13: Graphical illustration of the concept of functional capacity 
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Critical time periods of programming 
Periods of rapid cell division within a tissue are critical stages of development, and in 
humans most rapid cell division occurs during fetal development.  Humans undergo 
rapid growth before birth, with 42 cycles of cell division in utero and only 5 after 
delivery(105).  In a less developmentally mature animal, such as the rat, there may also 
be critical periods after birth.  The development of the human immune system is 
described in detail in a later section (see 1.8.2). 
 
Animal models have clearly demonstrated the importance of timing to programming 
effects.  For example, if female rats are injected with testosterone proprionate before 
they are 10 days old, ovulation is prevented throughout adulthood, but the same 
injection given to rats at 20 days old has no effect on later ovarian function(106).   
 
Undernutrition is an environmental insult which is likely to adversely affect tissue 
development and function.  It has been demonstrated that rats undernourished before 
weaning will never reach the size of their nourished counterparts in adulthood, even 
with the resumption of full feeding(107).  Similarly, rats subjected to undernutrition at 
3 6 weeks old (after weaning) or 6 9 weeks old will demonstrate accelerated growth 
upon refeeding, but will never fully catch up to the growth of controls.  In contrast, rats 
undernourished at 9 12 weeks will demonstrate catch up growth and even exceed the 
weight of controls(108).   
1.5.2 Evidence of programming from human studies 
The potential programming effects of the early life environment upon human health 
were initially identified in research which attempted to understand the mechanisms 
responsible for the development of non communicable diseases such as coronary heart 
disease (CHD).  It was identified that the risk of CHD during adulthood was twice as 
high among those whose siblings were stillborn or had died during early infancy(109), 
and that the risk of cardiovascular disease (CVD) mortality among adults (aged 40 69 
years) was strongly positively correlated with the infant mortality rates of this adult 
cohort’s early years of life(110).  Neonatal and infant mortality is strongly influenced 
by adverse circumstances during pregnancy, birth and infancy, and in these studies was 
used as an indirect measurement of the health status of the surviving siblings or other 
children born in the same area.  These studies therefore indicated that a poor   51 
environment during fetal development or infancy is a significant risk factor for CVD in 
adulthood. 
 
Similar studies have since been undertaken using UK cohorts.  Corresponding historical 
infant mortality rates were identified to be significantly correlated to rates of adult non 
communicable diseases including CVD, chronic bronchitis, stomach cancer and heart 
disease(111).  This association was seen for both men and women, and this study also 
indicated that the timing of adverse conditions was likely to be significant.  For 
example, heart disease was closely associated with both neonatal and post neonatal 
mortality rates while chronic bronchitis correlated more strongly with post neonatal 
mortality than with neonatal mortality.  This suggests that environmental factors 
predisposing to bronchitis in adulthood occur at a later developmental stage.   
 
Studies which used detailed records of birth weight and weight at one year as an 
indication of the quality of the fetal and infant environment within a cohort of 
Hertfordshire men(112) identified that men with birth weights under 5.5 lb (1 lb = 0.45 
kg) had the highest mortality rates from ischemic heart disease, chronic obstructive lung 
disease and death from all causes combined.  Those with the lowest weights at one year 
old also had a greater disk of death from ischemic heart disease.  This association 
between birth weight and disease risk was consistent across the full range of birth 
weights, including those within the normal range.   
 
The growth of the fetus is primarily determined by genetics but can also be modified by 
maternal size, maternal age and parity, maternal infection during pregnancy, the length 
of gestation, excessive energy expenditure after mid pregnancy, pre eclampsia and the 
availability of nutrients and oxygen to the fetus.  Although nutrition may only play a 
relatively minor role in determining fetal growth, it does provide the potential for 
interventions to improve the nutrition of the mother and fetus, in order to reduce the risk 
of disease in later life.  It is also likely that the effects of programming extend beyond 
simple relationships with fetal growth patterns, and may exert more subtle effects such 
as modification of tissue structure by altering cell types and cell numbers or alterations 
in patterns of gene expression or sensitivity to hormonal signals. 
 
A ‘mis match’ between the fetal and adult environment is also hypothesised to be 
associated with adverse programming effects.  For example, if the fetus is subject to in   52 
utero growth retardation as a result of impaired placental function, it may be 
‘programmed’ to survive within an environment which is nutrient poor.  If however, 
this is an inappropriate adaptation, and the infant is in fact exposed to a nutrient rich 
environment in early life, this may confer a further disadvantage.  There is evidence 
from human studies that this mis match occurs.  Data from a cohort of adults in 
Helsinki identified that infants with the lowest birth weight who went on to exhibit later 
‘compensatory’ growth (expressed as high BMI at age 11 years) were at an increased 
risk of type II diabetes and hypertension(113).  Migrant studies have also supported the 
importance of mis match to programming.  For example, Asian migrants to Britain have 
high mortality rates from CHD compared with the rest of the UK general population, 
which cannot be explained by traditional risk factors such as plasma cholesterol, 
smoking rates or intakes of saturated fats, but are found to relate to the lower birth 
weights among these populations(114).  
 
Data from human and animal studies which indicate that there are significant 
programming effects upon immune function will be discussed in detail in a later section 
(see section 1.9).  
1.5.3 Proposed mechanisms of programming 
The mechanisms of responsible for programming have not been fully characterised, but 
potential mechanisms include fetal nutrition, overexposure to glucocorticoids, and 
epigenetic changes.  It is likely that there is significant interaction between the 
mechanisms. 
 
Fetal nutrition 
Nutrient deficiencies, particularly low protein diets, have been demonstrated to induce 
programming effects.  For example, a study which provided a low protein diet (9% w/w, 
compared to 18% within a standard rat maintenance diet) to pregnant rats for just the 
four days following mating demonstrated that this induced significant effects upon 
offspring birth weight, postnatal growth, blood pressure and organ:body weight ratios 
which were still apparent up to age 12 weeks(115).   
In addition to the effect of nutritional deficiencies, provision of inappropriate excessive 
nutrients can also exert adverse programming effects.  Studies which have provided 
high protein energy supplements to pregnant mothers have exhibited deleterious effects 
on neonates including increased rates of pre term delivery and perinatal death(116 118).    53 
The protein content of the maternal diet during pregnancy has the capacity to alter 
offspring plasma cortisol concentrations.  For example, the adult children of women 
who had consumed a high protein (0.45 kg red meat daily) diet during pregnancy under 
the advice of their doctor were identified to have higher plasma cortisol concentrations 
and blood pressure than the children of women who did not receive or comply with this 
advice.  It is thought this may be a direct consequence of overexposure of the 
developing fetus to cortisol, programming the hypothalamic pituitary axis of the 
offspring to life long hypercortisolemia(119).   
Overexposure to glucocorticoids 
It is possible that some of the programming effects which are attributed to maternal diet, 
particularly a low protein diet during pregnancy, may be mediated by increased 
exposure of the fetus to corticosteroids(115).  Animal models which provide low 
protein diets have identified that this reduces the expression of 11β hydroxysteroid 
dehydrogenase (11β HSD) within the placenta.  This is an intracellular enzyme which 
converts active glucocorticoids such as cortisol and corticosterone into inactive 
metabolites such as cortisone and 11 dehydrocorticosterone(120).  The expression of 
this enzyme within the placenta suggests that it has a role in protecting the fetus from 
maternal glucocorticoids.  Changes in the activity of 11 βHSD in the placenta following 
dietary restriction is not a result of global reductions in placental enzyme activity as 
placental enzymes such as maltate dehydrogenase and pyruvate kinase are not 
significantly affected by maternal protein restriction(121).   
Fetal overexposure to maternal glucocorticoids is associated with reduced birth 
weight(122;123) and later hypertension in both animal models and humans 
studies(124;125).  Elevated glucocorticoid levels cause accelerated fetal maturation, and 
may therefore be an adaptive response to an adverse fetal environment(104). 
 
Glucocorticoids have immunosuppressive and anti inflammatory effects, which may 
affect the development of the fetal immune system.  Lymphocytes taken from rhesus 
monkeys exposed for 2 days prior to parturition to dexamethasone in utero had a 
reduced proliferative response at age 1year and reduced sensitivity to 
corticosteroids(126).  A similar effect has been documented among rhesus monkeys 
which were stressed during gestation(127).  Glucocorticoid hormone receptors are 
present in the thymus and it has been demonstrated that over exposure to   54 
glucocorticoids (induced by maternal stress during pregnancy) could induce involution 
of the fetus rat thymus(128). 
Epigenetics 
Epigenetic modifications are changes to DNA methylation patterns or chromatin 
packaging by histone acetylation which influence transcriptional activity and therefore 
gene expression.  These modifications are established early in life and maintained, and 
allow phenotypic change without changes to the DNA sequence.  Epigenetic 
modifications are involved in the tissue specific expression of genes and the process of 
imprinting which determines which parental gene allele is expressed.  Epigenetic 
processes are therefore a normal function of fetal development which may have the 
potential to exert long term effects upon adult tissue function(124;129).  
Maternal protein restriction during pregnancy has been demonstrated to significantly 
affect the methylation status of specific genes in the offspring, including the 
glucocorticoid receptor expression and PPAR α (a gene implicated in cardiovascular 
and metabolic disorders); with these effects lost if the maternal diet is supplemented 
with folic acid.  The effects of maternal diet were gene specific, with PPAR γ 
methylation status unaffected by maternal protein restriction(129).  These data suggest 
that the effects of maternal nutrition during pregnancy upon glucocorticoid exposure 
may be mediated by changes in gene methylation status.   
1.6 Gender and fatty acid composition 
Human studies have identified that men and women differ in their ability to synthesise 
LC n 3 PUFA from ALNA(130;131), with associated differences in plasma fatty acid 
composition(132 135).  The ability of humans to convert ALNA into LC n 3 PUFA has 
been studied using two approaches: the provision of ALNA labelled with stable isotopes 
or provision of additional dietary ALNA.  In studies where stable isotope labelled 
ALNA is provided, subsequent blood samples are collected to determine the circulating 
concentrations of stable isotope labelled metabolites of ALNA such as EPA, DPA and 
DHA.  These studies have the advantage of eliminating any doubt that these products 
may have come from alternative sources such as the diet or release from adipose tissue.  
By providing additional dietary ALNA it is possible to assess whether there are   55 
associated increases in circulating concentrations of LC n 3 PUFA in blood, cell and 
tissue pools, which would be indicative of LC n 3 PUFA synthesis.   
1.6.1 Studies of stable isotope labelled ALNA 
Data from studies using stable isotope labelled ALNA gave the first indications that 
there are gender differences in the ability to synthesis LC n 3 PUFA from ALNA.  
Studies which provided a dose of 
13C ALNA as part of a meal and subsequently 
collected blood and breath samples over a three week period indicated that young 
women (average age 28 y) converted a greater proportion of ALNA into EPA and DHA 
compared to men (average age 36 y)(130;131).   
This finding that women have a higher rate of synthesis of LC n 3 PUFA compared to 
men is supported by the work of other authors which used 
2H ALNA and mathematical 
modelling to determine rates of LC n 3 PUFA synthesis in a group of healthy mean and 
women(136;137).  When these data were assessed for gender differences(138) it was 
found that women receiving a beef based diet utilised a 3 fold greater amount of DPA 
to generate DHA compared with men.  A similar but non significant trend was observed 
in those subjects receiving an ad libitum diet.     
The studies undertaken using 
2H ALNA indicate that background diet interacts with the 
gender differences in rates of LC n 3 PUFA synthesis.  In these studies subjects were 
maintained upon controlled diets for two weeks prior to administration of the 
2H 
ALNA, and remained on this diet as blood samples were collected over a one week 
period.  The ability of men to generate DHA from DPA was not affected by the diet 
received, while women had lower DHA synthesis when receiving a fish based diet, 
exhibiting a rate of synthesis comparable to that observed in men(138).  The synthesis 
of LC n 3 PUFA in women therefore appears to be sensitive to the dietary availability 
of these fatty acids.  It is possible that diet also affects LC n 3 PUFA synthesis among 
men, as a study of older men (mean age 52 years) demonstrated that while an ALNA 
rich diet did not affect 
13C ALNA conversion to EPA, DPA or DHA, a diet enriched in 
EPA plus DHA decreased 
13C ALNA conversion to EPA and DPA(139).   
A primary limitation of the stable isotope studies is that they do not give insight into the 
extent to which LC n 3 PUFA might have been incorporated into metabolically relevant 
tissues such as the liver and adipose tissue.  These studies also give little indication of   56 
whether the differences between men and women in the ability to synthesise LC n 3 
PUFA relate to differences in the circulating concentrations of those fatty acids. 
1.6.2 The effects of dietary ALNA upon LC n-3 PUFA status 
Comprehensive reviews of studies which provided increased dietary ALNA and 
assessed the appearance of EPA and DHA are available(140;141).  To date, no study 
has been undertaken to investigate directly whether the effect of increased dietary 
ALNA upon LC n 3 PUFA status differs between men and women.  Increasing dietary 
ALNA intake has been found to result in dose dependent increases in EPA in plasma 
phospholipids; similar effects are likely for circulating cells such as leukocytes and 
platelets, although there are fewer studies investigating these.  The relationship between 
increasing dietary ALNA and DHA status is less clear, with some studies reporting a 
reduced DHA status with increasing dietary ALNA and others reporting no change in 
DHA status.  There is a plausible mechanism by which increasing dietary ALNA intake 
might reduce DHA synthesis.  The action of  6 desaturase is required in two stages of 
the synthesis of LC n 3 PUFA (see figure 1.6).  It is possible that increasing dietary 
ALNA increases substrate competition, inhibiting the  6 desaturation of 
tetracosapentaenoic acid to DHA(20). 
The studies which are currently available on the effect of increased dietary ALNA upon 
concentrations of LC n 3 PUFA vary in their design (see (140) for details).  There is 
wide variation between the studies in terms of duration (2 52 weeks), mode of 
supplementation (capsules, use of oil mixed into salads, incorporation of ALNA into 
dietary products such as spreads and muffins), whether LA intake was modified in 
parallel, and the blood lipid fraction analysed.  Studies to date have been conducted in 
men or mixed groups of men and women, with the exception of one study of lactating 
women(142).  The latter study demonstrated that increased dietary ALNA (20 g/day) 
increased ALNA, EPA and DPA in plasma, but did not alter plasma or breast milk 
DHA.  There is therefore limited data currently available to describe the effects that 
increased dietary ALNA may have upon blood and cell LC n 3 PUFA status in women, 
and no data in non lactating women.   57 
1.6.3 The effect of gender upon blood and tissue LC n-3 PUFA 
content 
Studies have been undertaken in humans to investigate the effect of gender upon 
circulating plasma concentrations of LC n 3 PUFA (see table 1.3).  While these studies 
vary in their sample size, degree of dietary control exerted and the range of blood lipids 
analysed, all have found that women have significantly higher circulating DHA 
concentrations compared to men and that this is independent of dietary intake(132 135).  
There is an indication from two of these studies that EPA and DPA are found in lower 
circulating concentrations in women compared to men which may indicate either a 
greater rate of conversion of these fatty acids into DHA or their displacement from 
lipids by DHA.
1.6.4 Potential mechanisms responsible for gender differences  
Mechanisms which have been proposed to be responsible for the gender differences 
observed in LC n 3 PUFA synthesis and tissue content include gender differences in 
rates of β oxidation, adipose tissue composition and mobilisation, and the possible 
influences of sex hormones upon the desaturase and elongase enzymes involved in the 
synthesis of LC n 3 PUFA(131;133).  
Studies using 
13C ALNA which collected breath samples enabled the rate of β oxidation 
of ALNA over 24 hours to be calculated via the recovery of 
13CO2(130;131).  These 
studies estimated the extent of β oxidation of 
13C ALNA to be 33% in men, and 22% in 
women.  These values and the sex difference observed are similar to those obtained in 
studies of other fatty acids (e.g. 
13C palmitate(143)) and may therefore reflect the 
differences in muscle mass between men and women, rather than any specific sparing of 
ALNA in women.  The lower rates of β oxidation of fatty acids observed in women 
could potentially leave more ALNA available as a substrate for metabolism into LC n 3 
PUFA. 
Sex differences in subcutaneous adipose tissue composition have been observed in 
human studies, with women found to have significantly more DPA and DHA in adipose 
tissue compared to men, although these fatty acids are relatively minor components of 
the total fatty acid content (< 0.3%)(144).  In the fasting state, plasma NEFA are fatty 
acids released from adipose tissue under the action of hormone sensitive lipase.  It has    58 
Table 1.3: Summary of human studies which have investigated the effect of gender upon the LC n 3 PUFA composition of blood lipids 
 
F, female; M, male
Effects of sex  Subjects  Country  Age (y)  Dietary control  Lipid fraction 
M > F  M = F  F > M 
Reference 
41 ♀   
41♂ 
Finland  ♀ mean 40 
♂ mean 43 
7 day weighed food 
record 
Serum CE 
Serum TAG 
Serum phospholipid 
  EPA 
DHA 
EPA 
DHA 
 
DHA 
(132) 
103 ♀   
72 ♂ 
Netherlands  18 67  Controlled diet 3 weeks 
 
Plasma CE    EPA, DPA  DHA  (135) 
23 ♀   
13 ♂ 
UK  18 35  Habitual diet (FFQ)  Plasma TAG 
Plasma NEFA 
Plasma PC 
Plasma CE 
Total plasma 
 
 
DPA 
EPA, DPA 
EPA, DPA 
EPA 
EPA, DPA, DHA 
DPA 
DHA 
DHA 
DHA 
 
EPA,DHA 
(133) 
1547 ♀   
1246 ♂ 
New Zealand  15 65+  Habitual diet (24 h 
recall) 
Serum phospholipid 
Serum TAG 
Serum CE 
EPA, DPA 
 
EPA 
 
EPA, DPA, DHA 
DHA 
 
DHA 
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been identified that women have higher fasting plasma NEFA concentrations compared 
to men(133) reflecting the greater proportion of body fat in women compared to men.  
Ex vivo studies have identified that the release of fatty acids from human adipose tissue 
is selective and dependent upon carbon chain length and the degree of unsaturation, 
with ALNA and EPA identified as being preferentially released in comparison to other 
n 3 PUFA(37;145).  It is therefore possible that gender differences in adipose tissue 
composition may directly affect circulating concentrations of LC n 3 PUFA or increase 
the availability of ALNA for synthesis of LC n 3 PUFA in women compared to men. 
Sex hormones and LC n 3 PUFA synthesis 
A role for sex hormones in mediating the sex differences in ALNA conversion and in 
LC n 3 PUFA content of blood (and tissue) lipids has been suggested from studies of 
women using oral contraceptives or HRT, a study of sex hormone treatment in trans 
sexual subjects and in vitro and animal studies.  
Oral contraceptives 
When 
13C ALNA was provided to women it was found that those women using the oral 
contraceptive pill had higher rates of DHA production over 21 days than women who 
did not use the pill(131).  This finding may indicate upregulation of the 
desaturase/elongase pathway by female sex hormones such as oestrogen or 
progesterone.  However, the number of female subjects in this study was low (n = 6) 
and data was not available for circulating sex hormone concentrations in these women.   
Data from studies of circulating LC n 3 PUFA concentrations support the suggestion 
that women using the contraceptive pill have higher rates of DHA synthesis.  When 32 
women who used oral contraceptives were compared with 72 women who did not use 
oral contraceptives, a trend was observed (p = 0.08) for higher concentrations of DHA 
in plasma CE among those women using oral contraceptives(135).  However, 
significant differences in age between these two groups of women were mentioned (but 
not detailed in the paper), which suggests potential differences in menopausal status as 
study participants were recruited from a wide age range (18 67 y); furthermore data was 
not collected on sex hormone concentrations in this study.  It is possible that the timing 
of blood sample collection during the menstrual cycle in this study (reported as day 5 9 
follicular stage), may be a confounding factor, as significant differences in the fatty acid 
composition of serum lipids have been identified across the menstrual cycle(146).    60 
Another study which attempted to address the impact of oral contraceptive use indicated 
that women using oral contraceptives had 60% higher total plasma DHA content, than 
those who did not use oral contraceptives(133).  However, due to the small number of 
subjects in this study (11 women using oral contraceptives, 12 women not using oral 
contraceptives) the study lacked statistical power to identify a significant effect of 
contraceptive pill use.  Good control over the stage of the menstrual cycle of subjects 
was achieved (all samples collected on day 10 of the menstrual cycle) but there was no 
data available upon circulating sex hormone concentrations, which could have 
supported the hypothesis that higher plasma sex hormones are responsible for the fatty 
acid composition differences between women using or not using the contraceptive pill. 
Hormone replacement therapy 
The effect that use of HRT has upon plasma LC n 3 PUFA status has been assessed.  A 
study of 104 postmenopausal Japanese women, 59 of whom received HRT (0.625 mg 
oestrogen + 2.5 mg progesterone per day) and 45 of whom received no treatment found 
that use of HRT for 12 months was associated with increased plasma EPA and 
DHA(147) which suggests that female sex hormones may up regulate the synthesis of 
LC n 3 PUFA from ALNA.  However, this study lacked a placebo group (with the 
subjects themselves deciding whether or not to receive HRT) and did not report any 
form of dietary assessment or restrictions.  It is therefore possible that the differences 
observed are an effect of differences in dietary LC n 3 PUFA intake between the two 
study groups.   
A placebo controlled study to investigate the effect of HRT or an oestrogen receptor 
modulator (Raloxifene) upon the fatty acid composition of plasma CE also found a 
significant increase in plasma CE DHA content with HRT(148).  The potential role of 
oestrogen rather than progesterone in these observed differences was indicated by the 
finding that Raloxifene also led to increased DHA content in CE.  This study reported a 
significant inverse relationship between ALNA and DHA content of CE among women 
using HRT or Raloxifene, which was suggested to be indicative of an enhanced capacity 
to synthesise DHA from ALNA.  An alternative explanation for this finding is that 
increased dietary ALNA can lead to reductions in DHA status(140).  As the women in 
this study were not controlled for dietary intake, it is possible that this inverse 
relationship reflects dietary variation in ALNA intake among these subjects rather than 
an increased conversion of ALNA into DHA.     61 
Sex hormone treatment of transsexual subjects 
A study of transsexual subjects was undertaken to assess the influence of cross sex 
hormone administration upon fatty acid status(135).  This study demonstrated that male 
to female transsexuals receiving a combination of oral ethyinyl oestradiol and 
cyproterone acetate had higher DHA concentrations in their plasma CE within 4 months 
of treatment.  Female to male transsexuals receiving intra muscular testosterone had 
significantly lower DHA content in plasma CE within 4 months of treatment.  This 
suggests that oestradiol up regulates, while testosterone down regulates, the synthesis of 
DHA from ALNA.  The authors suggested that the difference seen in female to male 
transsexuals was not due to the effect of testosterone treatment itself, but to the 
associated reductions in circulating oestrogen.  However, the effect of testosterone upon 
circulating oestrogen concentrations was only statistically significant in the subjects 
who received treatment for 4 months (p = 0.01), with the group treated for 12 months 
not differing significantly in their oestradiol status (p = 0.09).  The dietary intake of 
subjects was assessed using the Dutch EPIC food frequency questionnaire (FFQ)(149) 
but this was only conducted among subjects receiving hormone treatment for 12 
months.  While the design of this FFQ allows assessment of fish intake, this was not 
reported. 
In vitro and animal studies 
There is experimental evidence from animal studies that sex hormones might influence 
the activity of the desaturase enzymes involved in the conversion of n 3 and n 6 EFA 
into their longer chain, more unsaturated derivatives.  Work to date is limited to the use 
of n 6 rather than n 3 fatty acids as a substrate for assessment of enzyme activities and 
has investigated the effect of short term (less than 2 days) hormone treatment rather 
than the influence of normal circulating physiological concentrations of sex hormones.   
In vitro studies identified that  5 desaturase activity (assessed by production of the n 6 
PUFA AA) in liver microsomes isolated from female rats was reduced by 17β 
oestradiol and testosterone, and unaffected by progesterone(150).  An ex vivo study 
using rat liver microsomes to assess the effect of oestradiol treatment upon  6 
desaturase activity (assessed by production of the n 6 PUFA γ linolenic acid, 18:3n 6) 
identified that treatment of female rats for two days with 17β oestradiol led to reduced 
activity(151).  The effect of 17β oestradiol treatment upon serum fatty acid composition   62 
was also assessed, with significant reductions in serum AA content observed, although 
there was no significant effect upon DPA or DHA content.   
A study which assessed the effect of a single interperitoneal testosterone injection in 
both male and female rats found that 24 hours after testosterone treatment there was 
increased  9 desaturase activity, while  6 and  5 desaturase activities (assessed using 
n 6 fatty acid substrates) were inhibited(152).  Fatty acid composition analysis 
performed upon plasma and liver subcellular fractions confirmed that the decreases in 
 6 and  5 desaturase activities were associated with reduced DHA content in both the 
male and female rats.  This study also identified that the DHA content of plasma and 
liver fractions in both testosterone treated and control groups was higher in female rats 
compared to males, though the statistical significance of these sex differences was not 
presented. 
These studies using rat models support the observations from studies of human 
transsexual subjects that testosterone treatment may reduce the activity of  5 and  6 
desaturases, reducing the synthesis of LC PUFA, and leading to significant reductions 
in the tissue content of LC n 3 PUFA such as DHA.  Data also suggest that oestrogen 
may decrease  5 and  6 desaturase activity, though associated reductions in LC PUFA 
have only been identified for n 6 PUFA, with no significant effect of oestrogen 
treatment upon DHA content observed.  There are no data currently available upon the 
effect that circulating sex hormones may have upon the activity of the elongase 
enzymes involved in the synthesis of LC PUFA. 
1.7 Pregnancy and fatty acid composition 
Maternal lipid metabolism is significantly altered during pregnancy in order to meet 
changing maternal energy requirements and the requirements of the developing fetus.  
However, the nutrient crossing the placenta in the highest quantities is glucose, 
followed by amino acids, fatty acids and glycerol(153).  
Increased maternal appetite (hyperphagia) is a feature of early pregnancy(154), with 
fatty acids deposited in adipose tissue(155).  Gastrointestinal transit is reduced in later 
gestation, enabling increased absorption of dietary fat(156).  Fatty acids deposited in 
adipose tissue in early pregnancy become available for placental transfer to the fetus in 
the final trimester as a result of increased lipolytic activity in adipose tissue, mediated 
by increased mRNA expression and activity of hormone sensitive lipase and associated   63 
with maternal insulin resistance and reduced LPL activity of adipose tissue(154;155).  
Hypertriglyeridemia of pregnancy is a result of enhanced VLDL production in the liver, 
which may be mediated by the effects of oestrogen. 
The transport of fatty acids across the placenta releases free fatty acids into the fetal 
circulation (see figure 1.14).  Maternal lipoproteins do not cross the placenta intact; 
instead maternal TAG from plasma lipoproteins are taken up by the placenta via the 
action of lipoprotein receptors and lipase activity of the placenta, hydrolysed within the 
placenta to free fatty acids which are released into the fetal circulation.  Free fatty acids 
are also transported across the placenta in a process involving fatty acid binding 
proteins (FABP).  These transporters are selective, resulting in enrichment of the fetal 
circulation with LC PUFA(154).  The placenta has been demonstrated to preferentially 
transfer n 3 PUFA in comparison to n 6 PUFA, with perfusion experiments determining 
the overall selectivity to be DHA > ALNA > LA > AA(157).  Free fatty acids which are 
released into the fetal plasma bind to α fetoprotein, and are rapidly transported to the 
fetal liver(155). 
Figure 1.14: Transport of fatty acids across the placenta, diagram taken from (153) 
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1.7.1 Fatty acids and fetal tissue development 
 
Transfer of fatty acids to the fetus is essential to meet both the demands of de novo 
tissue synthesis and to lay down adipose tissue reserves.  In humans, 16% of body 
weight in the newborn is adipose tissue.  In contrast, the newborn rat has very low body 
fat, with white adipose tissue barely detectable at birth, indicating that for the rat there is 
a significant contribution of lactation to the accumulation of adipose tissue.   
 
Specific maternal dietary fatty acids have been demonstrated to be essential for 
successful fetal development and later tissue function in both human and animal studies, 
particularly n 3 PUFA.  Transfer of DHA to the developing fetus in human pregnancy 
predominantly occurs in the last 10 weeks of pregnancy, with the majority of this DHA 
accumulated within fetal adipose tissue(158).  The observation that DHA is found in 
high concentrations in the retina and accumulates in the fetal brain during early 
development (3 months gestation – 18 months after delivery) has led to the suggestion 
that an adequate dietary supply of this fatty acid is required for optimal brain and visual 
development(159).  Animal studies where n 3 fatty acid deficient diets are provided 
have demonstrated that dietary n 3 fatty acids are essential for normal cognitive and 
visual function, and a literature review is available(56). 
 
Human studies have investigated the role of LC n 3 PUFA, particularly DHA, when 
provided in infant milk formula to both preterm and healthy term infants.  Meta 
analyses indicate that the addition of DHA to pre term infant formula is beneficial for 
visual development in early life.  Whether these effects persist beyond early life (i.e. 
after 4 months of age) has not yet been established(58;160).  In term infants formula 
containing DHA was found to improve markers of cognitive function(57).  However, 
the clinical relevance of these reported statistically significant differences and the 
validity of the neurodevelopmental tests utilised in these studies has been 
questioned(161).   
1.7.2 Human studies of fatty acid status during pregnancy 
 
Human studies have been undertaken to examine the effect of pregnancy upon maternal 
circulating fatty acid status(162 166).  Full details of the findings of these studies are 
described in table 1.4.  These longitudinal human studies have not included pre 
conception data, and therefore can only provide information upon the variations in fatty 
acid status which occur after the first trimester.    65 
Table 1.4: Summary of human studies which have investigated the effect of pregnancy upon circulating fatty acid status (page 1 of 2) 
Reference  Study group  Sample type  Effects 
Al et al, 1995 (162)  
The Netherlands 
 
Longitudinal (n=110) 
 
10, 14, 18, 22, 26, 30, 32, 34, 36, 28, 
40 weeks 
Plasma phospholipids 
 
% and quantitative analysis 
 
No dietary assessment 
% effects: 
￿ total saturates throughout gestation  
￿ total MUFA throughout gestation 
￿ total n 3 and DHA until 18 weeks 
￿ total n 6 and AA throughout gestation 
 
Wijendran et al, 1999 (163)   
USA 
Longitudinal  
 
n=15 healthy controls 
n=15 gestational diabetes 
 
27 30 weeks 
33 35 weeks 
36 39 weeks 
 
Plasma phospholipids 
 
% and quantitative analysis 
 
Dietary assessment (24hr recall) 
% effects in healthy controls: 
￿ 16:0   ￿ 18:0   ￿ ALNA 
￿ 22:5n 6  ￿ 20:0   ￿ EPA 
    ￿ 20:3n 6  ￿ DPA 
    ￿ AA   ￿ DHA 
    ￿ 22:4n 6 
Stark et al, 2005 (164) 
African American cohort, 
USA 
Longitudinal (n=157) 
 
24 weeks 
Delivery 
Plasma and erythrocyte total 
lipid extracts 
 
% and quantitative analysis 
 
Dietary assessment (FFQ) 
% effects in plasma: 
￿16:0   ￿ 14:0 
￿ 22:0   ￿ 18:0 
￿ 24:0   ￿ 20:0 
￿ 18:1n 9  ￿ LA 
￿ 20:1n 9  ￿ GLA 
￿ 22:5n 6  ￿ EPA 
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Table 1.4 (contd.): Summary of human studies which have investigated the effect of pregnancy upon circulating fatty acid status (page 2 of 2) 
Reference  Study group  Sample type  Effects 
Burdge et al, 2006 (165) 
Trinidad 
 
Cross sectional 
 
non pregnant (n=10) 
20 22 weeks (n=6) 
30 34 weeks (n=13) 
 
 
Plasma 
 
Quantitative analysis 
 
No dietary assessment 
Quantitative effect in plasma: 
 
NEFA:       ￿ AA 
 
PC:      ￿LA    ￿ EPA 
    ￿ AA 
    ￿ DHA 
 
TAG:    ￿LA 
    ￿ALNA 
    ￿AA 
Stewart et al, 2007 (166)  
Scotland 
Longitudinal (n=47) 
 
12.5 weeks 
26.1 weeks 
35.3 weeks 
Erythrocyte 
 
% and quantitative analysis 
 
No dietary assessment 
 
% effects:  ￿ 22:5n 6  ￿ 18:0 
    ￿ ALNA  ￿ 20:0 
    ￿ DHA  ￿ 22:0 
    ￿ 16:1n 7 
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The effects of pregnancy upon maternal blood lipid fatty acid status observed in human 
studies have been mixed, with some studies have identifying a reduction in plasma 
phospholipid DHA status during prenancy(163), while others report an increased DHA 
content of plasma phospholipids(165) or red blood cells(166).  These differences 
between studies may be due to variations in sample size, the type of blood lipid sample 
analysed, and the possible confounding effect of maternal diet, with the potential for 
differences in mobilisation from maternal adipose stores and the composition of those 
stores. 
 
The effects observed in human studies have not been limited to LC n 3 PUFA status, 
with significant effects of pregnancy observed upon saturated fatty acids, MUFA and n 
6 PUFA(162 166).  No human study to date has determined whether the changes in 
fatty acid status observed relate to sex hormone status. 
1.7.3 Animal studies of fatty acid status during pregnancy 
 
Use of experimental animals provides a clear advantage in the investigation of the 
effects of pregnancy upon fatty acid composition – enabling control over several of the 
variables identified as likely confounding factors in human studies, such as variations in 
dietary intake of the quantity and quality of fats.  Animal studies also have the 
advantage of enabling sampling of fetal tissues to investigate the effects of maternal diet 
upon fetal tissue composition. 
 
Several studies have been undertaken using rats to investigate the effect of pregnancy 
upon the fatty acid composition of plasma and liver phospholipids and TAG(167 170).  
The full details of these studies are described in a later section (see chapter 4), and table 
4.1 summarises the results of these studies.  Animal studies to date have focused on the 
effects of pregnancy upon maternal plasma and liver lipid composition.  In brief, these 
studies have all identified that there are significant differences between the fatty acid 
content of rat tissues at the end of gestation compared to virgin females.  Consistent 
effects of pregnancy observed are higher 16:0 and DHA content, and lower 18:0 and 
AA content of both plasma and liver phospholipids.  The association of 16:0 with DHA 
status, and 18:0 with AA status, is likely to be due to the pairing of these fatty acids 
within phospholipid structure.   68 
1.8 Pregnancy and immune function 
 
The developing fetus expresses both maternal and paternal antigens, and so it is 
essential that adaptations occur to the maternal immune system in order to prevent the 
rejection of the developing fetus by the maternal immune system.  The principal 
mechanism which is understood to mediate this in humans is the Th2 switch, a process 
by which maternal immune function shifts away from a predominantly Th1 phenotype, 
to express a Th2 phenotype.  Other changes to the maternal immune system are also 
likely to be involved in the maintenance of successful pregnancy such as thymic 
involution. 
1.8.1 Maternal immune adaptations to pregnancy 
The Th2 switch 
The concept that successful pregnancy among both humans and mice is dependent upon 
regulation of the balance between Th1 and Th2 responses is widely accepted, with 
several reviews available upon this subject(171 174). 
A Th2 response during pregnancy may be advantageous as the Th2 response involves a 
humoral (antibody based) rather than cellular immune response.  This therefore reduces 
the activity of maternal immune cells which may target the feto placental unit, such as 
cytotoxic T cells or NK cells, while maintaining antibody production.  Maintenance of 
antibody production is beneficial to the fetus, as antibodies such as IgG can be 
transferred across the placenta and via breast milk, providing protective immunity for 
the neonate until the infant’s own immune system is sufficiently matured(175).  There 
may be disadvantages to the Th2 switch in terms of maternal immune function.  An 
impaired Th1 response may adversely affect maternal responses to pathogens such as 
bacteria and viral infections and an excessive Th2 response may exacerbate maternal 
allergies and predispose the infant to atopic disease.   
Evidence from human studies for the Th2 switch 
In vivo markers of disease status provide strong evidence for a Th2 switch during 
human pregnancy.  Rheumatoid arthritis is an auto immune disease associated with high 
levels of Th1 cytokine expression, and symptoms of this inflammatory condition are 
improved during pregnancy(175).  In contrast, systemic lupus erythematosus is an 
antibody mediated auto immune disease associated with Th2 cytokine expression, and   69 
primarily affects women during reproductive years(176).  The importance of down 
regulation of Th1 cytokine production to maintaining a successful pregnancy is apparent 
from studies which have demonstrated that women with recurrent spontaneous 
abortions have significantly higher ratios of production of Th1 to Th2 cytokines when 
compared to women during successful pregnancy(171).  There is also evidence to 
suggest placental deficiencies in IL 10, a Th2 cytokine, in women with recurrent 
miscarriage(177). 
Ex vivo studies also provide supportive evidence for a Th2 switch in human pregnancy.  
PBMC collected from healthy pregnant women have identified that while the 
proportions of CD4
+ and CD8
+ cells within the blood lymphocyte pool remain constant 
during pregnancy, these cells differ in terms of their cytokine production profile, with a 
shift towards Th2 producing cells(172).   
Evidence from animal studies for the Th2 switch 
Murine studies have been used extensively to study the Th1/Th2 balance during 
pregnancy.  In vivo disease models in mice have also demonstrated the importance of 
Th2 responses in the maintenance of successful pregnancy.  Infection of mice with the 
parasite Leishmania major induces a strong Th1 response.  When pregnant mice were 
infected with Leishmania major there was an increase in spontaneous resorptions which 
was associated with increased Th1 cytokine production(173).  Th1 responses induce NK 
cell activity which correlates with rates of fetal resorption in the mouse(175).  Murine 
studies have also demonstrated that the injection of Th1 cytokines induces 
abortion(178). 
The rat immune response to pregnancy has been less extensively characterised, with 
some contradictory findings(179 181).  Full details of these studies are provided in 
chapter 5 (see table 5.1).  It is clear that there may be fundamental species differences in 
the immune response to pregnancy.  A study which directly compared human and rat 
immune responses during pregnancy identified that while the human immune response 
adapts to have a lower proportion of IFN γ producing cells, the rat adapts to pregnancy 
by reducing total lymphocyte numbers(181).   70 
Potential mechanisms of the Th2 switch 
It is likely that the placenta is involved in maintaining the maternal Th2 phenotype.  For 
example, the placenta has been demonstrated to produce IL 4, IL 10, PGE2 and 
progesterone, which all down regulate Th1 function and upregulate Th2 function(182).  
An in vitro study of murine cells investigated whether gene methylation may be 
involved in determining whether Th cells express a Th1 or Th2 response.  The 
methylation status of the IFN γ gene in murine cloned Th cells was significantly 
different between Th1 and Th2 cells, with Th2 cells being methylated in this region, 
which would act to inhibit transcription of the IFN γ gene(183).  This finding is also 
supported by a study which used immature Th cells obtained from cord blood, and 
found that culturing these cells with IL 4 and PGE2 in order to induce the Th2 
phenotype was associated with methylated IFN γ promoter regions(184).  A study 
which compared the methylation status of IFN γ and IL 4 promoter regions in adult and 
cord blood immune cells identified that cord blood, which has lower production of IFN 
γ than adult blood samples, exhibited corresponding higher methylation status of the 
IFN γ promoter region(185).  
However, the findings of these studies on methylation status have been disputed by 
other authors who suggest that the mutually exclusive pattern of IFN γ and IL 4 
expression in murine Th1 and Th2 cells is not regulated by methylation, and identified 
that the promoter regions of both IL 4 and IFN γ had the same patterns of methylation 
in all Th phenotypes(186).  The authors proposed that conflicting results were a result of 
the long culture times used in other studies, which may cause spontaneous methylation 
and therefore not be representative of the in vivo profile of gene methylation. 
Other maternal immune adaptations to pregnancy 
Maternal thymus involution is a feature of pregnancy and involves neural, endocrine 
(e.g. progesterone(177;187), gonadotrophin releasing hormone and prohibitin(181)) and 
immune influences(176).  Involution is specific to the cortex (the outer structures of the 
thymus – containing immature T cells), while the medulla (the inner structure of the 
thymus – containing more mature T cells) undergoes hyperplasia(177).  These changes 
are transient, with the maternal thymus rapidly regenerating after lactation(176).   71 
1.8.2 Development of the fetal immune system 
The immune system undergoes complex developmental stages during gestation, with 
different cell types and organs therefore potentially having different critical periods of 
development during which specific interventions could be targeted.  An adverse 
condition during these developmental periods therefore has the potential to modify the 
lifelong immune response.   
 
Intrauterine growth retardation is associated with an increased risk of neonatal and post 
neonatal mortality from infectious diseases(188), which suggests impaired immunity.  
Small for gestational age infants are also at increased risk of infectious morbidity in 
infancy and early childhood, with impaired thymic development proposed as a key 
mediator of these processes(189).  In situations of nutrient deficiencies, the 
requirements for successful immune system development in early life may be 
compromised by the growth of other organs.  For example, brain development in utero 
is well conserved in situations of malnutrition and may occur at the expense of other 
organs such as the thymus. 
Organ differentiation occurs in the first trimester of pregnancy, and growth in overall 
body weight and length occurs in the second and third trimester.  A differentiated 
thymus is apparent by 7 9 weeks gestation, T and B lymphocytes are present in the 
circulation by the end of the first trimester and reach adult levels in the second, and 
complement proteins and monocytes are identified after 7 weeks.  The fetal immune 
system is capable of antigen recognition by 12 weeks, although immune system activity 
remains depressed throughout gestation.  Environmental allergens can reach the human 
fetus in utero, via placental transfer (demonstrated for ovalbumin, birch pollen and cat 
allergen) and transamniotic passage (demonstrated for β lactoglobulin and 
ovalbumin)(190).  It is therefore possible that allergic sensitisation may occur in utero, 
and indeed infants can be born with allergic hypersensitivity, having IgE present in cord 
blood, despite the fact that IgE does not cross the placenta, indicating that this was 
generated by the developing fetus(191).  
Infancy is a critical period of immunological development.  There is evidence that IFN 
γ production is down regulated in the lymphocytes of neonates(192) and the fetus has 
been described as Th2 polarised.  This results in the fetus/neonate being susceptible to 
infection, particularly as following birth the neonate enters a microbe dense   72 
environment, and the passive immunity provided by maternal IgG transferred across the 
placenta will provide only a temporary degree of protection.  After delivery, the infant 
must therefore switch to express a Th1 phenotype in order to cope with the wide range 
of infections and antigens experienced.    
 
The infant immune system is initially vulnerable due to the immaturity of the range of 
specific T and B lymphocytes, and as a result the immune system undergoes rapid 
development in early life.  In humans, the thymus reaches its maximum size by age 1 
year.  The proliferative potential of lymphocytes is maximised in infancy, the volume of 
functional tissue in the thymus is twice as high in infancy as in adulthood and the 
number of circulating T and B lymphocytes is three to four times higher(193).  The 
thymus is therefore an energy expensive organ, due both to the numerous cells produced 
de novo and the high rates of cell turnover as part of the mechanism involved in 
avoiding self reactivity.   
1.9 Programming of immune function  
Programming of immune function has not be studied as extensively as the programming 
of cardiovascular function, but data are available which have identified programming 
effects of fetal and infant growth, maternal total energy restriction and micronutrient 
deficiencies upon offspring immune function.  To date there is no conclusive evidence 
to support an effect of maternal dietary fatty acids during pregnancy upon offspring 
immune function, but available data from animal and human studies does indicate that 
there is a potential for fatty acids to mediate these effects. 
 
Data from human studies has indicated that programming effects upon immune function 
are associated with alterations in markers of fetal growth.  Raised serum IgE levels are 
indicative of a Th2 type immune response, and are characteristic of atopic disease.  A 
retrospective study identified that high serum IgE levels in adult men and women (> 50 
years old) were associated with larger head circumference at birth(194).  Head 
circumference is largely determined by brain growth, and is often used as a marker of 
accelerated fetal growth.  It is possible that those with accelerated fetal growth will be 
more sensitive to periods of undernutrition.  The authors of this paper suggested that 
selective ‘sparing’ of the brain during fetal development, results in reduced availability 
of blood and nutrients available to other organs, including immune organs, and 
therefore affects later risk of atopic disease.     73 
This association between fetal growth and immune function was further supported by 
the data from a prospective cohort which looked at how perinatal factors affected the 
incidence of atopic disease.  This study followed a cohort of 891 children from age 1 to 
16 years and monitored the incidences of asthma, eczema and other atopic illnesses such 
as allergic rhinitis, food allergies and insect bite/sting allergies in relation to measures 
of perinatal status such as gestational age at birth, birth weight, length and head 
circumference.  Recurrent asthma symptoms were found to associate with a head 
circumference of 37 cm or greater at birth.  Other risk factors which were identified for 
the development of asthma were gender (with males more likely to develop asthma) and 
parental asthma or allergic rhinitis(195).  The authors of this paper suggested that the 
effect upon head circumference may be indicative of maternal fatty acid intake, due to 
the essential role of fatty acids in brain development.   
1.9.1 Programming of immune function by total energy restriction 
The fact that breast feeding reduces occurrence of allergic disease, particularly in babies 
with a family history of atopic disease, is a strong indicator that nutrition in early life 
has the potential to modulate the risk of atopic disease(105).  Both human studies and 
animal models have demonstrated that total energy restriction during gestation can exert 
significant effects upon immune function.  It would not be ethical to establish human 
intervention studies of total energy restriction during pregnancy, but data from dietary 
interventions in developing countries and historical famines can be used as models of 
total energy restriction.   
 
In The Gambia there is considerable seasonal variation in energy expenditure and 
energy intake around the harvest seasons.  This has profound effect on birth weight 
resulting in a variation of 200 300 g between those born in the hungry season and those 
born in the harvest season.  Those born during the hungry season were found to have 
highest mortality rates in adulthood with deaths dominated by infectious and pregnancy 
related deaths(196).  Supplements providing an additional 1020 kcal/day from week 20 
gestation until term delivery among women in The Gambia were found to have a 
significant positive effect on birth weight, increasing it by an average of 136 g(197).  
This was also associated with reduced perinatal mortality, which suggests an effect of 
total energy intake on the development of the immune system.  
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Animal studies have also identified significant effects of energy restriction during 
pregnancy upon offspring immune function.  A study which provided adult female rats 
with a calorie restricted diet (25% of the amount given to ad libitum fed controls) for 6 
weeks prior to conception, and throughout pregnancy and lactation identified that this 
resulted in diminished antibody responses among both the F1 and F2 generations, despite 
ad libitum diet being provided at weaning to the F1 generation, and throughout F2 
generation development(198). 
 
A rat study of 50% energy restriction during pregnancy identified that this induced 
severe maternal weight loss and a reduction in offspring birth weight(199).  Ad libitum 
feeding was resumed after delivery, and by six weeks of age the undernourished 
offspring had exhibited catch up growth to reach the same weight as control offspring.  
Among male undernourished offspring at 4 6 weeks old there were no significant 
differences in urine volume, concentration of glucose in urine, blood pressure or heart 
rate in comparison with control.  However, several markers of the immune system were 
found to be altered.  In the undernourished offspring there was a reduction in the 
number of rolling leukocytes, reduced adhesion and migration and increased velocity of 
rolling.  L selectin (expressed on granulocytes, monocytes and most lymphocytes) and 
P selectin (expressed on platelets) were expressed at a lower level in response to TNF α 
in the undernourished group.  This study suggests that reduced leukocyte migration 
among undernourished offspring may be the mechanism which increases predisposition 
to infection after pre natal undernutrition. 
1.9.2 Programming of immune function by micronutrient restriction 
Micronutrient restriction during pregnancy has been demonstrated to significantly affect 
offspring immune function.  A study was undertaken which provided pregnant rats with 
a diet that would induce a moderate zinc deficiency (5 ppm zinc vs. 100 ppm in zinc 
sufficient diet) from day 7 of gestation to delivery.  At delivery pups from zinc deprived 
dams were cross fostered to control dams during lactation, ensuring that zinc deficiency 
was limited to fetal exposure.  This did not significantly affect plasma zinc 
concentrations, but the zinc deprived pups demonstrated significantly reduced IgM 
production, and these effects persisted into the F3 generation(200).  Zinc deprivation 
during pregnancy therefore created an immunodeficiency which persisted long after a 
zinc replete diet was resumed and for more than one generation.  
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A study provided rats with diets that were either iron adequate (250 ppm during 
pregnancy and lactation, 35 ppm after weaning), moderately iron deficient (12 ppm) or 
severely iron deficient (6 ppm) throughout pregnancy and lactation identified significant 
effects of iron deficiency during pregnancy and lactation upon offspring immune 
function.  Offspring of iron deficient dams had similar birth weights, but lower spleen 
weights, total white blood cells counts, and impaired IgG and IgM formation.  Iron 
repletion for three weeks following weaning did not reverse this impairment – this is a 
short repletion period, and it is unclear whether immune effects would persist into 
adulthood, which would indicate a true programming effect(201). 
1.9.3 Programming of immune function by maternal dietary fatty 
acids 
Little is known about the role of fatty acids in programming.  The limited data available 
from studies using rats indicates that dietary LC n 3 PUFA during pregnancy and early 
life have the potential to beneficially protect against accumulation of fatty acids within 
adipose tissue in later life by lowering lipoprotein lipase mRNA expression, but may 
increase long term oxidative stress as indicated by higher liver catalase activity(202).  
n 3 deficient diets provided to rats throughout pregnancy, lactation and in early life have 
also been demonstrated to result in significantly higher mean arterial blood pressure at 
age 34 weeks(203). 
Animal and human studies to date which investigate the potential effects of dietary fatty 
acids upon offspring immune function do not demonstrate ‘programming’ effects, as no 
study to date has yet investigated whether any effect observed persists into adulthood.   
Available data from animal models 
When rat pups were fed high fat diets (11.7% w/w) which varied in their EFA content 
(49.4% vs. 4.7% of total fatty acids) from birth to weaning at 22 days of age it was 
found that those pups receiving the low EFA diet had lower total body weight, thymus 
and spleen weights and proliferative responses by cells of the spleen and thymus at 30 
and 40 days old.  This was associated with changes to the fatty acid composition of the 
thymus.  This demonstrates that EFA deficiency in the postnatal period significantly 
affects the organ development of the rat and including its immune system(128). 
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Animal studies of survival rates after infection can be considered to reflect the capacity 
in vivo of immune function to successfully respond to stimuli.  Survival rates following 
exposure to streptococcal sepsis in neonatal rats were assessed after dams were fed a 
diet that provided 22% energy from fat (either corn oil or menhaden fish oil) throughout 
pregnancy and lactation.  At 7 days old pups were challenged with streptococcal 
infection.  Survival rates from streptococcal challenge were significantly higher in the 
fish oil group than in the corn oil fed groups(204).  Levels of AA and PGE2 were higher 
in the lungs of pups from the corn oil fed group than in the fish oil group.  This 
demonstrates that the fatty acid composition of the pre and postnatal diet significantly 
affects the in vivo response to neonatal immune challenge; with the LC n 3 PUFA rich 
fish oil diet conferring a benefit which is likely to reflect the effects of dietary fatty 
acids upon eicosanoid production.  
 
Varying the ratios of corn oil (rich in LA) and coconut oil (rich in saturated fatty acids) 
in high fat (10% w/w) diets provided to rats during pregnancy significantly affected 
lymphocyte proliferation in fetal lymphocytes, with spleen lymphocytes of the neonates 
of dams fed coconut oil proliferating more strongly in response to the mitogen 
concanavalin A (Con A) than those fed corn oil(205).  Diets were fed throughout 
pregnancy and dams were returned to a standard diet at birth.  When assessed at 4 
weeks old the offspring of dams fed corn oil had a significantly heavier thymus and 
spleen, although the effect on spleen weight was lost when spleen weight was expressed 
as proportion of body weight.  This indicates that the qualitative supply of fatty acids to 
the fetus may be important in determining the development of immune organs.  
 
A study which investigated intragastric treatment with 50 mg of a high fat (35% w/w) 
marine fish extract in addition to a high fat diet (10% w/w, fat source not stated) to rats 
before and during pregnancy and lactation identified that both the dams and the pups at 
3 weeks after birth had significantly higher expression of CD56 (expressed on NK 
cells), CD25 (IL 2 receptor), CD28 (T cell co stimulator) and CD62 (selectin adhesion 
molecule – expressed on most neutrophils and peripheral lymphocytes) in blood(206).  
However, this study could not determine whether these effects upon immune cell 
surface marker expression would persist beyond the period of dietary intervention.  
 
Rats provided with high fat (7% w/w) diets with various n 6 to n 3 EFA ratios (linseed, 
soyabean or sunflower oil) during the last 10 days of gestation, throughout lactation and   77 
after weaning demonstrated that these diets significantly affected offspring development 
of oral tolerance to later ovalbumin exposure.  Those on the n 3 fatty acid rich diet 
demonstrated a more pronounced oral tolerance response, with significantly lower 
delayed type hypersensitivity (DTH) responses and lower production of ovalbumin 
specific IgG, IgM and IgE among those exposed to dietary ovalbumin(207).  This 
indicates that the n 3 to n 6 EFA content of the diet can significantly affect development 
of atopic type responses, but again does not indicate which time period of dietary 
intervention was the critical period to effect this change, or whether these effects would 
persist beyond the period of dietary intervention. 
 
A study which provided diets to sows throughout lactation which varied in their n 6 to 
n 3 fatty acid ratio and vitamin E content identified that both the fatty acid composition 
and vitamin E content of the maternal diet significantly affected PGE2 production by 
offspring alveolar macrophages, with production lower among offspring from the fish 
oil dietary group, compared to the sunflower oil fed group.  However, the magnitude of 
this difference was diminished after weaning, when all piglets were returned to a 
standard feed, and so this does not strongly support a programming effect of dietary 
fatty acids during lactation in pigs(208). 
Available data from human studies 
Intervention studies where fatty acid supplements have been provided during gestation 
or early life have supported the suggestion from epidemiological studies that dietary LC 
n 3 PUFA are protective against childhood asthma.  Several studies have been 
undertaken which have provided either pregnant women or infants with dietary LC n 3 
PUFA and investigated the effect upon atopic disease or cytokine markers of Th1/Th2 
balance.   
Pregnant women with atopic symptoms were supplemented with 4 g fish oil per day 
from 20 weeks gestation until birth, and this resulted in significantly lower levels of IL 
13 (a Th2 cytokine) in cord blood of their infants compared to the olive oil control 
group, and demonstrated an inverse correlation with cord red cell membrane DHA 
status and a positive correlation with the proportion of B cells and NK cells in cord 
blood(209).  Cord blood IL 10 responses to house dust mite or cat hair extract were also 
significantly lower in the fish oil supplemented group, demonstrating significant inverse   78 
correlations with cord blood red cell membrane EPA(210).  However, the clinical 
significance of these changes in cytokine production is unclear. 
Studies have been undertaken in early infancy to assess the potential for dietary n 3 
fatty acids to reduce the risk of atopic disease.  The Childhood Asthma Prevention 
Study (CAPS) provided fish oil supplements to infants at risk of atopic disease after 6 
months of age or at the onset of bottle feeding and ALNA rich spreads and oils as part 
of a study design which also investigated dust mite avoidance strategies.  
Supplementation with fish oil was demonstrated to reduce the prevalence of parent 
reported symptoms of wheeze among infants at age 18 months(211).  Further analysis 
indicates that there is a benefit threshold rather than a dose response relationship of 
infant n 3 fatty acid status, with all quintiles demonstrating similar reductions in the 
parent reported wheeze prevalence compared to those within the lowest plasma 
phospholipid n 3 fatty acid quintile(212).  When these children were followed up at age 
3 years, there was a significantly lower prevalence of cough symptoms among children 
in the dietary intervention group(213).  At 5 years of age there was no significant effect 
of dietary intervention upon measures of atopic disease symptoms, indicating that the 
benefits of the intervention may be limited to early life(214;215). 
 
When fish oil capsules were provided to lactating mothers it was found that infants had 
significantly higher endotoxin stimulated IFN γ production and a significantly higher 
IFN γ:IL 10 ratio of whole blood cultures at 2.5 years age when compared to infants 
whose mothers were supplemented with olive oil during lactation(216).  This suggests 
that fish oil intake in early life promotes infant immune maturation, and that these 
effects are detectable long after maternal supplementation has ceased.  Immune function 
is not the only infant outcome significantly affected by maternal supplementation during 
lactation   another study in this cohort of children identified that fish oil 
supplementation during lactation had a positive effect upon problem solving among 
girls at 9 months age, but also associated with lower vocabulary comprehension among 
boys at 1 year old(217). 
1.10 Aims of the studies described in this thesis 
While human studies have demonstrated clear gender differences in the de novo 
synthesis of LC PUFA and corresponding significant differences in circulating DHA 
concentrations, investigations of the mechanisms which may be involved in maintaining   79 
these gender differences have not been undertaken.  This is in part due to difficulties in 
controlling for dietary variation between individuals and the limited range of tissues 
which can be collected in human studies.  Similarly, while animal studies have 
demonstrated that tissue fatty acid composition is significantly altered during 
pregnancy, there is no available information upon the mechanisms which may be 
responsible for these effects of pregnancy.   
 
Human and murine pregnancy has been extensively studied in order to investigate the 
maternal adaptations which allow maintenance of successful pregnancy in the face of 
potential immune rejection of paternal antigens.  However, the data currently available 
from studies in rats are limited and inconsistent, and indicates that there may be both 
species and strain variations in the adaptations observed during pregnancy.  Studies 
have been undertaken in rats which identified significant alterations in both maternal 
and fetal tissue fatty acid composition as a result of changes to the maternal diet during 
pregnancy.  However, there is little data available about the effect of maternal diet 
during pregnancy upon maternal or fetal immune tissue fatty acid composition, and the 
implications this may have upon immune function. 
 
This thesis therefore sets out to address these unanswered research questions.  It is 
hypothesised that: 
 
￿  the rat will demonstrate gender differences in fatty acid composition, which are 
induced by the effect of sex hormones upon the mRNA expression of desaturase 
and elongase enzymes.  Pregnant rats have higher circulating sex hormone 
concentrations and will therefore demonstrate an even more marked effect of 
sex hormones upon desaturase and elongase enzymes.   
￿  increasing the n 3 content of the maternal diet during pregnancy will increase 
the n 3 content of maternal and fetal immune tissues, reducing the production of 
PGE2 from n 6 fatty acid AA.  This will therefore reduce the Th2 promoting 
effects of PGE2 and confer benefits to fetal immunity by altering the Th1/Th2 
balance of cytokine production, with the potential to alter the development of 
atopic disease. 
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Chapter 2:  Materials and methods   81 
2.1 Animal husbandry 
All animal work was carried out in accordance with the Home Office Animals 
(Scientific Procedures) Act (1986).  Experimental procedures were covered by a Home 
Office Licence, and work undertaken in accordance with Personal Licence 
specifications.  Wistar rats were used throughout.  They were aged 10 weeks at the start 
of experiments and received standard laboratory maintenance chow during a 
rest/acclimatisation period (5 7 days) after their transport and delivery to the 
Biomedical Research Facility at the University of Southampton.  Animal weight was 
monitored weekly.   
 
Rats were housed individually while being fed experimental diets to enable accurate 
monitoring of food intake.  Food provided and remaining was weighed every 2 3 days.  
Diets which were powdery in consistency were sifted to avoid errors in weighed food 
intake.  Uneaten diet was removed to ensure that no food would become unpalatable 
due to oxidation or rancidity.  At the end of the dietary intervention period rats were 
culled by CO2 intoxication followed by cervical dislocation.   
 
Where pregnant females were used, mating was undertaken by monogamous breeding 
(the studs used were not part of any experimental diet group and received standard 
laboratory maintenance chow).  Efforts were made to ensure that a range of males was 
used for mating within each dietary group.  When mating was confirmed by the 
appearance of a vaginal plug, this was recorded as day 1 of gestation.  Females were 
then housed individually and started on experimental diets.  At day 20 of gestation, or 
for some experiments at day 12 of gestation, the pregnant rats were culled and fetuses 
collected; normal rat pregnancy is 21 24 days.   
 
The rate of successful pregnancies following mating was high, with few females failing 
to become pregnant (3 out of 87 females).  Day 20 pregnancies with a litter size of less 
than 6 pups (3 out of 75 pregnant females) were excluded from further data analysis.  A 
summary of successful pregnancies across all cohorts is shown in table 2.1. 
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Table 2.1: Successful pregnancies achieved over the course of the studies described in 
this thesis (number of pregnancies successful/number of pregnancies initiated, % 
success) 
 
    Chapter 
    Experimental diet  4  6  5  7 
12  5/6, 83% †    5/6, 83% †   
LF 
6/6, 100%  6/6, 100%  Soyabean oil 
  6/6, 100%    6/6, 100% 
Linseed oil    6/6, 100%    6/6, 100% 
Salmon oil    6/6, 100%    5/6, 83% * 
Sunflower oil    6/6, 100%    6/9, 67% †** 
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20 
HF 
Beef tallow    6/6, 100%    6/6, 100% 
 
LF  low fat     *   one litter with 3 pups 
HF  high fat    ** two litters with 3 pups 
†  one female with no visible fetal development 
 
2.2 Tissue sample collection and storage 
Tissues collected from adult animals included blood, liver, adipose tissue (intra 
abdominal and subcutaneous), spleen, thymus, mandibular lymph nodes and pancreas.  
When dissecting pregnant females, the uterus was placed into ice cold phosphate 
buffered saline (PBS) until fetal dissection was performed.  Placentas were collected 
from pregnant females.  Tissues collected from fetal rats included blood, liver, brain, 
thymus, spleen, gut and pancreas.   
 
The mandibular lymph nodes were chosen for collection as they were readily identified, 
and would not be adversely affected during the collection of other organs.  Pancreas 
samples were sent to Peninsula Medical School for histological assessment as part of an 
ongoing collaboration(218) and no data on the pancreas are reported in this thesis. 
 
Samples collected for ex vivo cell culture were stored on ice until processed.  Samples 
collected for fatty acid composition analysis or reverse transcription PCR (RT PCR) 
analysis of mRNA expression were immediately snap frozen in liquid nitrogen and 
stored at  80
oC.   83 
2.3 Composition of experimental diets 
A low fat (LF) diet with soyabean oil (3% w/w) as the fat source was used as a control 
diet for virgin and pregnant animals.  This is a standard maintenance chow (RM[1]; 
Special Diet Services, Witham, Essex) which all animals received during their 
acclimatisation period.   
 
The high fat (HF) experimental diets used were custom made by Special Diet Services, 
Witham, Essex.  These diets were made from standard rat maintenance CRM(1) chow 
in which 10% of the diet wheat content was replaced with the fat or oil of choice.  These 
diets therefore provide an extra 10% (w/w) dietary fat in addition to the 3% (w/w) 
soyabean oil contained in the CRM(1).  The dietary fats and oils used were soyabean 
oil, sunflower oil, linseed oil, salmon oil and beef tallow.   
2.3.1 Gross energy content 
The gross energy contents of the diets used were estimated using the compositional 
information provided for the base diet by Special Diet Services and adjusting for the 
removal of wheat and additional lipid content using Atwater factors (see table 2.2).   
 
Table 2.2: Energy and macronutrient content of experimental diets 
  LF Soyabean oil  HF Experimental diets 
Carbohydrate (g/100 g) 
   (Fibre) 
   (Sugar) 
   (Starch) 
66.4 
(17.1) 
(4.1) 
(45.0) 
54.4 
(13.3) 
(3.4) 
(37.4) 
Ash (g/100 g)  6.00  6.3 
Moisture (g/100 g)  9.5 11.5  9.5 11.5 
Protein (g/100 g)  14.4  17.1 
Fat (g/100 g)  2.7  13.1 
Vitamin mix (mg/100 g) 
   (Vitamin E, IU/kg) 
44.9 
(84.1) 
46.1 
(190.2) 
Mineral mix (mg/100 g)  10.5  14.9 
Energy (MJ/100 g)  1.5  1.71 
 
2.3.2 Vitamin E content 
Analysis of the vitamin E content of the component oils used to create the experimental 
diets by the manufacturer revealed variation between them (see table 2.3).  Additional 
vitamin E was therefore added to the oils used to produce the salmon oil, beef tallow,   84 
soyabean oil and linseed oil diets in order to standardise the vitamin E content to the 
level found in sunflower oil.   
 
Table 2.3: Vitamin E content of the fats and oils used to prepare the high fat 
experimental diets, prior to normalisation of vitamin E content 
 
Fat or oil  Vitamin E content  
(IU/kg) 
Salmon oil  117 
Sunflower oil  874 
Beef Tallow  ND 
Soyabean oil  66.2 
Linseed oil  9.7 
ND indicates not detected 
 
2.3.3 Fatty acid composition 
The fatty acid composition of the diets was analysed using samples taken from five 
pellets per diet, with samples taken from both the exterior and interior of the pellets.  
The detailed results of the fatty acid analysis can be found in chapter 6.  All diets 
contained a base of 3% soyabean oil and therefore were sufficient in the supply of 
essential fatty acids (EFA) linoleic acid (LA; 18:2n 6) and α linolenic acid (ALNA; 
18:3n 3).   
 
The principal components of the five HF experimental diets were as follows: 
•  HF soyabean oil – a high fat diet with comparable fatty acid composition to 
standard laboratory rat chow (LF soyabean oil diet) 
•  HF Linseed oil diet – rich in the n 3 polyunsaturated fatty acid (PUFA) ALNA 
•  HF Salmon oil – rich in longer chain (LC) n 3 PUFA including 
eicosapentaenoic acid (EPA; 20:5n 3), docosapentaenoic acid (DPA; 22:5n 3) 
and docosahexaenoic acid (DHA; 22:6n 3) 
•  HF Sunflower oil – rich in the n 6 PUFA LA 
•  HF Beef tallow – rich in saturates and monounsaturated fatty acids (MUFA). 
2.3.4 Other macro/micronutrients 
Data provided by the diet manufacturer indicates that the diets contained a wide range 
of amino acids including arginine, lysine, methionine, cysteine, tryptophan, histidine, 
threonine, isoleucine, leucine, phenylalanine, valine, tyrosine, glycine, aspartic acid, 
glutamine acid, proline, serine and alanine.   85 
Macrominerals incorporated in the diets included calcium, phosphorous, sodium, 
chloride, potassium and magnesium.  Microminerals within the diets included iron, 
copper, manganese, zinc, cobalt, iodine, selenium and fluorine. 
 
In addition to vitamin E, the diets included vitamins A, B1, B2, B6, B12, C, D, K, folic 
acid, nicotinic acid, panthothenic acid, choline, inositol and biotin. 
2.4 Blood collection and processing 
Whole blood was collected from culled adult animals by cardiac puncture, with heparin 
used as an anti coagulant.  Fetal whole blood was collected by decapitation over a 
heparinised Petri dish.  Typically 2 5 ml of blood was collected from adult animals, and 
1 2 ml from each litter.  Blood samples were kept on ice until processing to obtain 
mononuclear cells and plasma, which was undertaken on the day of collection.   
 
To collect peripheral blood mononuclear cells (PBMC) and plasma, whole blood was 
layered onto histopaque (density 1.077 g/ml; Sigma Aldrich) in a 15 ml tube.  The 
volume of histopaque used was twice that of the blood sample.  Samples were then 
centrifuged at 2000 rpm for 15 min at 15
oC.  Figure 2.1 illustrates sample appearance 
before and after centrifugation. 
 
Figure 2.1: Illustration of method utilised to isolate plasma and mononuclear cells from 
whole blood samples 
 
 
 
 
 
 
 
 
 
After centrifugation plasma was collected and stored at  80
oC until analysis.  PBMC 
were collected from the interface, washed in culture medium (RPMI) and pelleted by 
centrifugation at 1500 rpm for 7 min.  Supernatant from pelleted cells was decanted, and 
PBMC resuspended in 1 ml of RPMI.  PBMC were then counted using a Beckman 
Before centrifugation  After centrifugation 
Whole blood 
Histopaque 
Plasma 
Mononuclear cells 
Red blood cells   86 
coulter counter.  After counting, PBMC were either stored as a pellet at  80
oC until fatty 
acid composition analysis, or resuspended for use in ex vivo cell cultures. 
2.5 Collection of mononuclear cells from lymphoid organs 
For tissue rinsing and short term storage prior to cell culture, RPMI culture medium 
with additional glutamine (final concentration 2 mM, PAA Labs) and penicillin 
streptomycin (final concentration 10 U/ml penicillin + 10  g/ml streptomycin, PAA 
Labs) was used.  Glutamine supports the growth of cells that have high energy demands 
and synthesize large amounts of proteins and nucleic acids.  Use of both penicillin and 
streptomycin is effective against both gram positive and gram negative bacteria, and is 
important as the rat organs used for cell culture preparations were collected in a non 
sterile environment. 
 
Lymphoid organs (spleen, thymus, lymph nodes) from dams and fetuses were 
immediately placed into RPMI and kept on ice until processing, which was undertaken 
on the day of collection.  Fetal tissues from each litter were pooled together and handled 
as one sample.  Organs were passed through a wire mesh strainer to produce a cell 
suspension.  This suspension was filtered through lens cleaning tissue (Whatman) to 
remove debris and centrifuged at 1000 rpm for 10 min to pellet the cells.  The cells were 
resuspended in 5 ml of RPMI, layered over 10 ml of histopaque, and processed as per 
the protocol for blood samples (section 2.4).   
2.6 Fatty acid analysis by gas chromatography 
2.6.1 Sample preparation 
Before samples are analysed for their fatty acid composition by gas chromatography 
they must undergo processing to extract their lipid content.  The lipid content can then 
be separated into various polar and non polar lipid fractions and the resulting lipids 
must be saponified and methylated prior to analysis by gas chromatography.  Figure 2.2 
outlines these steps. 
 
The fatty acid composition of plasma was assessed using a 0.2 ml aliquot of plasma 
diluted with 0.6 ml saline (0.9% NaCl).  For analysis of the fatty acid composition of 
liver, placenta, brain, adipose tissue and experimental diets, a weighed sample 
(approximately 100 mg) was homogenised in 0.8 ml saline.  Mononuclear cells 
collected from immune tissues were resuspended in 0.8 ml saline prior to analysis.     87 
 
Figure 2.2:  Flow chart of methodologies used in preparation of samples for analysis of 
fatty acid composition by gas chromatography (PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; TAG, triacylglycerol; NEFA, non esterified fatty acid; CE, 
cholesteryl ester) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemicals used for preparation of samples for gas chromatography were obtained from 
Fisher (chloroform, sodium chloride, methanol, hexane, and toluene), Sigma Aldrich 
(butylated hydroxytoluene [BHT], glacial acetic acid, sulphuric acid, potassium 
bicarbonate, potassium carbonate) and BDH Lab Supplies (ethyl acetate). 
 
Sample to be analysed 
Homogenisation if required  Addition of internal standards 
Total lipid extraction 
Total lipid extract 
Lipid class separation by solid phase extraction 
PC  PE  TAG  NEFA  CE 
Methylation and saponification 
Fatty acid methyl esters (FAME) 
Analysis by gas chromatography 
Removal of free 
cholesterol by solid 
phase extraction   88 
To extract lipid, samples were mixed with 5 ml chloroform:methanol (2:1 v/v 
containing 50 mg/L of the anti oxidant BHT) and 1 ml 1 M NaCl in a glass screw cap 
test tube.  Test tubes were vortexed thoroughly and centrifuged at 2,000 rpm for 10 min 
in order to separate the lower solvent lipid phase from the upper aqueous phase.   
 
The lower phase containing the lipid was collected, dried down at 40
oC under nitrogen 
gas and redissolved in 1 ml chloroform.  Individual lipid classes were separated by solid 
phase extraction using NH2 bonded silica cartridges.  Full details of this method are 
found in Burdge et al, 2000 (219).  The total lipid extract (dissolved in 1 ml chloroform) 
was applied to a NH2 bonded silica column.  Lipid fractions were then eluted by the 
addition of solvent mixtures of varying polarity and acidity.  For plasma samples 2 ml 
chloroform was used to elute CE and TAG from the column.  Then 2 ml of 
chloroform:methanol 60:40(v/v) was used to elute PC from the column.  Finally, NEFA 
were eluted from the column using 2 ml chloroform:methanol:glacial acetic acid 
(100:2:2 v/v/v).  The CE and TAG phase that had been collected was dried down at 
40
oC under nitrogen gas and re dissolved 1 ml in hexane.  A new NH2 bonded silica 
cartridge column was pre treated with hexane washes before applying the combined CE 
and TAG fraction.  CE was then eluted using 2 ml of hexane followed by TAG using 2 
ml hexane:chloroform:ethyl acetate (100:5:5 v/v/v).  
 
A similar approach was used for tissue samples, except that PC was eluted using 1 ml 
chloroform:methanol 60:40 (v/v) and then PE was eluted using 1 ml methanol.  NEFA 
were not collected from tissue samples, and CE and TAG fractions were not collected 
from brain or immune cell samples as phospholipids were the primary interest in these 
tissue types. 
 
The separated lipid classes were saponified and methylated in a simultaneous reaction 
involving the addition of 0.5 ml toluene and 1 ml of a methanol:sulphuric acid mixture 
(2% H2SO4 v/v) and incubation at 50
oC for 2 hr.  Samples were then neutralised with a 
solution containing 0.25 M potassium bicarbonate (KHCO3) and 0.5 M potassium 
carbonate (K2CO3).  The fatty acid methyl esters (FAME) produced were recovered 
using hexane. 
 
FAME were separated and analysed by gas chromatography on a HP6890 Hewlett 
Packard GC System with a BPX 70 column (Agilent Technologies).  Samples were run   89 
under the following conditions:  initial temperature: 115
oC; hold 2 min; increase 
temperature at 10
oC/min to 200
oC; hold 10min; increase temperature at 60
oC/min to 
245
oC; hold 4 min. 
2.6.2 Calibration and analysis 
Identification of FAME peaks in gas chromatograms was achieved by comparing the 
retention time of the peaks of interest with the known retention time of FAME 
standards.  To ensure identification of a wide range of FAME, standards were purchased 
(Sigma Aldrich, Nuchek) to enable identification and calibration of the FAME within 
samples of interest: 
 
•  Saturates – 12:0, 14:0, 16:0, 18:0, 20:0, 22:0 
•  MUFA – 16:1n 7, 18:1n 9, 20:1n 9, 24:1n 9 
•  n 6 PUFA – 18:2n 6, 18:3n 6, 20:2n 6, 20:3n 6, 20:4n 6, 22:5n 6 
•  n 3 PUFA – 18:3n 3, 20:4n 3, 20:5n 3, 22:5n 3, 22:6n 3 
 
It is possible that two fatty acids may elute at the same time under these run conditions.  
Selected samples of placenta PE were therefore analysed by mass spectrometry (by Prof 
Tony Postle, School of Medicine, University of Southampton) to confirm the identity of 
peaks under question.  For example, high levels of what was initially identified as 
lignoceric acid (24:0) were observed within the tissues of animals on the diets with the 
lowest n 3 fatty acid content.  Mass spectrometry confirmed that this was in fact 22:5n 
6, a finding supported by positive correlations of the percentage contribution of this 
fatty acid with other LC n 6 PUFA such as arachidonic acid (20:4n 6, AA), and inverse 
correlations with LC n 3 PUFA such as DHA.   
 
Other fatty acids which were found to co elute under the running conditions used over 
the course of experiments included 20:3n 9/AA, 22:4n 6/22:3n 9 and 21:0/20:2n 6. 
 
Figure 2.3 demonstrates how sample peaks were identified using standard mixtures of 
FAME.  Data are presented as the mean % contribution of each identified fatty acid 
(excluding internal standards).  Fatty acids with a mean % contribution of < 0.1% are 
labelled as ND (negligible detected).  90 
Figure 2.3: Example of method used to identify fatty acid methyl esters within samples using prepared calibration mixes 
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2.6.3 Removal of free cholesterol 
Free cholesterol causes problems with the functioning of the gas chromatograph by 
accumulating on the column, and also causes increased background “noise” on 
chromatograms, making peak identification more difficult and time consuming.  A 
method was therefore developed to separate FAME from cholesteryl ester (CE) samples 
after they had been saponified and methylated based upon methods detailed at (220). 
 
Samples were dissolved in 1 ml hexane and applied to a silica gel column which was 
pre treated by washing with hexane.  The sample was washed with 3 ml hexane to 
remove any hydrocarbon contamination.  FAME were collected using 2 ml of 
hexane:diethyl ether (95:5 v/v).  Free cholesterol remains within the silica gel column.   
 
This method was developed after testing various hexane:diethyl ether solutions for 
effectiveness of recovery (99:1, 98:2, 95:5, 90:10 v/v).  95:5 was found to give good 
recovery of FAME when compared to untreated samples (78 ± 8%).  The volume of 
hexane:diethyl ether (95:5 v/v) required for recovery of FAME was tested using 2 to 5 
ml.  All volumes gave similar recovery and so 2 ml was used.  Attempts were made to 
reduce the volume of hexane required for pre treatment washing but this was found to 
adversely affect the recovery of FAME.  Thin layer chromatography (using 
hexane:chloroform:diethyl ether:acetic acid 80:10:10:1.5 v/v/v/v) was performed which 
confirmed that this method removed free cholesterol from samples.  
 
The FAME compositions of samples with free cholesterol removed were assessed to 
ensure there was no FAME specificity associated with this purification step.  Treated 
samples in fact had the advantage of facilitating the detection of trace fatty acids by 
reducing background interference. 
 
Example gas chromatograph traces illustrating the reduction in background interference 
achieved using this method can be seen in figure 2.4.  92 
Figure 2.4: Comparative gas chromatograph traces obtained with identical samples to illustrate the benefits of free cholesterol removal 
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2.7 Plasma lipid and glucose analysis  
Samples of maternal and fetal plasma were sent to Dr John Jackson (Institute of Human 
Nutrition, Southampton General Hospital) for analysis of the concentrations of total 
cholesterol, HDL cholesterol, LDL cholesterol, TAG, NEFA and glucose.   
 
These assays were performed on a Konelab auto analyser using colorimetric kits from 
Konelab, Thermo Electron Corporation, and Wako Chemicals.  The detection limits for 
these assays were: glucose, 0.1 mM; HDL cholesterol, 0.04 mM; LDL cholesterol, 0.04 
mM; TAG, 0.02 mM; cholesterol, 0.1 mM.  The detection limit for the NEFA assay was 
not provided.  Maternal and fetal LDL cholesterol levels and fetal HDL cholesterol 
levels were below detection limits for the assays and so these results are not presented.   
2.8 Assessment of liver dry weight and lipid content 
Dry weights for tissues were assessed by allowing tissues to dry at 80
oC until no further 
change in tissue weight was observed (48 hr).  Liver lipid content was assessed by 
weighing the total lipid extract from a known weight of tissue. 
2.9 Assessment of circulating sex hormone concentrations 
Plasma samples were sent to Linda Ogilvie Goddard (Chemical Pathology 
Division, Southampton General Hospital) for analysis of plasma testosterone, 
progesterone and oestradiol concentrations.  These assays were performed using 
Beckman Coulter radio immunoassays with detection ranges of: oestradiol, 36.7 3670 
pM; testosterone, 0.35 52.1 nM; progesterone 0.48 90.8 nM. 
2.10 Assessment of liver glycogen content 
Amyloglucosidase enzyme, rabbit liver glycogen standard, and sodium citrate were 
obtained from Sigma Aldrich.  A method for liver glycogen assessment was developed 
based upon available publications(221;222).  This involved an enzyme digest of liver 
glycogen into glucose, analysis of glucose concentrations, then back calculation to 
determine original tissue glycogen content, controlling for any basal levels of glucose 
within the liver.   
 
A weighed sample (approximately 100 mg) of liver was homogenised in 1 ml of 100 
mM sodium citrate buffer (pH 5.0) and kept on ice.  The homogenised sample was 
placed into a boiling water bath for 1 5 minutes to inactivate any endogenous glycolytic   94 
enzymes.  The homogenate was divided into two equal aliquots.  One aliquot was 
incubated for 2 hr at 55
oC with 25  l of 5 mg/ml amyloglucosidase (sufficient to 
liberate 200 mg glucose from glycogen over the two hour incubation period).  The 
second aliquot underwent identical incubation conditions but with sodium citrate buffer 
added in place of the enzyme.  After incubation the samples were centrifuged at 13,000 
rpm for 10 min, and supernatants collected and sent for analysis of glucose 
concentration analysis by Dr John Jackson (see section 2.7).   
 
Samples of 1 mg/ml rabbit liver glycogen (with and without enzyme treatment) were 
run alongside each batch of samples analysed to ensure both the quality of the glycogen 
standard and enzyme activity.  “Blank” samples comprised of sodium citrate buffer 
(with and without enzyme treatment) were also analysed to ensure there was no 
contamination with glycogen or free glucose during sample preparation.  1 mg of 
glycogen generates 1.11 mg glucose when enzyme digested.  The glycogen content of 
liver was calculated as follows: 
 
Glycogen (mg/ml) = [(Glucose reading of enzyme treated aliquot) – (glucose reading of 
untreated sample)] x [(Expected glucose reading for glycogen standard) / (observed 
glucose reading for glycogen standard)] 
 
The glycogen concentration (mg/ml) was then used to calculate the % glycogen content 
of liver wet weight using the known weight of the liver sample which was initially 
homogenised in 1ml of buffer. 
 
2.11 Measurement of markers of immune function 
2.11.1 Flow cytometry 
Stains which would allow the identification within lysed whole blood of total T cells 
(CD3
+ cells), T helper cells (CD3
+/CD4
+ cells), cytotoxic T cells (CD3
+/CD8
+ cells), 
splenic macrophages (CD163
+ cells), natural killer cells (CD161
+ cells) and B cells 
(CD3
 /CD45RA
+ cells) in mononuclear cell samples were purchased from AbD Serotec.    95 
Stains were conjugated with fluorescein isothiocyanate (FITC) or R.phycoerythrin 
(RPE) as follows: 
  Single stains:  Anti rat CD163 FITC (IgG1) 
      Anti rat CD161 FITC (IgG1)
   
  Dual stains:   Anti rat CD3 FITC (IgM)/anti rat CD8 RPE (IgG1) 
  Anti rat CD3 FITC (IgM)/anti rat CD4 RPE (IgG1)  
Anti rat CD3 FITC (IgM)/anti rat CD45RA RPE (IgG1)  
  Controls:   Mouse anti human IgG1 conjugated to FITC 
Mouse anti human IgM conjugated to FITC 
      Mouse anti human IgG1 conjugated to RPE 
 
Heparinised whole blood (100  l per stain) or mononuclear cell suspensions obtained 
from the thymus, spleen or lymph nodes (1 x 10
6 cells in 100  l RPMI per stain) were 
used for flow cytometry.   
 
Cells were stained for 30 min at room temperature with 10  l of each of the antibodies 
detailed above.  Whole blood samples were then lysed using 2 ml FACS lysing solution 
(BD Biosciences) for a further 10 min.  All samples were centrifuged to pellet the cells 
(1000 rpm for 7 min) which were then washed twice in 2 ml PBS containing 1 g/L 
bovine serum albumin and 0.65 g/L sodium azide.  These washing steps serve to 
remove any unbound antibodies.   
 
Cells were fixed in PBS containing 2% (v/v) formaldehyde and stored at 4
oC until 
analysis.  Flow cytometry was performed on a Becton Dickinson FacsCalibur within 24 
hours of sample preparation.  10
5 events were recorded per sample and data analysed 
using CellQuest software.  An example of a forward scatter, side scatter plot (FSC, 
SSC), fluorescence plot and flow cytometry statistics is in figure 2.5. 
 
Controls and unstained samples were used to ensure that there was no significant 
autofluorescence or non specific binding of antibody to target cells.  Lymphocyte gates 
were used for analysis of maternal blood, spleen and lymph node data, and the data for 
these tissues is expressed as a % of gated cells.  The mean fluorescence intensity (MFI) 
of gated cells within each quadrant was used to indicate the relative expression of these 
markers upon the cell surface.  Lymphocyte gating was not required for maternal or 
fetal thymus, as the cells recovered were a pure lymphocyte population.  A threshold of 
100FSC was routinely set for all samples.  Lymphocyte gates were drawn as appropriate 
for each sample.  Quadrant and region settings for positive staining were kept consistent 
within each tissue type throughout all sample analysis.   96 
Figure 2.5: Example flow cytometry profiles from a maternal lysed whole blood sample 
following dual staining for CD3 and CD4 
.
File: 131blood.005 Log Data Units: Linear Values
Tube: CD3/4 Panel: caroline1
Acquisition Date: 6-Oct-6 Gate: G1
Gated Events: 5749 Total Events: 10000
X Parameter: FL1-H CD3 FITC (Log) Y Parameter: FL2-H CD4 PE (Log)
Quad Location: 5, 10
Quad Events % Gated % Total X Mean X Geo Mean Y Mean Y Geo Mean
UL 1129 19.64 11.29 1.35 1.24 241.94 203.54
UR 1996 34.72 19.96 19.84 17.54 552.52 516.44
LL 2033 35.36 20.33 2.03 1.85 1.80 1.59
LR 591 10.28 5.91 18.42 16.31 1.83 1.57
 
2.11.2 T Lymphocyte proliferation in mononuclear cell cultures 
 
Incorporation of 
3H thymidine into cultured mononuclear cells was used as a measure 
of the proliferative activity of these cells.  5 x 10
5 mononuclear cells from the spleen, 
thymus or blood were cultured in triplicate in RPMI supplemented with glutamine and 
penicillin/streptomycin (see section 2.5) at 37
oC in a 5% CO2 atmosphere in the 
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presence of the T cell stimulant Concanavalin A (Con A; final concentrations in the 
range 0 30  g/ml; this range was identified in pilot studies).  The final culture volume 
was 200  l/well and contained 5% fetal calf serum (FCS).  After 48 h, 0.2  Ci 
3H 
thymidine (20  l) was added to each well and the samples cultured for a further 18 h.  
Cells were then harvested onto glass fibre filters using a cell harvester.  Filters were 
dried, transferred to scintillation counting vials, 0.1 ml scintillant (Optiphase Hisafe, 
Perkin Elmer) added and radioactive incorporation measured as counts per minute 
(CPM) using a liquid scintillation counter.  Maximum potential incorporation was 
verified by direct counting of 0.2 Ci 
3H thymidine to ensure a sufficient excess of 
thymidine was available to proliferating cells. 
 
The CPM achieved by Con A stimulated cells was expressed relative to the CPM 
achieved by unstimulated cells, and termed the stimulation index (SI).  This SI was then 
adjusted for the proportion of CD3
+ cells (T cells, which are responsive to Con A) 
identified by flow cytometry within the mononuclear cell suspensions.  
2.11.3 Cytokine (IFN-γ γ γ γ, IL-4) and PGE2 production by mononuclear 
cell cultures 
5 x 10
6 mononuclear cells from the spleen, thymus or blood were cultured at 37
oC in a 
5% CO2 atmosphere with/without the T cell stimulant Con A (final concentration 5 
 g/ml).  The final culture volume was 2 ml/well and cultures contained 5% FCS.  After 
48 h, culture plates were centrifuged (1000 rpm, 7 min) and supernatants collected and 
stored at  80
oC until analysis.  
 
ELISA kits were used to assess the concentrations of interferon γ (IFN γ), interleukin 4 
(IL 4) and prostaglandin E2 (PGE2) within cell culture supernatants.  Kits used for IFN 
γ and IL 4 were obtained from Biosource, and kits for PGE2 from Oxford Biosystems.  
The sensitivities of the IFN γ and IL 4 ELISA kits were < 13 pg/ml and < 2 pg/ml, 
respectively.  No sensitivity information was provided with the PGE2 ELISA kit.  No 
cross reactivity was reported for IFN γ or IL 4 ELISA.  The PGE2 ELISA reported 
100% cross reactivity with PGA1, A2, B1, B2, and E1.  This means that prostaglandins 
detected in cell culture supernatants could be derived from AA or di homo γ linolenic 
acid (DGLA).  Cross reactivity with PGE3 (derived from EPA) was 17.7%. 
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Kits were used as per the manufacturer’s instructions, with the exception of the IL 4 
ELISA, where the following adaptations were made: cell culture supernatant samples 
were not diluted; IL 4 controls provided to generate standard curve were diluted in 
RPMI cell culture medium rather than the buffer provided. 
2.11.4 Use of fetal calf serum in cell culture 
Fetal calf serum (FCS) was used as a medium supplement for cell culture.  Autologous 
plasma was not used because of difficulties in consistently obtaining sufficient plasma 
from animals to meet the requirements of cell culture and other plasma analysis to be 
performed such as total lipid and fatty acid composition analysis.  
 
The fatty acid composition of FCS (Sigma Aldrich) was analysed by quantitative gas 
chromatography to assess whether the fatty acids present within FCS may affect ex vivo 
cell culture results.  Both LC n 6 and n 3 PUFA were detectable in FCS, but the fatty 
acids found in the greatest amounts in fetal calf serum were 16:0, 18:0 and 18:1n 9 (see 
Table 2.4). 
 
Table 2.4: Fatty acid composition of a total lipid extract of fetal calf serum used in cell 
culture preparations (mean ± standard deviation, n = 3) 
 
  % total fatty acids 
Final concentration  
in cell culture* (nM) 
16:0  25.9 ± 0.6  19.79 ± 1.02 
16:1n 7  2.5 ± 0.1  1.92 ± 0.13 
18:0  19.4 ± 0.3  13.35 ± 0.51 
18:1n 9  26.0 ± 0.6  18.02 ± 0.21 
18:2n 6  8.5 ± 0.3  5.93 ± 0.07 
20:3n 6  2.7 ± 0.1  1.71 ± 0.01 
20:4n 6  6.5 ± 0.3  4.19 ± 0.06 
22:5n 3  3.9 ± 0.8  2.31 ± 0.56 
22:6n 3  4.5 ± 0.3  2.68 ± 0.10 
 
*when used at 5% final culture volume 
 
The final working concentrations used in cell culture were calculated based upon the 
use of 5% FCS in cell cultures.  Separation of individual lipid classes demonstrated that 
the majority of the fatty acids were in the form of PC (~50%) or TAG (~34%).  These 
final culture concentrations are significantly lower than those used in similar 
proliferation and cytokine production experiments which have identified functional 
effects of fatty acids upon lymphocytes e.g. 1 – 100  M(223;224).   99 
2.12 Analysis of hepatic gene expression by two step RT-PCR 
2.12.1 RNA extraction 
RNA was extracted from 100 mg liver samples by homogenisation in 1 ml Trizol 
(Sigma).  Homogenates were transferred to eppendorf tubes and centrifuged (12,000 g, 
5 min, 4
oC) to pellet out any fibrous tissue residues/unhomogenised tissue.  
Supernatants were transferred to new eppendorf tubes, 0.2 ml chloroform added, and 
tubes shaken for 15 sec.  Samples were then incubated at room temperature for 2 3 min 
and centrifuged (12,000g, 15 min, 4
oC).    
 
The upper aqueous phase containing the RNA was transferred to a new eppendorf tube, 
and RNA precipitated by addition of 0.5 ml isopropyl alcohol and incubation for 10 
min.  The sample was centrifuged to produce an RNA pellet (12,000g, 15 min, 4
oC).  
Supernatant was removed, and the RNA pellet allowed to air dry for 5 10 min.  RNA 
was resuspended in diethyl pyrocarbonate (DEPC) treated water and stored at  80
oC. 
2.12.2 RNA quality assessment 
Spectophotometry was used to assess the concentration and purity of the RNA sample 
obtained by measuring absorbance at 260 nm and 280 nm.  An absorbance of 1 at 260 
nm is equivalent to 40  g/ml RNA.  Therefore if 2  l of the RNA sample was assessed 
in 500  l H20 in a 1 cm cuvette: 
A260 x 40  g/ml x (0.5 ml)   =   Total RNA in cuvette 
(Total RNA in cuvette) / 2   =   RNA in  g/ l in original sample 
 
The ratio of absorbance at 260 nm and 280 nm (A260/A280) is often used to assess the 
purity of the RNA preparation.  Samples diluted in DEPC (RNase deactivator) treated 
water had a mean ratio of 1.69 and were accepted as sufficiently pure for further 
analysis(225). 
 
Integrity of the RNA sample was checked by gel electrophoresis.  The vast majority of 
RNA within a sample will be 18S and 28S ribosomal (r) RNA.  Visualisation of two 
clear bands demonstrates that the rRNA has not been degraded (which would be 
indicated by a ‘smeared’ appearance), and so the messenger (m) RNA of interest is 
likely to be intact.  The ratio of absorbance of these two rRNA bands can also be used to 
check sample quality: the 28S band should be approximately twice as intense as the 18S   100 
band.  Samples were prepared for running on a 1% agarose gel containing ethidium 
bromide (1.5  l of 10mg/ml solution in 50 ml gel) for 30 min at 100V as follows: 
 
x  H20 
1  l   Northern loading buffer 
2  l   formamide 
y  1  g RNA     
(Total volume = 10  l) 
 
All samples were assessed for rRNA integrity and a mean 28S:18S ratio of 1.67 was 
achieved.  An example gel image achieved is in figure 2.6. 
 
Figure 2.6: Example gel electrophoresis of RNA samples to assess integrity 
 
 
2.12.3 cDNA production 
1  g RNA was used to synthesise cDNA using M MLV Reverse Transcriptase (Sigma).  
RNA was incubated at 70
oC for 10 min as below:  
1  l   10 mM dNTP mix (Sigma) 
1  l   Random nonamers/primers (Sigma/Promega) 
x  Doubly distilled H2O  
y   1  g RNA     
(Total volume = 10  l)  
Origin 
28S 
18S   101 
Samples were placed on ice and the reverse transcriptase enzyme was added as below:   
6.5  l  Doubly distilled H2O 
2  l  10 x M MLV Reverse Transcriptase Buffer 
1  l  M MLV Reverse Transcriptase 
0.5  l  RNase inhibitor (40 U/ l, Promega) 
 (Total volume = 10  l)  
 
Samples were incubated at room temperature for 10 min, then at 37
oC for 50 min.  
Samples were then heated to 94
oC for 10 min to denature the M MLV reverse 
transcriptase and stored at  20
oC. 
 
Template free and enzyme free controls were prepared at the same time as samples of 
interest with each cDNA production run. 
2.12.4 Selection of housekeeping genes  
Careful selection of housekeeping genes used to normalize RT PCR results is essential 
to ensure that their use as internal controls is appropriate.  This was particularly 
important for this thesis as some commonly used housekeeping genes have 
demonstrated significant sex differences in expression(226).  Housekeeping genes were 
selected using the 12 gene genNorm rat housekeeping gene kit (PrimerDesign Ltd, 
Southampton), and results assessed for the most stable gene using geNorm 
software(227). 12 samples including random samples from each experimental group 
were assessed by real time PCR for the 12 housekeeping genes provided in the kit (18S 
rRNA, ATP synthase, topoisomerase I, malate dehydrogenase 1, cytochrome C 1, 
calnexin, ribosomal protein L13, tyrosine 3 monooxygenase, β2 microglobulin, 
ubiquitin C, glyceraldehyde 3 phosphate dehydrogenase and β actin). 
 
Real time PCR was performed under conditions recommended by the genNorm kit with 
the below reaction mix: 
 
1  l   Resuspended primer mix (300nM working concentration) 
10  l   2 x qPCR Mastermix  
4  l   H20 
5  l   cDNA (1 in 10 dilution of cDNA product)       
(Total volume = 20  l)  
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Based on genNorm analysis results, the housekeeping genes selected as most stable for 
use were:  calnexin, tyrosine 3 monooxygenase and topoisomerase 1 (gender + diet 
study, chapter 3); calnexin, tyrosine 3 monooxygenase and β2 microglobulin 
(pregnancy study, chapter 4).  Topoisomerase 1 (NM_022615) is involved in 
‘uncoiling’ the strands of the DNA double helix to enable replication or transcription.  
Tyrosine 3 monooxygenase (NM_013011) is a protein which mediates signal 
transduction by binding to phosphoserine containing proteins.  β2 microglobulin 
(NM_012512) is a component of major histocompatability class I molecules.  Calnexin 
(NM_172008) retains unfolded or unassembled N linked glycoproteins within the 
endoplasmic reticulum. 
2.12.5 Dissociation curve analysis 
The specificity of all primers was assessed by dissociation curve analysis to determine 
the melting temperature of the nucleic acid sequences within each sample.  If a single 
product is generated, there will be a single melting temperature achieved after PCR.  No 
primer dimer formation was observed for the any primers at any of the cDNA 
concentrations used to generate the standard curve.  An example dissociation curve 
achieved for B2 microglobulin is in figure 2.7. 
 
Figure 2.7: Example dissociation curve (fluorescence as a function of temperature) 
achieved for B2 microglobulin, illustrating formation of a single product  
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2.12.6 PCR using SYBR green 
Primers for genes of interest were obtained from Qiagen: FADS1 (Fatty acid desaturase 
1,  5 desaturase, Rn_FADS1_1_SG); FADS2 (Fatty acid desaturase 2,  6 desaturase, 
Rn_FADS2_1_SG); Elongase 5 (Rn_Elovl5_1_SG).   
 
Real time PCR with SYBR green was undertaken using Applied Biosciences 7500 Fast 
Real time PCR System and Applied Biosciences Fast Plates (PN 4346906).  PCR 
reaction mixtures were prepared as below using a 30 l final volume in duplicate and 
run conditions are as described in table 2.5.  NTC (no template controls) were run on 
every PCR plate for every gene assessed. 
 
2  l   cDNA 
25  l   2 x Universal Master mix (Low Rox, Primer Design) 
1.5  l  SYBR green (Primer Design) 
5  l   10 x Qiagen primer 
x  l   H2O               
50  l total volume 
 
Table 2.5: Reaction conditions used on PCR plates for genes of interest   
    Time  Temp (
oC) 
  Enzyme activation  2 min 
10 min 
50 
95 
Denaturation  15 s  95  Cycling  
x 40  Data collection  1 min  60 
 
2.12.7 Data analysis 
mRNA content was quantified using the standard curve method.  A concentration curve 
of a random sample of RNA (2  g, 1  g, 0.5  g, 0.25  g, 0.125  g, 0.0625  g, 0.03125 
 g) was used to generate a standard curve of cDNA for use in PCR.  Standard curves 
were run for every gene on each PCR plate.  An example amplification plot for a 
standard curve is in figure 2.8.   104 
Figure 2.8: Example amplification plot achieved with real time PCR (standard curve for 
B2 microglobulin) 
 
Arbitrary values were applied to represent cDNA concentration (100, 50, 25, 12.5, 6.25, 
3.125, and 1.5625) and a standard curve of Ct values was generated.  Samples of 
interest were then quantified relative to the arbitrary values applied to the standard 
curve.  Genes of interest were expressed relative to the expression of the geometric 
mean of the three best housekeeping genes.  The analysis settings used for each gene are 
detailed in table 2.6. 
 
Table 2.6: Analysis settings used for PCR data 
    Rn threshold  Baseline 
β2 microglobulin  0.2  3 13 
Topoisomerase 1  0.2  3 15 
Calnexin  0.2  3 15 
Tyrosine 3 monooxygenase  0.2  3 15 
FADS2 ( 6 desaturase)  0.28  3 11 
FADS1 ( 5 desaturase)  0.2  3 15 
Elovl5 (Elongase 5)  0.248  3 15 
 
2.13 Power calculations and statistics 
SPSS version 15.0 was used for statistical analysis.  When SPSS boxplots are displayed, 
the graphs indicate the median, the interquartile range (box length), Tukey’s hinges   105 
(12.5   82.5
th percentile range, ‘whiskers’ of box), outliers (1.5 3 interquartile ranges 
from the end of a box, labelled as ‘o’) and extreme values (more than three inter quartile 
ranges from the end of a box, labelled as *). 
 
Data were assessed for differences between groups by one way or two way ANOVA 
with significant differences between groups determined using the Bonferroni correction 
for multiple comparisons applied to minimise the risk of a type I error (accepting a 
‘false positive’ result).  The level of statistical significance required was p < 0.05.   
 
Where parametric tests were not appropriate, such as when ordinal values were 
involved, differences between groups were assessed using the Kruskal Wallis test.  
Correlation coefficients (r) were calculated using Pearson or Spearman test as 
appropriate after data were assessed for normality. 
 
Where stepwise multiple regression analysis was performed, the significant variables 
and Beta values are provided.  Beta values are a measure of how strongly predictor 
variables influence the variable of interest, and are measured in units of standard 
deviation.  The Beta value indicates the change in standard deviations that will be 
observed in the variable of interest when the predictor variable changes by one standard 
deviation.  
 
It was important to consider the number of animals to be studied so that the 
investigation was suitably powered to identify significant effects, minimize the risk of a 
type II error (accepting a ‘false negative’ result) and avoiding the unnecessary use of 
animals.  The primary objective of the studies described in this thesis was to assess the 
effect of maternal dietary fatty acids during pregnancy upon maternal and fetal immune 
function.  The principal hypothesis is that changes in fetal immune function can be 
induced by altering the maternal or fetal availability of fatty acids with roles in immune 
mediator generation such as AA and EPA.  One low fat (3%) and five high fat (13%) 
experiment diets will be used, which vary in their n 6 and n 3 fatty acid contents.  
Power calculations were therefore determined using available data on the changes in 
tissue fatty acid composition that can be achieved by maternal diet during pregnancy.   
 
F values indicate the effect size of a statistical test, and are equivalent to the Z score of a 
standard deviation.  This means that the F value specifies how many standard deviations   106 
the mean of one group is from the mean of the other.  The sensitivity of a statistical test 
can be assessed by calculating the minimum effect size which will be found to be 
statistically significant given the sample size and power required.  F values (effect size) 
were calculated with G*Power (version 3.0.10) using data from a comparable rat study 
which assessed the changes in maternal and fetal rat tissue fatty acid composition in 
response to various 10% fat diets during pregnancy(228).  F values achieved for 
variations in mean AA content of maternal and fetal plasma, liver and placenta in this 
study were in the range 2.90 – 5.70, and for EPA 0.72   3.10.  
 
Using these F values a priori power tests for ANOVA indicate that for a study with 6 
dietary groups, a sample size of 12 (based on lowest AA F value) to 48 (based on lowest 
EPA F value) would be required for a power of 0.95.  A power of 0.80 is a commonly 
accepted arbitrary value for power, and this would be achieved using a sample size of 
12 (based on lowest AA F value) to 36 (based on lowest EPA F value).  My studies will 
therefore use a sample size of n = 6 per group to give a total sample size of 36 when 6 
different dietary interventions are used.  Table 2.7 summarises the effect size sensitivity 
of all the study designs which will be undertaken in this thesis.    
 
Table 2.7: F value sensitivity of the studies to be undertaken in this thesis 
  Gender study  
(chapter 3) 
Pregnancy study  
(chapters 4 & 5) 
Maternal diet  
in pregnancy  
(chapters 6 & 7) 
n = 
 
36  18  36 
groups  2 genders 
3 dietary groups 
 
3 pregnancy  
time points 
6 dietary groups 
F value sensitivity (power = 0.80)  0.48 (gender) 
0.54 (diet) 
 
0.81  0.65 
F value sensitivity (power = 0.95)  0.62 (gender) 
0.69 (diet) 
 
1.03  0.81 
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Chapter 3:  Gender and the fatty acid 
composition of rat tissues   108 
3.1 Introduction 
3.1.1 Aims and hypothesis for current investigation 
 
It is the aim of this study to investigate the effect of gender upon tissue n 3 fatty acid 
composition in rats, and whether any effects are mediated by sex hormones and/or the 
expression of genes for enzymes involved in endogenous synthesis of longer chain (LC) 
n 3 polyunsaturated fatty acid (PUFA).  In this study rats will therefore be used to 
examine the hypotheses that: 
 
a)  females rats have higher plasma levels of LC n 3 PUFA compared to males  
b)  gender differences are also apparent within metabolically relevant tissues such 
as the liver and adipose tissue.   
c)  plasma docosahexaenoic acid (DHA) content and desaturase and elongase gene 
expression within the liver are related to plasma sex hormone concentrations. 
d)  females will show a greater elevation in LC n 3 PUFA in response to an α 
linolenic acid (ALNA) rich diet than males as a result of gender differences in 
desaturase and elongase gene expression. 
3.1.2 Dietary sources and typical intakes of n-3 fatty acids 
The essential fatty acid (EFA) ALNA (18:3n 3) is found in green leaves, some seeds, 
nuts and cooking oils, with linseeds and linseed oil having a very high content.  The 
principal dietary source of the LC n 3 PUFA eicosapentaenoic acid (EPA; 20:5n 3), 
docosapentaenoic acid (DPA; 22:5n 3) and docosahexaenoic acid (DHA; 22:6n 3) is 
oily fish.   
 
The average dietary intake of total n 3 PUFA for adults in the UK is 2.27 g/day for 
males and 1.71 g/day for females(4).  For most people the majority of this is in the form 
of ALNA, as dietary intake of LC n 3 PUFA is highly dependent upon consumption of 
fish.  It is estimated that only 27% of UK adults habitually eat oily fish(7), with an 
anticipated population average intake of LC n 3 PUFA of about 0.1 to l.2 g/day(6). 
3.1.3 Endogenous synthesis of LC n-3 PUFA 
LC n 3 PUFA can be generated via endogenous synthesis pathways from the EFA 
ALNA.  This pathway also generates LC n 6 PUFA such as arachidonic acid (AA,   109 
20:4n 6) from the n 6 EFA linoleic acid (LA, 18:2n 6).  Endogenous synthesis 
primarily occurs in the liver, and the pathway is outlined in chapter 1 (figure 1.6).   
 
The ability of humans to convert ALNA into LC n 3 PUFA has been studied using two 
approaches: provision of substantially increased amounts of ALNA in the diet for a 
period of weeks to months(140;141) or the provision of ALNA which is labelled with 
stable isotopes for a shorter period of time(130;131;136 138).   
 
Increasing dietary ALNA intake in humans has been demonstrated to cause dose 
dependent increases in the EPA content of plasma phospholipids, indicating that the 
conversion of ALNA to EPA is reasonably efficient, and subject to the dietary 
availability of ALNA.  The relationship between increasing dietary ALNA and DHA 
status is less clear, with some studies reporting a reduction in DHA status with 
increasing dietary ALNA while other studies report no change(140;141).  There is 
limited data currently available to describe the effects that increased dietary ALNA may 
have upon LC n 3 PUFA status in women(142), and no data from non lactating women. 
 
Studies using stable isotope labelled ALNA gave the first indications that there are 
gender differences in the ability to synthesis LC n 3 PUFA from ALNA.  Young 
women were found to convert a greater proportion of ALNA into EPA and DHA over 
21 days compared to men(130;131).  However, these studies did not give insight into 
the extent to which any LC n 3 PUFA generated might have been incorporated into 
metabolically relevant tissues such as the liver and adipose tissue, as only blood 
samples were collected.  These studies also lacked information on whether the gender 
differences in the ability to synthesise LC n 3 PUFA had any significant effect upon the 
total circulating content of these fatty acids. 
 
Other studies have confirmed that there are gender differences in circulating plasma 
concentrations of LC n 3 PUFA in humans.  While these studies vary in sample size, the 
degree of dietary control exerted and the range of blood lipids analysed, all have found 
that women have significantly higher circulating DHA concentrations compared to men 
and that this is independent of dietary intake of n 3 fatty acids(132 135).   
 
Mechanisms which have been proposed to account for the gender differences observed 
in rates of LC n 3 PUFA synthesis and the circulating concentrations of these fatty acids   110 
include gender differences in rates of β oxidation(143), adipose tissue composition and 
mobilisation(133), the influences of sex hormones upon desaturase and elongase 
enzymes involved in the synthesis of LC n 3 PUFA(131), or gender differences in 
enzyme specificity during phospholipid biosynthesis(229). 
 
The lower rates of β oxidation of fatty acids in women may result in more dietary 
ALNA remaining available for conversion into LC n 3 PUFA.  Gender differences in 
subcutaneous adipose tissue composition have been observed in human studies(144), 
with women found to have significantly more DPA and DHA in adipose tissue 
compared to men, although these fatty acids remain relatively minor components of the 
total fatty acid content (< 0.3%).  The higher adiposity of women compared to men and 
the selective release of fatty acids from human adipose tissue (ALNA and EPA are 
preferentially released in comparison to other n 3 PUFA(37;145)) may further enhance 
gender differences in LC n 3 PUFA synthesis and circulating concentrations.     
 
A role for sex hormones in mediating the gender differences in ALNA conversion and 
the LC n 3 PUFA content of blood (and tissue) lipids has been hypothesised based upon 
studies of women using oral contraceptives(131;133;135), hormone replacement 
therapy (HRT)(135;147) and a study of sex hormone treatment in transsexual 
subjects(135).   
 
Women using oral contraceptives were identified as having a higher rate of conversion 
of stable isotope labelled ALNA into LC n 3 PUFA than women not using oral 
contraceptives(131).  Women using oral contraceptives have also been identified as 
tending to have higher circulating concentrations (non significant) of LC n 3 
PUFA(133;135).  Similarly, women using hormone replacement therapy (HRT), or 
male to female transsexual subjects receiving synthetic oestrogens were found to have 
significantly higher circulating concentrations of LC n 3 PUFA(135;147;148). 
 
It has been suggested that the gender differences in LC n 3 PUFA status may relate to 
the requirement for females of reproductive age to have sufficient capacity to transfer 
adequate DHA to the developing fetus, while maintaining their own tissue 
requirements(133).   111 
3.1.4 In vitro and animal studies of fatty acid desaturase activities 
 
There is evidence from animal studies that sex hormones influence the activity of the 
desaturase enzymes involved in the synthesis of LC PUFA.  However, work to date has 
been limited to the use of n 6 rather than n 3 fatty acids as a substrate for assessment of 
enzyme activities and has investigated the effect of short term hormone treatment rather 
than the potential influence of normal circulating physiological concentrations of sex 
hormones.   
 
The results of some of these studies have been counter intuitive to those which would 
be expected based upon observed human gender differences in fatty acid composition.  
For example, in vitro and ex vivo studies demonstrated that 17β oestradiol reduced  5 
and  6 desaturase activity(150;151).  Other studies have been more consistent with the 
observations from human studies, such as a study of male and female rats which found 
that testosterone treatment inhibited  6 and  5 desaturase activities(152), which 
supports the observation within female to male transsexual subjects that the 
administration of testosterone led to significantly reduced plasma DHA content(135).   
3.2 Methods 
This study sets out to identify whether there are gender differences in the plasma and 
tissue LC n 3 PUFA content of rat tissues, whether these differences are affected by the 
dietary availability of ALNA, and whether sex hormones or expression of desaturase 
and elongase genes are involved in mediating these gender differences.  This will be 
assessed by determination of the fatty acid composition of tissues including plasma, 
liver and adipose tissue by gas chromatography, measurement of plasma sex hormone 
concentrations, and the assessment of liver mRNA expression of desaturase and 
elongase enzymes by RT PCR. 
 
All animal work was carried out in accordance with the Home Office Animals 
(Scientific Procedures) Act (1986) (see section 2.1).  Experimental diets were provided 
ad libitum over a 20 day period, and tissues collected at the end of the dietary 
intervention.  Fatty acid composition of experimental diets and tissues was determined 
by gas chromatography (see section 2.6).  Plasma circulating sex hormones analysis was 
provided by Southampton General Hospital (see section 2.9).  mRNA expression of 
desaturase and elongase genes was determined by RT PCR (see section 2.12).     112 
 
The effects of diet and gender and diet*gender interactions upon tissue fatty acid 
composition, plasma sex hormones and mRNA expression were assessed by two way 
ANOVA.  Correlation coefficients were calculated using Pearson or Spearman test as 
appropriate after data were assessed for normality. 
 
3.3 Results 
3.3.1 Experimental diets 
 
Animals received the experimental diets over a 20 day period.  Three diets were used: a 
low fat (LF, 3% w/w) soyabean oil diet, and two high fat (HF, 13% w/w) diets, one rich 
in soyabean oil, the other rich in linseed oil (a rich source of ALNA).  The fatty acid 
composition of these diets was analysed (see table 3.1).  Further information upon the 
nutrient composition of these diets is available (see section 2.3). 
 
The LF soyabean oil diet is standard laboratory rat chow, which all animals were 
maintained on prior to the start of experiments.  This diet contains both n 6 and n 3 
EFA (LA and ALNA).  The HF soyabean oil diet was used to reflect the higher dietary 
fat intake of a Western human diet, while maintaining the relative contributions of LA 
and ALNA observed in the LF soyabean oil diet.  The HF linseed oil diet is ALNA rich 
at the expense of LA, and was used to assess whether increased dietary ALNA could 
modulate gender differences in LC n 3 PUFA status. 
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Table 3.1: Fatty acid composition of total lipid extracts obtained from experimental 
diets (% total fatty acids, mean ± standard deviation, n = 5) 
 
Fatty acid  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA  
P value 
14:0  0.2 ± 0.2  0.1 ± 0.0  ND  0.683 
16:0  19.0 ± 1.1 
a  12.9 ± 0.5 
b  8.6 ± 0.3 
c  < 0.001 
18:0  4.6 ± 1.0  4.6 ± 0.3  3.7 ± 0.2  0.097 
20:0  0.5 ± 0.6  0.3 ± 0.1  0.3 ± 0.1  0.672 
22:0  0.2 ± 0.2  0.1 ± 0.2  ND  0.409 
Total saturated  24.4 ± 0.8 
a  18.0 ± 0.5 
b  12.7 ± 0.2 
c  < 0.001 
16:1n 7  0.4 ± 0.4  0.2 ± 0.1  0.1 ± 0.0  0.254 
18:1n 9  14.0 ± 1.4 
a  21.1 ± 0.5 
b  20.7 ± 0.4 
b  < 0.001 
20:1n 9  0.3 ± 0.3  0.2 ± 0.1  0.2 ± 0.1  0.689 
Total MUFA  14.6 ± 2.0 
a  21.5 ± 0.5 
b   21.1 ± 0.5 
b  < 0.001 
18:2n 6  53.7 ± 2.0 
a  52.8 ± 0.7 
a  27.7 ± 2.9 
b  < 0.001 
18:3n 6  ND 
a  0.2 ± 0.1 
b  0.2 ± 0.1 
b  < 0.001 
20:2n 6  0.4 ± 0.7  ND  ND  0.355 
20:4n 6  0.1 ± 0.2  ND  ND  0.505 
22:5n 6  0.4 ± 0.4  0.2 ± 0.1  0.1 ± 0.1  0.225 
Total n 6 PUFA  54.7 ± 1.7 
a  53.2 ± 0.4 
a  27.7 ± 2.7 
b  < 0.001 
18:3n 3  5.9 ± 0.5 
a  6.9 ± 0.2 
a  38.0 ± 2.8 
b  < 0.001 
20:4n 3  0.1 ± 0.2  0.2 ± 0.2  0.1 ± 0.1  0.530 
20:5n 3  0.2 ± 0.2  ND  ND  0.179 
22:5n 3  ND  ND  ND    
22:6n 3  ND  ND  ND  0.397 
Total n 3 PUFA  6.3 ± 0.5 
a  7.3 ± 0.3 
a  38.5 ± 2.9 
b  < 0.001 
   
ND  negligible detected (mean <0.1%) 
a,b,c  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts 
 
3.3.2 Weight gain and food intake 
 
Animal weights were recorded every 7 days over the study period (see figure 3.1).  
Food intake was monitored by weighing food provided and remaining every 2 3 days in 
order to calculate energy intake and to ensure that the HF experimental diets were not 
unpalatable compared to the LF soyabean oil diet. 
 
A clear effect of gender upon percentage weight gain and food (and energy) intake was 
identified (see table 3.2 and 3.3), with males in all dietary groups gaining significantly 
more weight and consuming more food and energy over the study period compared to 
females.   
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Whilst all groups gained weight, they showed a reduced rate of weight gain with time.  
This is likely to be an effect of individual caging during the course of the experiments.  
Prior to the start of experiments animals were housed in groups of 6 or 7, and so their 
access to food would be limited by social interactions within the group.  Individual 
housing removes this constraint, perhaps causing the initial increase in food 
consumption and growth, which then stabilises as the animal becomes acclimatised to 
being housed individually. 
 
There were no significant differences in weighed food intake over the study period 
between the dietary groups.  As would be expected, this led to a significant effect of diet 
upon the total energy consumed, with the LF soyabean oil group having significantly 
lower energy intake compared to the HF diet groups.   
 
Figure 3.1: Weight of rats provided with experimental diets over 20 day feeding period 
(mean ± standard deviation, n=6) 
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(p = 0.029).   115 
 
 
 
 
Table 3.2: Weekly % weight gain of rats fed experimental diets (mean ± standard deviation, n = 6 for all groups) 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
  Male  Female  Male  Female  Male  Female  Diet  Gender  Diet*Gender 
Day 7  5.7 ± 0.9  2.8 ± 3.6  8.0 ± 1.6  4.1 ± 1.8  4.8 ± 1.9  4.0 ± 1.9  0.087  0.001  0.187 
Day 14  5.4 ± 0.7  3.8 ± 2.8  6.6 ± 0.5  3.1 ± 1.5  7.2 ± 0.8  3.5 ± 1.1  0.480  < 0.001  0.180 
Day 20  3.3 ± 1.6  0.3 ± 3.1  5.0 ± 0.5  1.2 ± 2.1  3.9 ± 1.1  3.3 ± 1.7  0.069  < 0.001  0.115 
 
 
 
Table 3.3: Food and energy consumption by rats fed experimental diets (mean ± standard deviation, n = 6 for all groups) 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
  Male  Female  Male  Female  Male  Female  Diet  Gender  Diet*Gender 
Food consumption (g)  442.4 ± 19.2  321.2 ± 19.1  420.6 ± 12.1  283.8 ± 25.6  400.3 ± 24.9  313.6 ± 23.1  0.077  < 0.001  0.020 
Energy consumption (MJ)  6.2 ± 0.3  4.7 ± 0.3  7.2 ± 0.2  4.9 ± 0.4  6.9 ± 0.4  5.4 ± 0.4  < 0.001  < 0.001  0.007 
 
Diet   Bonferroni post hoc tests for multiple comparisons: 
 
Energy consumption (MJ)   LF soyabean oil significantly different from HF soyabean oil (p = 0.002) and HF Linseed oil (p < 0.001) 
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3.3.3 Plasma fatty acid composition 
The fatty acid compositions of plasma phosphatidlycholine (PC), triacylglycerol 
(TAG), cholesteryl esters (CE) and non esterified fatty acids (NEFA) were 
assessed by gas chromatography.  Full details of the fatty acid composition of 
these plasma lipids are shown in tables 3.4 to 3.7.   
 
The effect of diet upon plasma fatty acid composition 
Diet had a significant effect upon the fatty acid composition of all plasma lipid 
fractions assessed (see tables 3.4 to 3.7).  The HF linseed oil (ALNA rich) diet 
group had significantly higher ALNA content of all plasma lipids examined.   
 
The content of LC n 3 PUFA was also affected by diet.  The HF linseed oil diet 
groups had the highest EPA content in all plasma lipid fractions (see figure 3.2 for 
PC).  This effect was not a simple function of the quantity of ALNA available, as 
the HF soyabean oil group had the lowest EPA content, suggesting that the 
synthesis of LC n 3 PUFA may be suppressed in rats by a either a high fat diet 
per se or a high LA diet, but that this can be overcome by increasing the ALNA 
content of the diet.  The effect of diet upon other LC PUFA in plasma lipids such 
as DHA was less clear.  There was some indication of reduced DHA status in the 
ALNA rich diet group (see figure 3.3 for PC).  These observations are in 
accordance with those in human studies, where increased dietary ALNA has been 
demonstrated to result in significantly increased plasma EPA status, but without 
an associated increase in plasma DHA status(44;140).  It is of interest that the 
DHA content of plasma PC is maintained in the HF soyabean oil diet, despite the 
dramatic reductions in EPA content observed.  This may indicate that plasma 
DHA in being maintained at the expense of EPA, and so contributes to the fall in 
EPA status, or alternatively that DHA is being mobilized from alternative sources 
such as adipose tissue in order to maintain plasma DHA content in the face of 
reduced rates of LC PUFA synthesis. 
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Figure 3.2: Graph to illustrate the relationship between the EPA content (% total 
fatty acids, n = 6) of plasma PC after a 20 day feeding period and the essential 
fatty acid content of the experimental diets 
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Figure 3.3: Graph to illustrate the relationship between the DHA content (% total 
fatty acids, n = 6) of plasma PC after a 20 day feeding period and the essential 
fatty acid content of the experimental diets 
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ALNA intake (g/100g diet): 
       0.16         0.90         4.97 
LA intake (g/100g diet): 
       1.46                 6.91                 3.63   118 
Table 3.4: Fatty acid composition (% total fatty acids, mean ± standard deviation, n = 6 for all groups) of plasma PC 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
Fatty acid  Male  Female  Male  Female  Male  Female  Diet  Gender  Diet*Gender 
14:0  0.30 ± 0.04  0.19 ± 0.11  0.22 ± 0.03  0.17 ± 0.02  ND  ND  < 0.001  0.034  0.257 
16:0  24.45 ± 0.94  20.71 ± 1.23  21.49 ± 0.68  18.39 ± 1.57  18.78 ± 1.20  15.79 ± 1.09  < 0.001  < 0.001  0.698 
18:0  18.48 ± 0.81  26.72 ± 1.62  21.77 ± 0.82  27.60 ± 1.55  20.93 ± 0.81  27.85 ± 1.59  0.001  < 0.001  0.081 
20:0  0.18 ± 0.12  0.23 ± 0.27  0.21 ± 0.06  0.16 ± 0.04  0.24 ± 0.19  0.18 ± 0.03  0.916  0.639  0.589 
22:0  0.11 ± 0.12  0.11 ± 0.18  0.16 ± 0.11  0.12 ± 0.10  0.12 ± 0.29  ND  0.560  0.371  0.747 
Total saturated  43.52 ± 1.41  47.96 ± 1.24  43.85 ± 1.21  46.43 ± 0.97  40.15 ± 0.91  43.90 ± 0.99  < 0.001  < 0.001  0.145 
16:1n 7  0.93 ± 0.26  0.80 ± 0.57  0.22 ± 0.06  0.12 ± 0.02  0.47 ± 0.37  0.24 ± 0.11  < 0.001  0.140  0.853 
18:1n 9  4.83 ± 0.50  4.27 ± 0.90  3.38 ± 0.31  2.85 ± 0.21  5.18 ± 0.56  3.68 ± 0.45  < 0.001  < 0.001  0.053 
20:1n 9  0.26 ± 0.11  0.14 ± 0.16  0.28 ± 0.15  0.17 ± 0.03  0.39 ± 0.14  0.22 ± 0.03  0.085  0.002  0.730 
24:1n 9  ND  ND  0.10 ± 0.09  ND  ND  ND  0.175  0.227  0.084 
Total MUFA  6.04 ± 0.76  5.26 ± 1.33  3.97 ± 0.37  3.14 ± 0.20  6.04 ± 0.80  4.14 ± 0.47  < 0.001  < 0.001  0.133 
18:2n 6  25.23 ± 0.94  20.08 ± 1.79  30.86 ± 1.36  25.61 ± 1.18  35.62 ± 1.57  28.82 ± 2.36  < 0.001  < 0.001  0.382 
18:3n 6  0.49 ± 0.48  1.18 ± 0.86  ND  ND  0.63 ± 0.70  0.26 ± 0.22  0.002  0.455  0.049 
20:2n 6  0.54 ± 0.08  0.45 ± 0.13  0.73 ± 0.41  ND  0.84 ± 0.18  0.68 ± 0.29  0.001  < 0.001  0.006 
20:3n 6  0.86 ± 0.26  0.79 ± 0.41  0.47 ± 0.14  0.45 ± 0.07  0.83 ± 0.13  0.84 ± 0.08  < 0.001  0.727  0.887 
20:4n 6  18.67 ± 2.00  16.14 ± 1.51  17.30 ± 0.73  19.36 ± 0.81  10.10 ± 0.85  11.80 ± 1.53  < 0.001  0.360  < 0.001 
22:5n 6  0.34 ± 0.20  0.72 ± 0.22  0.12 ± 0.07  ND  ND  0.10 ± 0.08  < 0.001  0.003  0.001 
Total n 6 PUFA  46.14 ± 1.62  39.36 ± 1.85  49.48 ± 1.12  45.60 ± 1.33  48.01 ± 0.40  42.51 ± 1.56  < 0.001  < 0.001  0.053 
18:3n 3  0.23 ± 0.08  0.20 ± 0.13  0.58 ± 0.25  0.26 ± 0.04  2.05 ± 0.19  1.67 ± 0.35  < 0.001  0.001  0.100 
20:5n 3  0.25 ± 0.18  1.06 ± 0.85  ND  ND  1.45 ± 0.27  2.61 ± 0.49  < 0.001  < 0.001  0.009 
22:5n 3  0.76 ± 0.07  0.95 ± 0.11  0.42 ± 0.07  0.61 ± 0.11  0.90 ± 0.07  1.22 ± 0.25  < 0.001  < 0.001  0.422 
22:6n 3  3.01 ± 0.27  5.22 ± 1.02  1.64 ± 0.15  3.91 ± 0.49  1.33 ± 0.12  3.86 ± 1.12  < 0.001  < 0.001  0.814 
Total n 3 PUFA  4.25 ± 0.16  7.41 ± 1.32  2.65 ± 0.36  4.83 ± 0.49  5.73 ± 0.35  9.36 ± 1.51  < 0.001  < 0.001  0.128 
 
ND  negligible detected (mean <0.1%)   119 
Table 3.5: Fatty acid composition (% total fatty acids, mean ± standard deviation, n = 6 for all groups) of plasma TAG 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
Fatty acid  Male  Female  Male  Female  Male  Female  Diet  Gender  Diet*Gender 
14:0  0.83 ± 0.20  0.77 ± 0.27  0.44 ± 0.28  0.33 ± 0.08  0.21 ± 0.10  0.25 ± 0.07  < 0.001  0.504  0.611 
16:0  26.55 ± 4.22  26.70 ± 2.76  16.47 ± 1.54  17.20 ± 1.85  11.27 ± 0.42  12.40 ± 1.28  < 0.001  0.399  0.877 
18:0  2.89 ± 0.56  5.26 ± 2.61  4.88 ± 2.64  4.16 ± 0.40  3.67 ± 0.50  3.80 ± 0.46  0.483  0.265  0.059 
20:0  0.18 ± 0.08  0.18 ± 0.33  0.23 ± 0.07  0.26 ± 0.05  0.21 ± 0.06  0.14 ± 0.09  0.428  0.825  0.717 
22:0  0.16 ± 0.09  0.46 ± 0.66  0.20 ± 0.03  0.15 ± 0.12  0.16 ± 0.08  ND  0.247  0.570  0.207 
Total saturated  30.60 ± 4.64  33.37 ± 4.24  22.23 ± 4.00  22.10 ± 1.95  15.52 ± 0.51  16.67 ± 1.00  < 0.001  0.243  0.543 
16:1n 7  3.73 ± 1.61  3.02 ± 1.17  0.25 ± 0.17  0.32 ± 0.08  0.44 ± 0.21  0.40 ± 0.14  < 0.001  0.412  0.462 
18:1n 9  20.89 ± 2.04  22.29 ± 3.90  19.12 ± 1.65  17.92 ± 1.24  20.31 ± 0.19  19.65 ± 0.67  0.003  0.820  0.258 
20:1n 9  0.47 ± 0.11  0.34 ± 0.17  0.25 ± 0.10  0.40 ± 0.14  0.28 ± 0.03  0.26 ± 0.06  0.018  0.989  0.018 
24:1n 9  ND  0.12 ± 0.18  ND  ND  ND  ND  0.187  0.311  0.055 
Total MUFA  25.09 ± 3.37  25.77 ± 4.71  19.66 ± 1.52  18.63 ± 1.20  21.03 ± 0.35  20.31 ± 0.64  < 0.001  0.674  0.679 
18:2n 6  33.53 ± 4.59  29.97 ± 3.76  46.73 ± 3.92  45.32 ± 1.86  26.83 ± 1.25  26.17 ± 1.17  < 0.001  0.077  0.496 
18:3n 6  0.54 ± 0.26  1.03 ± 0.64  0.16 ± 0.05  0.40 ± 0.04  0.23 ± 0.18  0.27 ± 0.44  0.001  0.031  0.291 
20:2n 6  0.48 ± 0.13  0.40 ± 0.22  0.19 ± 0.21  0.11 ± 0.17  0.23 ± 0.07  ND  < 0.001  0.060  0.848 
20:3n 6  0.35 ± 0.12  0.38 ± 0.30  0.34 ± 0.08  0.52 ± 0.07  0.22 ± 0.17  0.14 ± 0.13  0.002  0.388  0.148 
20:4n 6  3.32 ± 1.21  3.85 ± 1.10  2.62 ± 0.64  5.06 ± 1.29  1.19 ± 0.24  1.82 ± 0.59  < 0.001  0.001  0.028 
22:5n 6  0.44 ± 0.16  0.45 ± 0.29  ND  0.29 ± 0.16  ND  ND  < 0.001  0.084  0.106 
Total n 6 PUFA  38.66 ± 6.16  36.07 ± 4.54  50.09 ± 4.25  51.72 ± 1.57  28.69 ± 1.31  28.50 ± 1.17  < 0.001  0.756  0.387 
18:3n 3  2.64 ± 0.28  2.24 ± 0.38  5.44 ± 0.57  4.91 ± 0.40  29.57 ± 1.74  27.42 ± 3.50  < 0.001  0.069  0.353 
20:4n 3  0.10 ± 0.09  ND  ND  0.17 ± 0.29  0.18 ± 0.10  0.28 ± 0.21  0.048  0.344  0.316 
20:5n 3  0.53 ± 0.18  0.81 ± 0.67  0.62 ± 0.25  0.51 ± 0.07  2.37 ± 0.56  3.41 ± 1.35  < 0.001  0.083  0.116 
22:5n 3  0.80 ± 0.32  0.67 ± 0.33  0.77 ± 0.27  0.67 ± 0.13  1.63 ± 0.51  1.81 ± 1.07  < 0.001  0.951  0.731 
22:6n 3  1.57 ± 0.57  1.05 ± 0.56  1.15 ± 0.33  1.30 ± 0.23  1.01 ± 0.31  1.59 ± 0.82  0.915  0.696  0.041 
Total n 3 PUFA  5.65 ± 1.37  4.81 ± 0.86  8.04 ± 0.91  7.56 ± 0.38  34.75 ± 1.46  34.51 ± 1.29  < 0.001  0.171  0.801 
ND  negligible detected (mean <0.1%)   120 
 
Table 3.6: Fatty acid composition (% total fatty acids, mean ± standard deviation, n = 6 for all groups) of plasma CE 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
Fatty acid  Male  Female  Male  Female  Male  Female  Diet  Gender  Diet*Gender 
14:0  0.28 ± 0.06  0.19 ± 0.21  0.34 ± 0.22  0.23 ± 0.15  0.16 ± 0.17  0.12 ± 0.07  0.114  0.153  0.871 
16:0  11.14 ± 1.65  11.82 ± 3.69  9.38 ± 1.77  7.59 ± 1.32  10.28 ± 2.13  7.92 ± 1.48  0.006  0.129  0.211 
18:0  1.65 ± 0.55  3.05 ± 1.52  2.75 ± 1.74  2.02 ± 0.55  2.81 ± 0.80  2.76 ± 1.25  0.605  0.610  0.102 
Total saturated  13.11 ± 2.12  15.09 ± 5.27  12.53 ± 3.74  9.83 ± 1.90  13.29 ± 3.01  10.81 ± 2.46  0.113  0.352  0.175 
16:1n 7  0.65 ± 0.16  1.24 ± 0.57  0.61 ± 0.07  0.40 ± 0.06  0.37 ± 0.07  0.42 ± 0.05  < 0.001  0.103  0.002 
18:1n 9  6.70 ± 2.60  5.61 ± 2.42  7.40 ± 1.43  4.58 ± 0.92  9.43 ± 2.19  6.99 ± 2.17  0.025  0.005  0.574 
20:1n 9  ND  ND  ND  0.12 ± 0.27  ND  ND  0.436  0.501  0.653 
Total MUFA  7.37 ± 2.63  6.92 ± 2.72  8.06 ± 1.54  5.09 ± 1.21  9.82 ± 2.27  7.41 ± 2.19  0.085  0.014  0.359 
18:2n 6  26.01 ± 1.83  20.64 ± 2.03  30.46 ± 1.66  24.41 ± 1.50  36.90 ± 1.67  29.60 ± 1.56  < 0.001  < 0.001  0.390 
18:3n 6  0.54 ± 0.18  0.75 ± 0.14  0.29 ± 0.03  0.36 ± 0.04  0.30 ± 0.05  0.44 ± 0.08  < 0.001  < 0.001  0.327 
20:2n 6  ND  ND  ND  ND  ND  0.11 ± 0.13  0.029  0.794  0.957 
20:3n 6  0.36 ± 0.10  0.26 ± 0.20  0.23 ± 0.02  0.21 ± 0.12  0.34 ± 0.09  0.43 ± 0.04  0.007  0.740  0.109 
20:4n 6  49.93 ± 6.44  52.88 ± 5.90  45.95 ± 3.99  56.75 ± 3.05  27.68 ± 2.72  35.07 ± 5.99  < 0.001  < 0.001  0.182 
Total n 6 PUFA  76.86 ± 4.76  74.58 ± 7.16  76.92 ± 4.86  81.73 ± 2.95  65.32 ± 3.95  65.65 ± 4.64  < 0.001  0.574  0.241 
18:3n 3  0.55 ± 0.43  0.29 ± 0.06  1.29 ± 0.20  0.94 ± 0.12  5.79 ± 0.64  4.64 ± 1.49  < 0.001  0.021  0.254 
20:4n 3  0.20 ± 0.14  ND  ND  ND  0.25 ± 0.24  0.27 ± 0.08  < 0.001  0.154  0.065 
20:5n 3  0.73 ± 0.38  1.26 ± 0.44  0.36 ± 0.07  0.41 ± 0.07  4.74 ± 0.80  9.70 ± 2.27  < 0.001  < 0.001  < 0.001 
22:5n 3  ND  ND  ND  ND  ND  0.13 ± 0.07  0.001  0.794  0.152 
22:6n 3  1.18 ± 0.32  1.86 ± 0.49  0.79 ± 0.15  1.99 ± 0.16  0.72 ± 0.55  1.40 ± 0.29  0.012  < 0.001  0.162 
Total n 3 PUFA  2.66 ± 0.58  3.41 ± 0.76  2.48 ± 0.37  3.33 ± 0.10  11.57 ± 1.07  16.14 ± 2.12  < 0.001  < 0.001  < 0.001 
 
ND  negligible detected (mean <0.1%)   121 
Table 3.7: Fatty acid composition (% total fatty acids, mean ± standard deviation) of plasma NEFA 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
 
Fatty acid 
Male 
(n=5) 
Female 
(n=5) 
Male 
(n=5) 
Female 
(n=6) 
Male 
(n=6) 
Female 
(n=6) 
Diet  Gender  Diet*Gender 
14:0  0.82 ± 0.24  1.39 ± 0.40  1.02 ± 0.47  1.12 ± 0.35  0.58 ± 0.16  0.45 ± 0.03  < 0.001  0.100  0.037 
16:0  25.66 ± 1.86  28.66 ± 3.38  21.15 ± 2.96  21.92 ± 2.40  16.89 ± 1.67  16.22 ± 2.22  < 0.001  0.238  0.234 
18:0  30.55 ± 9.69  20.21 ± 5.73  32.30 ± 6.46  30.19 ± 2.99  25.01 ± 4.68  21.99 ± 5.45  0.014  0.021  0.249 
20:0  0.29 ± 0.41  0.35 ± 0.34  0.94 ± 0.15  0.93 ± 0.31  1.50 ± 0.38  0.57 ± 0.17  < 0.001  0.010  0.001 
22:0  0.97 ± 0.85  0.12 ± 0.23  0.28 ± 0.09  0.24 ± 0.05  0.71 ± 0.64  ND  0.360  0.003  0.106 
Total saturated  58.28 ± 10.94  50.73 ± 7.25  55.77 ± 5.40  54.44 ± 2.28  44.69 ± 6.36  39.27 ± 7.33  < 0.001  0.060  0.585 
16:1n 7  3.52 ± 1.70  2.22 ± 1.61  0.81 ± 0.44  0.18 ± 0.16  1.51 ± 0.30  0.82 ± 0.25  < 0.001  0.013  0.665 
18:1n 9  12.34 ± 3.24  16.32 ± 3.20  9.19 ± 0.64  9.72 ± 0.77  10.97 ± 1.40  11.72 ± 1.77  < 0.001  0.021  0.118 
20:1n 9  0.26 ± 0.25  ND  0.46 ± 0.23  0.29 ± 0.27  0.53 ± 0.17  0.56 ± 0.73  0.076  0.417  0.739 
24:1n 9  0.20 ± 0.44  0.10 ± 0.14  ND  ND  0.17 ± 0.28  ND  0.489  0.391  0.456 
Total MUFA  16.32 ± 4.63  18.72 ± 3.94  10.45 ± 0.85  10.26 ± 0.74  13.19 ± 1.13  13.11 ± 1.18  < 0.001  0.421  0.415 
18:2n 6  16.66 ± 5.22  20.14 ± 4.43  21.60 ± 2.81  22.14 ± 3.52  17.35 ± 2.87  18.41 ± 3.69  0.041  0.212  0.647 
18:3n 6  0.14 ± 0.31  0.56 ± 0.62  0.16 ± 0.14  0.26 ± 0.14  ND  0.21 ± 0.13  0.157  0.021  0.443 
20:2n 6  ND  ND  0.38 ± 0.12  0.30 ± 0.16  ND  0.12 ± 0.30  < 0.001  0.526  0.316 
20:3n 6  0.24 ± 0.22  0.11 ± 0.26  0.33 ± 0.18  0.24 ± 0.19  ND  0.31 ± 0.14  0.274  0.734  0.025 
20:4n 6  5.62 ± 1.05  5.33 ± 1.15  4.31 ± 0.53  4.74 ± 1.24  2.74 ± 0.45  3.21 ± 0.63  < 0.001  0.521  0.560 
22:5n 6  ND  0.11 ± 0.11  ND  0.39 ± 0.52  ND  ND  0.138  0.049  0.138 
Total n 6 PUFA  22.65 ± 6.42  26.33 ± 5.63  26.78 ± 3.24  28.06 ± 2.51  20.12 ± 3.22  22.27 ± 3.10  0.005  0.114  0.801 
18:3n 3  1.20 ± 0.76  1.77 ± 0.44  4.91 ± 1.49  4.88 ± 1.77  19.43 ± 2.34  21.53 ± 4.24  < 0.001  0.286  0.531 
20:4n 3  0.11 ± 0.18  ND  0.61 ± 0.09  0.72 ± 0.45  0.37 ± 0.44  0.22 ± 0.13  < 0.001  0.689  0.550 
20:5n 3  0.15 ± 0.25  0.46 ± 0.36  ND  ND  0.82 ± 0.21  1.33 ± 0.33  < 0.001  0.006  0.028 
22:5n 3  0.41 ± 0.12  0.39 ± 0.13  0.36 ± 0.23  0.33 ± 0.20  0.84 ± 0.30  1.19 ± 0.32  < 0.001  0.238  0.112 
22:6n 3  0.88 ± 0.27  1.59 ± 0.67  1.05 ± 0.22  1.31 ± 0.63  0.55 ± 0.32  1.08 ± 0.27  0.061  0.003  0.503 
Total n 3 PUFA  2.76 ± 1.26  4.22 ± 0.70  6.99 ± 1.89  7.25 ± 2.76  22.01 ± 2.83  25.35 ± 3.60  < 0.001  0.064  0.345 
 
ND  negligible detected (mean <0.1%)   122 
The effect of gender upon plasma fatty acid composition 
Significant effects of gender were observed upon fatty acid composition of all 
plasma lipid fractions (see tables 3.4 to 3.7).  A summary of the significant gender 
differences observed is given in table 3.8.   
 
Table 3.8: Summary of the significant (p < 0.05) effects of gender observed upon 
fatty acids within plasma lipid fractions 
 
  PC  TAG  CE  NEFA 
Males > Females  14:0       
  16:0       
        18:0 
        22:0 
        16:1n 7 
  18:1n 9    18:1n 9   
  20:1n 9       
  18:2n 6    18:2n 6   
  20:2n 6       
  18:3n 3    18:3n 3   
Females > Males  18:0       
        18:1n 9 
    18:3n 6  18:3n 6  18:3n 6 
      20:4n 6   
        22:5n 6 
  22:5n 3       
  22:6n 3    22:6n 3  22:6n 3 
Gender*Diet 
interactions 
      14:0 
        20:0 
      16:1n 7   
  18:3n 6       
    20:1n 9     
  20:2n 6       
        20:3n 6 
  20:4n 6  20:4n 6     
  20:5n 3    20:5n 3  20:5n 3 
    22:6n 3     
 
Males were observed to have higher plasma contents of the EFA LA and ALNA 
across all dietary groups.  This may suggest that more EFA are being utilised for 
LC PUFA synthesis in females than in males.  Males also had higher plasma 
18:1n 9 content compared to females.  This fatty acid can be endogenously 
synthesised by the action of  9 desaturase upon 18:0, and so may indicate greater 
 9 desaturase activity within males compared to females.   123 
Females had higher plasma contents of 18:3n 6 and DHA across all dietary 
groups.  These data correspond well with the gender effects that have been 
identified in human studies, in particular, that females have significantly higher 
DHA content of plasma lipids compared to males, independent of diet(132 135).  
 
Several plasma fatty acids exhibited gender diet interactions.  The complex 
relationship between diet and gender upon plasma fatty acid composition is well 
illustrated by the AA content of plasma PC.  In the LF soyabean oil group males 
had a higher AA content.  HF feeding reversed this relationship, and HF linseed 
oil feeding resulted in significantly lower plasma AA content (see figure 3.4). 
 
Figure 3.4: Graph to illustrate the interaction between gender and diet upon the 
AA content (% total fatty acids, n = 6) of plasma PC after a 20 day feeding period 
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It is clear that the effect of dietary ALNA upon LC PUFA status differs between 
male and female rats.  For example, the EPA content of plasma lipids was 
increased in both male and female rats by the HF linseed oil diet, but the extent of 
this dietary effect was greater in females, indicating that females may be more 
responsive to a ALNA rich diet (see figure 3.5).  The same trend was also 
apparent upon DPA status, but not DHA status.   124 
Figure 3.5: The effect of gender upon the EPA content of plasma lipids (% total 
fatty acids) observed in response to dietary ALNA (mean HF linseed – mean HF 
soyabean) after a 20 day feeding period 
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3.3.4 Liver fatty acid composition 
 
The diet and gender relationships which were identified in plasma lipids were also 
reflected in liver lipid fatty acid composition (see tables 3.9 to 3.12).   
 
The ALNA rich HF linseed oil diet group demonstrated the highest ALNA and 
EPA contents in all liver lipid fractions examined.  There was also a higher 
content of DPA in liver lipids of the HF linseed oil group compared to the other 
dietary groups, and this was more pronounced than was observed within plasma 
lipids.  This may reflect the role of the liver as a primary site of LC PUFA 
synthesis, and it is possible that a longer feeding intervention might result in this 
effect of diet upon DPA status also being detectable within plasma lipids.  The HF 
linseed oil diet did not increase the DHA content of liver lipids. 
 
Gender demonstrated numerous significant effects upon liver fatty acid 
composition, particularly within liver phospholipids (PC and PE).  These effects 
were comparable to those observed within plasma lipids, with males having   125 
higher EFA (LA and ALNA) and 18:1n 9 contents compared to females, and 
females having higher DHA content.   
 
Males had significantly higher AA content compared to females in liver PC, PE 
and TAG.  This indicates that gender does not exert a simple effect upon the 
synthesis of all LC PUFA, as LC n 3 and n 6 PUFA demonstrate differential 
effects of gender.  
 
Strong and statistically significant correlations were identified between plasma 
and liver lipid fatty acid composition (see table 3.13), which supports a role of the 
liver in the maintenance of the fatty acid composition of plasma lipids, 
particularly for LC n 3 PUFA such as DHA (see figure 3.6). 
 
 
 
   126 
Table 3.9: Fatty acid composition (% total fatty acids, mean ± standard deviation, n = 6 for all groups) of liver PC 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
Fatty acid  Male  Female  Male  Female  Male  Female  Diet  Gender  Diet*Gender 
14:0  0.37 ± 0.06  0.22 ± 0.03  0.17 ± 0.04  0.10 ± 0.01  0.14 ± 0.01  0.11 ± 0.02  < 0.001  < 0.001  0.001 
16:0  22.70 ± 1.23  18.39 ± 0.67  17.52 ± 0.73  14.06 ± 1.11  16.31 ± 0.91  12.31 ± 0.62  < 0.001  < 0.001  0.514 
18:0  19.53 ± 0.93  28.62 ± 1.45  23.73 ± 0.93  30.32 ± 1.54  22.04 ± 1.07  29.66 ± 0.74  < 0.001  < 0.001  0.040 
20:0  ND  ND  0.22 ± 0.01  0.20 ± 0.06  0.16 ± 0.03  0.14 ± 0.02  < 0.001  0.153  0.955 
22:0  ND  ND  0.11 ± 0.04  0.08 ± 0.07  0.15 ± 0.02  ND  < 0.001  0.003  0.458 
Total saturated  42.71 ± 1.31  47.26 ± 1.13  41.73 ± 0.74  44.77 ± 0.87  38.80 ± 0.45  42.30 ± 0.29  < 0.001  < 0.001  0.110 
16:1n 7  1.36 ± 0.47  0.61 ± 0.21  0.06 ± 0.01  0.09 ± 0.06  0.20 ± 0.05  0.13 ± 0.04  < 0.001  0.001  < 0.001 
18:1n 9  4.20 ± 0.37  3.30 ± 0.48  3.21 ± 0.31  2.25 ± 0.31  4.74 ± 0.51  2.86 ± 0.18  < 0.001  < 0.001  0.005 
20:1n 9  0.14 ± 0.04  0.12 ± 0.15  0.30 ± 0.10  0.26 ± 0.10  0.28 ± 0.04  0.27 ± 0.06  < 0.001  0.348  0.951 
24:1n 9  ND  ND  0.01 ± 0.03  0.03 ± 0.05  ND  ND  0.565  0.655  0.442 
Total MUFA  5.71 ± 0.80  4.03 ± 0.72  3.58 ± 0.32  2.62 ± 0.41  5.23 ± 0.51  3.29 ± 0.21  < 0.001  < 0.001  0.084 
18:2n 6  16.47 ± 0.59  12.40 ± 1.22  18.05 ± 1.76  13.26 ± 0.77  23.99 ± 0.71  17.13 ± 1.81  < 0.001  < 0.001  0.027 
18:3n 6  0.23 ± 0.06  0.35 ± 0.08  0.17 ± 0.02  0.17 ± 0.05  0.15 ± 0.02  0.17 ± 0.02  < 0.001  0.009  0.009 
20:2n 6  0.50 ± 0.12  0.31 ± 0.06  1.62 ± 0.24  1.10 ± 0.21  0.83 ± 0.16  0.47 ± 0.13  < 0.001  < 0.001  0.067 
20:3n 6  1.00 ± 0.28  1.06 ± 0.13  0.68 ± 0.07  0.66 ± 0.08  1.20 ± 0.11  1.19 ± 0.17  < 0.001  0.817  0.811 
20:4n 6  26.38 ± 2.30  24.33 ± 1.24  28.72 ± 1.31  27.28 ± 1.15  18.69 ± 0.93  18.21 ± 1.63  < 0.001  0.012  0.441 
22:5n 6  0.38 ± 0.20  0.17 ± 0.19  0.17 ± 0.04  0.26 ± 0.11  0.24 ± 0.01  0.27 ± 0.15  0.495  0.494  0.028 
Total n 6 PUFA  44.96 ± 1.87  38.62 ± 2.02  49.41 ± 1.00  42.73 ± 1.44  45.10 ± 1.00  37.44 ± 2.01  < 0.001  < 0.001  0.589 
18:3n 3  ND  0.13 ± 0.11  0.29 ± 0.07  0.22 ± 0.04  1.66 ± 0.15  1.16 ± 0.17  < 0.001  < 0.001  < 0.001 
20:4n 3  ND  ND  0.17 ± 0.10  0.16 ± 0.24  0.19 ± 0.03  0.24 ± 0.04  0.006  0.795  0.415 
20:5n 3  0.43 ± 0.22  0.71 ± 0.15  0.21 ± 0.05  0.20 ± 0.03  4.05 ± 0.48  5.73 ± 0.80  < 0.001  < 0.001  < 0.001 
22:5n 3  1.11 ± 0.17  1.34 ± 0.08  0.93 ± 0.13  1.04 ± 0.13  1.82 ± 0.23  2.12 ± 0.33  < 0.001  0.003  0.499 
22:6n 3  4.90 ± 0.34  7.90 ± 1.12  3.68 ± 0.65  8.26 ± 1.02  3.15 ± 0.15  7.72 ± 1.37  0.041  < 0.001  0.059 
Total n 3 PUFA  6.62 ± 0.54  10.09 ± 1.06  5.28 ± 0.73  9.88 ± 1.33  10.86 ± 0.60  16.97 ± 1.92  < 0.001  < 0.001  0.027 
ND  negligible detected (mean <0.1%)   127 
Table 3.10: Fatty acid composition (% total fatty acids, mean ± standard deviation, n = 6 for all groups) of liver PE 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
Fatty acid  Male  Female  Male  Female  Male  Female  Diet  Gender  Diet*Gender 
16:0  19.33 ± 1.50  18.41 ± 0.64  14.68 ± 0.53  14.88 ± 1.04  11.90 ± 0.60  11.80 ± 0.32  < 0.001  0.339  0.270 
18:0  21.52 ± 1.17  26.77 ± 0.59  24.99 ± 0.93  27.49 ± 1.31  24.95 ± 1.25  28.92 ± 0.82  < 0.001  < 0.001  0.014 
20:0  ND  ND  0.18 ± 0.04  0.12 ± 0.03  0.13 ± 0.01  0.14 ± 0.06  < 0.001  0.039  0.164 
Total saturated  40.97 ± 0.99  45.20 ± 0.41  39.87 ± 0.93  42.52 ± 1.60  37.04 ± 0.84  40.93 ± 0.82  < 0.001  < 0.001  0.146 
16:1n 7  0.80 ± 0.26  0.33 ± 0.09  0.13 ± 0.02  0.04 ± 0.05  0.17 ± 0.11  0.15 ± 0.06  < 0.001  < 0.001  < 0.001 
18:1n 9  3.16 ± 0.52  2.17 ± 0.38  4.92 ± 0.65  2.93 ± 0.41  5.50 ± 0.57  2.96 ± 0.25  < 0.001  < 0.001  0.002 
20:1n 9  0.14 ± 0.06  0.22 ± 0.13  0.30 ± 0.04  0.14 ± 0.01  0.25 ± 0.03  0.29 ± 0.08  0.019  0.468  < 0.001 
Total MUFA  4.10 ± 0.46  2.72 ± 0.43  5.35 ± 0.69  3.11 ± 0.42  5.92 ± 0.61  3.40 ± 0.30  < 0.001  < 0.001  0.031 
18:2n 6  9.62 ± 1.13  6.40 ± 0.95  14.16 ± 0.93  8.39 ± 0.79  14.12 ± 0.89  8.59 ± 1.11  < 0.001  < 0.001  0.007 
18:3n 6  0.15 ± 0.03  0.21 ± 0.08  0.17 ± 0.04  ND  0.12 ± 0.01  0.12 ± 0.03  0.003  0.220  0.001 
20:2n 6  0.34 ± 0.12  0.22 ± 0.03  1.29 ± 0.23  0.73 ± 0.19  0.16 ± 0.04  ND  < 0.001  < 0.001  < 0.001 
20:3n 6  0.68 ± 0.11  0.61 ± 0.07  0.57 ± 0.03  0.48 ± 0.08  0.83 ± 0.07  0.71 ± 0.11  < 0.001  0.002  0.676 
20:4n 6  31.14 ± 0.79  25.80 ± 0.68  28.67 ± 0.70  25.66 ± 1.57  23.47 ± 1.54  19.75 ± 1.97  < 0.001  < 0.001  0.120 
22:5n 6  0.35 ± 0.77  ND  ND  ND  0.20 ± 0.02  0.21 ± 0.03  0.196  0.259  0.256 
Total n 6 PUFA  42.49 ± 0.93  33.24 ± 1.60  44.90 ± 1.23  35.76 ± 2.48  38.72 ± 1.27  29.26 ± 2.63  < 0.001  < 0.001  0.977 
18:3n 3  0.15 ± 0.01  0.23 ± 0.03  0.39 ± 0.08  0.27 ± 0.02  1.72 ± 0.14  1.44 ± 0.30  < 0.001  0.043  0.020 
20:4n 3  0.56 ± 0.12  ND  ND  0.45 ± 0.22  ND  ND  < 0.001  0.188  < 0.001 
20:5n 3  0.47 ± 0.14  0.49 ± 0.09  0.37 ± 0.07  0.25 ± 0.05  6.04 ± 0.63  6.48 ± 0.94  < 0.001  0.491  0.340 
22:5n 3  2.37 ± 0.22  3.00 ± 0.21  2.09 ± 0.24  2.17 ± 0.24  4.06 ± 0.41  4.20 ± 0.61  < 0.001  0.027  0.153 
22:6n 3  9.10 ± 0.86  15.11 ± 1.86  7.02 ± 0.94  15.93 ± 1.18  6.31 ± 0.36  14.09 ± 1.81  0.005  < 0.001  0.040 
Total n 3 PUFA  12.44 ± 0.83  18.84 ± 1.66  9.87 ± 1.02  18.61 ± 1.28  18.32 ± 0.90  26.41 ± 2.22  < 0.001  < 0.001  0.148 
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Table 3.11: Fatty acid composition (% total fatty acids, mean ± standard deviation) of liver TAG 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
 
Fatty acid 
Male 
(n=6) 
Female 
(n=6) 
Male 
(n=5) 
Female 
(n=5) 
Male 
(n=6) 
Female 
(n=6) 
Diet  Gender  Diet*Gender 
14:0  1.37 ± 0.48  1.03 ± 0.23  0.50 ± 0.05  0.44 ± 0.06  0.32 ± 0.05  0.32 ± 0.06  < 0.001  0.106  0.159 
16:0  31.41 ± 6.18  31.75 ± 3.86  18.29 ± 0.47  20.47 ± 1.76  13.37 ± 0.48  14.98 ± 0.79  < 0.001  0.219  0.783 
18:0  2.70 ± 0.36  3.88 ± 1.06  1.64 ± 0.14  2.68 ± 0.37  1.90 ± 0.32  2.48 ± 0.49  < 0.001  < 0.001  0.392 
20:0  0.12 ± 0.09  0.17 ± 0.14  0.06 ± 0.01  0.06 ± 0.06  0.60 ± 0.27  0.74 ± 0.15  < 0.001  0.243  0.591 
22:0  ND  ND  0.06 ± 0.04  0.01 ± 0.02  0.20 ± 0.03  0.10 ± 0.05  < 0.001  < 0.001  0.570 
Total saturated  35.69 ± 6.90  36.83 ± 4.77  20.54 ± 0.53  23.66 ± 1.77  16.39 ± 0.47  18.62 ± 1.10  < 0.001  0.096  0.818 
16:1n 7  5.28 ± 2.52  3.33 ± 1.22  0.56 ± 0.09  0.57 ± 0.19  0.47 ± 0.14  0.45 ± 0.12  < 0.001  0.122  0.094 
18:1n 9  21.63 ± 2.21  27.18 ± 3.58  14.89 ± 0.67  15.67 ± 1.34  17.43 ± 1.20  16.55 ± 0.59  < 0.001  0.011  0.001 
20:1n 9  0.43 ± 0.07  0.23 ± 0.19  0.19 ± 0.08  0.28 ± 0.05  0.24 ± 0.04  0.18 ± 0.03  0.009  0.126  0.004 
Total MUFA  27.34 ± 4.17  30.74 ± 4.21  15.64 ± 0.58  16.53 ± 1.47  18.14 ± 1.27  17.18 ± 0.60  < 0.001  0.232  0.146 
18:2n 6  26.03 ± 7.12  24.18 ± 2.88  47.12 ± 0.68  44.16 ± 0.57  28.70 ± 0.90  26.32 ± 1.08  < 0.001  0.045  0.926 
18:3n 6  0.36 ± 0.09  0.56 ± 0.15  0.69 ± 0.07  0.65 ± 0.09  0.29 ± 0.06  0.33 ± 0.07  < 0.001  0.056  0.024 
20:2n 6  0.58 ± 0.14  0.47 ± 0.18  0.64 ± 0.33  0.54 ± 0.28  0.36 ± 0.06  0.27 ± 0.07  0.005  0.167  0.989 
20:3n 6  0.41 ± 0.16  0.48 ± 0.17  0.92 ± 0.07  1.04 ± 0.26  0.38 ± 0.04  0.43 ± 0.08  < 0.001  0.110  0.850 
20:4n 6  3.94 ± 1.39  3.41 ± 1.15  3.84 ± 0.36  4.85 ± 0.55  1.29 ± 0.26  1.68 ± 0.43  < 0.001  0.317  0.110 
22:5n 6  0.47 ± 0.21  ND  0.25 ± 0.07  0.49 ± 0.21  ND  ND  < 0.001  0.081  < 0.001 
Total n 6 PUFA  31.79 ± 8.91  29.11 ± 4.30  53.46 ± 0.54  51.73 ± 1.36  31.01 ± 1.16  29.03 ± 1.04  < 0.001  0.159  0.963 
18:3n 3  1.61 ± 0.37  1.51 ± 0.29  4.17 ± 0.36  3.74 ± 0.23  21.75 ± 1.71  23.00 ± 2.24  < 0.001  0.565  0.236 
20:4n 3  0.35 ± 0.85  ND  0.16 ± 0.01  0.12 ± 0.03  0.67 ± 0.10  0.85 ± 0.12  < 0.001  0.611  0.222 
20:5n 3  0.47 ± 0.19  0.39 ± 0.14  1.21 ± 0.23  0.63 ± 0.16  4.45 ± 0.70  4.21 ± 0.43  < 0.001  0.026  0.306 
22:5n 3  1.06 ± 0.41  0.66 ± 0.20  2.27 ± 0.22  1.47 ± 0.31  4.84 ± 0.73  4.17 ± 0.57  < 0.001  < 0.001  0.567 
22:6n 3  1.69 ± 0.70  0.74 ± 0.13  2.54 ± 0.32  2.11 ± 0.49  2.74 ± 0.58  2.94 ± 0.45  < 0.001  0.027  0.026 
Total n 3 PUFA  5.18 ± 1.17  3.31 ± 0.63  10.34 ± 0.62  8.07 ± 1.08  34.36 ± 2.11  35.18 ± 1.09  < 0.001  0.013  0.015 
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Table 3.12: Fatty acid composition (% total fatty acids, mean ± standard deviation) of liver CE 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
 
Fatty acid 
Male 
(n=6) 
Female 
(n=6) 
Male 
(n=5) 
Female 
(n=5) 
Male 
(n=6) 
Female 
(n=6) 
Diet  Gender  Diet*Gender 
14:0  0.52 ± 0.35  0.61 ± 0.20  0.40 ± 0.08  0.31 ± 0.18  0.17 ± 0.04  0.23 ± 0.05  < 0.001  0.797  0.554 
16:0  36.69 ± 4.18  43.69 ± 3.16  31.55 ± 5.06  46.70 ± 4.86  20.11 ± 1.85  23.41 ± 2.21  < 0.001  < 0.001  0.003 
18:0  23.27 ± 3.62  21.07 ± 3.48  8.37 ± 3.10  13.78 ± 3.18  16.03 ± 3.10  22.13 ± 3.74  < 0.001  0.013  0.010 
20:0  ND  0.26 ± 0.32  ND  ND  ND  ND  0.354  0.100  0.066 
Total saturated  60.49 ± 7.03  65.62 ± 3.58  40.35 ± 7.96  60.84 ± 6.51  36.38 ± 4.88  45.84 ± 5.64  < 0.001  < 0.001  0.018 
16:1n 7  2.00 ± 0.63  2.04 ± 0.72  0.50 ± 0.38  0.49 ± 0.10  0.51 ± 0.23  0.37 ± 0.09  < 0.001  0.807  0.883 
18:1n 9  8.73 ± 1.05  7.47 ± 1.98  17.91 ± 2.91  10.88 ± 2.02  14.58 ± 2.02  9.94 ± 1.42  < 0.001  < 0.001  0.006 
20:1n 9  0.10 ± 0.11  0.34 ± 0.30  0.18 ± 0.24  ND  0.21 ± 0.06  0.14 ± 0.02  0.304  0.935  0.026 
Total MUFA  10.83 ± 1.58  9.84 ± 2.56  18.59 ± 2.53  11.40 ± 2.02  15.30 ± 2.14  10.46 ± 1.40  < 0.001  < 0.001  0.005 
18:2n 6  14.46 ± 3.25  13.43 ± 1.58  29.68 ± 6.33  17.63 ± 2.87  20.26 ± 1.08  17.30 ± 2.32  < 0.001  < 0.001  0.001 
18:3n 6  0.12 ± 0.10  0.37 ± 0.28  0.15 ± 0.15  ND  0.16 ± 0.03  0.17 ± 0.03  0.055  0.385  0.017 
20:2n 6  0.45 ± 0.24  0.35 ± 0.14  0.10 ± 0.21  ND  0.47 ± 0.15  0.27 ± 0.05  < 0.001  0.022  0.683 
20:3n 6  0.34 ± 0.18  0.21 ± 0.17  0.28 ± 0.16  ND  0.38 ± 0.04  0.38 ± 0.05  0.002  0.009  0.113 
20:4n 6  10.82 ± 1.84  7.84 ± 1.23  7.43 ± 1.39  7.80 ± 1.70  6.79 ± 0.37  6.65 ± 0.81  < 0.001  0.051  0.010 
Total n 6 PUFA  26.20 ± 5.39  22.19 ± 1.89  37.63 ± 5.38  25.50 ± 4.36  28.05 ± 1.25  24.77 ± 2.33  < 0.001  < 0.001  0.019 
18:3n 3  0.72 ± 0.39  0.99 ± 0.24  2.62 ± 0.31  1.88 ± 0.36  14.56 ± 1.78  12.42 ± 2.62  < 0.001  0.074  0.111 
20:4n 3  ND  0.26 ± 0.63  ND  ND  0.27 ± 0.04  0.33 ± 0.04  0.046  0.263  0.495 
20:5n 3  0.40 ± 0.21  0.22 ± 0.18  0.34 ± 0.03  ND  3.56 ± 0.63  4.05 ± 0.55  < 0.001  0.952  0.030 
22:5n 3  0.52 ± 0.26  0.20 ± 0.16  0.16 ± 0.25  ND  1.10 ± 0.17  1.07 ± 0.32  < 0.001  0.035  0.295 
22:6n 3  0.85 ± 0.46  0.66 ± 0.40  0.30 ± 0.18  0.38 ± 0.38  0.78 ± 0.10  1.08 ± 0.31  0.001  0.596  0.214 
Total n 3 PUFA  2.49 ± 1.24  2.34 ± 0.21  3.42 ± 0.20  2.26 ± 0.45  20.27 ± 2.44  18.94 ± 2.37  < 0.001  0.107  0.608 
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Table 3.13:  Correlations observed between plasma and liver lipid fatty acid 
composition (Pearson r values unless otherwise indicated) 
 
 
 
 
Plasma PC  
vs. Liver PC 
 (n = 36) 
Plasma PC  
vs. Liver PE  
(n = 35) 
Plasma TAG  
vs. Liver 
TAG (n = 36) 
Plasma CE  
vs. Liver CE  
(n = 34) 
14:0  0.603  ***  0.361†  *  0.862†  ***  0.074   
16:0  0.948  ***  0.778  ***  0.980  ***  0.093   
18:0  0.979  ***  0.893  ***  0.282†     0.064   
20:0  0.125†    0.211†     0.226†     0.249†   
22:0   0.074†     0.071†     0.053†        
Total saturated  0.937  ***  0.924  ***  0.931  ***  0.055   
16:1n 7  0.827†  ***  0.778†  ***  0.822†  ***  0.741  *** 
18:1n 9  0.863  ***  0.280    0.631  ***  0.486  ** 
20:1n 9  0.087  0.115    0.409  *  0.145†   
24:1n 9   0.065†                  
Total MUFA  0.862  ***  0.331    0.795†  ***  0.511  ** 
18:2n 6  0.911  ***  0.859  ***  0.729†  ***  0.463  ** 
18:3n 6  0.347†  *  0.239†    0.124    0.535  ** 
20:2n 6  0.124     0.032    0.406  *  0.140†   
20:3n 6  0.754  ***  0.557  **  0.520  **  0.186   
20:4n 6  0.914  ***  0.668  ***  0.816  ***  0.467†  ** 
22:5n 6   0.188     0.071 †    0.409†  *      
Total n 6 PUFA  0.905  ***  0.773  ***  0.749†  ***  0.029   
18:3n 3  0.870†  ***  0.868†  ***  0.945†  ***  0.896†  *** 
20:4n 3  0.529†  **  0.311†    0.404†  *  0.553†  ** 
20:5n 3  0.905  ***  0.864†  ***  0.739†  ***  0.724†  *** 
22:5n 3  0.880  ***  0.828  ***  0.721  ***  0.517†  ** 
22:6n 3  0.911  ***  0.912  ***  0.309    0.009   
Total n 3 PUFA  0.902  ***  0.908  ***  0.932†  ***  0.514†  ** 
 
† Spearman’s correlation r value  
* p < 0.05, **  p < 0.01, *** p < 0.001 
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Figure 3.6: Illustration of the correlation observed between liver and plasma PC DHA 
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3.3.5 Adipose tissue fatty acid composition 
 
The fatty acid composition of total lipid extracts of subcutaneous and intra abdominal 
adipose tissue was assessed (see table 3.14 and 3.15).  Diet had a significant effect upon 
the fatty acid composition of adipose tissue, indicating that an experimental dietary 
period of just 20 days was sufficient to significantly alter the adipose tissue pool of fatty 
acids in adult rats.   
 
Increasing the ALNA content of the diet significantly increased the ALNA content of 
adipose tissue.  The effect of increased dietary ALNA upon LC n 3 PUFA was 
complex, as had been observed in plasma and liver lipid analysis.  Increasing dietary 
ALNA increased the EPA content of both subcutaneous and intra abdominal adipose 
tissue.  However, the effect of diet upon DPA and DHA content of adipose tissue was 
less clear, with some indication that the high fat diets may inhibit the deposition of these 
LC n 3 PUFA.  
 
r = 0.911 
p < 0.001   132 
There was a clear trend for females to have significantly more LC PUFA in their 
adipose tissue than males.  This was apparent for both n 6 and n 3 LC PUFA, but these 
fatty acids remained a relatively minor component of total adipose tissue fatty acids 
(e.g. DHA < 0.4%, AA < 1.4%).   
 
It is possible that gender differences in plasma lipid composition are related to gender 
differences in the composition and mobilisation of fatty acids from adipose tissue.  
Plasma NEFA in the fasted state derive from the release of fatty acids from adipose 
tissue under the action of hormone sensitive lipase.  In accordance with this, statistically 
significant correlations were observed between adipose composition and plasma NEFA 
fatty acid composition (see table 3.16), though it should be noted that blood samples 
were collected from non fasted animals.   
 
From these correlations it is observed that while adipose tissue does demonstrate 
statistically significant correlations with plasma fatty acid composition, these are 
strongest among saturates, MUFA and EFA, and adipose tissue does not appear to 
demonstrate a strong relationship with plasma NEFA DHA content (see figure 3.7).     133 
Table 3.14: Fatty acid composition (% total fatty acids, mean ± standard deviation, n = 6 for all groups) of total lipid extracts obtained from 
subcutaneous adipose tissue 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
Fatty acid  Male  Female  Male  Female  Male  Female  Diet  Gender  Diet*Gender 
12:0  0.25 ± 0.08  0.29 ± 0.04  0.34 ± 0.15  0.15 ± 0.09  0.18  ± 0.07  0.40 ± 0.12  0.512  0.501  < 0.001 
14:0  1.54 ± 0.15  1.44 ± 0.16  1.18 ± 0.20  0.95 ± 0.11  1.06 ± 0.18  1.30 ± 0.12  < 0.001  0.582  0.002 
16:0  24.45 ± 1.22  22.33 ± 0.87  19.59 ± 1.06  18.56 ± 0.84  18.94 ± 1.26  18.68 ± 1.47  < 0.001  0.006  0.148 
18:0  3.08 ± 0.22  3.37 ± 0.36  3.22 ± 0.22  3.79 ± 0.26  3.27 ± 0.29  3.40 ± 0.48  0.112  0.004  0.231 
Total saturated  29.40 ± 1.26  27.45 ± 0.97  24.39 ± 0.97  23.50 ± 0.84  23.47 ± 1.47  23.84 ± 1.61  < 0.001  0.052  0.083 
16:1n 7  5.17 ± 0.86  3.86 ± 0.55  3.01 ± 0.88  2.24 ± 0.32  2.47 ± 1.43  3.08 ± 1.03  < 0.001  0.177  0.042 
18:1n 9  24.45 ± 0.89  25.96 ± 0.96  23.38 ± 0.73  26.04 ± 0.70  24.65 ± 1.52  26.52 ± 0.85  0.107  < 0.001  0.354 
20:1n 9  0.35 ± 0.04  0.49 ± 0.05  0.26 ± 0.05  0.28 ± 0.02  0.19 ± 0.15  0.32 ± 0.05  < 0.001  < 0.001  0.100 
Total MUFA  29.97 ± 1.44  30.31 ± 1.45  26.65 ± 1.36  28.56 ± 0.88  27.31 ± 1.70  29.92 ± 1.77  0.001  0.002  0.170 
18:2n 6  36.55 ± 1.96  37.43 ± 1.84  43.60 ± 1.99  42.84 ± 1.25  35.48 ± 2.82  32.67 ± 2.03  < 0.001  0.195  0.101 
18:3n 6  0.15 ± 0.04  0.23 ± 0.02  0.15 ± 0.06  0.18 ± 0.02  0.10 ± 0.05  0.16 ± 0.02  0.001  < 0.001  0.178 
20:2n 6  0.31 ± 0.07  0.32 ± 0.02  ND  ND  0.12 ± 0.13  ND  < 0.001  0.426  0.698 
20:3n 6  0.14 ± 0.03  0.24 ± 0.02  0.14 ± 0.02  0.24 ± 0.06  ND  0.18 ± 0.03  0.001  < 0.001  0.980 
20:4n 6  0.86 ± 0.07  1.30 ± 0.14  0.87 ± 0.25  1.12 ± 0.13  0.56 ± 0.13  0.86 ± 0.10  < 0.001  < 0.001  0.259 
22:5n 6  ND  0.17 ± 0.05  ND  0.10 ± 0.09  ND  ND  0.016  < 0.001  0.006 
Total n 6 PUFA  38.00 ± 1.94  39.69 ± 1.98  44.85 ± 1.95  44.47 ± 1.44  36.33 ± 2.76  33.99 ± 2.13  < 0.001  0.627  0.074 
18:3n 3  2.50 ± 0.18  1.92 ± 0.17  3.75 ± 0.39  2.93 ± 0.23  12.47 ± 3.16  11.22 ± 1.06  < 0.001  0.065  0.831 
20:5n 3  ND  ND  ND  ND  0.14 ± 0.10  0.29 ± 0.06  < 0.001  0.041  < 0.001 
22:5n 3  ND  0.24 ± 0.03  0.16 ± 0.04  0.24 ± 0.04  0.18 ± 0.12  0.39 ± 0.06  < 0.001  < 0.001  0.045 
22:6n 3  ND  0.38 ± 0.05  0.15 ± 0.05  0.27 ± 0.09  ND  0.33 ± 0.05  0.785  < 0.001  0.027 
Total n 3 PUFA  2.63 ± 0.31  2.54 ± 0.18  4.12 ± 0.43  3.47 ± 0.31  12.89 ± 3.43  12.25 ± 1.16  < 0.001  0.367  0.871 
 
ND  negligible detected (mean <0.1%)   134 
Table 3.15: Fatty acid composition (% total fatty acids, mean ± standard deviation, n = 6 for all groups) of total lipid extracts obtained from intra 
abdominal adipose tissue 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
Fatty acid  Male  Female  Male  Female  Male  Female  Diet  Gender  Diet*Gender 
12:0  0.10  ± 0.05  0.12 ± 0.05  0.13 ± 0.05  ND  ND  0.11 ± 0.03  0.358  0.634  0.006 
14:0  1.57 ± 0.19  1.18 ± 0.16  1.14 ± 0.09  0.75 ± 0.08  1.03 ± 0.13  0.93 ± 0.05  < 0.001  < 0.001  0.011 
16:0  27.23 ± 1.90  23.71 ± 1.32  21.52 ± 0.88  19.06 ± 0.44  20.28 ± 1.18  19.72 ± 1.19  < 0.001  < 0.001  0.020 
18:0  2.95 ± 0.17  3.41 ± 0.19  3.18 ± 0.23  3.54 ± 0.19  3.08 ± 0.21  3.41 ± 0.23  0.111  < 0.001  0.721 
20:0  ND  ND  ND  ND  ND  0.10 ± 0.03  0.598  0.573  0.236 
Total saturated  31.91 ± 1.93  28.49 ± 1.49  26.05 ± 1.12  23.49 ± 0.52  24.50 ± 1.23  24.28 ± 1.29  < 0.001  < 0.001  0.018 
16:1n 7  6.26 ± 1.12  3.87 ± 0.92  3.58 ± 0.57  2.27 ± 0.32  3.79 ± 1.06  2.95 ± 0.52  < 0.001  < 0.001  0.072 
18:1n 9  23.47 ± 0.63  25.08 ± 0.26  23.00 ± 0.77  24.86 ± 0.90  24.52 ± 0.95  25.63 ± 1.17  0.006  < 0.001  0.528 
20:1n 9  0.33 ± 0.04  0.57 ± 0.09  0.22 ± 0.04  0.36 ± 0.07  0.25 ± 0.07  0.32 ± 0.05  < 0.001  < 0.001  0.005 
Total MUFA  30.05 ± 0.85  29.54 ± 1.14  26.81 ± 1.33  27.49 ± 1.11  28.56 ± 1.71  28.90 ± 1.56  < 0.001  0.703  0.525 
18:2n 6  33.97 ± 2.77  37.45 ± 2.09  41.83 ± 1.93  43.66 ± 0.87  33.47 ± 2.75  32.83 ± 2.15  < 0.001  0.041  0.083 
18:3n 6  0.12 ± 0.06  0.22 ± 0.02  0.13 ± 0.01  0.18 ± 0.02  ND  0.17 ± 0.03  0.028  < 0.001  0.299 
20:2n 6  0.27 ± 0.04  0.29 ± 0.03  0.26 ± 0.04  0.28 ± 0.04  0.19 ± 0.10  0.21 ± 0.03  0.001  0.188  0.961 
20:3n 6  0.14 ± 0.08  0.22 ± 0.04  0.13 ± 0.02  0.22 ± 0.03  ND  0.17 ± 0.03  0.035  < 0.001  0.919 
20:4n 6  0.77 ± 0.22  0.97 ± 0.10  0.60 ± 0.13  0.85 ± 0.14  0.41 ± 0.13  0.65 ± 0.18  < 0.001  < 0.001  0.907 
22:5n 6  ND  0.10 ± 0.09  ND  ND  ND  ND  0.373  < 0.001  0.362 
Total n 6 PUFA  35.26 ± 2.65  39.26 ± 2.24  42.95 ± 1.96  45.27 ± 0.94  34.24 ± 2.74  34.08 ± 2.32  < 0.001  0.009  0.086 
18:3n 3  2.46 ± 0.13  2.20 ± 0.19  3.86 ± 0.25  3.27 ± 0.27  12.30 ± 1.76  11.83 ± 1.28  < 0.001  0.155  0.897 
20:5n 3  ND  ND  ND  ND  0.13 ± 0.12  0.26 ± 0.04  < 0.001  0.004  0.021 
22:5n 3  0.13 ± 0.08  0.17 ± 0.10  0.16 ± 0.07  0.17 ± 0.06  0.17 ± 0.16  0.36 ± 0.06  0.012  0.017  0.067 
22:6n 3  0.18 ± 0.13  0.29 ± 0.06  0.13 ± 0.05  0.25 ± 0.03  ND  0.24 ± 0.04  0.044  < 0.001  0.808 
Total n 3 PUFA  2.77 ± 0.23  2.71 ± 0.21  4.20 ± 0.33  3.74 ± 0.29  12.70 ± 2.11  12.74 ± 1.31  < 0.001  0.649  0.830 
 
ND  negligible detected (mean <0.1%)   135 
Table 3.16: Correlations observed between adipose tissue fatty acid composition and 
that of plasma NEFA (Pearson r values unless otherwise indicated) 
 
 
  
Subcutaneous adipose vs. 
Plasma NEFA (n=33) 
Intra abdominal adipose vs. 
Plasma NEFA (n=33) 
12:0   0.058†    0.125†   
14:0  0.090    0.002   
16:0  0.703  ***  0.711  *** 
18:0   0.052    0.151   
20:0   0.136     0.014†   
22:0   0.360†  *  0.084†   
Total saturated  0.458  **  0.437  * 
16:1n 7  0.731  ***  0.627  *** 
18:1n 9  0.169    0.313   
20:1n 9   0.210     0.219   
24:1n 9  0.082†        
Total MUFA  0.477  **  0.538  ** 
18:2n 6  0.492  **  0.456  ** 
18:3n 6  0.375†  *  0.308†   
20:2n 6  0.319†     0.428†  * 
20:3n 6  0.179†    0.128†   
20:4n 6  0.454  **  0.502  ** 
22:5n 6  0.707†  ***  0.417†  * 
Total n 6 PUFA  0.568  **  0.544  ** 
18:3n 3  0.884†  ***  0.863†  *** 
20:4n 3   0.151†     0.115†   
20:5n 3  0.540†  **  0.654†  *** 
22:5n 3  0.559  **  0.497  ** 
22:6n 3  0.376  *  0.294     
Total n 3 PUFA  0.874†  ***  0.862†  *** 
 
† Spearman’s correlation r value 
* p < 0.05, **  p < 0.01, *** p < 0.001 
   136 
Figure 3.7: Illustration of the correlation observed between DHA (22:6n 3) content (% 
total fatty acids) of subcutaneous adipose tissue total lipid extracts and plasma NEFA 
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3.3.6 Plasma sex hormones 
A significant effect of gender was observed upon plasma testosterone and progesterone 
concentrations (see table 3.17).  The lack of a gender effect upon circulating oestradiol 
is likely due to females not being controlled for their stage of the oestrus cycle, resulting 
in a high degree of variation.   
 
Animals on the HF diets had significantly higher testosterone and significantly lower 
oestradiol than those on the LF soyabean oil diet.  This effect of high fat diets upon 
testosterone has been observed in other studies using rat models(230) and has been 
attributed to high fat diets reducing levels of sex hormone binding globulin, increasing 
free testosterone(231).  However, the assay used to determine testosterone 
concentrations in this thesis is designed to measure testosterone bound to sex hormone 
binding globulin (Beckman Coulter, High Wycombe).  
 
Human studies which identified gender differences in fatty acid composition have all 
identified higher plasma lipid DHA content in females compared to males(132 135).  
r = 0.376 
p < 0.05   137 
One of the proposed mechanisms for this gender difference is the involvement of sex 
hormones, but human studies to date have not determined whether plasma DHA content 
correlates with circulating sex hormones.   
 
When rat plasma DHA levels were compared with circulating sex hormone 
concentrations, strong inverse relationships with testosterone, and strong positive 
relationships with progesterone were seen (see table 3.18 and figures 3.8 and 3.9).  
When plotted, it was apparent that the correlations achieved may be an artefact of the 
gender differences in sex hormone concentrations; r values were therefore calculated for 
each gender (see table 3.19).   
 
Calculation of correlations for each gender identified a significant relationship between 
oestradiol and DHA status within males.  However, when plotted, it is clear that the 
effect of HF diets upon oestradiol status was significantly involved in this relationship 
(see figure 3.10).  The confounding effects of diet and gender upon sex hormone status 
therefore make it unlikely that a simple correlation between sex hormone status and 
DHA content of plasma lipids can be confidently identified.   138 
 
 
 
Table 3.17: Plasma sex hormone concentrations (mean ± standard deviation) 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
  Males 
(n=5) 
Females  
(n=6) 
Males  
(n=6) 
Females 
(n=6) 
Males  
(n=5) 
Females 
(n=5) 
Diet  Gender  Diet*Gender 
Oestradiol (pM)  156.2 ± 21.6  141.5 ± 129.4  42.6 ± 26.0  54.8 ± 47.6  30.0 ± 18.0 †  52.9 ± 59.5  0.001  0.777  0.807 
Progesterone (nM)  1.7 ± 0.8 †  22.5 ± 25.8  7.7 ± 3.8  54.5 ± 26.4  4.6 ± 1.6   35.9 ± 24.3  0.221  < 0.001  0.549 
Testosterone (nM)  8.9 ± 4.6   1.8 ± 0.5  17.9 ± 12.7  5.9 ± 0.6  19.6 ± 6.3  4.7 ± 0.6  0.027  < 0.001  0.359 
 
† (n = 4) 
 
Diet   Bonferroni post hoc tests for multiple comparisons: 
 
Oestradiol – LF Soyabean oil significantly different from HF Soyabean oil (p = 0.004) and HF Linseed oil (p = 0.005) 
Testosterone – LF Soyabean oil significantly different from HF Soyabean oil (p = 0.042) and HF Linseed oil (p = 0.044)   139 
 
Table 3.18: Correlations between the DHA content (% total fatty acids) and circulating  
sex hormone concentrations (Pearson r values unless otherwise indicated) 
 
  Testosterone  Oestradiol  Progesterone 
PC   0.669 ** 
(n = 33) 
0.322 
(n = 32) 
0.720** † 
(n = 32) 
TAG   0.240 
(n = 33) 
 0.119 
(n = 32) 
0.246 † 
(n = 32) 
CE   0.553** 
(n = 33) 
0.048  
(n = 31) 
0.608** † 
(n = 31) 
NEFA   0.474** 
(n = 30) 
0.195 
(n = 29) 
0.529** 
(n = 30) 
 
† Spearman r value 
** p < 0.01 
 
Figure 3.8: Illustration of the correlation observed between plasma progesterone and the 
DHA content (22:6n 3, % total fatty acids) of plasma PC 
Plasma progesterone (nM)
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All data: r = 0.720, p < 0.01 
 
Males: r =  0.432, p = 0.108 
Females: r = 0.245, p = 0.344   140 
Figure 3.9: Illustration of the correlation observed between plasma testosterone and 
DHA content (22:6n 3, % total fatty acids) of plasma PC 
Plasma testosterone (nM)
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Table 3.19: Correlations between the DHA content (% total fatty acids) of plasma lipids 
and circulating sex hormone concentrations for each gender (Pearson r values) 
 
  MALES  FEMALES 
  Testosterone  Oestradiol  Progesterone  Testosterone  Oestradiol  Progesterone 
PC   0.457 
(n = 16) 
0.924*** 
(n = 15) 
 0.432 
(n = 15) 
 0.414 
(n = 17) 
0.272 
(n = 17) 
0.245 
(n = 17) 
TAG   0.416 
(n = 16) 
0.610 * 
(n = 15) 
 0.198 
(n = 15) 
0.290 
(n = 17) 
 0.495* 
(n = 17) 
0.342 
(n = 17) 
CE   0.231 
(n = 16) 
0.268 
(n = 15) 
 0.212 
(n = 15) 
0.014 
(n = 16) 
 0.107 
(n = 16) 
0.257 
(n = 16) 
NEFA   0.364 
(n = 14) 
0.200 
(n = 13) 
0.178 
(n = 14) 
 0.119 
(n = 16) 
0.167 
(n = 16) 
0.328 
(n = 16) 
 
* p < 0.05, *** p < 0.001 
All data: r =  0.669, p < 0.01 
 
Males: r =  0.457, p = 0.075 
Females: r =  0.414, p = 0.099   141 
Figure 3.10: Illustration of the correlation observed between plasma oestradiol and 
plasma PC DHA status (% total fatty acids) in males 
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3.3.7 Expression of desaturase and elongase enzymes in the liver 
Liver samples were assessed for mRNA expression of  5,  6 and elongase (see table 
3.20).  No significant effect of gender or diet was identified upon mRNA expression of 
elongase and  5 desaturase.   6 desaturase exhibited a significant effect of diet, with 
those rats fed on the HF linseed oil diet having significantly higher expression of  6 
desaturase than those on the HF soyabean oil diet.    
 
Liver mRNA expression of desaturases and elongase was correlated to plasma sex 
hormone concentrations to assess if there was any significant interaction (see table 
3.21).  Although mRNA expression data did not demonstrate significant gender 
differences, there are indications that the expression of these genes is influenced by sex 
hormones, as oestradiol demonstrated an inverse relationship with  5 desaturase 
expression (see figure 3.11).   
 
One way of inferring enzyme activity of desaturase and elongase enzymes within the 
liver is to calculate the substrate:product ratio of fatty acids found within phospholipids.  
A high substrate:product ratio would indicate low enzyme activity, and a low 
substrate:product ratio would indicate high enzyme activity.  A positive correlation of a 
r = 0.924 
p < 0.001   142 
given variable with the substrate:product ratio would indicate that this variable may be 
associated with inhibition of enzyme activity, and an inverse relationship would indicate 
increased enzyme activity.  Therefore, correlations between mRNA expression and the 
substrate:product ratios associated with each enzyme were calculated to investigate 
whether differences the mRNA expression of these enzymes bear a relationship to tissue 
fatty acid composition (see table 3.22).   
 
No consistent relationships were identified which would support a relationship between 
mRNA expression of these enzymes and the fatty acids they act upon within liver 
phospholipids.  This suggests that if there is an effect of sex hormones upon the 
synthesis of LC PUFA from their EFA precursors, the effect involves mechanisms other 
than changes in mRNA expression of the genes encoding these enzymes.       143 
 
 
 
 
 
 
 
 
 
 
Table 3.20: Liver mRNA expression of desaturase and elongase genes in response to diet and gender (arbitrary units of quantitative expression derived 
from standard curve and adjusted for geometric mean of three housekeeping genes, mean ± standard deviation) 
 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
  Male  
(n=6) 
Female  
(n=6) 
Male  
(n=6) 
Female  
(n=6) 
Male  
(n=6) 
Female  
(n=5) 
Gender  Diet  Gender*Diet 
Elovl5 (elongase)  0.91 ± 0.18  0.83 ± 0.11  0.72 ± 0.15  0.82 ± 0.11  0.72 ± 0.20  0.80 ± 0.12  0.494  0.159  0.305 
FADS1 ( 5 desaturase)  0.69 ± 0.08  0.61 ± 0.11  0.70 ± 0.09  0.68 ± 0.21  0.72 ± 0.17  0.77 ± 0.15  0.753  0.251  0.579 
FADS2 ( 6 desaturase)  0.64 ± 0.23  0.58 ± 0.17  0.63 ± 0.13  0.56 ± 0.13  0.76 ± 0.20  0.84 ± 0.24  0.793  0.025  0.565 
 
Diet   Bonferroni post hoc tests for multiple comparisons: 
 
FADS2 ( 6 desaturase) – HF Linseed oil significantly different from HF Soyabean oil (p = 0.046) 
   144 
Table 3.21: Correlations observed between liver mRNA expression of desaturase and 
elongase genes and circulating plasma sex hormone concentrations (Pearson R values) 
 
  Testosterone 
(nM) 
Oestradiol 
(pM) 
Progesterone 
(nM) 
Elovl5 (elongase)   0.265 
(n = 32) 
0.100 
(n = 31) 
0.253 
(n = 31) 
FADS1 ( 5 desaturase)  0.215 
(n = 32) 
 0.387 * 
(n = 31) 
0.180 
(n = 31) 
FADS2 ( 6 desaturase)  0.212 
(n = 32) 
 0.198 
(n = 31) 
0.035 
(n = 31) 
* p < 0.05 
 
Figure 3.11: Illustration of the correlation between plasma oestradiol and liver  5 
desaturase mRNA expression 
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Table 3.22: Correlations observed between liver mRNA expression and their respective 
substrate and product fatty acid ratios within liver lipids (Pearson r values) 
 
  Liver PC  Liver PE  Liver CE  Liver TAG 
 6 DESATURASE         
18:2n 6 to 18:3n 6 ratio  0.112 
(n = 35) 
0.226 
(n = 31) 
0.122 
(n=24) 
 0.003 
(n = 33) 
 5 DESATURASE         
20:3n 6 to 20:4n 6 ratio  0.093 
(n = 35) 
0.099 
(n = 34) 
 0.182 
(n=25) 
0.040 
(n = 33) 
20:4n 3 to 20:5n 3 ratio  0.100 
(n = 35) 
0.388* 
(n = 34) 
0.279 
(n=25) 
0.331 
(n = 33) 
ELONGASE         
18:3n 6 to 20:3n 6 ratio  0.113 
(n = 35) 
0.196 
(n = 34) 
0.137 
(n=25) 
0.163 
(n = 33) 
20:5n 3 to 22:5n 3 ratio   0.122 
(n = 35) 
 0.148 
(n = 34) 
 0.470* 
(n=22) 
 0.303 
(n = 33) 
* p < 0.05 
r =  0.387 
p < 0.05   145 
3.3.8 Indirect assessment of desaturase and elongase activities in 
the liver 
Although desaturase and elongase mRNA expression was not found to relate to gender 
or plasma sex hormones, it is possible that the activity of these enzymes may be 
affected by gender or sex hormones.  Substrate:product ratios within liver lipids were 
therefore calculated to assess the effect of gender or sex hormones upon LC PUFA 
synthesis. 
 
Substrate:product ratios will be significantly affected by diet, as the fatty acids used to 
calculate these ratios are provided in different proportions in the three dietary groups, 
but effects of gender upon substrate:product ratios may indicate that the gender 
differences in LC PUFA status are mediated by an effect upon enzyme activity.   
 
 9 desaturase 
 
Substrate:product ratios for  9 desaturase activity were found to be significantly 
affected by gender in all liver lipid fractions assessed, with females having significantly 
higher ratios (see table 3.23).  This indicates that males have higher  9 desaturase 
activity compared to females.  
 
Testosterone administration has been demonstrated to increase liver  9 desaturase 
activity in rat models(152).  Whether this effect can be observed within the 
physiological range of testosterone had not been determined.  The significant inverse 
relationships between testosterone and the substrate:product ratio observed here support 
a potential role of testosterone in promoting  9 desaturase activity (see table 3.24 and 
figure 3.12).  There was little indication of a relationship between plasma oestradiol and 
liver  9 desaturase activity, while progesterone demonstrated a significant positive 
correlation with the substrate:product ratio in liver lipids, indicating that circulating 
progesterone is associated with a reduction in this marker of  9 desaturase activity (see 
figure 3.13).   146 
 
 
 
 
 
 
 
Table 3.23: The  9 desaturase substrate:product ratio within liver lipids (% total fatty acid ratio of 18:0 to 18:1n 9, mean ± standard deviation, n = 6 
for all groups unless otherwise indicated) 
 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
  Males  Females  Males  Females  Males  Females  Diet  Gender  Diet*Gender 
Liver PC  4.7 ± 0.5  8.8 ± 1.5  7.5 ± 1.0  13.9 ± 3.1  4.7 ± 0.4  10.4 ± 0.8  < 0.001  < 0.001  0.194 
Liver PE  7.0 ± 1.1 (n=5)  12.6 ± 2.3  5.2 ± 0.9  9.6 ± 2.0  4.6 ± 0.5  9.8 ± 1.1  < 0.001  < 0.001  0.566 
Liver CE  2.7 ± 0.7  3.0 ± 1.1  0.5 ± 0.2 (n=5)  1.3 ± 0.5 (n=5)  1.1 ± 0.4  2.3 ± 0.7  < 0.001  0.002  0.279 
Liver TAG (x 10
2)  12.6 ± 2.3  14.8 ± 5.5  11.0 ± 0.6 (n=5)  17.1 ± 2.5 (n=5)  10.9 ± 1.7  15.0 ± 2.8  0.685  < 0.001  0.322 
 
Diet   Bonferroni post hoc tests for multiple comparisons: 
 
Liver PC: HF soyabean oil significantly different from LF soyabean oil (p < 0.001) and HF linseed oil (p < 0.001) 
Liver PE: LF soyabean oil significantly different from HF soyabean oil (p < 0.001) and HF linseed oil (p < 0.001) 
Liver CE: All groups significantly different (p < 0.05)  147 
 
Table 3.24: Correlations observed between the ratio of 18:0 to 18:1n 9 content (% total 
fatty acids) of liver lipids and circulating sex hormones concentrations (Pearson r values 
unless otherwise indicated) 
 
18:0 to 18:1n 9 ratio  Liver PC  Liver PE  Liver CE  Liver TAG 
Testosterone   0.401* 
(n=33) 
 0.675*** 
(n=32) 
 0.495** 
(n=31) 
 0.363* 
(n=31) 
Oestradiol   0.181 
(n=32) 
0.204 
(n=31) 
0.202 
(n=30) 
 0.356 
(n=30) 
Progesterone  0.870*** 
(n=32)† 
0.673** 
(n=31) 
0.209 † 
(n=30) 
0.556**† 
(n=30) 
 
* p < 0.05, ** p < 0.01, *** p < 0.001, † Spearman R values 
 
 
 
Figure 3.12: Illustration of the correlation observed between plasma testosterone and the 
ratio of 18:0 to 18:1n 9 within liver PE 
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r =  0.675 
p < 0.001   148 
Figure 3.13: Illustration of the correlation observed between plasma progesterone and 
the ratio of 18:0 to 18:1n 9 within liver PC  
Plasma progesterone (nM)
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 6 desaturase 
 6 desaturase activity can be inferred from by the conversion of the n 6 fatty acid 
18:2n 6 to 18:3n 6.   6 desaturase also converts 18:3n 3 to 18:4n 3.  Here the n 6 fatty 
acids were used, as 18:4n 3 could not be identified by the gas chromatography method 
used.  Significant gender differences in  6 desaturase substrate:product ratios were 
observed in all liver lipid fractions assessed, with females having significantly lower 
ratios across all dietary groups (see table 3.25).  This suggests that  6 activity is 
significantly greater in females than in males.   
 
Data were assessed for correlations between plasma sex hormone concentrations and 
fatty acid ratio markers of  6 desaturase activity.  The significant positive relationship 
between the 18:2n 6 to 18:3n 6 ratio in liver lipids with plasma testosterone suggests 
that  6 desaturase activity may be inhibited by testosterone (see table 3.26, figure 3.14).  
Likewise the observed negative correlations with oestradiol concentrations suggest that 
oestradiol is associated with an increased activity of  6 desaturase (see figure 3.15).  
There was also a non significant trend for progesterone to relate to this marker of  6 
desaturase activity (see figure 3.16).   
r = 0.870 
p < 0.001   149 
Table 3.25: The  6 desaturase substrate:product ratio of fatty acids within liver lipids (18:2n 6 to 18:3n 6, mean ± standard deviation, n = 6 per group 
unless otherwise indicated)  
 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
  Males  Females  Males  Females  Males  Females  Diet  Gender  Diet*Gender 
Liver PC   73.7 ± 17.9  36.7 ± 8.6  105.5 ± 5.7  82.5 ± 22.7  158.4 ± 24.9  103.8 ± 19.1  < 0.001  < 0.001  0.114 
Liver PE   65.2 ± 16.0  
(n=5) 
33.4 ± 10.2  88.1 ± 24.1  83.9 ± 2.8  
(n=3) 
118.3 ± 8.6  73.0 ± 14.5  < 0.001  < 0.001  0.020 
Liver CE  83.4 ± 14.4  
(n=4) 
38.9 ± 22.2  
(n=5) 
128.4 ± 17.5  
(n=3) 
107.4  
(n=1) 
130.9 ± 26.6  106.3 ± 20.4  < 0.001  0.010  0.534 
Liver TAG  73.0 ± 17.5  44.6 ± 7.1  68.9 ± 7.5  
(n=5) 
68.6 ± 9.6  
(n=5) 
104.0 ± 29.9  83.4 ± 19.1  < 0.001  0.011  0.182 
 
Diet   Bonferroni post hoc tests for multiple comparisons: 
Liver PC – All groups significantly different from each other (p < 0.001) 
Liver PE, CE – LF soyabean oil significantly different from HF soyabean oil (p < 0.001) and HF linseed oil (p < 0.001) 
Liver TAG – HF linseed oil significantly different from LF soyabean oil (p < 0.001) and HF soyabean oil (p = 0.008) 
 
 
 
Table 3.26: Correlations observed between plasma testosterone concentrations and the ratio of 18:2n 6 to 18:3n 6 within liver lipids (Pearson r values) 
 
18:2n 6 to 18:3n 6 ratio  Liver PC  Liver PE  Liver CE  Liver TAG 
Testosterone  0.545** (n=33)  0.660*** (n=29)  0.534* (n=22)  0.311 (n=31) 
Oestradiol   0.478** (n=32)   0.472* (n=28)   0.535* (n=21)   0.341 (n=30) 
Progesterone   0.324 (n=32)   0.338 (n=28)   0.340 (n=21)   0.240 (n=30) 
 
* p < 0.05, ** p < 0.01, *** p < 0.001   150 
 
Figure 3.14: Illustration of the correlation 
observed between plasma testosterone and 
the ratio of 18:2n 6 to 18:3n 6 within liver 
PE 
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Figure 3.15: Illustration of the correlation 
observed between plasma oestradiol and the 
ratio of 18:2n 6 to 18:3n 6 within liver PE 
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Figure 3.16: Illustration of the correlation 
observed between plasma progesterone and 
ratio of 18:2n 6 to 18:3n 6 within liver PC 
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p = 0.07   151 
 
 5 desaturase activity 
 
 5 desaturase activity can be assessed by the conversion of 20:3n 6 to AA, or of 20:4n 
3 to EPA.  There was no indication of an effect of gender upon  5 desaturase activity 
(see table 3.27).  Data were assessed for correlations of this marker of  5 desaturase 
activity with circulating sex hormones (see table 3.28).  While these correlations 
supports a relationship between oestradiol and enhanced  5 desaturase activity upon n 
3 fatty acids, it is clear when plotted (see figure 3.17) that this relationship is a statistical 
artefact of diet, with 20:4n 3 only detectable in the ALNA rich HF linseed oil diet.   
 
Elongase 
 
Elongase activity can be assessed by the conversion of 18:3n 6 to di homo γ linolenic 
acid (DGLA, 20:3n 6), or EPA to DPA.  There was some indication that when data for 
liver PC was used, females have reduced elongase activity compared to males (see table 
3.29).  No clear pattern of relationships of sex hormones with either n 6 or n 3 fatty 
acids in liver lipids were observed which would indicate an interaction with elongase 
activity (see table 3.30).  There was some limited indication that oestradiol and 
progesterone may correlate to increased elongase activity, but this was not observed in 
the PC fraction, where the significant gender differences in substrate:product ratios were 
observed.   152 
 
Table 3.27: The  5 desaturase substrate:product ratio of fatty acids within liver lipids (n 6 20:3n 6 to AA; n 3: 20:4n 3 to EPA, mean ± standard 
deviation, n = 6 per group unless otherwise indicated) 
 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
  Males  Females  Males  Females  Males  Females  Diet  Gender  Diet*Gender 
n 6 fatty acids                   
Liver PC (x 10
3)   3.87 ± 1.30  4.38 ± 0.70  2.36 ± 0.32  2.43 ± 0.24  6.42 ± 0.48  6.58 ± 1.15  < 0.001  0.363  0.776 
Liver PE (x 10
3)   21.7 ± 3.3  
(n=5) 
23.8 ± 2.4  20.0 ± 0.9  18.7 ± 2.2  35.6 ± 3.7  36.0 ± 5.0  < 0.001  0.730  0.450 
Liver CE (x 10
3)  30.7 ± 17.3  29.3 ± 25.5  40.2 ± 27.9  
(n=5) 
5.8 ± 13.0  
(n=5) 
56.0 ± 5.1  57.9 ± 11.4  < 0.001  0.082  0.056 
Liver TAG (x 10
2)  10.2 ± 1.1  14.1 ± 3.3  24.0 ± 2.4  
(n=5) 
21.4 ± 5.0  
(n=5) 
30.6 ± 7.6  26.3 ± 5.2  < 0.001  0.547  0.093 
n 3 fatty acids                   
Liver PC (x 10
1)   1.89 ± 3.93     7.70 ± 3.63   7.34 ± 1.00  0.46 ± 0.07  0.42 ± 0.08  < 0.001  0.624  0.872 
Liver PE (x 10
1)   5.67 ± 1.26  
(n=5) 
         0.33 ± 0.03  0.32 ± 0.05  0.309  0.245  0.273 
Liver CE (x 10
2)  ND  
(n=5) 
ND  
(n=4) 
ND  
(n=5) 
ND  
(n=5) 
7.59 ± 0.77  8.17 ± 1.39  < 0.001  0.404  0.404 
Liver TAG (x 10
1)  11.1 ± 27.2  ND  1.33 ± 0.28  
(n=5) 
2.00 ± 0.29  
(n=5) 
1.51 ± 0.18  2.06 ± 0.47  0.656  0.413  0.378 
 
Diet   Bonferroni post hoc tests for multiple comparisons: 
 
n 6 liver PC, PE, TAG: All groups significantly different from each other (p < 0.001) 
n 6 liver CE: HF linseed oil significantly different from LF soyabean oil (p = 0.003) and HF linseed oil (p < 0.001) 
 
n 3 liver PC: HF soyabean oil significantly different from LF soyabean oil (p = 0.005) and HF linseed oil (p = 0.002) 
n 3 liver CE: HF linseed oil significantly different from LF soyabean oil (p < 0.001) and HF soyabean oil (p < 0.001)   153 
Table 3.28: Correlations observed between plasma sex hormone concentrations and the 
ratio of  5 desaturase substrate and product fatty acids within liver lipids (Pearson r 
values unless otherwise indicated) 
 
 
20:3n 6 to AA ratio  PC  PE  CE  TAG 
Testosterone  0.018 
(n=33) 
0.131 
(n=32) 
0.280 
(n=31) 
0.430* 
(n=31) 
Oestradiol  0.067 
(n=32) 
 0.030 
(n=31) 
 0.046 
(n=30) 
 0.347 
(n=30) 
Progesterone   0.090 † 
(n=32) 
 0.248 
(n=31) 
 0.188 † 
(n=30) 
0.070 † 
(n=30) 
20:4n 3 to EPA ratio  PC  PE  CE  TAG 
Testosterone †  0.469** 
(n=33) 
0.259 
(n=32) 
0.149 
(n=23) 
0.273 
(n=31) 
Oestradiol †   0.433* 
(n=32) 
 0.220 
(n=31) 
 0.544** 
(n=22) 
 0.398* 
(n=30) 
Progesterone †   0.184 
(n=32) 
 0.261 
(n=31) 
0.136 
(n=22) 
0.280 
(n=30) 
 
† Spearman’s r value      * p < 0.05, ** p < 0.01 
 
 
Figure 3.17: Illustration of the correlation observed between plasma oestradiol and the 
ratio of 20:4n 3 to 20:5n 3 within liver cholesterol esters 
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r (all diets) =  0.544 (Spearman) 
      p < 0.001 
 
r (HF linseed oil) =  0.339 (Pearson) 
                  p = 0.373   154 
Table 3.29: The elongase substrate:product ratio of fatty acids within liver lipids (n 6: 18:3n 6 to 20:3n 6; n 3: EPA to DPA, mean ± standard 
deviation, n = 6 unless otherwise indicated) 
 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  ANOVA p value 
  Males  Females  Males  Females  Males  Females  Diet  Gender  Diet*Gender 
n 6 fatty acids                   
Liver PC (x 10
1)   2.39 ± 0.36  3.31 ± 0.63  2.56 ± 0.37  2.60 ± 0.75  1.29 ± 0.17  1.42 ± 0.18  < 0.001  0.023  0.053 
Liver PE (x 10
1)  2.26 ± 0.25  
(n=5) 
3.44 ± 1.46  2.97 ± 0.74  1.07 ± 1.17  1.45 ± 0.21  1.73 ± 0.39  0.005  0.627  0.001 
Liver CE (x 10
1)  3.6 ± 2.2  
(n=5) 
15.8 ± 12.4  
(n=4) 
5.6 ± 3.8  
(n=4) 
8.0  
(n=1) 
4.2 ± 0.8   4.4 ± 0.7   0.081  0.056  0.045 
Liver TAG (x 10
1)  9.7 ± 2.6  12.6 ± 3.9  7.6 ± 1.0  
(n=5) 
6.5 ± 1.4  
(n=5) 
7.6 ± 1.4  7.7 ± 1.8  < 0.001  0.415  0.131 
n 3 fatty acids                   
Liver PC (x 10
1)   3.77 ± 1.68  5.34 ± 1.23  2.32 ± 0.53  1.90 ± 0.37  22.5 ± 4.2  27.4 ± 4.2  < 0.001  0.027  0.055 
Liver PE (x 10
1)  1.98 ± 0.65  
(n=5) 
1.65 ± 0.31  1.79 ± 0.38  1.16 ± 0.32  15.0 ± 2.1  15.6 ± 2.5  < 0.001  0.794  0.548 
Liver CE (x 10
1)  7.65 ± 2.06  
(n=5) 
8.39 ± 6.11  
(n=4) 
10.35 ± 0.66  
(n=2) 
10.35 ± 0.66  
(n=2) 
32.8 ± 6.3   41.2 ± 1.5  < 0.001  0.263  0.345 
Liver TAG (x 10
1)  4.74 ± 1.67  5.87 ± 1.04  5.31 ± 0.82  
(n=5) 
4.27 ± 0.36  
(n=5) 
9.24 ± 1.01  10.1 ± 0.8  < 0.001  0.373  0.046 
 
Diet   Bonferroni post hoc tests for multiple comparisons: 
 
n 6 liver PC: HF linseed oil significantly different from LF soyabean oil (p < 0.001) and HF soyabean oil (p < 0.001) 
n 6 liver PE: HF linseed and LF soyabean oil significantly different (p = 0.003) 
n 6 liver TAG: LF soyabean oil significantly different from HF soyabean oil (p = 0.001) and HF linseed oil (p = 0.003) 
 
n 3 liver PC, PE, TAG: HF linseed oil significantly different from LF soyabean oil (p < 0.001) and HF soyabean oil (p < 0.001) 
n 3 liver CE: HF linseed oil significantly different from LF soyabean oil (p < 0.001) and HF soyabean oil (p = 0.003)   155 
Table 3.30: Correlations observed between plasma sex hormone concentrations and the 
substrate:product ratio of fatty acids within liver lipids (Pearson r values unless 
otherwise indicated) 
 
18:3n 6 to 20:3n 6 ratio  PC  PE  CE  TAG 
Testosterone   0.328 
(n=33) 
 0.108 
(n=32) 
 0.142 † 
(n=23) 
 0.289 
(n=31) 
Oestradiol  0.269 
(n=32) 
0.150 
(n=31) 
0.021 † 
(n=22) 
0.273 
(n=30) 
Progesterone  0.236 † 
(n=32) 
 0.022 
(n=31) 
0.304 † 
(n=22) 
 0.080 † 
(n=30) 
EPA to DPA ratio         
Testosterone   0.184 † 
(n=33) 
0.144 † 
(n=32) 
0.101 
(n=20) 
0.170 
(n=31) 
Oestradiol   0.061 † 
(n=32) 
 0.092 † 
(n=31) 
 0.493* 
(n=19) 
 0.205 
(n=30) 
Progesterone †   0.059 
(n=32) 
 0.388* 
(n=31) 
0.207 
(n=19) 
 0.083 
(n=30) 
 
 
 † Spearman’s r value   * p < 0.05 
 
3.4 Discussion 
 
This aim of this study was to investigate the effect of gender and the dietary availability 
of ALNA upon the n 3 fatty acid composition of rat tissues, and whether this effect was 
mediated by sex hormones and/or the expression of genes for enzymes involved in 
endogenous synthesis of LC PUFA.  The hypotheses being tested were: 
 
a)  females rats have higher plasma levels of LC n 3 PUFA compared to males  
b)  gender differences are also apparent within metabolically relevant tissues such 
as the liver and adipose tissue.   
c)  plasma docosahexaenoic acid (DHA) content and desaturase and elongase gene 
expression within the liver are related to plasma sex hormone concentrations. 
d)  females will show a greater elevation in LC n 3 PUFA in response to an α 
linolenic acid (ALNA) rich diet than males as a result of gender differences in 
desaturase and elongase gene expression. 
 
The data obtained in this study support hypotheses a, b and d; whether the data fully 
support hypothesis c is not entirely clear but some supportive evidence has been 
generated.  In addition, data collected demonstrated that dietary ALNA itself has a   156 
significant effect upon the expression of  6 desaturase, and indicated that individual 
housing of experimental animals has a significant effect upon patters of growth. 
 
Female rats had higher contents of EPA, DPA and DHA in plasma PC than males, and 
higher levels of DHA in the other plasma lipids examined.  These gender differences are 
comparable to those observed in human studies, confirming the suitability of the rat as a 
model for human gender differences in fatty acid composition.  
 
This study expands upon the currently available data from human studies by 
demonstrating that gender differences in LC n 3 PUFA content which are observed 
within plasma lipids are also apparent within liver lipids and adipose tissue, and 
demonstrates significant relationships between the fatty acid compositions of these 
tissues.  For example, the DHA content of plasma phospholipid exhibited strong and 
statistically significant correlations with the DHA content of liver phospholipids (PC, r 
= 0.902; PE, r = 0.908).  The DHA content of plasma NEFA exhibited a weaker, yet 
statistically significant, correlation to the DHA status of subcutaneous adipose tissue (r 
= 0.376).  These data indicate that both liver and adipose tissue are likely to have 
significant metabolic roles in contributing to the gender differences which are apparent 
plasma DHA content. 
 
Attempts were made to investigate the potential mechanistic basis of these gender 
differences, with the role of circulating sex hormones and the mRNA expression of 
enzymes involved in the synthesis of LC PUFA the focus of this study.  The role of diet 
in maintaining gender differences was also investigated, with male and female rats 
maintained upon one of three experimental diets.  These diets varied in their total fat 
content, and in the availability of ALNA within the diet.  The dietary availability of 
ALNA was under investigation due to its role as a metabolic substrate in the 
endogenous synthesis of LC n 3 PUFA. 
 
The use of three different experimental diets proved to be a confounding factor when 
attempts were made to examine the relationship between sex hormone concentrations 
and the DHA content of plasma lipids.  Diet itself exerted a significant effect upon 
circulating sex hormone concentrations, with both male and female rats on high fat diets 
having significantly higher plasma testosterone and lower plasma oestradiol than those 
maintained on a low fat diet.  The potential relationship between plasma sex hormones   157 
and DHA status may therefore be better investigated by examination of a larger group 
of male and female animals maintained upon a single diet.   
 
mRNA expression of desaturase and elongase enzymes within the liver was investigated 
in order to assess whether the relative abundance of these enzymes was responsible for 
the gender differences observed in plasma and tissue fatty acid composition.  Data did 
not support any significant effect of gender or of sex hormones concentrations upon  5 
desaturase,  6 desaturase or elongase mRNA expression in the liver.  While 
investigation of the mRNA expression of enzymes provides a measure of the quantity of 
these enzymes within the liver, this measure is limited by the lack of insight it allows 
into the numerous other processes which affect enzyme activity, such as efficiency of 
translation, post translational modifications, influence of inhibitors or activators or 
negative feedback mechanisms.  An alternative hypothesis for the mechanisms which 
underpin gender differences in tissue fatty acid composition which could be proposed is 
that there are in fact gender differences in the relative activity of desaturase and 
elongase enzymes within the liver, and not in the relative abundance of these enzymes.   
 
Direct assessment of enzyme activity was not performed during this study, but an 
indirect measure of enzyme activity was made by calculation of substrate:product ratios 
of fatty acids within liver lipids.  Use of substrate:product ratios are a relatively crude 
measure of enzyme activity as they cannot take into account the potential influence of 
specificity in lipid assembly, which is likely to be regulated by more complex processes 
than the simple availability of intra cellular fatty acids, and so data obtained from this 
calculation should be used with caution.  However, there were some clear and strong 
relationships apparent between this marker of enzyme activity and both gender and sex 
hormone concentrations. 
 
Substrate: product ratios in liver lipids indicated clear gender differences in  9 
desaturase activity (males > females) and  6 desaturase activity (females > males).  
Data also supports a role of sex hormones in maintaining these gender differences, with 
ratios indicating a positive correlation between  9 desaturase activity and testosterone 
status, and an inverse relationship with progesterone.  This may account for the 
significantly higher plasma content of 18:1n 9 observed in males compared to females 
across all dietary groups.   6 desaturase substrate:product ratios of activity were 
inversely related to testosterone status, and demonstrated a positive relationship with   158 
oestradiol status, which may account for the higher plasma content of 18:3n 6 and DHA 
observed in females compared to males.  While these correlations were found to be 
consistent across numerous liver lipid classes, indicating a close relationship between 
circulating sex hormone status and this proxy marker of enzyme activity, it must be 
noted that correlations cannot infer causality, and may be significantly influenced by 
data which is not normally distributed.  Efforts were made to check the nature of the 
correlations observed by plotting the data, and this did in fact identify ‘false positive’ 
correlations, such as was the case for the statistically significant correlation observed 
between oestradiol status and this fatty acid marker of  5 desaturase activity (see figure 
3.17). 
 
The fatty acid composition of rat plasma and tissues were found to respond to increased 
dietary ALNA in a way which was comparable to available data from human studies, 
demonstrating significant increases in the EPA content of plasma lipids, but without any 
concurrent increase in DHA content.  The increase in EPA was greater for female than 
male rats, indicating that the LC n 3 PUFA status of females is more responsive to the 
availability of dietary ALNA.  There can be confidence that this effect is not a reflection 
of simple differences in dietary intake between males and females, as males in fact 
consumed more diet over the study period, and therefore more ALNA, than their female 
counterparts.  There was a clear indication that the influence of dietary ALNA was 
lipid fraction specific, with the effects of the HF linseed oil diet most marked upon the 
EPA status of CE fractions obtained from plasma and liver lipids.  This is likely to 
reflect a level of cholesterol ester synthase selectivity for fatty acids during lipid 
assembly.  
 
Diet was observed to exert a significant effect upon  6 desaturase mRNA expression, 
with the HF linseed oil group having the highest expression.  As  6 desaturase is the 
rate limiting enzyme in the synthesis of LC PUFA formation, increasing the expression 
of this single gene may affect the production of down stream LC PUFA.  The 
specificity of this effect upon n 3 fatty acids may relate to ALNA being the preferred 
substrate for the action of  6 desaturase, with 2 3 times higher maximal enzyme 
activity compared to LA as a substrate(232). 
 
While using increased dietary ALNA is a relatively inexpensive and non invasive 
method of assessing LC PUFA synthesis, one of the principal limitations of using   159 
increased dietary ALNA is the lack of certainty about the metabolic origins of the LC 
PUFA detected.  The findings of this study could be supported further using stable 
isotope labelled ALNA to determine the rates of de novo synthesis of LC n 3 PUFA in 
rats, and their flux into other metabolic tissues such as the liver and adipose tissue.  This 
approach would also enable the rates of enzyme activity to be directly assessed within 
the liver.   
 
Further studies would be required to confirm whether the correlations observed between 
sex hormone status and the substrate:product ratios used to infer enzyme activity do in 
fact reflect a causal relationship.  One possible approach to this would be the use of 
isotope labelled fatty acids in hepatocyte cultures in the presence of physiological 
concentrations of sex hormones.  This approach would enable direct measurement of the 
effect of sex hormones upon enzyme activity.  The use of hepatocyte cultures would 
also be an improvement over the currently available liver microsome data, as this would 
allow integrated whole cell responses, with sex hormone receptors and their signalling 
pathways intact.   
 
An additional feature of this study was the effect of individual housing upon weight 
gain of both male and female rats.  Based on this observation, future dietary studies 
should be conducted in animals which have been allowed to acclimatise to a period of 
individual housing prior to start of the experimental diet.  This would be particularly 
important in studies of young animals, in order to avoid any confounding influence of 
changes in the rate of growth which relate to animal housing rather than the 
experimental diet under investigation. 
 
A 20 day feeing period was arbitrarily used in this study, in part to allow direct 
comparison with data from studies of experimental diets provided during pregnancy.  
The data obtained indicate that a more prolonged feeing period may also be worthy of 
further investigation.  This would enable the effects of the HF soyabean oil diet upon 
LC n 3 PUFA status to be studied further.  This is of particular interest, as those rats 
receiving the HF soyabean oil diet were found to have significantly lower levels of EPA 
within plasma and liver phospholipids, while maintaining their DHA status (see figure 
3.2 and 3.3).  It would worthwhile to determine whether more prolonged HF soyabean 
oil feeding would result in the eventual compromise of plasma and liver DHA status   or   160 
whether there are mechanisms in place which ensure maintenance of DHA status, such 
as reduced β oxidation of DHA or its metabolic precursors.   
 
This work undertaken using a rat model also provides some direction for potential 
future human studies.  It would be of interest to determine whether circulating sex 
hormone concentrations can be correlated to plasma DHA status in humans, though it is 
likely that rigorous dietary control may be required to prevent a confounding effect of 
dietary ALNA intake.  These studies could be performed in women at various stages of 
the menstrual cycle, and a study in men would identify whether variation in testosterone 
status interacts with DHA status.  The collection of samples of subcutaneous adipose is 
possible from human subjects and could be used to determine whether  6 desaturase 
expression or activity within adipose tissue is affected by gender or sex hormones in 
humans.   
 
Human studies to date have lacked detailed information about the responses of females 
to increased dietary ALNA.  The observation that the EPA status of female rats on an 
ALNA rich diet reaches much higher levels than is seen in males rats (see figure 3.5) is 
therefore of relevance to human health, and might indicate that for women, dietary 
ALNA supplementation can confer some of the health benefits which are associated 
with LC n 3 PUFA supplementation.    161 
 
 
 
 
 
 
Chapter 4:  Pregnancy and the fatty acid 
composition of rat tissues    162 
4.1 Introduction 
4.1.1 Aims and hypothesis for current investigation  
 
This study sets out to address the hypothesis that changes to rat tissue fatty acid 
composition during pregnancy are mediated by sex hormones and/or the expression of 
genes for enzymes involved in endogenous synthesis of LC PUFA.  
 
Human studies have identified that men and women differ in their ability to synthesise 
longer chain (LC) n 3 polyunsaturated fatty acids (PUFA)(130;131;138) and that 
women have higher circulating concentrations of docosahexaenoic acid (DHA, 22:6n 3) 
than men(132 135).  The study described in chapter 3 has demonstrated that these 
gender differences are also apparent in the rat.  It has been proposed that these gender 
differences are established in order to ensure an adequate supply of LC PUFA to the 
developing fetus during pregnancy(133).  If this is the case, then it is possible that LC 
PUFA synthesis may be further upregulated during pregnancy.  This may be under the 
control of sex hormones, and potentially mediated via an effect upon expression of 
genes involved in the desaturation and elongation of essential fatty acids (EFA) into LC 
PUFA.  
 
Studies in rats comparing virgin animals with those at the end of pregnancy have shown 
that the fatty acid composition of phospholipids from plasma and liver is significantly 
altered in response to pregnancy with higher DHA and lower arachidonic acid (AA) 
contents(167 170).  Human studies also suggest an effect of pregnancy upon blood lipid 
fatty acid composition, but the effects described are inconsistent.  Human studies to date 
have not included pre pregnancy data and may be complicated by dietary differences, 
and the effect of past diet upon adipose tissue composition.  It is therefore necessary to 
use a more controlled setting to evaluate the effect of pregnancy upon tissue fatty acid 
composition and the potential mechanisms involved.  This study is cross sectional in 
design to enable sampling of organs such as liver and adipose tissue, which would not 
be possible in a longitudinal study. 
4.1.2 Animal studies of pregnancy and fatty acid composition 
 
Several studies have been undertaken using rats to investigate the effect of pregnancy 
upon the fatty acid composition of plasma and liver phospholipids and triglycerides.  A   163 
summary of the findings of these studies can be found in table 4.1.  These studies have 
all identified that there are significant differences between the fatty acid content of rat 
tissues at the end of gestation compared to virgin females.  Consistent effects of 
pregnancy observed are higher 16:0 and DHA content, and lower 18:0 and AA content 
of both plasma and liver phospholipids.  The association of 16:0 with DHA status, and 
18:0 with AA status, is due to the common pairing of these fatty acids within 
phospholipid structure.  Animal studies to date have not yet identified whether the 
changes observed in fatty acid composition correlate to changes in circulating sex 
hormones or in the expression of desaturase and elongase genes in the liver. 
4.1.3 Human studies of pregnancy and fatty acid composition 
 
Human studies have been undertaken to examine the effect of pregnancy upon maternal 
fatty acid status(162 166).  Full details of the findings of these studies are described in 
chapter 1 (see table 1.4).  Longitudinal human studies to date have not included pre 
conception data, and therefore can only indicate variations in fatty acid status which 
occur after the first trimester.   
 
The effects observed in human studies have been mixed, which can probably be 
attributed to variations in sample size, the type of blood lipid sample analysed, potential 
dilution effects from changes in maternal blood volume during pregnancy, and the 
confounding effect of maternal diet, with the potential for differences in mobilisation 
from maternal adipose stores and the composition of those stores.  For example, while 
some studies have identified a reduction in plasma phospholipid DHA status during 
pregnancy(163), others have reported increased DHA content of plasma 
phospholipids(165) or red blood cells(166).   
 
The effects observed in human studies have not been limited to LC n 3 PUFA, with 
significant effects of pregnancy also observed upon saturated fatty acids, 
monounsaturated fatty acids (MUFA) and n 6 PUFA(162 166).  No human study to 
date has determined whether the changes in fatty acid status observed relate to sex 
hormone status.   164 
 
Table 4.1: Summary of rat studies which have investigated the effect of pregnancy upon plasma or liver fatty acid composition 
 
  Study groups  Plasma phospholipids  Liver phospholipids  Liver triglycerides 
Smith, 1975 (167)  
(% content) 
virgin 
day 21 pregnant 
    ￿ 16:0  ￿ 18:0 
￿ AA 
￿18:2n 6 
Cunnane, 1989 (168)  
(% content) 
 
virgin 
day 21 pregnant 
    ￿ 16:0 
￿ DHA 
￿ 18:0 
￿ 18:2n 6 
￿ AA 
￿ AA 
Chen et al, 1992 (169)  
(% content) 
 
virgin 
day 13 pregnant 
day 15 pregnant 
day 21 pregnant † 
￿ 16:0 
￿ DHA 
￿ 18:0 
￿ 18:2n 6 
￿ AA 
￿ 16:0 
￿ DHA 
￿ 18:0 
￿ 18:2n 6 
￿ AA 
 
Burdge et al, 1994 (170) 
(absolute quantity) 
 
virgin 
day 16 pregnant 
day 21 pregnant 
 
￿ 16:0/DHA 
 
￿ 18:0/AA 
 
￿ 16:0/DHA 
 
 
￿ 18:0/AA * 
 
 
 
￿ Significantly higher content during pregnancy    ￿ Significantly lower content during pregnancy 
 
* Exception was liver phosphatidylcholine (PC), where 18:0/AA was significantly higher compared to virgin at day 16 of pregnancy, but significantly 
lower compared to virgin at day 21 of pregnancy.  
 
† Significant differences were between day 21 of pregnancy and virgin only 
   165 
4.2 Methods 
This study sets out to identify the effects of pregnancy upon plasma and tissue fatty acid 
composition and to identify whether effects seen are mediated by sex hormones and/or 
the expression of desaturase and elongase genes.  This will be assessed by 
determination of the fatty acid composition of tissues including plasma, liver and 
adipose tissue by gas chromatography, measurement of plasma sex hormone 
concentrations, and the assessment of liver mRNA expression of desaturase and 
elongase genes by RT PCR. 
 
All animal work was carried out in accordance with the Home Office Animals 
(Scientific Procedures) Act (1986); for pregnant females, mating was carried out by 
monogamous breeding (see section 2.1), and maternal tissues collected on either day 12 
or day 20 of gestation.  Fatty acid composition of experimental diet and tissues was 
determined by gas chromatography (see section 2.6).  Liver lipid, dry weight and 
glycogen content were assessed (see sections 2.8 and 2.10).  Plasma lipid, glucose and 
circulating sex hormones analysis was provided by Southampton General Hospital (see 
sections 2.7 and 2.9).  mRNA expression of desaturase and elongase genes was 
determined by RT PCR (see section 2.12).   
 
The effect of pregnancy upon tissue fatty acid composition, plasma sex hormones and 
mRNA expression was assessed by one way ANOVA.  Correlation coefficients (r) were 
calculated using Pearson or Spearman test as appropriate after data were assessed for 
normality. 
4.3 Results 
4.3.1  Experimental diets 
Animals received a standard maintenance chow throughout the study period.  This was 
a low fat (LF, 3% w/w) soyabean oil based diet (SDS, Witham, UK) which contains 
adequate n 3 and n 6 EFA.  The full details of the nutrient composition of this diet 
provided by the manufacturer are described in chapter 2 (see section 2.3).  The fatty 
acid composition of the LF soyabean oil diet was assessed by gas chromatography and 
was described in the previous chapter (see table 3.1).  This diet contains little dietary LC 
PUFA, and so any DHA detected within tissue lipids would derive from endogenous 
synthesis rather than from direct dietary sources.   166 
4.3.2  Weight gain and food intake 
Virgin females had their weight and food intake monitored every 7 days over the study 
period.  Food intake was monitored by weighing food provided and remaining every 2 3 
days.  Typical rat pregnancy is 21 24 days.  Pregnant rats had their weight and food 
intake monitored over either a 12 or 20 day period from day 1 of gestation (see table 
4.2, figure 4.1).    
 
Table 4.2: Weight gain and weighed dietary intake of virgin and pregnant rats over 
study period (mean ± standard deviation) 
 
   
Virgin  
(n=6) 
Day 12 of 
pregnancy  
(n=5) 
Day 20 of 
pregnancy  
(n=6) 
 
ANOVA  
p value 
Weight gain (g/day)  0.7 ± 0.1 
a  3.2 ± 0.2 
b  3.2 ± 1.0 
b  < 0.001 
Food intake (g/day)  16.1 ± 1.0  17.3 ± 0.7  17.9 ± 2.2  0.134 
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts  
 
Figure 4.1:  The weight of virgin and pregnant rats over study period (mean ± SEM) 
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*  Significantly different from virgin females (T test, p = 0.19)   167 
 
Pregnant rats gained significantly more weight per day compared to virgin females.  
There was a non significant trend for increased food consumption with pregnancy, 
indicating that pregnancy only induces modest hyperphagia during pregnancy in the rat. 
4.3.3  Plasma glucose and lipid concentrations 
Plasma glucose concentration was lower and plasma non esterified fatty acid (NEFA) 
concentrations higher with pregnancy (table 4.3).  Hypertriglyceridemia is a feature of 
pregnancy which has been observed in both human and rat models(153), yet this was 
not observed in the current study.  However, in this study animals were not fasted prior 
to collection of blood samples, which may have resulted in a confounding effect of fed 
status.  
 
Table 4.3: Plasma glucose and lipid concentrations observed in virgin and pregnant rats 
(mean ± standard deviation) 
 
  Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
Plasma glucose (mM)  13.5 ± 2.0 
a  12.2 ± 3.3 
a  7.3 ± 2.8 
b  0.004 
Total cholesterol (mM)  1.3 ± 0.3  1.4 ± 0.4  1.3 ± 0.4  0.930 
HDL cholesterol (mM)  0.9 ± 0.2  0.9 ± 0.3  0.9 ± 0.2  0.980 
TAG (mM)  1.4 ± 0.4  1.3 ± 0.3  1.5 ± 0.7  0.916 
NEFA (mM)  0.27 ± 0.18  0.40 ± 0.32  0.68 ± 0.28  0.048 † 
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts 
†  no significant differences between groups when Bonferroni post hoc test applied 
4.3.4 Plasma fatty acid composition 
The fatty acid compositions of plasma phosphatidylcholine (PC), TAG, cholesteryl 
esters (CE) and NEFA were assessed by gas chromatography (see tables 4.4 to 4.7).  
Other studies using rat models have identified higher 16:0 and DHA and lower 18:0 and 
AA with pregnancy in rat plasma phospholipids(169;170).  These trends were also 
apparent in the current study (see figures 4.2 and 4.3).   
 
It is clear from the data that the changes in fatty acid content of plasma phospholipids 
are not simple linear relationships of change over the course of pregnancy.  For 
example, the 18:0 and AA content of plasma phospholipids is significantly higher at day 
12 of gestation than in either virgin females or day 20 gestation females.  
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A summary of the trends observed across all plasma lipid fractions during pregnancy is 
found in table 4.8.  As well as DHA being higher in plasma PC in pregnancy it was also 
higher in plasma TAG and CE (see figure 4.4).  In addition, 22:5n 6 was increased in 
plasma PC, TAG and CE in pregnancy (see figure 4.5).  This indicates that pregnancy 
exerts complex effects upon endogenous synthesis of n 6 LC PUFA during pregnancy; 
the lower AA content in plasma PC in pregnancy may indicate increased conversion of 
AA to 22:5n 6.    
 
Reduced linoleic acid (LA, 18:2n 6) and α linolenic acid (ALNA, 18:3n 3) contents of 
plasma PC, TAG and CE were also observed among pregnant females (see figure 4.6 
and 4.7).  This indicates that as pregnancy progresses EFA status is reduced, perhaps 
due to the increased demands of endogenous synthesis of LC PUFA.  There was an 
indication that the ALNA content of some plasma lipids is higher at day 12 gestation, 
which may indicate either increased mobilisation of ALNA from adipose tissue or lower 
rates of LC n 3 PUFA synthesis at this point of gestation. 
 
Figure 4.2: The 16:0 and DHA content (% total fatty acids) of plasma PC in virgin and 
pregnant female rats (mean ± standard deviation) 
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Figure 4.3: The 18:0 and AA content (% total fatty acids) of plasma PC of virgin and 
pregnant female rats (mean ± standard deviation) 
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Table 4.4: Fatty acid composition (% total fatty acids) of plasma PC in virgin and 
pregnant female rats (mean ± standard deviation) 
 
 
Fatty acid 
Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
14:0  0.19 ± 0.11  0.27 ± 0.08  0.24 ± 0.08  0.437 
16:0  20.71 ± 1.23 
a  16.78 ± 0.90 
b  27.38 ± 1.58 
c  < 0.001 
18:0  26.72 ± 1.62 
a  30.08 ± 2.18 
b  19.86 ± 2.08 
c  < 0.001 
20:0  0.23 ± 0.27  ND  0.24 ± 0.29  0.424 
22:0  0.11 ± 0.18  0.04 ± 0.06  0.29 ± 0.43  0.313 
Total saturated  47.96 ± 1.24  48.47 ± 1.62  48.02 ± 1.84  0.849 
16:1n 7  0.80 ± 0.57  0.40 ± 0.08  1.17 ± 0.80  0.129 
18:1n 9  4.27 ± 0.90  4.45 ± 0.79  4.60 ± 0.84  0.802 
20:1n 9  0.14 ± 0.16  0.12 ± 0.13  ND  0.125 
Total MUFA  5.26 ± 1.33  5.40 ± 1.43  5.78 ± 1.42  0.805 
18:2n 6  20.08 ± 1.79 
a  17.59 ± 2.61 
a  12.18 ± 1.84 
b  < 0.001 
18:3n 6  1.18 ± 0.86  0.13 ± 0.17  1.32 ± 0.93  0.046 
20:2n 6  0.45 ± 0.13 
a  0.16 ± 0.22 
b  0.22 ± 0.18 
ab  0.034 
20:3n 6  0.79 ± 0.41 
a  1.27 ± 0.37 
a  0.15 ± 0.24 
b  < 0.001 
20:4n 6  16.14 ± 1.51 
a  20.20 ± 1.42 
b  11.99 ± 1.37 
c  < 0.001 
22:5n 6  0.72 ± 0.22 
a  1.24 ± 0.46 
a  6.05 ± 0.71 
b  < 0.001 
Total n 6 PUFA  39.36 ± 1.85 
a  39.35 ± 2.32 
a  31.90 ± 2.67 
b  < 0.001 
18:3n 3  0.20 ± 0.13 
ab  0.84 ± 0.73 
a  0.13 ± 0.10 
b  0.022 
20:4n 3  ND  0.41 ± 0.61  ND  0.097 
20:5n 3  1.06 ± 0.85  0.50 ± 0.29  0.88 ± 0.86  0.480 
22:5n 3  0.95 ± 0.11 
a  0.50 ± 0.30 
b  1.28 ± 0.34 
a  0.001 
22:6n 3  5.22 ± 1.02 
a  4.94 ± 1.48 
a  12.00 ± 1.73 
b  < 0.001 
Total n 3 PUFA  7.42 ± 1.32 
a  6.78 ± 1.15 
a  14.30 ± 2.26 
b  < 0.001 
 
ND  negligible detected (mean < 0.1%) 
a, b, c  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts 
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Table 4.5: Fatty acid composition (% total fatty acids) of plasma TAG in virgin and 
pregnant female rats (mean ± standard deviation) 
 
 
Fatty acid 
Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
14:0  0.77 ± 0.27 
a  1.24 ± 0.07 
b  0.34 ± 0.19 
c  < 0.001 
16:0  26.70 ± 2.76 
ab  28.27 ± 2.79 
a  22.74 ± 2.85 
b  0.014 
18:0  5.26 ± 2.61  4.10 ± 0.38  5.10 ± 1.58  0.550 
20:0  0.18 ± 0.33  0.16 ± 0.09  0.30 ± 0.46  0.758 
22:0  0.46 ± 0.66  ND  0.62 ± 0.86  0.315 
Total saturated  33.37 ± 4.24  33.80 ± 2.97  29.10 ± 3.05  0.073 
16:1n 7  3.02 ± 1.17  3.18 ± 0.56  2.85 ± 1.00  0.850 
18:1n 9  22.29 ± 3.90 
ab  28.02 ± 1.52 
a  19.27 ± 4.38 
b  0.004 
20:1n 9  0.34 ± 0.17  0.26 ± 0.20  0.14 ± 0.22  0.241 
24:1n 9  0.12 ± 0.18  ND  ND  0.141 
Total MUFA  25.77 ± 4.71 
ab  31.46 ± 2.04 
a  22.26 ± 4.93 
b  0.010 
18:2n 6  29.97 ± 3.76  25.01 ± 2.35  26.74 ± 4.12  0.096 
18:3n 6  1.03 ± 0.64 
ab  0.39 ± 0.12 
a  4.00 ± 3.72 
b  0.038 
20:2n 6  0.40 ± 0.22  0.27 ± 0.09  0.27 ± 0.29  0.544 
20:3n 6  0.38 ± 0.30  0.43 ± 0.24  0.40 ± 0.34  0.951 
20:4n 6  3.85 ± 1.10 
a  3.05 ± 0.94 
a  8.34 ± 2.56 
b  < 0.001 
22:5n 6  0.45 ± 0.29 
a  0.59 ± 0.19 
a  1.10 ± 0.18 
b  < 0.001 
Total n 6 PUFA  36.07 ± 4.54 
a  29.75 ± 3.68 
b  40.85 ± 2.63 
a  0.001 
18:3n 3  2.24 ± 0.38 
a  1.76 ± 0.30 
ab  1.35 ± 0.40 
b  0.003 
20:4n 3  ND  0.13 ± 0.18  ND  0.154 
20:5n 3  0.81 ± 0.67  0.45 ± 0.34  2.11 ± 2.29  0.159 
22:5n 3  0.67 ± 0.33 
ab  0.54 ± 0.32 
a  1.20 ± 0.51 
b  0.034 
22:6n 3  1.05 ± 0.56 
a  2.11 ± 1.03 
ab  3.14 ± 1.90 
b  0.047 
Total n 3 PUFA  4.81 ± 0.86  5.00 ± 2.05  7.80 ± 4.23  0.161 
 
ND  negligible detected (mean < 0.1%) 
a, b, c  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts   172 
 
 
Table 4.6: Fatty acid composition (% total fatty acids) of plasma CE in virgin and 
pregnant female rats (mean ± standard deviation) 
 
Fatty acid 
Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
14:0  0.19 ± 0.20  0.35 ± 0.05  0.21 ± 0.23  0.351 
16:0  11.82 ± 3.70  9.72 ± 1.20  14.38 ± 3.33  0.069 
18:0  3.05 ± 1.52  2.62 ± 0.94  5.28 ± 2.12  0.034 
22:0  ND 
a  0.47 ± 0.26 
b  ND 
a  < 0.001 
Total saturated  15.08 ± 5.27  13.38 ± 2.27  19.92 ± 5.48  0.086 
16:1n 7  1.24 ± 0.57  1.58 ± 0.06  1.40 ± 0.36  0.406 
18:1n 9  5.61 ± 2.42  5.76 ± 0.76  6.84 ± 1.34  0.420 
20:1n 9  ND  0.63 ± 0.75  ND  0.050 
Total MUFA  6.92 ± 2.72  7.99 ± 0.85  8.25 ± 1.61  0.479 
18:2n 6  20.65 ± 2.03 
a  18.69 ± 2.35 
ab  16.99 ± 2.53 
b  0.050 
18:3n 6  0.75 ± 0.14  0.79 ± 0.08  0.90 ± 0.19  0.236 
20:2n 6  ND 
a  0.20 ± 0.07 
b  ND 
a  < 0.001 
20:3n 6  0.26 ± 0.20  0.44 ± 0.26  0.31 ± 0.76  0.817 
20:4n 6  52.88 ± 5.90  53.50 ± 6.22  46.41 ± 3.36  0.070 
22:5n 6  ND 
a  0.16 ± 0.16 
a  1.48 ± 0.22 
b  < 0.001 
Total n 6 PUFA  74.58 ± 7.16  73.62 ± 4.20  66.09 ± 5.49  0.050 
18:3n 3  0.29 ± 0.06
 a  1.07 ± 0.54 
b  0.33 ± 0.09 
a  0.001 
20:5n 3  1.26 ± 0.44 
a  1.69 ± 0.77 
a  0.44 ± 0.27 
b  0.004 
22:6n 3  1.86 ± 0.49 
a  2.26 ± 0.54 
a  4.88 ± 1.00 
b  < 0.001 
Total n 3 PUFA  3.42 ± 0.75 
a  5.02 ± 1.36 
ab  5.76 ± 1.04 
b  0.006 
 
ND  negligible detected (mean < 0.1%) 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts    173 
 
 
Table 4.7: Fatty acid composition (% total fatty acids) of plasma NEFA in virgin and 
pregnant female rats (mean ± standard deviation) 
 
Fatty acid 
Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
14:0  1.38 ± 0.34   2.11 ± 0.56  1.19 ± 0.74   0.047 
16:0  27.47 ± 3.14   23.61 ± 1.97  25.22 ± 1.93   0.060 
18:0  19.38 ± 5.16 
a  17.05 ± 2.73 
ab  11.17 ± 1.81 
b   0.004 
20:0  0.33 ± 0.30  0.93 ± 0.35  0.52 ± 0.69  0.164 
22:0  0.72 ± 0.97  0.26 ± 0.18  0.45 ± 0.33  0.483 
Total saturated  49.29 ± 6.99 
a  45.12 ± 3.95 
ab  38.59 ± 3.19 
b  0.009 
16:1n 7  2.55 ± 1.64  2.49 ± 0.52  3.13 ± 2.62  0.813 
18:1n 9  15.85 ± 2.74 
ab  13.92 ± 3.77 
a  19.23 ± 1.13 
b   0.016 
20:1n 9  ND 
ab  0.39 ± 0.39 
a  ND 
b  0.031 
24:1n 9  0.15 ± 0.17  0.26 ± 0.26  ND  0.154 
Total MUFA  18.60 ± 3.51   17.49 ± 3.65  22.41 ± 2.72   0.059 
18:2n 6  19.09 ± 4.77 
ab  12.14 ± 9.36 
a  23.91 ± 3.03 
b  0.021 
18:3n 6  1.84 ± 3.19  0.76 ± 0.83  1.79 ± 1.75  0.677 
20:2n 6  0.57 ± 1.24  0.51 ± 0.25  0.27 ± 0.44  0.784 
20:3n 6  0.10 ± 0.23 
a  0.52 ± 0.08 
b  ND 
a  0.003 
20:4n 6  5.38 ± 1.12 
a  11.17 ± 3.08 
b  3.65 ± 1.25 
a  < 0.001 
22:5n 6  0.12 ± 0.10  0.74 ± 0.63  0.68 ± 0.36  0.038 
Total n 6 PUFA  27.12 ± 4.36  25.10 ± 6.31  30.38 ± 4.79   0.257 
18:3n 3  1.66 ± 0.48 
a  6.66 ± 3.06 
b  2.20 ± 0.80 
a  0.001 
20:4n 3  ND 
a  0.56 ± 0.39 
b  0.13 ± 0.32 
ab  0.018 
20:5n 3  1.20 ± 1.86  3.27 ± 2.90  1.74 ± 1.82  0.308 
22:5n 3  0.36 ± 0.13   0.30 ± 0.18  0.93 ± 0.92   0.143 
22:6n 3  1.76 ± 0.75  1.92 ± 0.33  3.60 ± 2.64  0.144 
Total n 3 PUFA  5.00 ± 2.12  12.29 ± 6.03  8.61 ± 6.12  0.091 
 
ND  negligible detected (mean < 0.1%) 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts 
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Table 4.8: Summary of the significant differences observed in fatty acid composition 
between virgin and pregnancy female rats within plasma lipids during the study period 
 
  PC  TAG  CE  NEFA 
Day 20 > Day 12 > Virgin  22:5n 6  22:5n 6 
22:6n 3 
22:5n 6 
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Figure 4.4: Graph to illustrate the DHA content (% total fatty acids) of plasma lipids in 
virgin and pregnant female rats (mean ± standard deviation) 
 
0
5
10
15
0 (virgin
females)
12 20
Day of gestation
%
 
t
o
t
a
l
 
f
a
t
t
y
 
a
c
i
d
s
PC
TAG
CE
 
* significantly different from virgin females (p < 0.05) 
 
Figure 4.5: Graph to illustrate the 22:5n 6 content (% total fatty acids) of plasma lipids 
in virgin and pregnant female rats (mean ± standard deviation) 
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Figure 4.6: Graph to illustrate the LA (18:2n 6) content (% total fatty acids) of plasma 
lipids in virgin and pregnant female rats (mean ± standard deviation) 
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* significantly different from virgin females (p < 0.05) 
 
 
Figure 4.7: Graph to illustrate the ALNA (18:3n 3) content (% total fatty acids) of 
plasma lipids in virgin and pregnant female rates (mean ± standard deviation) 
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4.3.5 Liver size and composition 
 
Relative liver size and lipid content were highest and liver dry weight lowest in the mid 
gestation group (see table 4.9).  This suggests that during mid gestation there is natural 
accumulation of lipids within the liver.  Other studies have also demonstrated higher 
liver lipid content in pregnant rats than in virgin rats(233).  Liver glycogen stores were 
depleted during pregnancy.  
 
Table 4.9: Liver size and composition in virgin and pregnant female rats (mean ± 
standard deviation) 
 
  Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
Liver (% body weight)  3.7 ± 0.1 
a  4.3 ± 0.4 
b  3.6 ± 0.3 
a  0.006 
Liver dry weight (% wet weight)  29.4 ± 0.9 
a  27.2 ± 0.8 
b  28.4 ± 1.3 
ab  0.012 
Liver lipid (% wet weight)  3.2 ± 0.3 
a  4.5 ± 0.5 
b  3.4 ± 0.2 
a  < 0.001 
Liver glycogen (% wet weight)  5.2 ± 1.0 
a  4.1 ± 0.7 
a  1.4 ± 1.6 
b  < 0.001 
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts 
 
4.3.6 Liver fatty acid composition 
The fatty acid compositions of liver lipids in virgin and pregnant rats are shown in 
tables 4.10 to 4.13.  Previous studies have demonstrated that pregnancy in rats results in 
higher 16:0 and DHA and lower 18:0, AA and LA content of liver phospholipids(167 
170).  These features were observed in the current dataset for liver PC and PE (see 
figures 4.8 to 4.11).  As was the case in plasma phospholipids, these effects of 
pregnancy were not simple linear changes with pregnancy.  For example, 18:0 and AA 
content was significantly higher at day 12 gestation compared to virgin females, but fell 
to significantly lower levels than those in virgin females by day 20 of gestation.  
 
Liver CE fatty acid composition was also altered in response to pregnancy, with some 
effects mirroring those observed in liver phospholipids, such as increased DHA and 
reduced 18:0 at day 20 gestation compared to virgin females.  The effects upon other 
fatty acids differed from those observed in liver phospholipids, with higher LA and AA, 
and no significant effect on 16:0 content.  This indicates that there are lipid fraction 
specific responses to pregnancy.   178 
 
Liver TAG fatty acid composition also demonstrated a markedly different response to 
pregnancy than liver phospholipids, with 18:0 and AA content in liver TAG 
significantly higher at day 20 gestation than in virgin females, and increased LA content 
(see figure 4.11), the opposite pattern to that observed within liver phospholipids.   
 
Correlations between the fatty acid composition of liver lipids and plasma lipids were 
used to determine to what extent plasma lipid composition was related to liver 
composition (see table 4.14, figure 4.12).  Plasma phospholipid and TAG fatty acid 
composition demonstrated strong and statistically significant correlations with liver 
phospholipid and TAG fatty acid composition, respectively.  These significant 
correlations were observed across the full range of fatty acids identified, including 
saturates, MUFA, and n 6 and n 3 PUFA.   
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Figure 4.8: Graph to illustrate the 16:0 and DHA (22:6n 3) content (% 
total fatty acids) within liver PC in virgin and female pregnant rats 
(mean ± standard deviation) 
 
0
5
10
15
20
25
30
35
0 (virgin females) 12 20
Day of gestation
%
 
t
o
t
a
l
 
f
a
t
t
y
 
a
c
i
d
s
16:0
22:6n-3
 
* significantly different from virgin females (p < 0.05) 
 
 
Figure 4.9: Graph to illustrate the 18:0 and AA (20:4n 6) content (% 
total fatty acids) within liver PC in virgin and female pregnant rats 
(mean ± standard deviation) 
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Figure 4.10: Graph to illustrate the LA (18:2n 6) content (% total fatty 
acids) of liver PE in virgin and pregnant female rats (mean ± standard 
deviation) 
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Figure 4.11: Graph to illustrate the LA (18:2n 6) and AA (20:4n 6) 
content (% total fatty acids) in liver TAG in virgin and pregnant female 
rats (mean ± standard deviation) 
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Table 4.10: Fatty acid composition (% total fatty acids) of liver PC in virgin and 
pregnant female rats (mean ± standard deviation) 
 
Fatty acid 
Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
14:0  0.22 ± 0.03 
a  0.19 ± 0.03 
ab  0.15 ± 0.02 
b  0.002 
16:0  18.39 ± 0.67 
a  13.70 ± 0.98 
b  28.39 ± 1.73 
c  < 0.001 
18:0  28.62 ± 1.45 
a  31.45 ± 1.14 
b  20.25 ± 1.42 
c  < 0.001 
22:0  ND  0.10 ± 0.03  ND  0.037 
Total saturated  47.26 ± 1.13 
ab  46.51 ± 1.68 
a  48.91 ± 1.36 
b  0.033 
16:1n 7  0.61 ± 0.21  0.55 ± 0.04  0.68 ± 0.17  0.434 
18:1n 9  3.30 ± 0.48  3.84 ± 0.25  3.63 ± 0.73  0.268 
20:1n 9  0.12 ± 0.15  ND  0.11 ± 0.10  0.929 
24:1n 9  ND 
a  0.11 ± 0.07 
b  ND 
a  0.004 
Total MUFA  4.03 ± 0.71  4.62 ± 0.37  4.35 ± 0.88  0.388 
18:2n 6  12.39 ± 1.22  10.96 ± 1.96  10.55 ± 0.91  0.089 
18:3n 6  0.35 ± 0.08 
a  0.24 ± 0.03 
b  0.38 ± 0.04 
a  0.003 
20:2n 6  0.31 ± 0.06 
a  0.13 ± 0.03 
b  0.27 ± 0.05 
a  < 0.001 
20:3n 6  1.06 ± 0.13 
a  1.26 ± 0.19 
a  0.35 ± 0.08 
b  < 0.001 
20:4n 6  24.33 ± 1.24 
a  26.94 ± 1.54 
b  18.54 ± 0.49 
c  < 0.001 
22:5n 6  0.18 ± 0.19 
a  1.01 ± 0.71 
b  0.24 ± 0.13 
a  0.008 
Total n 6 PUFA  38.62 ± 2.03 
a  39.54 ± 2.51 
a  30.33 ± 1.49 
b  < 0.001 
18:3n 3  0.13 ± 0.11  0.25 ± 0.20  0.19 ± 0.05  0.327 
20:5n 3  0.71 ± 0.15 
a  0.83 ± 0.40 
a  0.17 ± 0.11 
b  0.001 
22:5n 3  1.34 ± 0.08 
a  0.80 ± 0.09 
b  1.37 ± 0.21 
a  < 0.001 
22:6n 3  7.90 ± 1.12 
a  7.45 ± 1.41 
a  14.59 ± 1.47 
b  < 0.001 
Total n 3 PUFA  10.09 ± 1.06 
a  9.33 ± 1.44 
a  16.33 ± 1.52 
b  < 0.001 
 
ND  negligible detected (mean <0.1%) 
a, b, c  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts   182 
Table 4.11: Fatty acid composition (% total fatty acids) of liver 
phosphatidylethanolamine (PE) in virgin and pregnant female rats (mean ± standard 
deviation) 
 
Fatty acid 
Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
16:0  18.41 ± 0.64 
a  14.93 ± 0.87 
b  22.16 ± 1.35 
c  < 0.001 
18:0  26.77 ± 0.59 
a  28.46 ± 0.70 
b  27.18 ± 1.43 
ab  0.037 
Total saturated  45.20 ± 0.41 
a  45.19 ± 1.83 
a  49.42 ± 0.99 
b  < 0.001 
16:1n 7  0.33 ± 0.09 
a  0.32 ± 0.03 
a  0.21 ± 0.05 
b  0.010 
18:1n 9  2.17 ± 0.38 
ab  2.61 ± 0.34 
a  1.89 ± 0.40 
b  0.023 
20:1n 9  0.22 ± 0.13  ND  0.16 ± 0.15  0.220 
Total MUFA  2.72 ± 0.44  3.02 ± 0.40  2.26 ± 0.54  0.051 
18:2n 6  6.40 ± 0.95 
a  6.20 ± 1.65 
a  3.60 ± 0.38 
b  0.001 
18:3n 6  0.21 ± 0.08  ND  ND  0.064 
20:2n 6  0.22 ± 0.03 
a  0.13 ± 0.03 
b  0.21 ± 0.07 
a  0.013 
20:3n 6  0.61 ± 0.07 
a  0.76 ± 0.17 
a  0.25 ± 0.10 
b  < 0.001 
20:4n 6  25.81 ± 0.69 
a  28.03 ± 2.43 
a  19.79 ± 0.67 
b  < 0.001 
22:5n 6  ND 
a  1.75 ± 1.49 
b  ND 
a  0.004 
Total n 6 PUFA  33.24 ± 1.60 
a  35.20 ± 4.01 
a  23.91 ± 0.92 
b  < 0.001 
18:3n 3  0.23 ± 0.03 
ab  0.29 ± 0.20 
a  ND 
b  0.035 
20:5n 3  0.49 ± 0.09 
a  0.65 ± 0.31 
a  0.12 ± 0.08 
b  0.001 
22:5n 3  3.00 ± 0.21 
a  1.66 ± 0.25 
b  1.83 ± 0.22 
b  < 0.001 
22:6n 3  15.11 ± 1.86 
a  13.99 ± 2.74 
a  22.38 ± 1.14 
b  < 0.001 
Total n 3 PUFA  18.84 ± 1.66 
a  16.59 ± 2.77 
a  24.41 ± 1.10 
b  < 0.001 
 
ND  negligible detected (mean <0.1%) 
a, b, c  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts    183 
Table 4.12: Fatty acid composition (% total fatty acids) of liver CE in virgin and 
pregnant female rats (mean ± standard deviation) 
 
Fatty acid 
Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
14:0  0.61 ± 0.20  0.45 ± 0.08  0.34 ± 0.18  0.058 
16:0  43.69 ± 3.16  39.68 ± 7.02  42.95 ± 3.39  0.357 
18:0  21.07 ± 3.48 
a  35.16 ± 9.15 
b  15.54 ± 2.61 
a  < 0.001 
20:0  0.26 ± 0.32  ND  0.42 ± 0.42  0.131 
22:0  ND 
a  0.29 ± 0.18 
b  ND 
a  < 0.001 
Total saturated  65.62 ± 3.58 
a  75.58 ± 2.22 
b  59.26 ± 4.73 
c  < 0.001 
16:1n 7  2.04 ± 0.73  1.13 ± 0.23  1.96 ± 0.72  0.061 
18:1n 9  7.47 ± 1.98  6.26 ± 0.92  9.06 ± 2.83  0.126 
20:1n 9  0.34 ± 0.30  ND  0.44 ± 0.33  0.073 
Total MUFA  9.84 ± 2.56  7.43 ± 1.14  11.46 ± 3.37  0.068 
18:2n 6  13.43 ± 1.58 
a  8.33 ± 1.17 
b  15.01 ± 1.63 
a  < 0.001 
18:3n 6  0.37 ± 0.28  ND  0.35 ± 0.35  0.155 
20:2n 6  0.35 ± 0.14 
a  ND 
b  0.38 ± 0.27 
a  0.007 
20:3n 6  0.21 ± 0.17  0.32 ± 0.18  0.12 ± 0.15  0.169 
20:4n 6  7.84 ± 1.24 
ab  6.42 ± 2.01 
a  9.64 ± 1.73 
b  0.021 
22:5n 6  ND 
a  ND 
a  0.40 ± 0.07 
b  < 0.001 
Total n 6 PUFA  22.19 ± 1.89 
a  15.13 ± 1.26 
b  25.90 ± 2.40 
c  < 0.001 
18:3n 3  0.99 ± 0.24  0.86 ± 0.34  0.98 ± 0.29  0.725 
20:4n 3  0.26 ± 0.63  ND  ND  0.554 
20:5n 3  0.22 ± 0.18  0.23 ± 0.15  0.23 ± 0.51  0.999 
22:5n 3  0.20 ± 0.16  ND  0.22 ± 0.24  0.498 
22:6n 3  0.66 ± 0.40 
a  0.67 ± 0.39 
a  1.88 ± 0.39 
b  < 0.001 
Total n 3 PUFA  2.34 ± 0.21 
a  1.85 ± 0.30 
a  3.38 ± 0.77 
b  0.001 
 
ND  negligible detected (mean <0.1%) 
a, b, c  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts   184 
Table 4.13: Fatty acid composition (% total fatty acids) of liver TAG in virgin and 
pregnant female rats (mean ± standard deviation) 
 
Fatty acid 
Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
14:0  1.03 ± 0.23 
a  1.49 ± 0.12 
b  0.45 ± 0.06 
c  < 0.001 
16:0  31.75 ± 3.86 
a  32.76 ± 3.60 
a  25.25 ± 1.05 
b  0.002 
18:0  3.88 ± 1.06  4.43 ± 0.48  3.53 ± 0.41  0.158 
20:0  0.17 ± 0.14 
ab  ND 
a  0.26 ± 0.13 
b  0.031 
Total saturated  36.83 ± 4.77 
a  38.71 ± 3.97 
a  29.57 ± 0.98 
b  0.002 
16:1n 7  3.33 ± 1.22  3.77 ± 0.76  2.35 ± 0.75  0.065 
18:1n 9  27.18 ± 2.58 
ab  29.70 ± 1.88 
a  22.65 ± 3.35 
b  0.006 
20:1n 9  0.23 ± 0.19  0.30 ± 0.16  0.35 ± 0.05  0.429 
Total MUFA  30.74 ± 4.21 
ab  33.77 ± 2.51 
a  25.34 ± 3.96 
b  0.006 
18:2n 6  24.18 ± 2.88 
a  20.19 ± 3.84 
a  30.40 ± 1.20 
b  < 0.001 
18:3n 6  0.56 ± 0.15 
a  0.38 ± 0.13 
a  0.90 ± 0.15 
b  < 0.001 
20:2n 6  0.47 ± 0.18 
a  0.20 ± 0.07 
b  0.48 ± 0.09 
a  0.004 
20:3n 6  0.48 ± 0.17  0.35 ± 0.14  0.60 ± 0.21  0.108 
20:4n 6  3.41 ± 1.15 
a  2.71 ± 0.74 
a  7.89 ± 2.97 
b  0.001 
22:5n 6  ND 
a  0.50 ± 0.20 
b  ND 
a  < 0.001 
Total n 6 PUFA  29.11 ± 4.31 
a  24.33 ± 4.88 
a  40.27 ± 3.11 
b  < 0.001 
18:3n 3  1.52 ± 0.29 
ab  1.13 ± 0.34 
a  1.61 ± 0.22 
b  0.035 
20:5n 3  0.39 ± 0.14  0.28 ± 0.17  0.20 ± 0.12  0.098 
22:5n 3  0.67 ± 0.20 
a  0.48 ± 0.28 
a  1.48 ± 0.73 
b  0.007 
22:6n 3  0.74 ± 0.13  1.24 ± 0.63  1.53 ± 0.66  0.059 
Total n 3 PUFA  3.31 ± 0.63  3.17 ± 1.38  4.82 ± 1.42  0.062 
 
ND  negligible detected (mean <0.1%) 
a, b, c  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts 
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Table 4.14: Correlations observed between liver and plasma fatty acid composition 
(Pearson r values unless otherwise indicated) 
 
 
R values 
Plasma PC  
vs. Liver PC  
(n=17) 
Plasma PC  
vs. Liver PE  
(n=17) 
Plasma TAG  
vs. Liver TAG  
(n=17) 
Plasma CE  
vs. Liver CE 
(n=17) 
14:0   0.029     0.193 †    0.860  ***   0.090   
16:0  0.981  ***  0.926  ***  0.861  ***  0.232   
18:0  0.971  ***  0.443    0.160     0.398   
20:0  0.014 †    0.160 †    0.258    0.043 †   
22:0  0.612  **  0.457 †    0.587 †  *  0.925 †  *** 
Total saturated  0.271    0.102    0.725  **   0.394   
16:1n 7  0.772  ***  0.101    0.733  **  0.474   
18:1n 9  0.741  **  0.571  *  0.815  ***  0.575  * 
20:1n 9   0.282 †     0.101 †    0.039     0.290   
24:1n 9  0.052 †                  
Total MUFA  0.753  ***  0.531  *  0.876  ***  0.439   
18:2n 6  0.725  **  0.884  ***  0.330     0.038   
18:3n 6  0.555  *  0.385    0.741  **  0.451   
20:2n 6  0.496  *  0.477    0.386     0.751 †   
20:3n 6  0.861  ***  0.811  ***  0.558  *   0.053   
20:4n 6  0.940  ***  0.846  ***  0.954  ***   0.253   
22:5n 6   0.208     0.070 †     0.175 †    0.856 †  *** 
Total n 6 PUFA  0.929  ***  0.875  ***  0.895  ***   0.446   
18:3n 3   0.107 †     0.003 †    0.299     0.338   
20:4n 3  0.784 †  ***       0.836 †  ***  0.247 †   
20:5n 3  0.049    0.106    0.216    0.021   
22:5n 3  0.797  ***  0.148    0.882  ***      
22:6n 3  0.991  ***  0.972  ***  0.932  ***  0.856  *** 
Total n 3 PUFA  0.964  ***  0.910  ***  0.893  ***  0.402   
 
* p < 0.05, ** p < 0.01, *** p < 0.001, † Spearman r value  
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Figure 4.12: Graph of the correlation observed between plasma and liver PC DHA 
contents (% total fatty acids) 
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4.3.7 Adipose tissue fatty acid composition 
The fatty acid composition of subcutaneous adipose tissue was more affected by 
pregnancy than intra abdominal adipose tissue (tables 4.15 and 4.16), indicating that 
subcutaneous adipose tissue is the more labile store.  In subcutaneous adipose tissue, 
reductions in the content of EFA (see figure 4.13 and 4.14) were observed, supporting 
the hypothesis that these fatty acids are selectively released from adipose tissue during 
pregnancy to enable increased LC PUFA synthesis(166).   
 
There was significantly higher AA content of subcutaneous adipose tissue with 
pregnancy (see figure 4.14).  This may indicate that this LC n 6 PUFA is either 
preferentially deposited in subcutaneous adipose tissue during pregnancy, or that it is 
not mobilised from adipose tissue as readily as alternative fatty acids.  There were low 
levels of DHA in adipose tissue and these were not significantly affected by pregnancy. 
 
Correlations were performed to assess the strength of the relationship between adipose 
tissue and plasma NEFA fatty acid composition (see table 4.17).  Few significant 
r = 0.991 
p < 0.001   187 
correlations were observed, in contrast to the observations in chapter 3 (see table 3.16), 
which indicates that changes in diet are a more potent modulator of adipose tissue fatty 
acid composition than the effects of pregnancy.  However, there were significant inverse 
correlations between EFA in subcutaneous adipose and their contribution to plasma 
NEFA (see figure 4.15 and 4.16).  This may suggest that as pregnancy progresses, more 
EFA is mobilised from adipose to the circulating NEFA pool, in order to meet the 
increasing demands of endogenous synthesis of LC PUFA during pregnancy.  Higher 
plasma NEFA concentrations were observed with pregnancy, which may indicate a 
greater mobilisation of adipose tissue during pregnancy (see table 4.3).  However, as 
animals were not fasted prior to blood sampling, it is possible that these data may be 
confounded by fed status.   
 
 
 
Figure 4.13: The LA (18:2n 6) content (% total fatty acids) of total lipid extracts 
isolated from subcutaneous adipose tissue in virgin and pregnant female rats (mean ± 
standard deviation)  
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* significantly different from virgin females (p < 0.05) 
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Figure 4.14: The ALNA (18:3n 3) and AA (20:4n 6) content (% total fatty acids) of 
total lipid extracts isolated from subcutaneous adipose tissue of virgin and pregnant 
female rats (mean ± standard deviation)  
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Table 4.15: Fatty acid composition (% total fatty acids) of subcutaneous adipose tissue 
in virgin and pregnant female rats (mean ± standard deviation) 
 
Fatty acid 
Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
12:0  0.29 ± 0.04  0.41 ± 0.20  0.44 ± 0.16  0.193 
14:0  1.44 ± 0.16  1.56 ± 0.11  1.67 ± 0.22  0.112 
16:0  22.33 ± 0.87 
a  24.00 ± 0.85 
b  25.97 ± 0.93 
c  < 0.001 
18:0  3.37 ± 0.35  3.36 ± 0.44  3.93 ± 0.36  0.036 
Total saturated  27.44 ± 0.97 
a  29.38 ± 1.09 
a  32.03 ± 1.50 
b  < 0.001 
16:1n 7  3.86 ± 0.55 
a  4.96 ± 0.59 
ab  5.15 ± 1.00 
b  0.022 
18:1n 9  25.96 ± 0.96 
a  26.80 ± 1.22 
ab  28.02 ± 1.47 
b  0.037 
20:1n 9  0.49 ± 0.05  0.41 ± 0.15  0.38 ± 0.12  0.250 
24:1n 9  ND  ND  ND    
Total MUFA  30.31 ± 1.45 
a  32.17 ± 1.64 
ab  33.56 ± 2.39 
b  0.032 
18:2n 6  37.43 ± 1.84 
a  33.76 ± 1.30 
b  27.97 ± 3.02 
c  < 0.001 
18:3n 6  0.23 ± 0.02 
a  0.23 ± 0.03 
a  0.42 ± 0.09 
b  < 0.001 
20:2n 6  0.32 ± 0.02 
a  ND 
b  0.48 ± 0.13 
c  < 0.001 
20:3n 6  0.24 ± 0.03 
a  0.24 ± 0.02 
a  0.51 ± 0.15 
b  < 0.001 
20:4n 6  1.30 ± 0.14 
a  1.58 ± 0.23 
a  2.80 ± 0.72 
b  < 0.001 
22:5n 6  0.17 ± 0.05  0.24 ± 0.14  0.21 ± 0.06  0.416 
Total n 6 PUFA  39.69 ± 1.98 
a  36.05 ± 1.35 
ab  32.38 ± 3.88 
b  < 0.001 
18:3n 3  1.92 ± 0.17 
a  1.86 ± 0.14 
a  1.20 ± 0.22 
b  < 0.001 
22:5n 3  0.24 ± 0.03 
a  0.20 ± 0.06 
a  0.42 ± 0.12 
b  0.001 
22:6n 3  0.38 ± 0.05  0.34 ± 0.12  0.40 ± 0.05  0.531 
Total n 3 PUFA  2.55 ± 0.18 
a  2.40 ± 0.15 
a  2.03 ± 0.15 
b  < 0.001 
 
ND  negligible detected (mean <0.1%) 
a, b, c  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts   190 
 
Table 4.16: Fatty acid composition (% total fatty acids) of intra abdominal adipose in 
virgin and pregnant female rats (mean ± standard deviation) 
 
Fatty acid 
Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
12:0  0.13 ± 0.05  ND  0.10 ± 0.01  0.569 
14:0  1.19 ± 0.16  1.25 ± 0.13  1.17 ± 0.04  0.539 
16:0  23.71 ± 1.31  25.09 ± 0.81  24.48 ± 0.66  0.097 
18:0  3.41 ± 0.19  3.27 ± 0.34  3.09 ± 0.38  0.237 
Total saturated  28.49 ± 1.49  29.75 ± 1.24  28.93 ± 0.86  0.267 
16:1n 7  3.87 ± 0.92  4.84 ± 0.24  4.50 ± 0.96  0.165 
18:1n 9  25.08 ± 0.26  26.48 ± 1.08  26.08 ± 1.25  0.071 
20:1n 9  0.57 ± 0.08  0.44 ± 0.15  0.51 ± 0.16  0.296 
Total MUFA  29.54 ± 1.14  31.76 ± 0.92  31.08 ± 2.03  0.066 
18:2n 6  37.45 ± 2.08 
a  34.15 ± 1.48 
b  35.73 ± 1.31 
ab  0.019 
18:3n 6  0.22 ± 0.02  0.23 ± 0.04  0.21 ± 0.02  0.712 
20:2n 6  0.30 ± 0.03 
a  ND 
b  0.30 ± 0.01 
a  < 0.001 
20:3n 6  0.22 ± 0.04  0.20 ± 0.03  0.20 ± 0.03  0.761 
20:4n 6  0.97 ± 0.10  1.07 ± 0.22  0.86 ± 0.12  0.115 
22:5n 6  0.10 ± 0.09  0.14 ± 0.08  0.15 ± 0.05  0.444 
Total n 6 PUFA  39.26 ± 2.24 
a  35.85 ± 1.76 
b  37.46 ± 1.36 
ab  0.026 
18:3n 3  2.21 ± 0.20  2.11 ± 0.11  2.08 ± 0.13  0.353 
22:5n 3  0.17 ± 0.10  0.20 ± 0.09  0.20 ± 0.06  0.768 
22:6n 3  0.30 ± 0.05  0.34 ± 0.09  0.26 ± 0.07  0.172 
Total n 3 PUFA  2.71 ± 0.21  2.65 ± 0.24  2.53 ± 0.13  0.325 
 
ND  negligible detected (mean <0.1%) 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts   191 
 
Table 4.17: Correlations observed between the fatty acid composition (% total fatty 
acids) of adipose tissue total lipid extracts and plasma NEFA (Pearson r values unless 
otherwise indicated) 
 
  Subcutaneous adipose vs. 
Plasma NEFA (n=17) 
Intra abdominal adipose vs. 
Plasma NEFA (n=17) 
12:0   0.061 †     0.476 †   
14:0   0.320     0.311   
16:0   0.059     0.329   
18:0  0.088    0.280   
20:0   0.121 †    0.143   
22:0       0.409 †   
Total saturated   0.173     0.269   
16:1n 7  0.203    0.193   
18:1n 9  0.320     0.240   
20:1n 9  0.132 †    0.003†   
24:1n 9       0.138 †   
Total MUFA  0.263     0.174   
18:2n 6   0.514  *   0.141   
18:3n 6   0.114     0.094   
20:2n 6  0.176    0.060   
20:3n 6   0.297 †     0.126 †   
20:4n 6   0.291 †    0.378 †   
22:5n 6  0.037    0.299   
Total n 6 PUFA   0.199 †     0.542 †  * 
18:3n 3   0.531  *   0.219   
20:4n 3           
20:5n 3   0.383 †     0.276 †   
22:5n 3  0.804  ***  0.122   
22:6n 3  0.411    0.153   
Total n 3 PUFA   0.349     0.132   
 
* p < 0.05, ** p < 0.01, *** p < 0.001, † Spearman r value 
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Figure 4.15: Graph to illustrate the relationship observed between the LA (18:2n 6) 
content (% total fatty acids) of subcutaneous adipose tissue total lipid extracts and 
plasma NEFA 
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Figure 4.16: Graph to illustrate the relationship observed between the ALNA (18:3n 3) 
content (% total fatty acids) of subcutaneous adipose tissue total lipid extracts and 
plasma NEFA 
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4.3.8 Plasma sex hormones 
 
Plasma concentrations of oestradiol, progesterone and testosterone were measured (see 
table 4.18).  Pregnancy was associated with higher progesterone and testosterone 
concentrations, but oestradiol was not significantly affected.  This is likely to be due to 
the high variability of oestradiol status among the virgin females, which were not 
controlled for their stage of the oestrus cycle.  Progesterone concentrations were higher 
mid pregnancy than at the end of pregnancy.  Progesterone and testosterone 
concentrations demonstrated a significant positive correlation (r = 0.804, p < 0.001).  
 
Sex hormone concentrations were assessed for correlations with plasma DHA status 
(see table 4.19).  These correlations gave little indication that the trend for increasing 
DHA status with pregnancy is related to plasma sex hormone concentrations.  Where a 
significant correlation was observed between testosterone status and plasma TAG DHA 
content, there was a clear difference in the pattern of relationships observed between 
virgin and pregnant females (see figure 4.17).  Plasma testosterone has a significant 
inverse relationship with plasma TAG DHA status in virgin females (r =  0.840, p = 
0.036), but a trend for a positive relationship among pregnant females (r = 0.558, p = 
0.094).   
 
It is important to consider that the circulating concentrations of fatty acids such as DHA 
during pregnancy will be affected by the transfer of fatty acids to the developing fetus, 
which cannot be quantified from the results of this study. 
 
Table 4.18: Plasma sex hormone concentrations in virgin and pregnant female rats  
(mean ± standard deviation) 
 
  Virgin 
(n=6) 
Day 12 of 
pregnancy 
Day 20 of 
pregnancy 
ANOVA  
p value 
Oestradiol (pM)  141.5 ± 129.4 
(n=6) 
127.2 ± 41.7 
(n=5) 
82.8 ± 6.7 
(n=4) 
0.582 
Progesterone (nM)  33.5 ± 25.8 
a 
(n=6) 
340.4 ± 35.2 
b 
(n=4) 
180.0 ± 18.6 
c 
(n=5) 
< 0.001 
Testosterone (nM)  1.8 ± 0.5 
a 
(n=6) 
3.9 ± 0.3 
b 
(n=5) 
3.5 ± 0.9 
b 
(n=5) 
< 0.001 
 
a, b, c  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts 
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Table 4.19: Correlations observed between the DHA content (% total fatty acids) of 
plasma lipids and circulating sex hormone concentrations (Pearson r values) 
 
  Testosterone 
(n=16) 
Oestradiol 
(n=15) 
Progesterone 
(n=15) 
PC  0.379   0.232  0.094 
TAG  0.614*   0.368  0.299 
CE  0.487   0.309  0.218 
NEFA  0.449   0.188  0.247 
 
* p < 0.05 
 
 
Figure 4.17: Illustration of the correlation observed between plasma TAG DHA content 
(% total fatty acids) and plasma testosterone concentrations 
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4.3.9 Expression of desaturase and elongase genes in the liver 
 
mRNA expression of  6 desaturase,  5 desaturase and elongase in the liver was 
assessed to determine whether the expression of the genes for these enzymes changes in 
response to pregnancy.  There were no significant differences between the level of 
expression of these genes in virgin and pregnant females (see table 4.20).  
 
The mRNA expression of desaturase and elongase genes was correlated to the fatty acid 
substrates and products of the respective enzymes in liver lipids, to assess whether the 
r = 0.614 
p = 0.011   195 
expression of the genes for these enzymes has a direct effect upon their activity within 
the liver (see table 4.21).  High enzyme activity would be indicated by an inverse 
relationship between mRNA expression and the substrate:product ratio of the fatty acids 
metabolised by that enzyme.  The only significant correlation observed was for the 
expression of elongase with its n 3 fatty acid substrates and products.  However, when 
plotted, this can be attributed to a single outlier (see figure 4.18).  The mRNA 
expression of desaturase and elongase genes during pregnancy therefore does not appear 
to exert control over the relative activity of these enzymes.   
 
Expression of desaturase and elongase genes was correlated to plasma sex hormone 
concentrations (see table 4.22).  A significant correlation was identified between plasma 
progesterone and the expression of the  6 desaturase gene (see figure 4.19).  This 
indicates that the expression of the  6 desaturase gene, coding for the rate limiting 
enzyme in the production of LC PUFA, may be influenced by the increasing plasma 
progesterone concentrations which are a feature of pregnancy. 
 
Table 4.20: Liver fatty acid desaturase and elongase mRNA expression in virgin and 
pregnant female rats (arbitrary units of expression derived from standard curve and 
adjusted for geometric mean of three housekeeping genes, mean ± standard deviation) 
 
   Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
Elovl5 (elongase)  0.74 ± 0.14  0.85 ± 0.28  0.66 ± 0.13  0.287 
FADS1 ( 5 desaturase)  0.54 ± 0.09  0.60 ± 0.19  0.66 ± 0.23  0.529 
FADS2 ( 6 desaturase)  0.51 ± 0.11  0.91 ± 0.29  0.86 ± 0.59  0.198 
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Table 4.21: Correlations observed between liver fatty acid desaturase and elongase 
mRNA expression and their respective substrate and product fatty acid ratios within 
liver lipids (Pearson r values) 
 
  Liver PC  Liver PE  Liver CE  Liver TAG 
 6 DESATURASE         
18:2n 6 to 18:3n 6 ratio   0.007 
(n=17) 
0.237 
(n=12) 
 0.269 
(n=11) 
 0.117 
(n=17) 
 
 5 DESATURASE 
       
20:3n 6 to 20:4n 6 ratio   0.313 
(n=17) 
 0.275 
(n=17) 
 0.340 
(n=17) 
0.020 
(n=17) 
20:4n 3 to 20:5n 3 ratio   0.402 † 
(n=16)      0.536 
(n=10) 
 0.417 
(n=16) 
 
ELONGASE 
       
18:3n 6 to 20:3n 6 ratio   0.438 
(n=17) 
 0.286 
(n=17) 
 0.106 
(n=11) 
 0.247 
(n=17) 
20:5n 3 to 22:5n 3 ratio  0.638** 
(n=17) 
0.595* 
(n=17) 
0.680* 
(n=9) 
0.408 
(n=17) 
 
* p < 0.05, ** p < 0.01 
 
 
Figure 4.18:  Illustration of the correlation observed between liver elongase mRNA 
expression and the ratio of 20:5n 3 to 22:5n 3 within liver PC 
Elongase mRNA expression in liver
1.4 1.2 1.0 0.8 0.6 0.4
R
a
t
i
o
 
o
f
 
E
P
A
 
t
o
 
D
P
A
 
i
n
 
l
i
v
e
r
 
P
C
2.0
1.5
1.0
0.5
0.0
Day 20
Day 12
Virgin
 
r = 0.638 
p = 0.006   197 
Table 4.22: Correlations observed between plasma sex hormone concentrations and the 
expression of fatty acid desaturase and elongase mRNA within the liver (Pearson r 
values) 
 
  Testosterone  
(nM) 
(n=16) 
Oestradiol  
(pM) 
(n=15) 
Progesterone  
(nM) 
(n=15) 
Elovl5 (elongase)  0.027  0.087  0.251 
FADS1 ( 5 desaturase)  0.001   0.126  0.182 
FADS2 ( 6 desaturase)  0.312  0.066  0.580 * 
 
* p < 0.05 
 
 
Figure 4.19: Illustration of the correlation observed between liver  6 desaturase mRNA 
expression and plasma progesterone concentration 
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4.3.10 Indirect assessment of desaturase and elongase activities in 
the liver 
 
Substrate:product ratios of fatty acids within liver lipids were calculated as a method of 
indirectly assessing whether the activities of desaturase and elongase enzymes in the 
liver change in response to pregnancy.  Higher enzyme activity could be inferred by a 
lower substrate:product ratio.   
 
r = 0.580 
p = 0.023   198 
 9 desaturase 
Substrate:product ratios were calculated to assess  9 desaturase activity (see table 
4.23).  Data from liver PC and CE suggests that  9 desaturase activity is higher in 
pregnant females than in virgin females, though these effects were mixed.  
Substrate:product ratios in liver PC indicate that  9 desaturase activity is significantly 
higher in day 20 pregnant females compared with both virgin and day 12 pregnant 
females.  In liver CE, there was also a trend for  9 desaturase activity to be higher in 
day 20 pregnant females compared to virgin females, but these data suggest that  9 
desaturase activity may be lower at day 12 gestation than in either virgin or day 20 
pregnant females.    
 
Correlations were then performed to assess whether there is a relationship between  9 
desaturase activity and circulating sex hormone concentrations (see table 4.24).  There 
were no consistent trends across lipid fractions which might indicate a role of 
circulating sex hormones upon the differences observed in the substrate:product ratios 
of  9 desaturase.   
 
Table 4.23: The  9 desaturase substrate:product fatty acid ratio within liver lipids in 
virgin and pregnant female rats (18:0 to 18:1n 9, mean ± standard deviation) 
 
  Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
Liver PC  8.8 ± 1.5 
a  8.2 ± 0.8 
a  5.8 ± 1.3 
b  0.002 
Liver PE  12.7 ± 2.3  11.0 ± 1.4  15.0 ± 3.5  0.072 
Liver CE  3.0 ± 1.1 
a  5.9 ± 2.1 
b  1.9 ± 1.0 
a  0.001 
Liver TAG (x 10
1)  1.5 ± 0.5  1.5 ± 0.1  1.6 ± 0.1  0.878 
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts 
 
 
 
Table 4.24: Correlations observed between the ratio of 18:0 to 18:1n 9 within liver 
lipids and circulating sex hormone concentrations (Pearson r values) 
 
18:0 to 18:1n 9 ratio  Liver PC  Liver PE  Liver CE  Liver TAG 
Testosterone (n=16)   0.249   0.009  0.364   0.027 
Oestradiol (n=15)  0.040   0.253   0.158   0.735** 
Progesterone (n=15)   0.088   0.085  0.548*  0.090 
 
* p < 0.05, ** p < 0.01 
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 6 desaturase 
Substrate:product ratios to assess  6 desaturase activity indicated that the activity of 
this enzyme is lower at day 12 gestation than in virgin or day 20 gestation females (see 
table 4.25).  There were no significant differences between virgin females and day 20 
gestation females. 
 
When data for plasma sex hormones was correlated to this marker of  6 desaturase 
activity, there was a trend for reduced  6 desaturase activity with increasing 
progesterone concentrations (see table 4.26).  However, when plotted it was clear that 
this relationship between progesterone and  6 desaturase activity is an artefact of the 
distinct relationships exhibited in virgin females compared to pregnant females, and of 
the lack of detectable 18:3n 6 in pregnant females (see figure 4.20).   
 
Table 4.25: The  6 desaturase substrate:product fatty acid ratio within liver lipids of 
virgin and pregnant female rats (LA to 18:3n 6, mean ± standard deviation) 
 
  Virgin  Day 12 of 
pregnancy 
Day 20 of 
pregnancy 
ANOVA  
p value 
Liver PC  36.9 ± 9.0 
ab 
(n=6) 
45.2 ± 5.5 
a 
(n=5) 
28.0 ± 4.0 
b 
(n=6) 
0.003 
Liver PE  33.6 ± 10.6 
a 
(n=6) 
58.0 ± 8.0 
b 
(n=4) 
28.1 ± 24.8 
ab 
(n=2) 
0.022 
Liver CE  38.9 ± 22.2 
(n=5) 
65.1 ± 25.9 
(n=2) 
33.9 ± 15.5 
(n=4) 
0.253 
Liver TAG  44.5 ± 7.1 
ab 
(n=6) 
54.7 ± 9.9 
a 
(n=5) 
34.3 ± 5.4 
b 
(n=6) 
0.002 
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts 
 
 
 
Table 4.26: Correlations observed between the 18:2n 6 to 18:3n 6 ratio within liver 
lipids and circulating sex hormone concentrations (Pearson r values) 
 
LA to 18:3n 6 ratio  Liver PC  Liver PE  Liver CE  Liver TAG 
Testosterone  0.012 
(n=16) 
0.330 
(n=12) 
0.248 
(n=10) 
0.138 
(n=16) 
Oestradiol   0.044 
(n=15) 
0.015 
(n=12) 
 0.255 
(n=9) 
0.189 
(n=15) 
Progesterone  0.317 
(n=15) 
0.609* 
(n=11) 
0.383 
(n=10) 
0.446 
(n=15) 
 
* p < 0.05 
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Figure 4.20: Illustration of the correlation observed between the ratio of 18:2n 6 to 
18:3n 6 in liver PE and circulating progesterone concentration 
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 5 desaturase activity 
 
Substrate:product ratios of n 6 fatty acids indicate that the activity of  5 desaturase was 
higher at day 20 gestation than at day 12 gestation or in virgin females (see table 4.27).  
The lack of a relationship with n 3 fatty acids is likely to be due to 20:4n 3 often being 
undetectable in liver lipids.  There was no indication that the effect of pregnancy 
observed upon  5 desaturase activity correlated to plasma sex hormone concentrations 
(see table 4.28). 
 
r (all data) = 0.609 
p = 0.047 
 
r (virgin) =  0.718 
* data points for some  
    pregnant animals are  
    missing due to  
    undetectable 18:3n 6 
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Table 4.27: The  5 desaturase substrate:product fatty acid ratio within liver lipids of 
virgin and pregnant female rats (n 6: 20:3n 6 to AA;  n 3: 20:4n 3 to EPA, mean ± 
standard deviation) 
 
  Virgin  Day 12 of 
pregnancy 
Day 20 of 
pregnancy 
ANOVA  
p value 
n 6 fatty acids 
Liver PC (x 10
3)  43.9 ± 7.0 
a 
(n=6) 
46.9 ± 8.8 
a 
(n=5) 
18.7 ± 3.8 
b 
(n=6) 
< 0.001 
Liver PE (x 10
3)  23.8 ± 2.4 
a 
(n=6) 
26.8 ± 5.4 
a 
(n=5) 
12.4 ± 4.7 
b 
(n=6) 
< 0.001 
Liver CE (x 10
3)  29.3 ± 25.5 
ab 
(n=6) 
58.8 ± 35.5 
a 
(n=5) 
14.1 ± 18.1 
b 
(n=6) 
0.045 
Liver TAG (x 10
2)  14.1 ± 3.2 
(n=6) 
12.5 ± 2.5 
(n=5) 
8.8 ± 4.7 
(n=6) 
0.066 
n 3 fatty acids 
Liver PC (x 10
3)  ND 
(n=6) 
16.9 ± 23.8 
(n=5) 
ND 
(n=5) 
0.096 
Liver PE  ND 
(n=6) 
ND 
(n=5) 
ND 
(n=5) 
  
Liver CE  ND 
(n=4) 
ND 
(n=4) 
1.9 ± 2.7 
(n=2) 
0.128 
Liver TAG (x 10
2)  ND 
(n=6) 
9.6 ± 13.7 
(n=5) 
ND 
(n=5) 
0.100 
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts 
 
Table 4.28: Correlations observed between  5 desaturase substrate:product fatty acid 
ratios within liver lipids and circulating sex hormone concentrations (Pearson r values) 
 
20:3n 6 to AA ratio  Liver PC  Liver PE  Liver CE  Liver TAG 
Testosterone   0.193   0.179  0.197   0.470 
Oestradiol  0.318  0.286  0.179  0.463 
Progesterone  0.020  0.068  0.280   0.299 
20:4n 3 to EPA ratio  Liver PC  Liver PE  Liver CE  Liver TAG 
Testosterone  0.328     0.407  0.318 
Oestradiol   0.205         0.177 
Progesterone †  0.459     0.137  0.447 
 
 
Elongase activity 
 
There was limited evidence to support an effect of pregnancy upon elongase activity as 
assessed using n 6 fatty acid substrates, with only substrate:product ratios in liver PC 
demonstrating a significant reduction in activity at day 20 gestation compared to day 12 
gestation or virgin females.  In contrast, there was a clear trend apparent across all liver   202 
lipid fractions for increased elongase activity upon n 3 substrates with pregnancy (see 
table 4.29).  The effects observed upon elongase activity during pregnancy did not 
correlate to plasma sex hormone concentrations (see table 4.30). 
 
Table 4.29: The ratio of elongase substrate:product fatty acid content of liver lipids in 
virgin and pregnant female rats (n 6: 18:3n 6 to 20:3n 6; n 3 EPA to 22:5n 3, mean ± 
standard deviation) 
 
  Virgin  Day 12 of 
pregnancy 
Day 20 of 
pregnancy 
ANOVA  
p value 
n 6 fatty acids 
Liver PC (x 10
1)  3.3 ± 0.6 
a 
(n=6) 
2.0 ± 0.4 
a 
(n=5) 
11.7 ± 4.3 
b 
(n=6) 
< 0.001 
Liver PE (x 10
1)  3.5 ± 1.5 
(n=6) 
1.2 ± 0.7 
(n=5) 
3.4 ± 0.7 
(n=6) 
0.625 
Liver CE  1.6 ± 1.2 
(n=4) 
0.2 ± 0.2 
(n=4) 
1.8 ± 0.6 
(n=3) 
0.060 
Liver TAG  1.3 ± 0.4 
(n=6) 
1.2 ± 0.3 
(n=5) 
1.7 ± 0.6 
(n=6) 
0.066 
n 3 fatty acids 
Liver PC (x 10
1)  5.3 ± 1.3 
a 
(n=6) 
10.2 ± 0.4 
b 
(n=5) 
1.2 ± 0.7 
c 
(n=6) 
< 0.001 
Liver PE (x 10
1)  1.6 ± 0.3 
a 
(n=6) 
3.9 ± 1.6 
b 
(n=5) 
0.6 ± 0.5 
a 
(n=6) 
< 0.001 
Liver CE (x 10
1)  8.4 ± 6.1 
(n=4) 
10.9 ± 4.0 
(n=2) 
0.8 ± 1.4 
(n=3) 
0.102 
Liver TAG (x 10
1)  5.9 ± 1.0 
a 
(n=6) 
6.0 ± 2.0 
a 
(n=5) 
1.3 ± 0.7 
b 
(n=6) 
< 0.001 
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts 
 
 
Table 4.30: Correlations observed between elongase substrate:product fatty acid ratios 
circulating sex hormone concentrations (Pearson r values) 
 
18:3n 6 to 20:3n 6 ratio  Liver PC  Liver PE  Liver CE  Liver TAG 
Testosterone  0.339  0.075   0.347  0.315 
Oestradiol   0.246   0.154  0.194   0.168 
Progesterone   0.034   0.221   0.497  0.044 
EPA to 22:5n 3 ratio  Liver PC  Liver PE  Liver CE  Liver TAG 
Testosterone  0.227  0.340   0.380   0.219 
Oestradiol  0.087  0.122   0.372  0.373 
Progesterone  0.415  0.506  0.067   0.035 
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4.4 Discussion 
 
This study set out to address the hypothesis that changes to rat tissue fatty acid 
composition during pregnancy are mediated by sex hormones and/or the expression of 
genes for enzymes involved in endogenous synthesis of LC PUFA.  Data was generated 
in support of this hypothesis, and in addition novel features of the effects of pregnancy 
upon tissue 22:5n 6 content and the complex nature of the changes in fatty acid 
composition during pregnancy were identified. 
 
My data confirms the findings of other authors who have identified that the 16:0 and 
DHA content of both plasma and liver phospholipids is higher at day 20 of pregnancy 
than in virgin females, and that the 18:0 and AA content is lower.  The concurrent 
effects upon 16:0 with DHA and 18:0 with AA, are most likely to be due to their 
common pairing within phospholipid structure.  The pattern of effects observed upon 
TAG were markedly different, with the AA content of plasma and liver TAG 
significantly higher during pregnancy than in virgin females, again confirming the 
previous findings of other authors(168) and indicating that there are significant 
functional differences between these lipid pools.   
 
My data highlights additional significant features of the effects of pregnancy upon 
plasma and tissue fatty acid composition.  In particular, the 22:5n 6 content of plasma 
lipids was found to be significantly higher among pregnant rats at day 20 of gestation 
compared to virgin females, indicating that the effects of pregnancy upon LC PUFA 
synthesis are not limited to LC n 3 PUFA.  Indeed, the marked increases in the content 
of 22:5n 6 in plasma and tissues may account for some of the reductions in AA content 
observed to occur with pregnancy.   
 
The effects of pregnancy on fatty acid composition were also tissue specific.  For 
example, the fatty acid 22:5n 6 was found at the highest levels in plasma lipids at day 
20 of pregnancy.  In contrast, the content of 22:5n 6 within liver lipids PC, PE and TAG 
was markedly lower, and peaked at day 12 of gestation, while 22:5n 6 content within 
adipose tissue was unchanged by pregnancy.  The high content of this fatty acid within 
the maternal plasma, rather than its incorporation into maternal tissues, gives some 
indication that this fatty acid may in fact be preferentially mobilised into the maternal 
plasma in order to be available to the fetus.     204 
 
The mid gestation (day 12 of pregnancy) group used in this study provides further 
information upon the nature of the changes in fatty acid composition which occur 
during pregnancy.  There is clearly a complex relationship between fatty acid status and 
pregnancy, as the day 12 group did not represent a simple ‘mid point’ of fatty acid 
composition status when compared to virgin and day 20 gestation animals.  In fact, the 
fatty acid status of this group was often the opposite of what would be expected by 
simple extrapolation.  For example, plasma and liver phospholipid 16:0 and DHA 
contents were significantly lower in the day 12 group when compared to virgin females, 
yet these fatty acids were significantly higher than virgin females by day 20 of 
gestation.  Further studies could be conducted to investigate the timing of these extreme 
changes in fatty acid composition, with a longitudinal study of plasma phospholipids 
providing a greater potential for insight into these differences than was achieved within 
the current study design. 
 
Plasma fatty acid composition was observed to have a close relationship with the fatty 
acid composition of the liver, but a much more limited relationship with adipose tissue 
composition.  This finding is in contrast to the numerous and significant correlations 
which had been observed between adipose tissue and plasma NEFA fatty acid 
composition in chapter 3, and indicates that there was a strong influence of dietary fatty 
acids upon the relationship between adipose tissue and plasma lipids in that study.   
 
Adipose tissue responded to pregnancy in a depot specific manner, with subcutaneous 
adipose tissue demonstrating a greater number of changes in fatty acid composition in 
response to pregnancy than was observed in intra abdominal adipose tissue.  There was 
a reduction in the EFA content of subcutaneous adipose tissue during pregnancy, 
indicating that under low fat feeding conditions, EFA may be preferentially released 
from subcutaneous adipose tissue during pregnancy in order to meet the requirements 
for LC PUFA synthesis.  However, it would be necessary to demonstrate that these 
reductions in EFA content of adipose tissue were accompanied by a reduction in total 
fat mass in order to fully support this suggestion, data which was not available in this 
study.   
 
As was the case in chapter 3 no significant correlations between plasma DHA content 
and plasma sex hormones were observed.  In chapter 3, this was attributed to the   205 
confounding effects of diet, a variable which was controlled within this study.  
However, it is possible that within this cohort of pregnant animals, any potential effect 
of sex hormones upon plasma DHA content may have been obscured by transfer of 
DHA to the fetus, a variable that could not be assessed in this study, but which could be 
investigated further using stable isotope labelled fatty acids. 
 
No significant effects of pregnancy were observed upon the mRNA expression of 
elongase or  6 and  5 desaturase genes in the liver.  When mRNA expression was 
assessed for potential relationships with sex hormone status, it was found that there was 
a significant positive correlation between plasma progesterone and the expression of  6 
desaturase mRNA in the liver.  This indicates that the increasing progesterone 
concentrations which are a feature of pregnancy associate with an increased availability 
of  6 desaturase, a finding of particular importance given that  6 desaturase is the rate 
limiting step in the synthesis of LC PUFA.  This supports the hypothesis that sex 
hormones and the expression of enzymes involved in LC PUFA synthesis mediate the 
effect of pregnancy upon tissue fatty acid composition.  However, when data from 
chapter 3 was re examined, no correlation was identified between mRNA expression of 
 6 desaturase and progesterone status within non pregnant females (Pearsons R = 
0.257, p = 0.337).  This suggests that the relationship between progesterone and mRNA 
expression of  6 desaturase during pregnancy may not be directly causal, but may 
indicate the influence of an additional variable which associates with changes to 
progesterone status during pregnancy.   
 
The activities of enzymes involved in LC PUFA synthesis in the liver were indirectly 
assessed using the substrate:product ratios in liver lipids.  Though this marker is a 
relatively crude index of enzyme activity, as it cannot for example take into account the 
potential influence of specificity in lipid assembly, it was used to assess whether 
pregnancy might have an effect upon enzyme activity.  These data indicate that there is 
a complex pattern of changes in enzyme activity with pregnancy.   6 desaturase activity 
as assessed by this marker was lowest at day 12 gestation, and  5 and  9 desaturase 
activities higher in day 20 pregnant females than in virgin or day 12 gestation females.  
There was also a trend for greater elongase activity upon n 3 substrates among day 20 
gestation females.  Data therefore indicate that pregnancy may induce changes in both 
the relative abundance, and the activity of the enzymes involved in LC PUFA synthesis.     206 
Few correlations were observed between substrate:product ratios of liver fatty acids and 
plasma sex hormone status.  Of the statistically significant correlations which were 
observed, there was evidence when plotted that these correlations were in fact artefacts 
of outliers (see figure 4.18).  The statistically significant relationship between 
testosterone and progesterone status (r = 0.804, p < 0.001) also make it difficult to say 
with certainty which of these variables was responsible for any relationship observed 
between these hormones and markers of enzyme activity.  The current data therefore 
provides some indication of a role of pregnancy upon the activity of desaturase and 
elongase enzymes, but does not support a relationship between this change in activity 
and the circulating concentrations of sex hormones assessed. 
 
Testosterone, oestradiol and progesterone are not the only hormones whose 
concentrations alter in response to pregnancy.  It is possible that other hormones which 
are altered during pregnancy such as relaxin (see figure 4.21), prolactin, aldosterone and 
corticosterone(234) may also have a role in mediating the effects observed upon fatty 
acid composition. 
 
Figure 4.21: Levels of ovarian hormones during rat gestation(235) 
 
 
Based upon the finding of this study, future investigations would benefit from additional 
time points during rat pregnancy, particularly given the distinct and non linear patterns 
of change during pregnancy in both tissue fatty acid composition, and the 
substrate:product ratio of fatty acids in liver lipids as an index of desaturase and 
elongase enzymes.  Direct assessment of enzyme activity by use of a method such as 
provision of dietary stable isotopes would be of use to confirm the indications from the   207 
current data, as well as providing the possibility of gaining quantitative data upon the 
rates of transfer to the developing fetus.  Analysis of additional sex, and other, 
hormones may provide further information upon the mechanisms controlling fatty acid 
status during pregnancy. 
 
Among human longitudinal studies of maternal blood lipid fatty acid status during 
pregnancy, the main information which is currently lacking is pre conceptional fatty 
acid status.  Given the dramatic differences in the pattern of fatty acid composition 
between day 12 gestation and virgin data in the rat, this could be of importance.  
Analysis of plasma samples from large prospective studies of women of child bearing 
age such as the Southampton Women’s Survey may enable the effects of pregnancy 
upon fatty acid synthesis, metabolism and status to be investigated further.     208 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5:   Pregnancy and immune 
function in the rat   209 
5.1  Introduction 
5.1.1  Aims and hypothesis of current study 
 
This study sets out to identify the effects of pregnancy upon markers of maternal 
immune function in the rat.  Pregnancy requires maternal immune adaptations in order 
to allow tolerance to paternal antigens and avoid rejection of the developing fetus.  
Adaptations to maternal immunity during pregnancy which have been observed in 
murine and human studies include thymic involution and the Th1/Th2 switch, but the 
immune adaptations of the rat during pregnancy are less clear.  The effects of pregnancy 
upon rat immune function will therefore be investigated, in order to later assess whether 
these normal responses to pregnancy are altered by changing maternal dietary fatty 
acids during pregnancy. 
 
Immune cell phenotype and selected markers of immune function including lymphocyte 
proliferation and production of signalling molecules such as prostaglandin (PG) E2 and 
the cytokines interferon (IFN) γ and interleukin (IL) 4, will be assessed.  Gross markers 
of immune adaptations such as lymphoid organ size and cellularity will also be 
monitored.  It is hypothesised that: 
 
a)  rat pregnancy causes thymic involution and reduced lymphoid organ cellularity 
b)  changes in lymphoid organ cellularity are associated with changes to the profile 
of immune cell subsets present 
c)  the rat will demonstrate changes in Th1/Th2 balance in response to pregnancy, 
favouring production of Th2 cytokines such as IL 4. 
5.1.2 Thymic involution of pregnancy 
 
Maternal thymic involution is a feature of pregnancy which involves neural, endocrine 
and immune influences(176).  Involution is specific to the cortex (the outer structures of 
the thymus – containing immature T cells), while the medulla (the inner structure of the 
thymus – containing more mature T cells) undergoes hyperplasia(177).  These changes 
may therefore prevent the generation of new conceptus targeted T cells, while 
maintaining an adequate historical T cell repertoire.  Suggested mechanisms involved in 
thymic involution during pregnancy include the role of mediators such as   210 
progesterone(177;187), gonadotrophin releasing hormone and prohibitin(181).  The 
maternal thymus then rapidly regenerates after the end of lactation(176). 
5.1.3 Th1/Th2 balance during pregnancy 
Th1 and Th2 cells are two subsets of CD4
+ T helper cells.  These cells cannot be 
distinguished morphologically, but differ according to the cytokines they produce.  Th1 
cells secrete predominantly pro inflammatory cytokines such as IFN γ, tumour necrosis 
factor (TNF) β, IL 2 and TNF α which activate macrophages and cell mediated 
immune responses.  Th2 cells secrete cytokines including IL 4, IL 5, IL 6, IL 10 and 
IL 13 which promote antibody or humoral responses.  The cytokines of one T helper 
subset inhibit the activation of the other subset, and so Th1 and Th2 responses are 
mutually exclusive.  The development of Th1 or Th2 dominated responses is affected 
by the cytokines produced during antigen presentation, with IFN γ promoting Th1 
responses, and IL 4 promoting Th2 responses.  It has been identified that progesterone, 
a sex hormone associated with pregnancy, can induce production of Th2 type cytokines 
by human peripheral blood mononuclear cells (PBMC) or established human Th1 
clones in vitro(174).  
A Th2 response during pregnancy is advantageous as the Th2 response involves a 
humoral (antibody based) rather than cellular immune response.  This prevents maternal 
immune cells targeting the feto placental unit, while maintaining antibody production.  
Maintenance of antibody production is beneficial to the fetus, as antibodies (particularly 
IgG) can be transferred across the placenta and via breastmilk, providing protective 
immunity for the neonate until the infant’s own immune system is sufficiently 
matured(175).  
5.1.4 Human studies of immune function during pregnancy 
Pregnancy associated changes in auto immune disease symptoms provide evidence for 
human changes in Th1/Th2 balance during pregnancy.  Rheumatoid arthritis is an auto 
immune disease associated with high levels of Th1 cytokine expression, which 
demonstrates improvements during pregnancy(175), while systemic lupus 
erythematosus is an antibody mediated auto immune disease associated with Th2 
cytokine expression, which primarily affects women during reproductive years(176).  
These data suggest that a ‘switch’ towards Th2 cytokine production is a feature of 
human pregnancy. 
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Studies which used PBMC collected from healthy pregnant women have identified that 
in humans the proportions of CD4
+ and CD8
+ cells within the blood lymphocyte pool 
remain constant during pregnancy, but differ in terms of their cytokine production 
profile, with a shift towards Th2 producing cells(172).  Women with recurrent 
spontaneous abortions have demonstrated elevated Th1/Th2 ratios when compared to 
women who have successful pregnancies(171).  Evidence therefore suggests that a Th2 
switch is essential for successful maintenance of pregnancy in humans(172). 
5.1.5 Animal studies of immune function during pregnancy 
Disease models in mice have also demonstrated the importance of Th2 responses in the 
maintenance of successful pregnancy.  Infection of mice with the parasite Leishmania 
major induces a strong Th1 response.  When pregnant mice were infected with 
Leishmania major there was an increase in spontaneous resorptions which was 
associated with increased Th1 cytokine production(173).  Murine studies have also 
demonstrated that the injection of Th1 cytokines induces abortion(178).  Th1 responses 
induce natural killer (NK) cell activity, and the presence of NK cells correlates with 
fetal resorption in the mouse(175). 
Although the murine model has been studied extensively in relation to the immune 
adaptations of pregnancy, the rat response has been less extensively characterised, with 
some contradictory findings (see table 5.1).  For example, IL 4 producing cells have 
been identified as being increased(181), decreased(179) or unaffected(180) in rat 
models during pregnancy. 
A study which directly compared human and rat immune responses has identified that 
there are fundamental species differences in the response to pregnancy, with humans 
demonstrating reductions in the number of IFN γ producing cells but without affecting 
total lymphocyte numbers in the blood, while the rat adapts to pregnancy by reducing 
total lymphocyte numbers(181).  212 
 
 
Table 5.1: Summary of rat studies of immune function during pregnancy 
Study  Model and samples used  Response to pregnancy 
Zhang et al, 2004 
(181) 
Lewis rat 
 
PBMC, spleen and mesenteric 
lymph node cells 
 
￿ MHC II expression in spleen 
￿ CD11c (dendritic cell marker) 
￿ antibody production to acetylcholine 
receptor 
￿ antibody production to ovalbumin 
 
 
￿ IL 10 producing cells in spleen and PBMC 
￿ IL 4 producing PBMC 
￿ proliferation of mesenteric lymph node 
cells 
 
Faas et al, 2005 
(179) 
Wistar rat 
 
Whole blood, in vitro 
stimulation with PMA 
 
 
￿ IL 4 producing Th lymphocytes  
￿ IL 4 producing cytotoxic T cells 
 
 
￿ IFN γ producing cytotoxic T cells  
￿ IFN γ producing NK cells 
 
Faas et al, 2006 
(180) 
Wistar rat 
 
Whole blood, in vitro 
stimulation with PMA 
 
￿ T lymphocytes 
￿ Th lymphocytes 
￿ cytotoxic T cells  
 
￿NK cells 
￿ IFN γ producing Th cells and  
￿ IFN γ producing cytotoxic T cells 
 
    No effect on IL 4 producing cells 
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5.2 Methods 
This study set out to identify whether there are changes in the immune system in normal 
rat pregnancy.  This was assessed by monitoring immune organ weight and cellularity, 
immune cell subset phenotyping by flow cytometry, lymphocyte proliferation and the 
production of cytokines and prostaglandins by cultured blood and immune organ 
mononuclear cells. 
 
All animal work was carried out in accordance with the Home Office Animals 
(Scientific Procedures) Act (1986); for pregnant females, mating was carried out by 
monogamous breeding (see section 2.1), and maternal tissues collected on either day 12 
or day 20 of gestation.  Immune cell phenotypes were identified by flow cytometry of 
lysed whole blood or immune organ mononuclear cell preparations (see section 2.11.1).  
Ex vivo culture was performed to assess lymphocyte proliferation (see section 2.11.2) 
and the production of IFN γ, IL 4 and PGE2 in response to concanavalin A (see section 
2.11.3).   
 
The effect of pregnancy upon tissue immune organ weight and cellularity, immune cell 
subsets, lymphocyte proliferation and the production of cytokines and prostaglandins 
was assessed by one way ANOVA.  The effect of pregnancy upon the sensitivity of 
lymphocytes to Concanavalin A (Con A) stimulation was assessed by Kruskal Wallis 
test.   
5.3 Results 
5.3.1 Experimental diets 
Animals received a low fat (LF, 3% w/w) soyabean oil based diet (SDS, Witham, UK) 
which is a standard rat maintenance diet (RM[1]).  The nutrient content and fatty acid 
composition of this diet are described in chapters 2 and 3 (see tables 2.2 and 3.1). 
5.3.2 Weight gain and food intake 
Virgin females had their weight and food intake monitored over a 20 day period.  
Pregnant rats had their weight and food intake monitored over either 12 or 20 days of 
pregnancy (see table 5.2, figure 5.1); typical rat pregnancy is 21 24 days.  As would be 
expected, pregnant females gained significantly more weight per day compared to virgin 
females.  The day 20 gestation group also has significantly higher weight gain per day   214 
compared with the day 12 gestation group, indicating that further accelerated weight 
gain was occurring during the 2
nd half of gestation.  In contrast to the observations in 
chapter 4 (see table 4.2), this cohort demonstrated a significant increase in food 
consumption throughout gestation, indicating these rats exhibited significant 
hyperphagia in response to pregnancy. 
 
Table 5.2: Weight gain and weighed food consumption by virgin and pregnant female 
rats over the study period (mean ± standard deviation) 
 
  Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
Weight gain (g/day)  0.7 ± 0.2 
a  3.1 ± 0.4 
b  4.2 ± 0.2 
c  < 0.001 
Food consumption (g/day)  14.9 ± 1.1 
a  17.0 ± 1.3 
b  19.1 ± 1.2 
c  < 0.001 
 
a, b, c  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts 
 
Figure 5.1:  Weights of virgin and pregnant female rats over the study period (mean ± 
SEM) 
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5.3.3 Immune organ size and cellularity 
 
Immune organs were weighed prior to preparation of cell suspensions, and the number 
of mononuclear cells recovered counted using a Beckman Coulter counter in order to 
assess organ cellularity (see table 5.3).  Spleen and lymph node weights were 
maintained throughout pregnancy, while the thymus reduced in absolute weight over 
gestation.  Thymic involution has been reported in other animal models of pregnancy, 
and is reported to reverse after delivery(176).  In the rat, thymic involution was not yet 
apparent at day 12 of pregnancy.  Trends were seen in all immune organs for reduced 
cellularity with pregnancy, though this only reached significance in the mandibular 
lymph nodes, which is likely to be due to the high degree of variability in the results 
obtained for the spleen and thymus. 
 
Table 5.3: Immune organ weight and cellularity of virgin and pregnant female rats 
(mean ± standard deviation) 
 
  Virgin 
(n=6) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=6) 
ANOVA  
p value 
SPLEEN 
weight (mg)  519.3 ± 36.9  625.5 ± 104.1  523.5 ± 105.4  0.115 
% body weight  0.23 ± 0.03 
ab  0.27 ± 0.05 
a  0.19 ± 0.02 
b  0.007 
total mononuclear cells 
recovered (x 10
 6)  63.1 ± 33.0  59.9 ± 28.4  44.3 ± 46.5  0.657 
mononuclear cells  
(x 10
 3) per mg  122.7 ± 65.6  93.1 ± 33.7  75.5 ± 68.9  0.408 
 
THYMUS 
weight (mg)  476.1 ± 113.6 
a  492.9 ± 49.2 
a  304.7 ± 67.8 
b  0.003 
% body weight  0.21 ± 0.04 
a  0.21 ± 0.02 
a  0.11 ± 0.02 
b  < 0.001 
total mononuclear cells 
recovered (x 10
 6)  211.6 ± 128.2  174.5 ± 160.1  64.0 ± 111.2  0.173 
mononuclear cells  
(x 10
 3) per mg  469.9 ± 313.6  334.7 ± 268.6  182.4 ± 291.6  0.270 
 
MANDIBULAR LYMPH NODES 
weight (mg)  134.2 ± 80.0  111.9 ± 7.9  113.9 ± 47.9  0.756 
% body weight  0.058 ± 0.037  0.048 ± 0.004  0.042 ± 0.012  0.479 
total mononuclear cells 
recovered (x 10
 6)  4.9 ± 2.6 
a  1.9 ± 0.6 
b  1.1 ± 0.6 
b  0.004 
mononuclear cells  
(x 10
 3) per mg  46.4 ± 22.6 
a  16.5 ± 5.3 
b  10.4 ± 4.6 
b  0.001 
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts   216 
5.3.4 Cell phenotyping by flow cytometry 
 
Flow cytometry was performed to assess whether the proportions of immune cell 
subsets or the relative expression of their cell surface markers was altered in response to 
pregnancy.  
 
T lymphocytes (CD3
+) were the predominant cell type within the lymphocyte gate of 
maternal lysed whole blood (see table 5.4), with the majority of these T cells being T 
helper cells (CD3
+CD4
+).  The proportions of T cells, CD4
+ cells, CD4
+ T cells, B cells 
and NK cells in the blood lymphocyte population were not significantly altered by 
pregnancy, although absolute numbers were not determined.  Pregnancy was associated 
with a significantly higher proportion of CD8
+ cells in the lymphocyte population.  
CD8
+ cells include cytotoxic T cells (CD3
+CD8
+), which also demonstrated a non 
significant trend to increase during pregnancy.   
 
The mean fluorescence intensity (MFI) of CD161 on cells in maternal blood was 
significantly lower in pregnant animals than in virgin females.  CD161 is also known as 
NKR P1, and is a receptor on NK cells which activates cytotoxicity, and is directly 
involved in target recognition(65).  Decreased expression of this cell surface marker 
may therefore indicate a reduced capacity for target recognition, which fits with the 
need to decrease NK cell activity in pregnancy. 
 
The overall proportions of mononuclear cells within the maternal spleen were similar to 
those observed within maternal lysed blood, with the addition of CD163
+ cells, a marker 
expressed upon mature tissue macrophages.  Pregnancy did not affect the proportions of 
mononuclear cell types isolated from the spleen (table 5.5).  Within lymphocytes 
isolated from the maternal spleen there was significantly lower expression of CD161 
upon NK cells among pregnant females.   
 
The predominant cell type within the mononuclear cells isolated from the maternal 
thymus was T lymphocytes.  No significant effects of pregnancy upon relative cell 
subsets or cell surface marker expression were identified upon mononuclear cells 
isolated from the maternal thymus (see table 5.6).  The lack of an effect of pregnancy 
within the maternal thymus indicates that all the cell types are equally affected by 
thymic involution, remaining in constant proportion to each other with pregnancy.  The   217 
thymus is a primary lymphoid organ and a site of T cell maturation, and so there will be 
significant numbers of immature T cells within the thymus.  The results obtained here 
suggest that there are a significant number of CD4
+CD8
+ (double positive) immature T 
cells (approx. 60   70 %), although these could not be directly identified with the 
staining protocol used.  Other studies using rat models have demonstrated that there are 
significant numbers (> 80%) of double positive immature T cells in the thymus of adult 
male (age 3 month) rats(236). 
 
The immune cells identified within the maternal lymph nodes were comparable to those 
within the spleen and PBMC, with significant numbers of T lymphocytes, NK cells and 
B lymphocytes.  No significant effects of pregnancy were observed upon the cell 
subsets or cell surface marker expression of mononuclear cells isolated from the 
mandibular lymph nodes (see table 5.7), despite the significant reductions in cellularity 
that were observed to occur in this tissue with pregnancy.  This indicates that all cell 
types are equally affected by the reductions in cellularity, and remain in the same 
proportions to each other. 
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Table 5.4: Immune cell subsets identified in lysed whole blood of virgin and pregnant 
female rats (% within lymphocyte gate, MFI, mean ± standard deviation) 
 
  Virgin 
Day 12 of 
pregnancy 
Day 20 of 
pregnancy  ANOVA  
  (n = 6)  (n = 5)  (n = 6)  p value 
CD3
+ (%)  39.3 ± 10.6  47.5 ± 6.8  45.5 ± 7.0  0.268 
CD8
+ (%)  29.5 ± 3.4 
ab  25.6 ± 3.8 
a  33.1 ± 3.5 
b  0.019 
CD4
+ (%)  45.1 ± 9.0  51.7 ± 5.7  45.1 ± 7.2  0.293 
         
CD3
+CD8
+ (%) 
(Cytotoxic T cells)   11.0 ± 3.2 
 
13.8 ± 2.5  14.2 ± 2.0  0.120 
   mean CD3 intensity  38.3 ± 8.0  34.0 ± 9.7  33.4 ± 5.8  0.522 
   mean CD8 intensity  71.6 ± 21.6  80.5 ± 32.0  54.3 ± 14.9  0.200 
         
CD3
+CD4
+ (%) 
(T helper cells)   27.7 ± 7.1 
 
31.2 ± 8.2  31.1 ± 6.7  0.658 
   mean CD3 intensity  44.7 ± 9.2  38.7 ± 12.7  41.2 ± 9.8  0.644 
   mean CD4 intensity  594.8 ± 71.9  589.1 ± 28.3  590.7 ± 28.0  0.979 
         
CD161
+ (%) 
(NK cells)   24.2 ± 3.7 
 
19.0 ± 4.9  21.4 ± 2.7  0.104 
   mean CD161 intensity  303.5 ± 44.9 
a  209.3 ± 52.0 
b  247.9 ± 37.9 
ab  0.012 
         
CD3
 CD45
+ (%) 
(B cells)  24.9 ± 7.3 
 
21.8 ± 4.7  23.3 ± 6.4  0.729 
   mean CD45 intensity  316.4 ± 98.1  272.9 ± 56.1  292.6 ± 35.5  0.591 
         
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts 
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Table 5.5: Immune cell subsets identified within the spleen of virgin and pregnant 
female rats (% within lymphocyte gate, MFI, mean ± standard deviation) 
 
  Virgin 
Day 12 of 
pregnancy 
Day 20 of 
pregnancy  ANOVA  
  (n = 6)  (n = 5)  (n = 6)  p value 
CD3
+ (%)  48.1 ± 7.3  52.2 ± 8.9  52.8 ± 9.7  0.619 
CD8
+ (%)  29.0 ± 7.1  25.7 ± 5.9  28.9 ± 5.8  0.625 
CD4
+ (%)  44.1 ± 6.7  48.2 ± 7.6  49.0 ± 6.7  0.448 
         
CD3
+CD8
+ (%) 
(Cytotoxic T cells)   12.7 ± 3.5 
 
13.4 ± 4.5 
 
14.5 ± 4.6  0.766 
   mean CD3 intensity  22.4 ± 5.1  22.2 ± 3.4  21.2 ± 2.9  0.840 
   mean CD8 intensity  29.0 ± 7.0  30.5 ± 5.9  25.2 ± 5.5  0.361 
         
CD3
+CD4
+ (%) 
(T helper cells)   36.3 ± 7.4 
 
39.3 ± 8.1 
 
39.8 ± 7.4  0.706 
   mean CD3 intensity  37.2 ± 8.5  34.8 ± 7.2  33.4 ± 6.9  0.687 
   mean CD4 intensity  457.1 ± 51.5  449.8 ± 30.9  439.1 ± 10.2  0.685 
         
CD161
+ (%) 
(NK cells)   18.7 ± 7.7 
 
14.7 ± 4.0 
 
13.1 ± 4.0  0.238 
   mean CD161 intensity  143.2 ± 42.9 
a  61.5 ± 18.9 
b  69.2 ± 25.3 
b  0.001 
         
CD3
 CD45
+ (%) 
(B cells)  29.5 ± 11.2 
 
35.5 ± 6.5 
 
34.0 ± 7.5  0.508 
   mean CD45 intensity  126.5 ± 27.1  128.6 ± 30.9  125.2 ± 22.0  0.978 
         
CD163
+ (%) 
(splenic macrophages)  20.1 ± 5.9 
 
28.0 ± 5.7 
 
26.7 ± 7.0  0.112 
   CD163 intensity  33.6 ± 4.9  42.7 ± 9.5  42.0 ± 11.2  0.185 
         
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts   220 
Table 5.6: Immune cell subsets identified within the thymus of virgin and pregnant 
female rats (% total cells, MFI, mean ± standard deviation) 
 
  Virgin 
Day 12 of 
pregnancy 
Day 20 of 
pregnancy  ANOVA  
  (n = 6)  (n = 5)  (n = 6)  p value 
CD3
+ (%)  30.6 ± 7.7  30.0 ± 11.6  30.7 ± 6.9  0.989 
CD8
+ (%)  72.7 ± 5.5  72.2 ± 9.6  72.0 ± 4.6  0.983 
CD4
+ (%)  86.1 ± 4.4  83.2 ± 6.0  84.4 ± 2.3  0.555 
         
CD3
+CD8
+ (%) 
(Cytotoxic T cells)   12.6 ± 4.1 
 
12.3 ± 4.3 
 
12.6 ± 2.3  0.986 
   mean CD3 intensity  47.7 ± 8.7  48.1 ± 7.7  46.6 ± 2.9  0.933 
   mean CD8 intensity  36.9 ± 3.8  38.4 ± 7.8  37.9 ± 5.8  0.917 
         
CD3
+CD4
+ (%) 
(T helper cells)   27.6 ± 6.3 
 
26.5 ± 9.3 
 
28.1 ± 6.5  0.932 
   mean CD3 intensity  59.2 ± 9.0  51.3 ± 5.7  54.8 ± 9.9  0.333 
   mean CD4 intensity  340.3 ± 19.9  342.6 ± 29.5  348.4 ± 53.0  0.929 
         
CD161
+ (%) 
(NK cells)†   4.6 ± 2.0 
 
3.7 ± 1.5 
 
5.5 ± 2.2  0.327 
   mean CD161 intensity  105.1 ± 32.1  97.5 ± 46.6    79.2 ± 13.5  0.393 
         
CD3
 CD45
+ (%) 
(B cells)  2.1 ± 0.5 
 
1.9 ± 1.0 
 
2.7 ± 0.9  0.226 
   mean CD45 intensity  113.7 ± 25.8  86.4 ± 33.3  82.1 ± 13.3  0.095 
         
 
†These are not likely to be NK cells, but to be another cell type bearing CD161 on the 
surface 
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Table 5.7: Immune cell subsets identified within the mandibular lymph nodes of virgin 
and pregnant female rats (% within lymphocyte gate, MFI, mean ± standard deviation) 
 
  Virgin 
Day 12 of 
pregnancy 
Day 20 of 
pregnancy  ANOVA  
  (n = 5)  (n = 5)  (n = 6)  p value 
CD3
+ (%)  50.5 ± 6.1  46.2 ± 5.5  52.9 ± 10.1  0.381 
CD8
+ (%)  16.8 ± 8.4  13.4 ± 1.7  13.8 ± 2.7  0.072 
CD4
+ (%)  50.0 ± 4.1  50.3 ± 6.6  56.3 ± 2.7  0.083 
         
CD3
+CD8
+ (%) 
(Cytotoxic T cells)   11.5 ± 6.9 
 
8.7 ± 1.8  9.5 ± 3.6  0.617 
   mean CD3 intensity  16.2 ± 2.7  15.5 ± 1.3  15.6 ± 1.9  0.865 
   mean CD8 intensity  20.2 ± 6.0  21.0 ± 2.8  17.3 ± 0.7  0.249 
         
CD3
+CD4
+ (%) 
(T helper cells)   39.3 ± 6.4 
 
39.1 ± 5.3  43.8 ± 6.6  0.377 
   mean CD3 intensity  24.0 ± 4.8  24.4 ± 3.6  24.6 ± 4.8  0.975 
   mean CD4 intensity  438.8 ± 65.2  432.9 ± 34.3  399.4 ± 49.0  0.404 
         
CD161
+ (%) 
(NK cells)   10.0 ± 4.5 
 
9.8 ± 2.3  8.8 ± 2.8  0.814 
   mean CD161 intensity  42.7 ± 12.0  43.2 ± 3.9  41.5 ± 8.0  0.942 
         
CD3
 CD45
+ (%) 
(B cells)  33.4 ± 10.2 
 
40.2 ± 5.5  32.2 ± 5.6  0.199 
   mean CD45 intensity  117.7 ± 29.4  105.4 ± 11.0  102.2 ± 18.7  0.486 
         
 
 
 
5.3.5 Lymphocyte proliferation 
 
Lymphocyte proliferation stimulation index in response to Con A (adjusted for CD3
+ 
cells) was assessed in mononuclear cell suspensions from the maternal spleen, thymus 
or whole blood samples (see figures 5.2 to 5.4).  Proliferative responses were assessed 
by calculation of area under the curve (AUC) of the Con A dose response (see table 
5.8). 
 
No statistically significant effects upon the proliferative response or changes in 
sensitivity to Con A stimulation were observed as a result of pregnancy.  The lack of 
significant effect probably reflects the large variability between individual rats, and is a 
limitation of the cross sectional design of this study.   
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Figure 5.2: Mean proliferation of spleen lymphocytes from virgin and pregnant rats 
(stimulation index, adjusted for CD3
+ cell numbers) 
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Error bars are omitted for clarity 
 
 
Figure 5.3: Mean proliferation of thymic lymphocytes from virgin and pregnant rats 
(stimulation index, adjusted for CD3
+ cell numbers) 
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Error bars are omitted for clarity   223 
 
Figure 5.4: Mean proliferation of peripheral blood lymphocytes from virgin and 
pregnant rats (stimulation index, adjusted for CD3
+ cell numbers) 
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Table 5.8: Proliferation of lymphocytes from virgin and pregnant rats 
(AUC, adjusted for CD3
+ cell numbers, mean ± standard deviation) 
 
  Virgin 
Day 12  
of pregnancy 
Day 20  
of pregnancy 
ANOVA p value 
  (n=3)  (n=4)  (n=3)   
Spleen  23.3 ±11.5  26.0 ± 14.5  10.1 ± 4.0  0.240 
   (n=6)   (n=5)   (n=5)   
Thymus  36.5 ± 16.3  21.3 ± 14.7  37.3 ± 26.8  0.374 
  (n=3)  (n=3)  (n=2)   
PBMC  33.8 ± 21.6  24.8 ± 24.7  29.9 ± 19.3  0.888 
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5.3.6 Production of immune signalling molecules 
 
PGE2 
PGE2 is an eicosanoid mediator produced by monocytes and macrophages from the cell 
membrane fatty acid arachidonic acid (AA).  Significant effects of pregnancy have been 
observed upon the phospholipid content of AA in tissues including the liver (see chapter 
4), and it is possible that these changes with pregnancy also affect the fatty acid 
composition of immune cells.   
 
No significant effect of pregnancy was observed upon the concentration of PGE2 in 
plasma or upon the basal or Con A stimulated production of PGE2 by spleen 
mononuclear cells or PBMC (see table 5.9).  Con A is a T cell stimulator, and PGE2 is 
not generated within T cells, but from antigen presenting cells such as monocytes and 
macrophages.  Thus PGE2 measured in the cell cultures is likely to be generated by 
macrophages in spleen cell cultures and monocytes in PBMC cultures and in turn these 
cells would have been stimulated by T cell derived products.  
 
Spleen cell cultures did not respond well to Con A in terms of PGE2 production 
suggesting that the T cell   macrophage interaction is not strong in these cultures.  In 
contrast, PBMC cultures produced more PGE2 when stimulated by Con A, suggesting a 
functional T cell   monocyte interaction in these cultures.  This indicates that circulating 
monocytes respond to Con A stimulation in a way which differs from the responses of 
resident macrophages within tissues.  
 
Table 5.9: PGE2 concentration in plasma and PGE2 production by spleen and peripheral 
blood lymphocytes in virgin and pregnant female rats (ng/ml; mean ± standard 
deviation) 
  Virgin  Day 12 of 
pregnancy 
Day 20 of 
pregnancy 
ANOVA  
p value 
Plasma  (n=6)  (n=5)  (n=6)   
  27.0 ± 17.1  21.6 ± 7.7  33.3 ± 32.0  0.688 
Spleen  (n=5)  (n=5)  (n=5)   
No Con A   2.5 ± 0.4  3.4 ± 1.7  2.2 ± 1.1  0.315 
5  g/ml Con A   2.5 ± 0.6  2.5 ± 1.1  2.5 ± 0.4  0.998 
Mean SI  1.0 ± 0.2  0.8 ± 0.2  1.3 ± 0.7  0.162 
PBMC  (n=2)  (n=5)  (n=5)   
No Con A  3.9 ± 3.2  4.2 ± 2.4  3.4 ± 2.7  0.896 
5  g/ml Con A   11.7 ± 13.4  14.7 ± 2.7  11.3 ± 5.9  0.676 
Mean SI  2.4 ± 1.5  4.9 ± 3.0  4.5 ± 3.3  0.622   225 
IFN γ 
 
IFN γ is a cytokine produced by T helper cells, cytotoxic T cells and NK cells, and is 
typically used as a marker of Th1 activity.  Con A stimulation led to a dramatic increase 
(several thousand fold) in IFN γ production by spleen, thymus and peripheral blood 
lymphocytes.  No significant effects of pregnancy were observed upon IFN γ 
production by maternal spleen, thymus or peripheral blood cells (see table 5.10).   
 
Table 5.10: IFN γ production by spleen, thymus and peripheral blood lymphocytes of 
virgin and pregnant female rats (pg/ml, mean ± standard deviation) 
 
  Virgin  Day 12 of 
pregnancy 
Day 20 of 
pregnancy 
ANOVA  
p value 
Spleen  (n=5)  (n=5)  (n=5)   
No Con A  2.92 ± 6.53  0.52 ± 1.16  0.00 ± 0.00  0.461 
5  g/ml Con A (x 10
 3)   44.7 ± 22.5  46.9 ± 38.7  38.7 ± 30.9  0.915 
Mean SI (x 10
 3)  33.9 ± 27.1  44.0 ± 41.3  38.7 ± 30.9  0.894 
Thymus  (n=6)  (n=5)  (n=5)   
No Con A  8.1 ± 15.1  4.4 ± 3.4  39.5 ± 54.0  0.185 
5  g/ml Con A (x 10
 3)   14.3 ± 9.6  20.9 ± 12.8  15.1 ± 7.9  0.543 
Mean SI (x 10
 3)  7.1 ± 10.0  13.3 ± 16.9  4.5 ± 4.1  0.476 
PBMC  (n=2)  (n=5)  (n=5)   
No Con A  299.9 ± 424.1  76.1 ± 161.3  47.3 ± 31.4  0.272 
5  g/ml Con A (x 10
 3)   23.5 ± 27.5  13.9 ± 15.7  26.1 ± 25.3  0.676 
Mean SI (x 10
 3)  2.0 ± 2.8  5.0 ± 9.3  0.5 ± 0.3  0.546 
 
SI, stimulation index: ConA stimulated cytokine production / unstimulated cytokine 
production 
 
IL 4 
 
IL 4 is a Th2 type cytokine generated by T cells.  There was no increase in production 
of IL 4 between unstimulated and stimulated cells.  This may in part be due to the 
antagonistic nature of Th1 and Th2 cytokines, with the dramatically increased 
production of IFN γ inhibiting IL 4 production.  No significant effects of pregnancy 
were observed upon IL 4 production by maternal spleen, thymus or peripheral blood 
lymphocytes (see table 5.11).   
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Table 5.11: IL 4 production by spleen, thymus and peripheral blood lymphocytes in 
virgin and pregnant female rats (pg/ml; mean ± standard deviation) 
 
  Virgin  Day 12 of 
pregnancy 
Day 20 of 
pregnancy 
ANOVA  
p value 
Spleen  (n=5)  (n=5)  (n=5)   
No Con A   11.7 ± 12.5  20.2 ± 7.4  11.9 ± 9.1  0.330 
5  g/ml Con A   8.0 ± 6.6  12.6 ± 8.1  7.5 ± 5.3  0.444 
Thymus  (n=6)  (n=5)  (n=5)   
No Con A   24.5 ± 21.9  33.4 ± 17.3  16.3 ± 12.9  0.357 
5  g/ml Con A   20.5 ± 21.3  23.8 ± 7.2  6.7 ± 9.0  0.183 
PBMC  (n=2)  (n=5)  (n=5)   
No Con A   10.8 ± 2.9  5.1 ± 5.3  6.6 ± 3.2  0.326 
5  g/ml Con A   7.7 ± 3.0  5.2 ± 5.1  5.3 ± 4.6  0.803 
 
 
Th1 vs. Th2 
 
The relative balance of Th1 and Th2 cytokine production may be more important than 
absolute concentrations generated.  For this reason, the ratio of IFN γ to IL 4 produced 
by Con A stimulated cells was calculated (see table 5.12).  There was no effect of 
pregnancy on the ratio of IFN γ to IL 4 production by stimulated spleen cells or PBMC.  
However, in the thymus there was a significantly increased Th1:Th2 ratio in late 
pregnancy. 
 
Table 5.12: IFNγ:IL 4 ratios produced by Con A stimulated spleen, thymus and 
peripheral blood lymphocytes in virgin and pregnant female rats (mean ± standard 
deviation) 
 
  Virgin 
(n=5,6,2) 
Day 12 of 
pregnancy 
(n=5) 
Day 20 of 
pregnancy 
(n=5) 
ANOVA 
p value 
Spleen IFNγ:IL 4 x 10
 3  15.5 ± 17.7  11.3 ± 19.1  6.1 ± 4.0  0.631 
Thymus IFNγ:IL 4 x 10
 3  1.2 ± 1.1 
a  0.9 ± 0.5 
a  6.6 ± 5.2 
b  0.015 
PBMC IFNγ:IL 4 x 10
 3  2.6 ± 2.6  9.1 ± 16.3  9.1 ± 9.2  0.802 
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have 
different superscripts 
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5.4  Discussion 
 
The aim of this study was to characterise the normal range of immunological changes in 
the Wistar rat during pregnancy, in order that the effect of maternal dietary fatty acids 
upon this process can be evaluated in later studies (chapter 7).  The immunological 
parameters assessed included immune organ weight and cellularity, immune cell 
subsets, T cell proliferation, and the production of cytokines (IFN γ and IL 4) and 
PGE2.  The hypotheses being tested were that: 
 
a)  rat pregnancy causes thymic involution and reduced lymphoid organ cellularity 
b)  changes in lymphoid organ cellularity are associated with changes to the profile 
of immune cell subsets present 
c)  the rat will demonstrate changes in Th1/Th2 balance in response to pregnancy, 
favouring production of Th2 cytokines such as IL 4. 
 
The data from this study fully support hypothesis a.  There is some data from immune 
tissues which is supportive of hypothesis b, though no significant changes in the 
proportion of cells types were observed within the thymus.  Hypothesis c is not 
supported by the current data, and in fact the Th1:Th2 ratio of cytokines was highest 
among rats at day 20 of gestation.  In addition, data obtained demonstrated that cell 
surface markers upon maternal NK cells were lower among pregnant females than in 
virgin female rats. 
   
This study confirms that thymic involution is a feature of Wistar rat pregnancy, as has 
been observed previously in rats(237), mice and humans(176).  Trends for reductions in 
the absolute numbers of cells recovered from the thymus, spleen and lymph nodes and 
cellularity of these organs (i.e. number of cells per unit weight) were observed, with this 
reaching statistical significance within mandibular lymph nodes.  This may present an 
advantage during pregnancy by reducing the number of lymphocytes which may target 
fetal antigens.  However, data was not collected to assess any change within the 
absolute number of PBMCs during pregnancy and future studies would benefit from 
this additional information. 
 
There were significant but selected changes in immune cell populations and the 
expression of cell surface makers in the rat during pregnancy.  The changes observed   228 
were increased proportions of CD8
+ cells in the PBMC population, and reduced 
expression of CD161 on NK cells in PBMC and the spleen.  No significant effects of 
pregnancy were observed upon cell populations in the thymus, despite the thymic 
involution observed.  Increasing CD8
+ cell numbers suggests that cytotoxic T cell 
responses are increased in the rat during pregnancy, which may improve the response to 
viral infection.  It has been identified that the presence of NK cells correlates to fetal 
resorption in the mouse(175).  The current data suggests that while the proportion of 
NK cells in the maternal blood are not affected by pregnancy, the responsiveness of 
these cells to cytotoxic stimulus may be impaired by the reduced expression of cell 
surface markers.  This would be consistent with the need to reduce NK cell activity 
during pregnancy.  However, data was not collected to assess any change within the 
absolute number of PBMCs during pregnancy, which may provide further information 
upon the relevance of these changes in proportions of cell types or their relative cell 
surface marker expression. 
 
No significant effects of pregnancy were observed upon lymphocyte proliferative 
responses, or their sensitivity to Con A stimulation.  It is possible that any effect of 
pregnancy upon lymphocyte proliferation was obscured by the degree of biological 
variation between animals.  Some of this variation could have been accounted for if 
blood samples were taken from the same animal throughout pregnancy rather than 
comparing different animals.  However, it would not have been possible to assess the 
proliferative response of cells from immune organs such as spleen, thymus and lymph 
nodes in a longitudinal study. 
 
No significant changes were observed in the absolute production of PGE2, IFN γ or IL 4 
in response to pregnancy.  However, the Th1/Th2 ratio of cytokine production within 
the thymus was significantly higher among day 20 pregnant rats.  Although this is in 
contradiction to the Th2 shift which has been described in human and murine systems, it 
is consistent with the findings of other studies of Wistar rats where an increase in IFN γ 
producing CD4
+ cells was seen(179;180).  The rat may therefore not be a suitable 
animal model for use in investigation of changes to the balance of Th1/Th2 cytokine 
production which have been observed during human pregnancy.  A further timecourse 
of maternal immune function after delivery and lactation would provide useful 
information upon the duration of the maternal adaptations observed in the rat. 
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The cultures used to assess cytokine production in this study were of mixed 
mononuclear cell populations.  It would be advantageous for future studies to 
investigate the cytokine production of specific cell types, either by purifying specific 
immune cell subsets prior to culture (e.g. by cell sorting), or use of alternative methods 
to assess cytokine production, such as flow cytometry techniques which allow 
simultaneous cell phenotype identification.  The use of ELISAs to assess cytokine 
production limited the number of cytokines which could be assessed within the sample 
quantity which was available.  Use of a multiplex kit which enables the simultaneous 
analysis of a wider panel of cytokines from a much smaller sample volume would allow 
further insight into the effect of pregnancy upon cytokine production in the rat, and in 
particular allow assessment of whether the changes observed reflect a change in the 
overall capacity for cytokine production, or are limited to specific mediators.   
 
The findings of this study could be taken further by assessing the functional effects of 
the changes in lymphocyte subsets and cell surface marker expression identified.  For 
example, assays of cytotoxicity or sensitivity to activation could be used to investigate 
whether the effects of pregnancy which were observed upon the expression of CD8 
upon PBMC has a direct functional outcome which may be of relevance to health or 
disease resistance during pregnancy.  Similarly, NK cell activity could be assessed to 
determine the functional effects of reduced CD161 expression upon NK cell 
cytotoxicity during pregnancy.  A comprehensive understanding of the normal 
physiological changes in immune function of the rat during pregnancy is essential for 
future studies to investigate the potential for these processes to be modulated by diet 
during pregnancy, and whether these changes are likely to be beneficial, or may 
represent an increased risk of either pregnancy loss or disease risk during pregnancy.  230 
 
 
 
 
 
 
 
Chapter 6:  The effect of maternal dietary 
fatty acids during pregnancy 
upon maternal and fetal 
tissue fatty acid composition 
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6.1 Introduction 
6.1.1 Aims and hypothesis for current investigation 
 
The aim of this study is to investigate the effects of maternal diet during pregnancy 
upon maternal and fetal plasma and tissue fatty acid composition.  In particular, the 
effect that increasing the α linolenic acid (ALNA) and longer chain n 3 polyunsaturated 
fatty acid (LC n 3 PUFA) content of the maternal diet has upon LC n 3 PUFA status of 
the fetus will be investigated.  Data will be used to identify potential predictors of fetal 
immune tissue fatty acid composition from samples which could feasibly be collected in 
human studies.  These data will also used for later comparison with a parallel cohort in 
which immune function parameters will be assessed (chapter 7).   
 
This chapter therefore sets out to addresses the following hypotheses: 
a)  that a change in maternal dietary fatty acid intake during pregnancy will alter 
maternal plasma fatty acid composition, thereby altering the availability of fatty 
acids to the developing fetus, including LC n 3 PUFA. 
b)  that the changes to maternal dietary fatty acid intake during pregnancy will 
significantly affect maternal tissue composition, including the maternal liver, 
adipose tissue and immune tissues.  
c)  that a change in the availability of fatty acids to the developing fetus will alter 
the fatty acid composition of fetal plasma and developing fetal tissues such as 
the liver, brain and immune tissues. 
6.1.2 Metabolic fates of maternal dietary fatty acids during 
pregnancy  
 
The transfer of fatty acids to the developing fetus is unlikely to be a simple reflection of 
the maternal diet, but will also be influenced by processes such as endogenous maternal 
lipogenesis, maternal LC PUFA metabolism and the effectiveness and selectivity of 
placental transfer (see figure 6.1).  It is therefore necessary to analyse the fatty acid 
composition of a wide range of maternal and fetal tissues in order to evaluate the 
metabolic fate of dietary fatty acids during pregnancy. 
 
Differences in the relative transfer of fatty acids to the developing fetus may have 
functional effects upon fetal tissues due to the important physiological roles of fatty   232 
acids within those tissues.  For example, fatty acids are precursors for the generation of 
immune signalling molecules; for example, eicosapentaenoic acid (EPA, 20:5n 3) and 
arachidonic acid (AA, 20:4n 6) are used to generate eicosanoids under the action of 
cyclooxygenase and lipoxygenase enzymes.  The relative availability of these fatty acids 
within immune tissues may therefore result in functional effects. 
 
Figure 6.1: The potential causal pathway by which changes to maternal dietary fatty 
acids may alter fetal tissue fatty acid composition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.1.3 Animal studies of diet during pregnancy and the fatty acid 
composition of tissues 
 
Though there are numerous studies which have demonstrated a significant effect of diet 
upon tissue fatty acid composition using animal models, there are relatively few studies 
which have been carried out to date which have demonstrated that fetal rat tissue fatty 
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acid composition can be altered in response to maternal diet during pregnancy.  Those 
which have been undertaken have often also included feeding experimental diets during 
the neonatal period, and so it is difficult to identify whether the effects upon tissue 
composition occurred in utero, or during lactation. 
 
One of the more comprehensive studies available to date investigated the effect of 
feeding diets rich in saturates (palm oil), monounsaturates (olive oil), n 6 PUFA 
(sunflower oil) and LC n 3 PUFA (fish oil) during pregnancy upon maternal and fetal 
plasma and tissue fatty acid composition(228).  This study identified that maternal diet 
during pregnancy significantly affected the fatty acid composition of maternal adipose 
tissue, liver, plasma, and placenta and of fetal plasma and liver.  The limitations of this 
study are the relatively narrow range of fatty acids assessed within tissues (9 fatty acids 
identified) and the use of total lipid extracts from tissues rather than isolation of specific 
lipid fractions such as phospholipids and triglycerides from all tissues except the 
placenta.  A study of ALNA and docosahexaenoic acid (DHA, 22:6n 3) rich diets 
during pregnancy(238) identified that a maternal diet rich in n 3 fatty acids during 
pregnancy has the capacity to significantly alter the n 3 fatty acid composition of the 
uterus and placenta.  There are no animal studies to date which have investigated the 
effect of maternal dietary fatty acids during pregnancy upon maternal and fetal immune 
tissue fatty acid composition. 
6.2 Methods 
 
All animal work was carried out in accordance with the Home Office Animals 
(Scientific Procedures) Act (1986); mating was carried out by monogamous breeding 
(see section 2.1).  Experimental diets were provided ad libitum over a 20 day period, 
starting immediately after conception.  Maternal tissues were collected at day 20 
gestation and included plasma, liver, subcutaneous adipose, intra abdominal adipose, 
and mononuclear cells isolated from lymphoid organs and blood samples.  Fetal tissues 
were collected at day 20 gestation and included plasma, liver, brain, and mononuclear 
cells isolated from the thymus and blood samples.  Fatty acid compositions of 
experimental diets and both maternal and fetal tissues were determined by gas 
chromatography (see section 2.6).  Liver glycogen, lipid and dry weight content were 
assessed (see section 2.8, 2.10).  Plasma lipid and glucose concentration analysis was 
provided by Southampton General Hospital (see section 2.7, 2.9).  
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The effects of maternal diet upon variables of interest were determined by one way 
ANOVA with Bonferroni post hoc correction for multiple comparisons.  Correlation 
coefficients (r) were calculated using Pearson or Spearman test as appropriate after data 
were assessed for normality.  Where stepwise multiple regression analysis was 
performed, the significant variables and Beta values are provided.   
6.3 Results 
6.3.1 Experimental diets 
Pregnant animals received experimental diets from conception to day 20 of gestation.  
Six diets were used, a low fat (LF, 3% w/w) soyabean oil diet, and five high fat (HF, 
13% w/w) diets: HF soyabean oil, HF linseed oil, HF salmon oil; HF sunflower oil, HF 
beef tallow.  The fatty acid composition of these diets was analysed (see table 6.1).   
 
The LF soyabean oil diet is a standard laboratory rat chow, which all animals were 
maintained upon prior to the start of experiments.  This diet contains both n 6 and n 3 
essential fatty acids (EFA; linoleic acid (LA) and ALNA).  This diet was therefore used 
as a ‘control’ diet; with animals receiving this diet not exposed any dietary change 
during pregnancy.   
 
The HF diets were used in order to represent a % energy from fat which is more 
representative of that typically consumed in a Western human diet.  The HF soyabean 
oil diet maintained the relative contributions of LA and ALNA as were present in the 
LF soyabean oil diet, and so allowed the effect of quantitative change in fat intake to be 
assessed.  The remaining HF diets were chosen based upon their characteristic fatty acid 
compositions, which can be summarised as follows: 
  
￿  HF linseed oil   rich in the n 3 fatty acid ALNA 
￿  HF salmon oil – rich in monounsaturates (MUFA) and LC n 3 PUFA and 
containing some LC n 6 PUFA 
￿  HF sunflower oil – rich in LA 
￿  HF beef tallow – rich in saturates and oleic acid (OA, 18:1n 9) at the expense of 
n 6 PUFA, and therefore representative of the typical UK diet prior to the 
widespread use of margarine and vegetable oils. 
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Table 6.1:  The fatty acid composition of total lipid extracts obtained from experimental diets (% of total fatty acids, mean ± standard deviation, n=5 
per group) 
Fatty acids  LF Soyabean   HF Soyabean   HF Linseed  HF Salmon  HF Sunflower  HF Beef Tallow  ANOVA 
14:0  0.2 ± 0.2  0.1 ± 0.0  ND  4.4 ± 0.5 *  0.1 ± 0.0  2.6 ± 0.2 *  < 0.001 
16:0  19.0 ± 1.1 *  12.9 ± 0.5 *  8.6 ± 0.3  17.1 ± 1.1 *  9.5 ± 0.4  25.2 ± 1.3 *  < 0.001 
18:0  4.6 ± 1.0  4.6 ± 0.3  3.7 ± 0.2  3.3 ± 0.3  4.0 ± 0.2  18.3 ± 0.6 *  < 0.001 
20:0  0.5 ± 0.6  0.3 ± 0.1  0.3 ± 0.1  1.0 ± 0.7  0.3 ± 0.1  0.4 ± 0.1  0.067 
22:0  0.2 ± 0.2  0.1 ± 0.2  ND  ND  0.2 ± 0.3  ND  0.479 
Total saturated  24.4 ± 0.8  18.0 ± 0.5 *  12.7 ± 0.2  25.7 ± 0.9  14.0 ± 0.7  46.6 ± 1.6 *  < 0.001 
16:1n 7  0.4 ± 0.4  0.2 ± 0.1  0.1 ± 0.0  5.1 ± 0.5 *  0.1 ± 0.0  1.8 ± 0.2 *  < 0.001 
18:1n 9  14.0 ± 1.4 *  21.1 ± 0.5  20.7 ± 0.4  18.4 ± 0.5 *  21.4 ± 0.6  30.3 ± 1.5 *  < 0.001 
20:1n 9  0.3 ± 0.3  0.2 ± 0.1  0.2 ± 0.1  6.1 ± 0.3 *  0.2 ± 0.1  0.3 ± 0.1  < 0.001 
24:1n 9  ND  ND  ND  0.2 ± 0.2 *  ND  ND  < 0.001 
Total MUFA  14.6 ± 2.0 *  21.5 ± 0.5  21.1 ± 0.5  29.8 ± 0.9 *  21.7 ± 0.6  32.4 ± 1.5 *  < 0.001 
18:2n 6  53.7 ± 2.0  52.8 ± 0.7  27.7 ± 2.9 *  21.1 ± 1.0  61.8 ± 0.6 *  18.4 ± 1.6  < 0.001 
18:3n 6  ND  0.2 ± 0.1  0.2 ± 0.1  0.1 ± 0.1  ND  ND  < 0.001 
20:2n 6  0.4 ± 0.7  ND  ND  0.3 ± 0.2  ND  ND  0.306 
20:3n 6  ND  ND  ND  0.2 ± 0.1 *  ND  ND  < 0.001 
20:4n 6  0.1 ± 0.2  ND  ND  0.5 ± 0.1 *  ND  ND  < 0.001 
22:5n 6  0.4 ± 0.4  0.2 ± 0.1  0.1 ± 0.1  0.2 ± 0.1  0.2 ± 0.0  ND  0.189 
Total n 6 PUFA  54.7 ± 1.7  53.2 ± 0.4  27.7 ± 2.7 *  22.3 ± 1.0 *  62.0 ± 0.5 *  18.6 ± 1.5 *  < 0.001 
18:3n 3  5.9 ± 0.5  6.9 ± 0.2  38.0 ± 2.8 *  3.5 ± 0.4  1.7 ± 0.1  2.1 ± 0.2  < 0.001 
20:4n 3  0.1 ± 0.2  0.2 ± 0.2  0.1 ± 0.1  2.1 ± 1.8 *  0.4 ± 0.4  ND  0.001 
20:5n 3  0.2 ± 0.2  ND  ND  6.5 ± 1.1 *  ND  ND  < 0.001 
22:5n 3  ND  ND  ND  2.4 ± 0.5 *  ND  0.1 ± 0.1  < 0.001 
22:6n 3  ND  ND  ND  7.6 ± 0.4 *  ND  ND  < 0.001 
Total n 3 PUFA  6.3 ± 0.5  7.3 ± 0.3  38.5 ± 2.9 *  22.2 ± 1.9 *  2.2 ± 0.4  2.4 ± 0.3  < 0.001 
LA: ALNA ratio  9.1  7.6  0.7 *  6.0 *  36.4 *  8.8  < 0.001 
 
ND  negligible detected (mean <0.1%)    * significantly different (p < 0.05) from all other dietary groups  236 
6.3.2 Weight gain and food intake 
Once conception was confirmed, dams were housed individually, their weight 
monitored weekly (see figure 6.2) and food consumption assessed by weighed food 
intake.  Dams on the HF diets exhibited a faster rate of weight gain (see table 6.2), 
particularly in the final week of gestation.  This was not associated with any significant 
effect of food (g) or energy (MJ) intake or on litter or placental size (see table 6.3).  The 
effects of diet upon maternal weight gain primarily appear to reflect increased maternal 
organ growth and adiposity.  There was no significant effect of maternal diet upon the 
ratio of fetal:placental weight (an index of placental function, see table 6.4). 
 
Figure 6.2: Mean weight of pregnant females over the study period 
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Error bars omitted for clarity 
 
6.3.3 Maternal plasma glucose and lipid concentrations 
 
Significant effects of diet were observed upon maternal high density lipoprotein (HDL) 
cholesterol and triacylglycerol (TAG) concentrations and on the total cholesterol:HDL 
cholesterol ratio, but not upon plasma glucose, non esterified fatty acids (NEFA) or 
total cholesterol (see table 6.5).  
p < 0.05 
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Table 6.2: Weight gain and weighed food and energy intake during pregnancy in rats fed experimental diets  
(mean ± standard deviation, n = 6 per group) 
 
  LF Soyabean   HF Soyabean   HF Linseed   HF Salmon   HF Sunflower   HF Beef tallow  ANOVA  
p value 
Weight gain (g/day)   3.2 ± 1.0 
a  4.5 ± 0.7  4.4 ± 0.3  4.7 ± 0.5 
b  4.4 ± 0.6  4.9 ± 0.8 
b  0.004 
Food intake (g/day)   17.9 ± 2.2  17.5 ± 2.3  16.7 ± 1.1  16.2 ± 1.8  17.3 ± 1.3  17.5 ± 2.4  0.695 
Energy intake (MJ/day)  0.26 ± 0.03  0.30 ± 0.04  0.29 ± 0.02  0.28 ± 0.03  0.30 ± 0.02  0.30 ± 0.04  0.347 
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have different superscripts  
 
 
 
Table 6.3: Placenta weight and litter development during pregnancy of rats fed experimental diets (mean ± standard deviation) 
 
  LF Soyabean  
(n=5) 
HF Soyabean  
(n=6) 
HF Linseed  
(n=5) 
HF Salmon  
(n=6) 
HF Sunflower  
(n=5) 
HF Beef tallow 
(n=6) 
ANOVA  
p value 
Placenta weight (g)  5.65 ±1.27  5.63 ± 0.73
  5.69 ± 0.86
  6.15 ± 0.57
  6.06 ± 1.62
  6.54 ± 0.76
  0.601 
Litter weight (g)   27.90 ± 6.69  29.11 ± 7.23
  28.46 ± 5.69
  28.41 ± 3.22
  28.22 ± 10.27
  29.65 ± 6.38
  0.998 
Litter size (range)  8 14  9 14  9 16  12 16  6 14  12 15   
Litter size (n)  12.2 ± 2.1  11.8 ± 1.7  11.7 ± 2.6  13.7 ± 1.6  11.2 ± 3.0  13.3 ± 1.5  0.313 
Fetal:placental weight  4.9 ± 0.7  5.1 ± 0.8  5.2 ± 0.8  4.6 ± 0.4  4.8 ± 1.2  4.5 ± 0.6  0.590 
Pup weight (g)  2.29 ± 0.40  2.47 ± 0.55  2.57 ± 0.65  2.09 ± 0.23  2.55 ± 0.49  2.24 ± 0.57  0.533 
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Table 6.4: The placenta and litter as a proportion of maternal weight during pregnancy in rats fed experimental diets (mean ± standard deviation) 
 
  LF Soyabean  
(n=5) 
HF Soyabean  
(n=6) 
HF Linseed  
(n=5) 
HF Salmon  
(n=6) 
HF Sunflower  
(n=5) 
HF Beef tallow 
(n=6) 
ANOVA  
p value 
Placenta (% body weight)  2.07 ± 0.32  1.85 ± 0.24
  1.80 ± 0.26
  1.94 ± 0.23
  2.02 ± 0.56
  2.03 ± 0.29
  0.719 
Litter (% body weight)  10.14 ± 1.80  9.59 ± 2.37
  9.00 ± 1.77
  8.96 ± 1.21
  9.28 ± 2.91
  9.23 ± 2.46
  0.938 
Placenta (% pregnancy weight gain)  9.23 ± 2.45  6.38 ± 1.12
  6.40 ± 0.79  6.60 ± 0.56
  6.82 ± 1.58
  6.84 ± 1.19
  0.885 
Litter (% pregnancy weight gain)  44.37 ± 10.21  32.76 ± 7.51
  26.50 ± 5.23  30.49 ± 3.65
  31.60 ± 7.68
  31.33 ± 9.36
  0.064 
 
 
 
Table 6.5: Plasma lipid and glucose concentrations in pregnant rats fed experimental diets (mean ± standard deviation, n=6 per group) 
 
   LF Soyabean   HF Soyabean   HF Linseed   HF Salmon   HF Sunflower   HF Beef tallow  ANOVA 
p value 
Glucose (mM)  7.3 ± 2.8
  7.8 ± 2.3
  7.5 ± 1.3  7.4 ± 1.4
  7.8 ± 1.3
  7.9 ± 1.3  0.993 
Total cholesterol (mM)  1.3 ± 0.4  1.7 ± 0.3  1.5 ± 0.2  1.1 ± 0.2  1.5 ± 0.3  1.7 ± 0.4  0.026 † 
HDL cholesterol (mM)  0.9 ± 0.2 
b  1.0 ± 0.2 
b  1.0 ± 0.2 
b  0.8 ± 0.2  0.9 ± 0.2 
b  0.6 ± 0.2 
a  0.001 
Total cholesterol:HDL ratio  1.4 ± 0.26 
a  1.71 ± 0.18 
a  1.59 ± 0.18 
a  1.40 ± 0.15 
a  1.62 ± 0.26 
a  3.23 ± 1.48 
b  < 0.001 
NEFA ( M)  678.6 ± 280.2
  902.7 ± 503.4  717.2 ± 415.6  483.1 ± 339.0  892.5 ± 405.8  951.1 ± 444.7  0.366 
TAG (mM)  1.5 ± 0.7 
a  3.1 ± 1.1 
b  2.3 ± 0.5  1.7 ± 0.5 
a  2.1 ± 0.5  3.4 ± 0.9 
b  < 0.001 
 
†   no significant differences between groups when Bonferroni post hoc test applied  
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have different superscripts 
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The HF beef tallow diet group had the lowest plasma HDL cholesterol concentration, 
and the highest total:HDL cholesterol ratio.  The total:HDL cholesterol ratio is 
commonly used to assess cardiovascular risk in humans, with higher values indicating 
increased risk(239).  This diet during pregnancy may therefore increase maternal 
cardiovascular risk.   
 
The HF salmon oil group exhibited plasma TAG concentrations which were as low as 
those observed with the LF soyabean oil diet, which is consistent with the lipid lowering 
effects of fish oil that have been observed in both rat models(240) and human studies of 
both normolipidemic and hyperlipidemic subjects(241).  However, as animals were not 
fasted prior to blood collection, it is possible that the effects observed may be 
confounded by variation in fed status. 
6.3.4 Maternal plasma fatty acid composition 
 
The fatty acid composition of phosphatidylcholine (PC), TAG, cholesteryl esters (CE) 
and NEFA in maternal plasma was determined by gas chromatography (see tables 6.6 to 
6.9).  Significant effects of maternal diet were observed in all plasma lipid fractions, and 
across virtually all fatty acids assessed, in line with the properties of the diet consumed.   
 
By comparing the plasma lipids from pregnant rats fed the LF and HF soyabean oil 
diets, we can infer some of the effects of changing the quantity of dietary fat upon fatty 
acid composition.  The EFA (LA and ALNA) content of plasma lipids was higher in the 
HF soyabean oil group compared to the LF soyabean oil group.  There was also a trend 
for the LC n 6 PUFA status of the LF soyabean oil group to be greater than the HF 
soyabean oil group, with 22:5n 6 being significantly higher in plasma PC and CE, and 
AA significantly higher in plasma TAG.  This implies that HF feeding may reduce the 
endogenous synthesis of LC n 6 PUFA.  There was a trend for a similar effect upon LC 
n 3 PUFA, particularly in plasma TAG and NEFA. 
 
The HF linseed oil diet, which has the highest ALNA content, resulted in the highest 
ALNA content within plasma lipids, and this was significantly different from all other 
dietary groups.  ALNA is an EFA which can be used for the endogenous synthesis of 
LC n 3 PUFA.  There was a trend for the HF linseed oil group to have higher LC n 3 
PUFA status than other HF diet groups (with the exception of the HF salmon oil group), 
with EPA in the CE fraction in particular being significantly higher than all other   240 
dietary groups (except HF salmon oil).  This indicates that endogenous synthesis of LC 
n 3 PUFA had occurred, as this diet contained no pre formed LC n 3 PUFA. 
 
The HF salmon oil diet is rich in LC n 3 PUFA, and rats fed this diet had the highest LC 
n 3 PUFA status, with this observation apparent across all plasma lipids.  This higher 
content of LC n 3 PUFA occurred at the expense of n 6 PUFA, with the HF salmon oil 
group demonstrating the lowest AA and total n 6 PUFA in the CE fraction.  Other fatty 
acids which were unique to the salmon oil diet such as 20:1n 9 also exhibited levels 
which were higher than those of any other dietary group. 
 
The HF sunflower oil diet contains the highest LA content of all the diets, and 
consequently the highest LA content in plasma TAG, CE and NEFA.  LA can be used 
for the endogenous synthesis of LC n 6 PUFA.  Despite this, the HF sunflower oil 
group did not consistently demonstrate the highest LC n 6 PUFA content of plasma 
lipids.  For example, while the AA content of plasma lipids was higher in the HF 
sunflower oil group than in the HF soyabean, linseed or salmon oil groups, it did not 
reach levels as high as those observed in the LF soyabean oil or HF beef tallow groups.  
The 22:5n 6 status of plasma lipids was highest in the sunflower oil group.  These 
changes in n 6 PUFA content were at the expense of LC n 3 PUFA, with the HF 
sunflower oil group having the lowest DHA content in plasma PC, CE and NEFA. 
 
The HF beef tallow diet contained the highest 16:0, 18:0 and OA content of all the 
experimental diets.  This group had the highest OA content in all plasma lipids when 
compared to all other dietary groups.  This group demonstrated the highest 16:0 and 
18:0 content within plasma TAG, but this effect upon saturates was not observed in 
other plasma lipid fractions.  These effects were at the expense of LC n 3 PUFA, with 
the beef tallow group exhibiting lower levels of DHA than virtually all other dietary 
groups (with the exception of HF sunflower oil, which had the lowest levels of DHA).   
Changes to the maternal diet during pregnancy can therefore significantly affect 
circulating maternal fatty acid composition.  This will in turn alter the availability of 
fatty acids for transport across the placenta and incorporation into maternal tissues.  241 
Table 6.6: Fatty acid composition of plasma PC in pregnant rats fed experimental diets (% of total fatty acids, mean ± standard deviation, n=6 per 
group) 
 
Fatty acids  LF Soyabean   HF Soyabean   HF Linseed   HF Salmon   HF Sunflower   HF Beef 
tallow 
ANOVA  
p value 
14:0  0.24 ± 0.08  0.15 ± 0.08  0.24 ± 0.09  0.33 ± 0.08  0.22 ± 0.08  0.24 ± 0.08  0.034 
16:0  27.38 ± 1.58  22.99 ± 1.04  22.79 ± 1.32  25.67 ± 1.25  22.64 ± 1.85  24.47 ± 1.56  < 0.001 
18:0  19.86 ± 2.08  21.28 ± 1.34  21.96 ± 1.42  18.50 ± 1.28  20.10 ± 1.91  20.16 ± 1.05  0.012 
20:0  0.24 ± 0.29  ND  0.29 ± 0.18  ND  0.19 ± 0.24  0.11 ± 0.13  0.117 
22:0  0.29 ± 0.43  ND  0.36 ± 0.15  ND  0.23 ± 0.25  0.10 ± 0.13  0.197 
Total saturated  48.03 ± 1.83  44.49 ± 1.60  45.63 ± 1.07  44.66 ± 0.62  43.39 ± 2.29  45.08 ± 1.05  < 0.001 
16:1n 7  1.17 ± 0.80  0.32 ± 0.24  0.84 ± 0.63  0.67 ± 0.37  0.54 ± 0.34  0.56 ± 0.23  0.080 
18:1n 9  4.60 ± 0.84  3.92 ± 0.73  5.32 ± 0.74  5.04 ± 0.68  4.41 ± 0.34  6.88 ± 0.67 *  < 0.001 
20:1n 9  ND  ND  ND  1.38 ± 0.17 *  ND  ND  < 0.001 
Total MUFA  5.78 ± 1.42  4.30 ± 0.89  6.15 ± 1.31  7.14 ± 0.49  5.02 ± 0.52  7.44 ± 0.78  < 0.001 
18:2n 6  12.18 ± 1.84 *  23.73 ± 3.01  21.87 ± 1.40  18.62 ± 0.95  23.11 ± 1.86  20.22 ± 2.54  < 0.001 
18:3n 6  1.32 ± 0.93  0.77 ± 0.73  1.18 ± 0.68  0.71 ± 0.65  2.12 ± 1.69  0.90 ± 0.68  0.150 
20:2n 6  0.22 ± 0.18  0.44 ± 0.26  0.39 ± 0.11  0.40 ± 0.16  0.63 ± 0.11  0.21 ± 0.20  0.003 
20:3n 6  0.15 ± 0.24  0.36 ± 0.45  0.30 ± 0.33  0.62 ± 0.22  0.12 ± 0.19  0.42 ± 0.25  0.056 
20:4n 6  11.99 ± 1.37  10.40 ± 1.80  5.80 ± 0.79  4.32 ± 0.35  9.65 ± 1.48  12.02 ± 1.24  < 0.001 
22:5n 6  6.05 ± 0.71 *  2.24 ± 0.45 *  ND  ND  8.48 ± 1.18 *  4.23 ± 0.62 *  < 0.001 
Total n 6 PUFA  31.90 ± 2.68  37.95 ± 2.07  29.55 ± 1.02  24.67 ± 0.86 *  44.11 ± 1.49 *  38.00 ± 0.98  < 0.001 
18:3n 3  0.13 ± 0.10  0.38 ± 0.11  1.95 ± 0.24 *  0.29 ± 0.08  0.12 ± 0.10  0.23 ± 0.04  < 0.001 
20:4n 3  ND  ND  ND  0.22 ± 0.11 *  ND  ND  < 0.001 
20:5n 3  0.88 ± 0.86  0.81 ± 0.90  1.66 ± 0.37  4.86 ± 0.35 *  1.63 ± 1.51  0.64 ± 0.59  < 0.001 
22:5n 3  1.28 ± 0.34  1.03 ± 0.22  1.91 ± 0.32  1.65 ± 0.17  0.40 ± 0.16  0.78 ± 0.20  < 0.001 
22:6n 3  12.00 ± 1.73  11.04 ± 1.62  13.14 ± 1.47  16.51 ± 0.86 *  5.33 ± 0.78 *  7.84 ± 1.02 *  < 0.001 
Total n 3 PUFA  14.30 ± 2.26  13.26 ± 1.75  18.66 ± 1.70 *  23.52 ± 0.91 *  7.48 ± 2.20  9.48 ± 1.35  < 0.001 
 
ND  negligible detected (mean <0.1%)    * significantly different from all other groups (Bonferroni p < 0.05)   242 
Table 6.7: Fatty acid composition of plasma TAG in pregnant rats fed experimental diets (% of total fatty acids, mean ± standard deviation, n=6 per group) 
   
ND  negligible detected (mean <0.1%)    *   significantly different from all other groups (p < 0.05)     
†   no significant differences between groups when Bonferroni post hoc test applied  
Fatty acid   LF Soyabean   HF Soyabean   HF Linseed   HF Salmon   HF Sunflower   HF Beef tallow  ANOVA  
p value 
14:0  0.34 ± 0.19  0.30 ± 0.19  0.20 ± 0.10  1.42 ± 0.41  0.15 ± 0.08  1.25 ± 0.10  < 0.001 
16:0  22.74 ± 2.85  15.96 ± 1.21  12.97 ± 1.80  17.25 ± 1.09  13.91± 1.13  24.77 ± 1.17  < 0.001 
18:0  5.10 ± 1.58  4.66 ± 1.32  4.31 ± 0.48  4.15 ± 0.92  4.34 ± 0.58  9.51 ± 1.10 *  < 0.001 
20:0  0.30 ± 0.46  0.41 ± 0.10  0.23 ± 0.15  0.72 ± 0.38  0.16 ± 0.29  0.63 ± 0.08  0.009 
22:0  0.62 ± 0.86  0.20 ± 0.14  0.23 ± 0.13  0.09 ± 0.15  0.24 ± 0.19  ND  0.123 
Total saturates  29.10 ± 3.06 *  21.53 ± 2.35  17.93 ± 2.15  23.64 ± 1.70  18.80 ± 1.28  36.16 ± 1.83 *  < 0.001 
16:1n 7  2.85 ± 1.00  0.66 ± 0.36  0.45 ± 0.27  3.11 ± 0.52  0.29 ± 0.27  1.55 ± 0.19  < 0.001 
18:1n 9  19.27 ± 4.38  20.59 ± 0.69  21.14 ± 1.30  18.43 ± 0.92  20.37 ± 0.50  36.33 ± 1.59 *  < 0.001 
20:1n 9  0.14 ± 0.22  0.19 ± 0.21  0.33 ± 0.06  4.58 ± 0.59 *  0.34 ± 0.29  0.47 ± 0.24  < 0.001 
24:1n 9  ND  ND  ND  0.33 ± 0.11 *  ND  ND  < 0.001 
Total MUFA  22.25 ± 4.92  21.44 ± 0.53  21.92 ± 1.44  26.44 ± 1.67  20.99 ± 0.55  38.39 ± 1.38 *  < 0.001 
18:2n 6  26.74 ± 4.12  44.42 ± 3.57 *  24.76 ± 1.02  19.63 ± 0.82  49.48 ± 2.80 *  19.40 ± 1.54  < 0.001 
18:3n 6  4.00 ± 3.72 *  0.99 ± 0.36  0.57 ± 0.32  0.44 ± 0.47  1.06 ± 0.48  0.59 ± 0.23  0.003 
20:2n 6  0.27 ± 0.29  0.57 ± 0.14  0.26 ± 0.06  0.42 ± 0.04  0.74 ± 0.20  0.37 ± 0.10  < 0.001 
20:3n 6  0.40 ± 0.34  0.42 ± 0.29  0.12 ± 0.13  0.12 ± 0.14  0.54 ± 0.35  0.28 ± 0.16  0.033 † 
20:4n 6  8.34 ± 2.56 *  2.93 ± 1.73  1.15 ± 0.75  0.90 ± 0.15  4.06 ± 0.97  1.47 ± 0.12  < 0.001 
22:5n 6  1.10 ± 0.18  0.50 ± 0.22  ND  0.28 ± 0.08  1.39 ± 0.34  0.45 ± 0.06  < 0.001 
Total n 6 PUFA  40.85 ± 2.64 *  49.84 ± 2.09 *  26.87 ± 1.18 *  21.81 ± 0.82  57.28 ± 1.36 *  22.55 ± 1.36  < 0.001 
18:3n 3  1.35 ± 0.40  4.75 ± 0.78 *  27.44 ± 1.59 *  3.01 ± 0.31  1.26 ± 0.06  1.64 ± 0.22  < 0.001 
20:4n 3  ND  ND  0.18 ± 0.09 *  0.97 ± 0.07 *  ND  ND  < 0.001 
20:5n 3  2.11 ± 2.29  0.65 ± 0.39  1.75 ± 0.66  7.70 ± 1.05 *  0.71 ± 0.51  0.40 ± 0.28  < 0.001 
22:5n 3  1.20 ± 0.51  0.58 ± 0.47  1.56 ± 0.53  4.13 ± 0.54 *  0.25 ± 0.05  0.29 ± 0.13  < 0.001 
22:6n 3  3.14 ± 1.90  1.21 ± 0.61  2.36 ± 0.40  12.30 ± 1.23 *  0.67 ± 0.28  0.56 ± 0.13  < 0.001 
Total n 3 PUFA  7.80 ± 4.23  7.19 ± 0.43  33.28 ± 2.06 *  28.11 ± 2.25 *  2.93 ± 0.87  2.89 ± 0.32  < 0.001   243 
Table 6.8: Fatty acid composition of plasma CE in pregnant rats fed experimental diets (% of total fatty acids, mean ± standard deviation, n=6 per 
group) 
 
Fatty acid  LF Soyabean   HF Soyabean   HF Linseed   HF Salmon   HF Sunflower   HF Beef tallow  ANOVA  
p value 
14:0  0.21 ± 0.23  0.21 ± 0.17  0.28 ± 0.25  0.33 ± 0.43  ND  0.21 ± 0.19  0.689 
16:0  14.38 ± 3.33  12.42 ± 3.37  15.00 ± 2.76  15.56 ± 2.74  11.74 ± 3.25  12.87 ± 2.12  0.188 
18:0  5.28 ± 2.12  4.67 ± 2.75  5.91 ± 3.69  5.04 ± 2.73  3.77 ± 0.79  5.97 ± 3.35  0.742 
Total saturates  19.91 ± 5.48  17.30 ± 6.21  21.20 ± 6.08  20.93 ± 4.98  15.60 ± 3.86  19.06 ± 5.17  0.435 
16:1n 7  1.40 ± 0.36  0.37 ± 0.09  0.49 ± 0.15  1.80 ± 0.29  0.39 ± 0.15  0.94 ± 0.22 *  < 0.001 
18:1n 9  6.84 ± 1.34  7.40 ± 1.24  8.31 ± 0.76  7.51 ± 1.94  7.15 ± 1.16  11.20 ± 1.90 *  < 0.001 
Total MUFA  8.25 ± 1.61  7.78 ± 1.27  8.85 ± 0.89  9.39 ± 2.10  7.54 ± 1.30  12.14 ± 2.01  < 0.001 
18:2n 6  16.99 ± 2.53 *  30.20 ± 2.50  29.07 ± 4.77  22.34 ± 2.18  32.46 ± 1.31  22.73 ± 2.55  < 0.001 
18:3n 6  0.90 ± 0.19  0.76 ± 0.20  0.38 ± 0.09  0.25 ± 0.22  0.88 ± 0.13  0.60 ± 0.13  < 0.001 
20:3n 6  0.31 ± 0.76  ND  ND  ND  ND  ND  0.641 
20:4n 6  46.41 ± 3.36  37.78 ± 5.54  23.42 ± 2.35 *  16.24 ± 2.52 *  39.11 ± 4.80  40.65 ± 3.76  < 0.001 
22:5n 6  1.48 ± 0.22 *  0.46 ± 0.24  ND  ND  2.15 ± 0.47 *  0.94 ± 0.21 *  < 0.001 
Total n 6 PUFA  66.09 ± 5.49  69.27 ± 6.27  52.92 ± 6.33 *  38.91 ± 4.35 *  74.60 ± 4.87  65.04 ± 5.12  < 0.001 
18:3n 3  0.33 ± 0.08  0.75 ± 0.13  4.64 ± 0.70 *  0.59 ± 0.07  ND  0.28 ± 0.16  < 0.001 
20:4n 3  0.10 ± 0.11  ND  ND  0.47 ± 0.24 *  ND  ND  < 0.001 
20:5n 3  0.44 ± 0.27  0.30 ± 0.18  7.07 ± 1.78 *  22.02 ± 2.17 *  ND  0.32 ± 0.17  < 0.001 
22:5n 3  ND  ND  ND  0.18 ± 0.21  ND  ND  0.022 † 
22:6n 3  4.88 ± 1.00  4.57 ± 0.62  5.25 ± 0.91  7.52 ± 1.12 *  2.13 ± 0.41  3.13 ± 0.62  < 0.001 
Total n 3 PUFA  5.75 ± 1.04  5.66 ± 0.73  17.02 ± 1.98 *  30.77 ± 2.98 *  2.25 ± 0.44  3.79 ± 0.66  < 0.001 
 
ND  negligible detected (mean <0.1%) 
*   significantly different from all other groups (p < 0.05) 
†   no significant differences between groups when Bonferroni post hoc test applied   244 
Table 6.9: Fatty acid composition of plasma NEFA in pregnant rats fed experimental diets (% of total fatty acids, mean ± standard deviation, n=6 per 
group) 
 
Fatty acid  LF Soyabean   HF Soyabean   HF Linseed   HF Salmon   HF Sunflower   HF Beef tallow  ANOVA  
p value 
14:0  1.19 ± 0.74  0.71 ± 0.43  0.55 ± 0.19  1.93 ± 0.42  0.68 ± 0.19  1.05 ± 0.23  < 0.001 
16:0  25.22 ± 1.93  19.21 ± 2.36  15.70 ± 1.62  23.46 ± 4.77  17.82 ± 2.20  22.97 ± 2.05  < 0.001 
18:0  11.17 ± 1.81  11.50 ± 2.85  10.05 ± 2.68  15.37 ± 7.05  11.34 ± 2.64  15.38 ± 1.56  0.055 
20:0  0.52 ± 0.69  0.30 ± 0.39  0.22 ± 0.29  0.41 ± 0.66  0.33 ± 0.29  0.14 ± 0.22  0.761 
22:0  0.45 ± 0.33  0.55 ± 0.44  0.39 ± 0.51  0.64 ± 0.46  0.75 ± 0.19  0.46 ± 0.39  0.624 
Total saturates  38.60 ± 3.19  32.31 ± 5.40  26.91 ± 4.06  41.89 ± 11.16  30.99 ± 3.60  39.99 ± 3.60  < 0.001 
16:1n 7  3.14 ± 2.62  0.96 ± 0.84  1.12 ± 0.58  4.07 ± 2.57  3.12 ± 4.36  3.14 ± 1.12  0.183 
18:1n 9  19.24 ± 1.13  17.04 ± 1.31  17.19 ± 1.01  15.40 ± 2.74  16.55 ± 1.97  27.12 ± 3.92 *  < 0.001 
20:1n 9  ND  ND  ND  1.94 ± 2.24  ND  0.98 ± 2.40  0.085 
Total MUFA  22.41 ± 2.72  18.07 ± 0.95  18.31 ± 1.10  21.49 ± 4.92  19.66 ± 2.70  31.30 ± 1.78 *  < 0.001 
18:2n 6  23.91 ± 3.04  35.98 ± 5.09  20.23 ± 2.97  16.22 ± 4.03  37.48 ± 5.61  17.21 ± 2.59  < 0.001 
18:3n 6  1.79 ± 1.75  0.92 ± 1.23  1.64 ± 1.53  1.10 ± 2.70  2.96 ± 3.39  0.97 ± 1.95  0.610 
20:2n 6  0.27 ± 0.45  0.51 ± 0.59  0.41 ± 0.35  1.07 ± 0.79  0.81 ± 0.43  0.70 ± 0.50  0.152 
20:3n 6  0.08 ± 0.20  0.53 ± 0.80  1.15 ± 1.60  1.08 ± 2.44  0.16 ± 0.40  0.77 ± 1.88  0.723 
20:4n 6  3.65 ± 1.26  3.09 ± 1.27  1.48 ± 0.16  1.37 ± 0.71  2.91 ± 0.35  3.06 ± 0.50  < 0.001 
22:5n 6  0.68 ± 0.36  0.43 ± 0.17  ND  ND  1.31 ± 0.26 *  0.60 ± 0.11  < 0.001 
Total n 6 PUFA  30.38 ± 4.78  41.46 ± 4.52  24.92 ± 1.64  20.87 ± 4.12  45.63 ± 2.71  23.32 ± 2.88  < 0.001 
18:3n 3  2.20 ± 0.80  4.58 ± 0.62  23.55 ± 3.62 *  2.60 ± 1.15  1.07 ± 0.23  1.61 ± 0.46  < 0.001 
20:4n 3  0.13 ± 0.32  ND  0.17 ± 0.16  0.61 ± 0.35 *  ND  ND  < 0.001 
20:5n 3  1.74 ± 1.82  0.54 ± 0.78  1.48 ± 0.98  3.55 ± 1.04  1.14 ± 1.44  0.65 ± 1.58  0.006 
22:5n 3  0.94 ± 0.92  0.49 ± 0.32  1.30 ± 0.54  2.20 ± 1.12  ND  0.23 ± 0.08  < 0.001 
22:6n 3  3.60 ± 2.64  2.53 ± 0.59  3.36 ± 1.64  6.79 ± 2.74  1.46 ± 0.32  2.90 ± 1.14  < 0.001 
Total n 3 PUFA  8.61 ± 6.12  8.16 ± 0.70  29.86 ± 3.92 *  15.75 ± 5.81  3.76 ± 1.58  5.39 ± 1.66  < 0.001 
 
ND  negligible detected (mean <0.1%)    *  significantly different from all other groups (p < 0.05)   245 
6.3.5 Maternal liver size and composition 
Maternal liver size and composition were assessed, with a significant effect of maternal 
diet observed upon maternal liver weight.  The liver weight of dams in the HF linseed, 
salmon and beef tallow groups was significantly higher than that in the LF soyabean oil 
group (see table 6.10).  However, this significant effect is likely to be related to the 
differences in maternal weight gain in these groups, as liver weight expressed as a % 
total body weight was not significantly affected by maternal diet.  No significant effect 
of maternal diet was observed upon maternal liver dry weight, lipid content or glycogen 
content. 
6.3.6 Maternal liver fatty acid composition  
The fatty acid compositions of PC, phosphatidylethanolamine (PE), TAG and CE in 
liver were determined by gas chromatography (see tables 6.11 to 6.14).  Significant 
effects of maternal diet were observed in all liver lipid fractions, and across virtually all 
fatty acids assessed.  The effects observed were in line with the properties of the diets 
consumed, and comparable, but not identical, to those observed in the maternal plasma. 
 
Within the HF linseed oil group, there was a stronger effect upon LC n 3 PUFA status 
in the liver than was observed in the plasma, with higher EPA status observed in all 
liver lipids and higher DHA status in liver phospholipids (PC and PE) in comparison to 
all other dietary groups (except HF salmon oil).  These features were associated with 
lower AA status of liver phospholipids, and lower LA content of liver TAG.  This 
suggests that accumulation of ALNA within liver TAG is at the expense of LA 
accumulation, and that synthesis of LC n 3 PUFA occurs at the expense of LC n 6 
PUFA synthesis.   
 
The HF sunflower oil diet demonstrated the highest AA content of liver phospholipids 
out of all dietary groups, a feature which had not been apparent in plasma lipids.  This 
suggests that the synthesis of LC n 6 PUFA is enhanced by a high LA diet.  It is 
possible that this increase is not apparent in plasma lipids due to selective incorporation 
of AA into other maternal tissues or transfer to the fetus.  The effect of the sunflower oil 
in increasing 22:5n 6 content was only apparent in liver CE, with this fatty acid 
undetectable in liver PE and TAG.    246 
 
 
 
 
 
Table 6.10: Liver weight, lipid and glycogen content in pregnant rats fed experimental diets (mean ± standard deviation, n=6) 
 
   LF Soyabean   HF Soyabean   HF Linseed   HF Salmon   HF Sunflower   HF Beef tallow  ANOVA  
p value 
Liver wet weight (g)  9.82 ± 1.57 
a  12.24 ± 1.61
  12.72 ± 0.97 
b  13.24 ± 1.15 
b  11.71 ± 1.35
  13.04 ± 1.80 
b  0.003 
Liver wet weight (% body weight)  3.60 ± 0.35  4.01 ± 0.36
  4.03 ± 0.36
  4.16 ± 0.13
  3.88 ± 0.32
  4.01 ± 0.39
  0.097 
Liver dry weight (% of wet weight)  28.4 ± 1.3  29.0 ± 0.9  27.8 ± 1.4  28.0 ± 0.6  28.2 ± 0.9  28.4 ± 1.1  0.552 
Liver lipid (g/100 g liver)  3.4 ± 0.2  4.3 ± 1.4  3.9 ± 0.5  3.7 ± 0.3  3.5 ± 0.3  3.5 ± 0.3  0.162 
Liver glycogen (g/100 g liver)  1.3 ± 1.6  2.5 ± 1.5  2.7 ± 1.1  2.9 ± 0.9  3.1 ± 0.8  3.1 ± 1.5  0.241 
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have different superscripts  247 
Table 6.11: Fatty acid composition of liver PC in pregnant rats fed experimental diets (% of total fatty acids, mean ± standard deviation, n=6 per group) 
 
Fatty acid  LF Soyabean   HF Soyabean   HF Linseed   HF Salmon   HF Sunflower   HF Beef tallow  ANOVA  
p value 
14:0  0.16 ± 0.02  0.14 ± 0.02  0.15 ± 0.02  0.23 ± 0.03  0.19 ± 0.04  0.25 ± 0.04  < 0.001 
16:0  28.39 ± 1.73  23.88 ± 1.51  22.32 ± 1.40  25.10 ± 0.89  26.30 ± 2.10  25.51 ± 0.93  < 0.001 
18:0  20.25 ± 1.42  23.19 ± 0.75  21.85 ± 1.41  19.74 ± 1.52  24.50 ± 1.45  23.02 ± 1.29  < 0.001 
20:0  ND  ND  ND  ND  ND  0.12 ± 0.07  0.002 
22:0  0.10 ± 0.11  ND  ND  ND  0.12 ± 0.10  ND  0.170 
Total saturates  48.91 ± 1.36  47.27 ± 1.24  44.39 ± 1.94  45.06 ± 0.89  51.13 ± 1.72  48.92 ± 0.99  < 0.001 
16:1n 7  0.68 ± 0.17 *  0.18 ± 0.05  0.19 ± 0.07  0.45 ± 0.10  0.15 ± 0.02  0.38 ± 0.06  < 0.001 
18:1n 9  3.63 ± 0.73  2.69 ± 0.25  3.12 ± 0.55  2.46 ± 0.38  3.02 ± 0.26  5.20 ± 0.64 *  < 0.001 
20:1n 9  0.11 ± 0.10  0.10 ± 0.08  0.22 ± 0.49  0.48 ± 0.05  0.11 ± 0.11  0.44 ± 0.27  0.020 † 
24:1n 9  ND  ND  ND  0.26 ± 0.07 *  ND  ND  < 0.001 
Total MUFA  4.44 ± 0.88  2.97 ± 0.22  3.53 ± 0.97  3.65 ± 0.47  3.28 ± 0.28  6.05 ± 0.71 *  < 0.001 
18:2n 6  10.55 ± 0.91  12.74 ± 1.79  12.43 ± 1.30  9.13 ± 0.23  15.19 ± 0.80 *  9.98 ± 1.46  < 0.001 
18:3n 6  0.38 ± 0.04  0.27 ± 0.04  0.13 ± 0.07  0.10 ± 0.08  0.37 ± 0.06  0.47 ± 0.17  < 0.001 
20:2n 6  0.27 ± 0.05  0.46 ± 0.10  0.49 ± 0.62  0.18 ± 0.03  0.67 ± 0.05  0.24 ± 0.05  0.021 
20:3n 6  0.35 ± 0.08  0.38 ± 0.07  0.57 ± 0.13  0.44 ± 0.07  0.42 ± 0.10  0.51 ± 0.07  0.001 
20:4n 6  18.54 ± 0.49  16.73 ± 0.87  10.37 ± 0.21 *  6.95 ± 0.19 *  19.43 ± 1.76  17.94 ± 1.56  < 0.001 
22:5n 6  0.24 ± 0.13  0.10 ± 0.16  0.22 ± 0.19  ND  0.24 ± 0.19  0.10 ± 0.15  0.048 † 
Total n 6 PUFA  30.33 ± 1.49  30.69 ± 2.26  24.21 ± 1.32 *  16.80 ± 0.38 *  36.32 ± 1.63 *  29.23 ± 2.79  < 0.001 
18:3n 3  0.19 ± 0.05  0.23 ± 0.06  1.37 ± 0.21 *  0.14 ± 0.05  0.11 ± 0.07  0.14 ± 0.11  < 0.001 
20:4n 3  ND  ND  ND  0.16 ± 0.01 *  ND  ND  < 0.001 
20:5n 3  0.17 ± 0.11  0.17 ± 0.09  3.50 ± 0.95 *  6.30 ± 0.50 *  ND  0.89 ± 0.75  < 0.001 
22:5n 3  1.37 ± 0.21  1.41 ± 0.18  2.60 ± 0.41  2.26 ± 0.14  0.54 ± 0.06 *  1.38 ± 0.36  < 0.001 
22:6n 3  14.59 ± 1.47  17.26 ± 1.75  20.40 ± 1.45 *  25.63 ± 1.11 *  8.62 ± 0.48 *  13.39 ± 2.49  < 0.001 
Total n 3 PUFA  16.32 ± 1.52  19.07 ± 1.66  27.87 ± 1.29 *  34.49 ± 1.15 *  9.27 ± 0.49 *  15.80 ± 3.09  < 0.001 
ND  negligible detected (mean <0.1%)  *      significantly different from all other groups (p < 0.05)  
†   no significant differences between groups when Bonferroni post hoc test applied   248 
 
Table 6.12: Fatty acid composition of liver PE in pregnant rats fed experimental diets (% of total fatty acids, mean ± standard deviation, n=6 per group) 
 
Fatty acid  LF Soyabean   HF Soyabean   HF Linseed   HF Salmon   HF Sunflower   HF Beef tallow  ANOVA  
p value 
16:0  22.16 ± 1.35  17.78 ± 0.61  15.82 ± 0.62 *  18.64 ± 0.47  21.00 ± 1.22  20.13 ± 0.41  < 0.001 
18:0  27.18 ± 1.43  28.26 ± 0.71  27.87 ± 0.56  25.03 ± 0.66 *  32.80 ± 1.00 *  28.85 ± 0.56  < 0.001 
20:0  ND  0.11 ± 0.14  ND  ND  ND  ND  0.167 
Total saturates  49.42 ± 0.99  46.18 ± 0.35 *  43.69 ± 0.82  43.80 ± 0.65  53.82 ± 2.20 *  49.03 ± 0.37  < 0.001 
16:1n 7  0.21 ± 0.05  0.12 ± 0.20  ND  0.11 ± 0.11  ND  ND  0.006 
18:1n 9  1.89 ± 0.40  2.07 ± 0.43  2.05 ± 0.44  1.19 ± 0.29  2.52 ± 0.28  2.36 ± 0.46  < 0.001 
20:1n 9  0.15 ± 0.15  0.21 ± 0.23  0.17 ± 0.20  0.41 ± 0.21  ND  ND  0.019 
Total MUFA  2.26 ± 0.54  2.40 ± 0.48  2.26 ± 0.55  1.72 ± 0.26  2.60 ± 0.33  2.44 ± 0.46  0.037 
18:2n 6  3.60 ± 0.38  4.73 ± 0.66  4.59 ± 0.41  2.86 ± 0.36  6.00 ± 0.51 *  3.65 ± 0.44  < 0.001 
18:3n 6  ND  0.10 ± 0.17  0.12 ± 0.20  0.14 ± 0.19  0.11 ± 0.12  0.14 ± 0.10  0.969 
20:2n 6  0.21 ± 0.07  0.28 ± 0.15  0.21 ± 0.14  0.10 ± 0.05  0.51 ± 0.04 *  ND  < 0.001 
20:3n 6  0.25 ± 0.10  0.31 ± 0.11  0.27 ± 0.03  0.24 ± 0.10  0.34 ± 0.09  0.31 ± 0.06  0.299 
20:4n 6  19.79 ± 0.68  19.91 ± 0.59  13.40 ± 0.57 *  7.32 ± 0.51 *  23.32 ± 0.89  22.98 ± 0.52  < 0.001 
Total n 6 PUFA  23.91 ± 0.92  25.34 ± 1.00  18.58 ± 0.95 *  10.65 ± 0.88 *  30.28 ± 1.29 *  27.14 ± 0.77 *  < 0.001 
18:3n 3  ND  0.13 ± 0.08  0.67 ± 0.08 *  ND  ND  ND  < 0.001 
20:4n 3  ND  ND  ND  0.13 ± 0.07 *  ND  ND  < 0.001 
20:5n 3  0.12 ± 0.08  0.12 ± 0.10  3.53 ± 0.69 *  5.98 ± 0.57 *  ND  0.17 ± 0.03  < 0.001 
22:5n 3  1.82 ± 0.22  1.76 ± 0.27   3.24 ± 0.44  2.60 ± 0.17  0.75 ± 0.13 *  1.72 ± 0.59  < 0.001 
22:6n 3  22.38 ± 1.14  24.07 ± 1.62  28.03 ± 1.50 *  35.07 ± 1.70 *  12.55 ± 1.06 *  19.44 ± 1.28 *  < 0.001 
Total n 3 PUFA  24.41 ± 1.10  26.09 ± 1.62  35.46 ± 0.84 *  43.83 ± 1.26 *  13.30 ± 1.11 *  21.38 ± 0.81 *  < 0.001 
 
ND  negligible detected (mean <0.1%) 
*       significantly different from all other groups (p < 0.05) 
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Table 6.13: Fatty acid composition of liver TAG in pregnant rats fed experimental diets (% of total fatty acids, mean ± standard deviation, n=6 per 
group) 
 
Fatty acid  LF Soyabean   HF Soyabean   HF Linseed   HF Salmon   HF Sunflower   HF Beef tallow  ANOVA  
p value 
14:0  0.44 ± 0.06  0.38 ± 0.07  0.36 ± 0.08  0.83 ± 0.09  0.40 ± 0.08  0.84 ± 0.12  < 0.001 
16:0  25.25 ± 1.05 *  19.74  ± 1.33  16.93 ± 1.50  20.97 ± 0.54  18.73 ± 0.92  27.74 ± 1.15 *  < 0.001 
18:0  3.53 ± 0.41  4.53 ± 0.26  4.84 ± 0.47  3.74 ± 0.50  4.24 ± 0.18  6.83 ± 0.94 *  < 0.001 
20:0  0.26 ± 0.14  0.21 ± 0.15  0.49 ± 0.1  0.40 ± 0.07  ND  0.49 ± 0.05  < 0.001 
22:0  ND  ND  0.16 ± 0.20  ND  ND  ND  0.097 
Total saturates  29.57 ± 0.98 *  24.86 ± 1.39  22.77 ± 1.33  25.94 ± 0.65  23.48 ± 0.85  35.90 ± 1.87 *  < 0.001 
16:1n 7  2.35 ± 0.75  0.55 ± 0.20  0.60 ± 0.18  1.71 ± 0.38  0.38 ± 0.10  1.39 ± 0.30  < 0.001 
18:1n 9  22.65 ± 3.35  21.28 ± 1.12  21.83 ± 2.38  17.90 ± 2.20  20.16 ± 0.55  37.40 ± 2.32 *  < 0.001 
20:1n 9  0.35 ± 0.04  0.46 ± 0.09  0.31 ± 0.10  1.61 ± 0.35 *  0.42 ± 0.08  0.55 ± 0.10  < 0.001 
Total MUFA  25.34 ± 3.96  22.28 ± 1.24  22.74 ± 2.43  21.23 ± 2.73  20.96 ± 0.66  39.34 ± 2.49 *  < 0.001 
18:2n 6  30.40 ± 1.21 *  40.58 ± 2.46 *  24.86 ± 1.99 *  20.75 ± 1.87  45.90 ± 1.40 *  19.46 ± 2.64  < 0.001 
18:3n 6  0.90 ± 0.15  0.86 ± 0.12  0.36 ± 0.10  0.26 ± 0.09  1.04 ± 0.12  0.57 ± 0.09 *  < 0.001 
20:2n 6  0.48 ± 0.09  0.79 ± 0.17 *  0.37 ± 0.07  0.31 ± 0.04  1.02 ± 0.12 *  0.32 ± 0.03  < 0.001 
20:3n 6  0.60 ± 0.21  0.66 ± 0.19  0.33 ± 0.07  0.32 ± 0.04  0.86 ± 0.34  0.22 ± 0.11  < 0.001 
20:4n 6  7.89 ± 2.97 *  4.47 ± 1.14  1.77 ± 0.22  1.70 ± 0.31  5.07 ± 1.03  2.10 ± 0.43  < 0.001 
Total n 6 PUFA  40.27 ± 3.11 *  47.36 ± 2.20 *  27.68 ± 1.81 *  23.33 ± 1.94  53.89 ± 0.62 *  22.67 ± 3.09  < 0.001 
18:3n 3  1.61 ± 0.22  3.07 ± 0.30  20.00 ± 1.46 *  2.77 ± 0.47  0.82 ± 0.08  1.21 ± 0.26  < 0.001 
20:4n 3  ND  ND  0.39 ± 0.11 *  0.53 ± 0.07 *  ND  ND  < 0.001 
20:5n 3  0.20 ± 0.12  0.22 ± 0.13  1.54 ± 0.72 *  6.00 ± 0.49 *  ND  ND  < 0.001 
22:5n 3  1.48 ± 0.73  0.82 ± 0.26  2.32 ± 1.02  6.80 ± 0.64 *  0.30 ± 0.04  0.31 ± 0.21  < 0.001 
22:6n 3  1.53 ± 0.66  1.38 ± 0.47  2.56 ± 0.73  13.41 ± 1.57 *  0.51 ± 0.09  0.51 ± 0.22  < 0.001 
Total n 3 PUFA  4.82 ± 1.42  5.49 ± 0.58  26.81 ± 3.16  29.51 ± 1.83  1.66 ± 0.10  2.08 ± 0.63  < 0.001 
 
ND  negligible detected (mean <0.1%) 
*       significantly different from all other groups (p < 0.05)   250 
Table 6.14: Fatty acid composition of liver CE in pregnant rats fed experimental diets (% of total fatty acids, mean ± standard deviation, n=6 per group) 
 
Fatty acid  LF Soyabean   HF Soyabean   HF Linseed   HF Salmon   HF Sunflower   HF Beef tallow  ANOVA  
p value 
14:0  0.35 ± 0.18  0.34 ± 0.18  0.49 ± 0.26  0.77 ± 0.08  0.33 ± 0.17  0.64 ± 0.09  < 0.001 
16:0  42.95 ± 3.38  37.72 ± 2.14  35.13 ± 3.10  44.69 ± 2.46  34.67 ± 3.68  42.77 ± 3.18  < 0.001 
18:0  15.54 ± 2.61  16.60 ± 3.26  15.33 ± 1.97  14.69 ± 2.55  16.74 ± 2.44  17.01 ± 3.77  0.668 
20:0  0.41 ± 0.42  0.16 ± 0.19  0.43 ± 0.26  0.40 ± 0.34  0.59 ± 0.36  0.40 ± 0.31  0.363 
22:0  ND  ND  ND  ND  0.32 ± 0.52  ND  0.229 
Total saturates  59.26 ± 4.73  54.82 ± 4.21  51.47 ± 4.12  60.56 ± 0.85  52.66 ± 5.15  60.90 ± 5.32  0.001 
16:1n 7  1.96 ± 0.72  0.74 ± 0.40  0.86 ± 0.33  1.81 ± 0.25  1.02 ± 1.48  1.34 ± 0.66  0.041 † 
18:1n 9  9.06 ± 2.83  10.09 ± 1.91  10.52 ± 2.13  7.45 ± 1.24  10.26 ± 1.56  13.29 ± 2.44  0.002 
20:1n 9  0.44 ± 0.34  0.21 ± 0.30  0.30 ± 0.40  0.73 ± 0.06  0.41 ± 0.62  0.43 ± 0.31  0.271 
24:1n 9  ND  ND  ND  ND  ND  ND  0.496 
Total MUFA  11.46 ± 3.37  11.03 ± 2.40  11.68 ± 2.32  10.01 ± 1.46  11.69 ± 2.68  15.15 ± 3.35  0.050 
18:2n 6  15.01 ± 1.64  21.33 ± 1.50 *  15.67 ± 1.61  12.43 ± 0.82  24.15 ± 1.57 *  12.08 ± 1.16  < 0.001 
18:3n 6  0.35 ± 0.35  0.48 ± 0.23  0.41 ± 0.32  0.12 ± 0.19  0.64 ± 0.44  0.39 ± 0.38  0.190 
20:2n 6  0.38 ± 0.27  0.55 ± 0.19  0.35 ± 0.19  0.36 ± 0.11  0.72 ± 0.23  0.43 ± 0.30  0.052 
20:3n 6  0.12 ± 0.15  0.31 ± 0.26  0.25 ± 0.30  ND  0.33 ± 0.34  0.16 ± 0.19  0.400 
20:4n 6  9.64 ± 1.73  7.48 ± 1.24  4.82 ± 0.69  3.52 ± 0.63  7.12 ± 0.42  8.28 ± 0.98  < 0.001 
22:5n 6  0.40 ± 0.08  ND  ND  ND  0.71 ± 0.17 *  0.15 ± 0.18  < 0.001 
Total n 6 PUFA  25.90 ± 2.40 *  30.24 ± 2.08  21.56 ± 1.97  16.50 ± 1.20 *  33.66 ± 2.61  21.49 ± 2.23  < 0.001 
18:3n 3  0.97 ± 0.29  1.79 ± 0.14  10.55 ± 1.11 *  1.50 ± 0.13  0.66 ± 0.23  0.90 ± 0.34  < 0.001 
20:4n 3  ND  ND  ND  0.22 ± 0.20  ND  ND  0.102 
20:5n 3  0.23 ± 0.51  0.04 ± 0.10  1.97 ± 0.57 *  6.36 ± 0.87 *  0.08 ± 0.20  0.14 ± 0.32  < 0.001 
22:5n 3  0.22 ± 0.25  0.20 ± 0.17  0.56 ± 0.29  1.11 ± 0.23 *  ND  0.13 ± 0.15  < 0.001 
22:6n 3  1.88 ± 0.39  1.84 ± 0.40  2.16 ± 0.36  3.75 ± 0.66 *  1.26 ± 0.56  1.25 ± 0.39  < 0.001 
Total n 3 PUFA  3.38 ± 0.77  3.91 ± 0.25  15.29 ± 1.31 *  12.93 ± 1.30 *  2.00 ± 0.72  2.45 ± 0.68  < 0.001 
 
ND  negligible detected (mean <0.1%)      *  significantly different from all other groups (p < 0.05)     
†   no significant differences between groups when Bonferroni post hoc test applied  251 
Correlations were used to assess the relationship between fatty acid compositions of 
maternal liver and plasma lipids (see table 6.15).  Plasma and liver TAG fatty acids 
were strongly correlated across virtually all fatty acids assessed.  The relationship 
between plasma and liver phospholipids was strongest for LC n 3 and n 6 PUFA (see 
figure 6.3).  This reflects the role of the liver as a primary site of LC PUFA synthesis.  
However, the fatty acid 22:5n 6 was virtually undetectable across all maternal liver lipid 
fractions with the exception of CE, despite making a significant contribution to maternal 
plasma composition.  This indicates that this fatty acid is either rapidly and selectively 
exported into the circulation from the liver, or that it is generated by a mechanism which 
does not involve the liver. 
 
 
 
Table 6.15: Correlations observed between the fatty acid composition of liver and 
plasma lipids in pregnant rats (Pearsons r values unless otherwise indicated, n = 36) 
 
Fatty acid  Plasma PC vs. 
Liver PC 
Plasma PC vs.  
Liver PE 
Plasma TAG vs. 
Liver TAG 
Plasma CE vs.  
Liver CE 
12:0                     
14:0  0.384  *  0.101†    0.777†  ***  0.226   
16:0  0.645  ***  0.455  **  0.953  ***  0.326   
18:0  0.522  **  0.227    0.429†  **  0.180   
20:0  0.084†     0.053†    0.454  **  0.319†   
22:0  0.117†    0.388†  *  0.186†        
Total saturated   0.143     0.146    0.951  ***  0.313   
16:1n 7  0.433  **  0.210†    0.866  ***  0.592  *** 
18:1n 9  0.745  ***  0.282    0.829†  ***  0.561  *** 
20:1n 9  0.321†    0.304†    0.660†  ***  0.364†  * 
24:1n 9  0.391†  *                
Total MUFA  0.669†  ***  0.099    0.612†  ***  0.484  ** 
18:2n 6  0.587  ***  0.589  ***  0.950†  ***  0.707  *** 
18:3n 6  0.175    0.198†    0.697†  ***  0.416  * 
20:2n 6  0.293    0.541  **  0.723  ***  0.049†   
20:3n 6  0.354†  *   0.017†    0.642  ***   0.114†   
20:4n 6  0.891  ***  0.727†  ***  0.898†  ***  0.896   
22:5n 6  0.343†  *            0.821†  *** 
Total n 6 PUFA  0.901  ***  0.929  ***  0.990  ***  0.821  *** 
18:3n 3  0.613†  ***  0.584†  ***  0.889†  ***  0.915†  *** 
20:4n 3  0.864†  ***  0.740†  ***  0.933†  ***  0.537†  ** 
20:5n 3  0.543†  **  0.540†  **  0.793†  ***  0.741†  *** 
22:5n 3  0.915  ***  0.920  ***  0.944†  ***  0.380†  * 
22:6n 3  0.925  ***  0.938  ***  0.931†  ***  0.845  *** 
Total n 3 PUFA  0.938  ***  0.948  ***  0.929†  ***  0.873†  *** 
 
† Spearman’s r value 
* p < 0.05, ** p < 0.01, *** p < 0.001 
 
   252 
 
Figure 6.3: Graph to illustrate the observed correlation between the DHA content (% 
total fatty acids) of plasma and liver PC in pregnant rats 
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6.3.7 Maternal adipose tissue fatty acid composition 
Maternal subcutaneous and intra abdominal adipose tissue fatty acid compositions were 
assessed in order to determine how maternal diet might affect accumulation of fatty 
acids within adipose tissue (see tables 6.16 and 6.17).  Both adipose tissue depots 
demonstrated a significant effect of maternal diet across virtually all fatty acids 
assessed. 
 
When LF and HF soyabean oil groups are compared, adipose tissue in the former had 
higher 16:0 and OA content (fatty acids which can be generated by de novo synthesis) 
and lower LA and ALNA content.  This indicates that increasing dietary intake of EFA 
results in these being stored in adipose tissue. 
 
r = 0.925 
p < 0.001   253 
The HF linseed oil group demonstrated a high level of accumulation of ALNA in both 
subcutaneous and intra abdominal adipose tissue.  There was also a higher content of 
LC n 3 PUFA content than in other dietary groups (except salmon oil), particularly in 
subcutaneous adipose tissue where EPA and DPA status achieved levels close to those 
observed in the salmon oil group.  These changes were at the expense of 16:0 and LA 
content. 
 
The HF salmon oil group had significantly higher LC n 3 PUFA content of adipose 
tissue than any other dietary group.  These fatty acids remained a relatively low 
proportion of adipose tissue content (e.g. mean DHA in subcutaneous adipose tissue  = 
3.78 % in salmon oil group), with the total n 3 content of the salmon oil group being 
significantly lower than that achieved in the linseed oil group. 
 
The sunflower oil group had the highest LA and AA content of adipose tissue.  This 
indicates that AA may be preferentially incorporated into adipose tissue, or that it may 
be endogenously synthesised within adipose tissue from its EFA precursor. 
 
The HF beef tallow group had the highest adipose tissue content of OA and 18:0 of all 
the dietary groups, in accordance with the dietary content of these fatty acids.  
 
Correlations between adipose tissue and plasma NEFA fatty acid compositions were 
used to assess the relationship between adipose tissue and the fatty acid composition of 
plasma NEFA (see table 6.18).  The composition of adipose tissue was found to be 
closely related to plasma NEFA composition, particularly in relation to the EFA ALNA 
and LA and some LC PUFA such as docosapentaenoic acid (DPA, both n 6 and n 3).  
This demonstrates that adipose tissue plays a significant role in determining plasma 
fatty acid composition during late pregnancy.   
 
The strong positive relationship between ALNA content of adipose tissue and plasma 
NEFA were not an artefact of the very high ALNA content of adipose tissue achieved in 
the HF linseed oil diet, and remained highly significant even when this group was 
excluded (Pearsons r = 0.790, p < 0.001, see figure 6.4).   254 
Table 6.16: Subcutaneous adipose tissue fatty acid total lipid extract composition in pregnant rats fed experimental diets  
(% total fatty acids, mean ± standard deviation, n=6 per group) 
 
Fatty acid  LF Soyabean   HF Soyabean   HF Linseed   HF Salmon   HF Sunflower   HF Beef tallow  ANOVA  
p value 
12:0  0.44 ± 0.15  0.23 ± 0.06  0.32 ± 0.06  0.39 ± 0.08  0.24 ± 0.13  0.31 ± 0.07  0.006 
14:0  1.67 ± 0.22  1.04 ± 0.19  1.16 ± 0.08  2.45 ± 0.24 *  1.02 ± 0.12  1.98 ± 0.15  < 0.001 
16:0  25.97 ± 0.93 *  19.18 ± 1.18  17.72 ± 0.87  21.62 ± 0.86  17.52 ± 0.78  22.97 ± 1.48  < 0.001 
18:0  3.94 ± 0.36  4.01 ± 0.31  4.00 ± 0.61  3.97 ± 0.39  3.94 ± 0.21  6.15 ± 0.64 *  < 0.001 
20:0  ND  ND  0.33 ± 0.19  0.15 ± 0.12  ND  0.17 ± 0.15  0.001 
Total saturates  32.03 ± 1.50  24.54 ± 1.17  23.54 ± 1.34  28.58 ± 1.25 *  22.78 ± 0.94  31.59 ± 1.85  < 0.001 
16:1n 7  5.15 ± 1.00  2.51 ± 0.76  2.44 ± 0.37  4.07 ± 0.59  1.93 ± 0.24  3.37 ± 0.98  < 0.001 
18:1n 9  28.02 ± 1.47 *  24.82 ± 0.76  25.15 ± 0.93  25.10 ± 0.55  24.63 ± 1.03  33.22 ± 0.77 *  < 0.001 
20:1n 9  0.38 ± 0.12  0.31 ± 0.04  0.28 ± 0.04  0.21 ± 0.24  0.31 ± 0.03  0.27 ± 0.14  0.348 
Total MUFA  33.55 ± 2.39 *  27.64 ± 1.13  27.87 ± 1.19  29.38 ± 0.73  26.87 ± 1.12  36.86 ± 1.14 *  < 0.001 
18:2n 6  27.97 ± 3.03  38.60 ± 2.34  29.71 ± 2.20  28.52 ± 1.35  42.24 ± 1.71  24.91 ± 2.82  < 0.001 
18:3n 6  0.42 ± 0.08  0.61 ± 0.10  0.36 ± 0.06  0.35 ± 0.07  0.76 ± 0.13  0.46 ± 0.14  < 0.001 
20:2n 6  0.48 ± 0.13  0.60 ± 0.11  0.42 ± 0.11  0.46 ± 0.09  0.65 ± 0.10  0.39 ± 0.10  0.001 
20:3n 6  0.51 ± 0.14  0.66 ± 0.14  0.39 ± 0.11  0.48 ± 0.16  0.73 ± 0.11  0.48 ± 0.18  0.002 
20:4n 6  2.79 ± 0.72  3.15 ± 0.48  1.73 ± 0.40  1.78 ± 0.31  3.88 ± 0.57  2.99 ± 0.95  < 0.001 
22:5n 6  0.21 ± 0.06  ND  ND  ND  0.30 ± 0.17  ND  < 0.001 
Total n 6 PUFA  32.38 ± 3.27  43.68 ± 2.17 *  32.61 ± 1.91  31.64 ± 1.81  48.56 ± 1.61 *  29.24 ± 2.73  < 0.001 
18:3n 3  1.20 ± 0.22  2.78 ± 0.32 *  12.08 ± 0.43 *  2.11 ± 0.17 *  1.24 ± 0.09  1.33 ± 0.26  < 0.001 
20:4n 3  ND  ND  0.31 ± 0.10  0.68 ± 0.77  ND  ND  0.003 
20:5n 3  ND  0.30 ± 0.06  1.44 ± 0.43 *  1.84 ± 0.30 *  ND  0.14 ± 0.08  < 0.001 
22:5n 3  0.42 ± 0.12  0.54 ± 0.17  1.48 ± 0.48 *  1.99 ± 0.14 *  0.20 ± 0.10  0.41 ± 0.15  < 0.001 
22:6n 3  0.40 ± 0.05  0.51 ± 0.08  0.68 ± 0.15  3.78 ± 0.36 *  0.28 ± 0.16  0.43 ± 0.11  < 0.001 
Total n 3 PUFA  2.03 ± 0.15  4.13 ± 0.26 *  15.98 ± 1.19 *  10.40 ± 0.97 *  1.79 ± 0.32  2.31 ± 0.18  < 0.001 
 
ND  negligible detected (mean <0.1%)      *       significantly different from all other groups (p < 0.05)     255 
Table 6.17: Intra abdominal fatty acid total lipid extract composition in pregnant rats fed experimental diets (% total fatty acids, mean ± standard 
deviation, n=6 per group) 
 
Fatty acid  LF Soyabean   HF Soyabean   HF Linseed   HF Salmon   HF Sunflower   HF Beef tallow  ANOVA  
p value 
12:0  0.11 ± 0.01  ND  ND  0.13 ± 0.06  ND  ND  0.297 
14:0  1.17 ± 0.04  0.77 ± 0.12 *  0.80 ± 0.09  2.00 ± 0.24 *  0.83 ± 0.12  1.52 ± 0.21 *  < 0.001 
16:0  24.48 ± 0.66  19.17 ± 0.97  18.17 ± 0.92  22.45 ± 0.89  18.74 ± 1.52  22.51 ± 1.29  < 0.001 
18:0  3.09 ± 0.38  3.71 ± 0.44  3.45 ± 0.29  3.50 ± 0.26  3.46 ± 0.17  5.57 ± 0.75 *  < 0.001 
20:0  ND  ND  ND  ND  ND  0.26 ± 0.06 *  < 0.001 
Total saturates  28.92 ± 0.86  23.81 ± 1.10  22.53 ± 0.78  28.14 ± 0.87  23.13 ± 1.79  29.94 ± 2.00  < 0.001 
16:1n 7  4.49 ± 0.96  1.92 ± 0.53  2.26 ± 0.57  4.06 ± 0.57  2.29 ± 0.35  3.07 ± 0.80  < 0.001 
18:1n 9  26.08 ± 1.26  24.25 ± 0.66  25.29 ± 0.66  25.05 ± 1.20  24.65 ± 0.89  32.23 ± 1.34 *  < 0.001 
20:1n 9  0.51 ± 0.16  0.34 ± 0.03  0.35 ± 0.07  0.51 ± 0.05  0.34 ± 0.02  0.42 ± 0.06  0.001 
Total MUFA  31.08 ± 2.03  26.52 ± 0.92  27.90 ± 1.15  29.61 ± 1.50  27.29 ± 1.15  35.72 ± 2.00 *  < 0.001 
18:2n 6  35.73 ± 1.31  43.65 ± 1.36  33.67 ± 1.06  32.00 ± 1.54  45.28 ± 2.23  30.83 ± 3.04  < 0.001 
18:3n 6  0.22 ± 0.03  0.20 ± 0.01  0.16 ± 0.02  0.19 ± 0.04  0.23 ± 0.03  0.17 ± 0.03  < 0.001 
20:2n 6  0.30 ± 0.01  0.29 ± 0.02  0.23 ± 0.04  0.31 ± 0.02  0.29 ± 0.03  0.21 ± 0.03  < 0.001 
20:3n 6  0.20 ± 0.03  0.24 ± 0.04  0.17 ± 0.03  0.22 ± 0.02  0.28 ± 0.04  0.14 ± 0.08  < 0.001 
20:4n 6  0.86 ± 0.12  1.06 ± 0.17  0.65 ± 0.15  0.79 ± 0.16  1.24 ± 0.22  0.68 ± 0.13  < 0.001 
22:5n 6  0.15 ± 0.05  ND  ND  0.12 ± 0.08  0.21 ± 0.10  ND  < 0.001 
Total n 6 PUFA  37.46 ± 1.36  45.47 ± 1.37  34.89 ± 1.10  33.63 ± 1.68  47.53 ± 2.31  32.07 ± 3.18  < 0.001 
18:3n 3  2.08 ± 0.13  3.65 ± 0.25 *  13.57 ± 1.10 *  2.61 ± 0.20  1.72 ± 0.12  1.96 ± 0.18  < 0.001 
20:4n 3  ND  ND  ND  0.55 ± 0.61 *  ND  ND  0.003 
20:5n 3  ND  ND  0.28 ± 0.08 *  1.30 ± 0.24 *  ND  ND  < 0.001 
22:5n 3  0.20 ± 0.05  0.22 ± 0.05  0.41 ± 0.17  1.18 ± 0.22 *  0.10 ± 0.13  ND  < 0.001 
22:6n 3  0.25 ± 0.07  0.31 ± 0.04  0.38 ± 0.12  2.98 ± 0.58 *  0.20 ± 0.14  0.22 ± 0.10  < 0.001 
Total n 3 PUFA  2.54 ± 0.13  4.21 ± 0.21 *  14.67 ± 1.30 *  8.62 ± 1.42 *  2.04 ± 0.35  2.27 ± 0.26  < 0.001 
 
ND  negligible detected (mean <0.1%)    *       significantly different from all other groups (p < 0.05)     256 
Table 6.18: Correlations observed between fatty acids in adipose tissue total lipid 
extracts and plasma NEFA in pregnant rats (Pearsons r values unless otherwise 
indicated, n=36) 
 
Fatty acid  Subcutaneous adipose 
vs. Plasma NEFA 
Intra abdominal adipose 
vs. Plasma NEFA 
12:0  0.156†    0.073†   
14:0  0.666  ***  0.696  *** 
16:0  0.731  ***  0.757  *** 
18:0  0.223†    0.209†   
20:0   0.207†     0.112†   
22:0   0.155†        
Total saturated  0.580  ***  0.616  *** 
16:1n 7  0.294    0.421  * 
18:1n 9  0.574†  ***  0.556†  *** 
20:1n 9  0.211†    0.283†   
24:1n 9        0.068†   
Total MUFA  0.801  ***  0.828  *** 
18:2n 6  0.833  ***  0.837  *** 
18:3n 6   0.109†    0.046†   
20:2n 6  0.265    0.176   
20:3n 6   0.065†     0.097†   
20:4n 6  0.349  *  0.220   
22:5n 6  0.574†  ***  0.415†  * 
Total n 6 PUFA  0.726†  ***  0.880  *** 
18:3n 3  0.799†  ***  0.877†  *** 
20:4n 3  0.564†  ***  0.524†  ** 
20:5n 3  0.269†    0.535†  ** 
22:5n 3  0.712†  ***  0.807†  *** 
22:6n 3  0.586†  ***  0.405†  * 
Total n 3 PUFA  0.791†  ***  0.816†  *** 
 
† Spearman’s R value   * p < 0.05, ** p < 0.01, *** p < 0.001   257 
Figure 6.4: Graph to illustrate the correlation between the ALNA content (% total fatty 
acids) of intra abdominal adipose tissue total lipid extracts and plasma NEFA in 
pregnant rats  
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6.3.8 Maternal immune cell and tissue fatty acid composition 
The effect of maternal dietary fatty acid intake upon maternal immune cell and tissue 
phospholipid (PC and PE) fatty acid composition was assessed.  This would indicate 
whether there was a potential for maternal immune function to be altered via changes in 
the availability of fatty acids, for example EPA and AA which are utilised for 
prostaglandin synthesis. 
 
Maternal PBMC PC demonstrated little change in fatty acid composition in response to 
diet (see table 6.19).  In contrast, maternal PBMC PE demonstrated numerous 
significant effects of diet upon fatty acid status, particularly in relation to LC n 3 PUFA 
(see table 6.20).  The HF salmon oil group had significantly higher 20:4n 3 and EPA 
content than any other dietary group and higher DPA and DHA content than any of the 
other dietary groups except the HF linseed oil group.  No significant effects of maternal 
diet upon AA status were observed in maternal PBMC PC or PE. 
  
r = 0.861 
p < 0.001 
HF linseed oil group excluded:  
Intra abdominal adipose mean = 13.6% 
Plasma NEFA mean = 23.6% 
   258 
Within the maternal spleen there were significant effects of diet upon PC and PE fatty 
acid composition across a wide range of fatty acids assessed, and in particular the n 6 
and n 3 fatty acids (see table 6.21 and 6.22).  There was significant accumulation of 
ALNA in maternal spleen phospholipids within the HF linseed oil group.  The salmon 
oil diet also raised levels of DHA, 14:0 and 20:1n 9 to levels higher than any other 
dietary group in maternal spleen PC and PE. 
 
In terms of AA and EPA content, significant effects of maternal diet were observed 
within maternal spleen PC and PE (see figures 6.5 and 6.6).  The HF salmon oil group 
had the lowest AA content in maternal spleen PC and PE, though this was not 
statistically significant in the PE fraction when Bonferroni correction for multiple 
comparisons was applied due to the wide variation in AA content observed.  The EPA 
content of spleen phospholipids was highest in the salmon oil group, with the linseed oil 
diet also increasing EPA levels in maternal spleen PE to higher levels than in any other 
dietary group (except HF salmon oil group). 
 
 
Figure 6.5: The AA content (% total fatty acids) of spleen PC in pregnant rats fed 
experimental diets (mean ± SEM) 
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Figure 6.6: The EPA content (% total fatty acids) of spleen PE in pregnant rats fed 
experimental diets (mean ± SEM) 
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Within the maternal thymus there were significant effects of diet upon PC and PE fatty 
acid composition (see tables 6.23 and 6.24).  As was the case for maternal PBMC, there 
were fewer significant effects of diet on maternal thymus PC compared to PE. 
 
Within maternal thymus PC there was significant accumulation of ALNA in the HF 
linseed oil diet group.  Maternal diet significantly affected the AA content of maternal 
thymus PC, with the HF linseed and HF salmon oil groups exhibiting the lowest 
content.  There was a trend for the HF linseed and HF salmon oil groups to have the 
highest EPA content, but this was not significant when Bonferroni post hoc correction 
was applied due to the degree of variation within these groups. 
 
There was no significant effect of maternal diet upon AA content of maternal thymus 
PE.  Maternal diet had a significant effect upon the LC n 3 PUFA status of the maternal 
thymus, with EPA, DPA and DHA content highest in the HF linseed and HF salmon oil 
groups (see figure 6.7). 
 
* 
*  Significantly different (p < 0.05) from all other dietary groups 
ND 
ND   Negligible detected (mean < 0.1% total fatty acids) 
   260 
Figure 6.7: The LC n 3 PUFA content of thymus PE in pregnant rats fed experimental 
diets (mean ± SEM) 
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These data for maternal immune tissue fatty acid composition demonstrate that the 
maternal diet during pregnancy has the capacity to alter the fatty acid composition of 
tissues which are not directly involved in lipid metabolism.   
 
The extent of the effects observed varied with the tissue assessed, with the greatest 
effect observed upon the spleen, a moderate effect upon the thymus, and few effects on 
PBMC.  This indicates that not all maternal tissues are affected equally by changes to 
maternal diet, which may reflect the rate of turnover of cells within these tissues, or 
preferential incorporation of fatty acids into specific cells and tissues.  The effects 
observed upon AA and EPA content in phospholipids will influence substrate 
availability for eicosanoid synthesis, and so may result in changes in immune function. 
* 
Significantly different (p < 0.05) from all other dietary groups 
* 
#  Significantly different (p < 0.05) from LF soyabean, HF soyabean, HF sunflower 
and HF beef tallow 
# 
 # 
 ‡ 
‡ 
Significantly different (p < 0.05) from LF soyabean   261 
Table 6.19: Fatty acid composition of PBMC PC in pregnant rats fed experimental diets (% total fatty acids, mean ± standard deviation) 
 
  LF Soyabean  
(n = 6) 
HF Soyabean  
(n = 4) 
HF Linseed  
(n = 4) 
HF Salmon  
(n = 5) 
HF Sunflower 
(n = 6) 
HF Beef tallow 
(n = 4) 
ANOVA 
p value 
14:0  0.36 ± 0.29 
b  ND 
b  0.40 ± 0.29  1.00 ± 0.06 
a  0.39 ± 0.44  0.35 ± 0.48  0.004 
16:0  46.33 ± 7.28  42.70 ± 6.30  49.67 ± 5.92  46.59 ± 9.90  40.65 ± 8.17  46.03 ± 12.30  0.639 
18:0  20.16 ± 1.82  21.34 ± 0.46  19.83 ± 1.54  15.75 ± 2.11  19.88 ± 5.01  20.16 ± 0.83  0.066 
20:0  0.30 ± 0.35  0.52 ± 0.19  0.30 ± 0.20  ND  0.23 ± 0.32  0.45 ± 0.16  0.110 
22:0  0.49 ± 0.11 
b  0.40 ± 0.12 
b  0.33 ± 0.10  ND 
a  0.24 ± 0.22  0.44 ± 0.04 
b  0.001 
Total saturates  67.65 ± 7.81  64.96 ± 6.44  70.53 ± 5.06  63.45 ± 11.16  61.40 ± 6.66  67.42 ± 12.77  0.620 
16:1n 7  0.58 ± 0.20  ND  0.36 ± 0.27  0.91 ± 0.79  1.20 ± 1.61  0.31 ± 0.25  0.334 
18:1n 9  14.43 ± 4.89  12.69 ± 1.59  9.98 ± 1.64  14.23 ± 9.49  13.03 ± 7.37  10.80 ± 4.07  0.831 
20:1n 9  0.25 ± 0.39  0.37 ± 0.73  0.79 ± 0.39  0.81 ± 0.53  1.72 ± 2.85  1.21 ± 0.81  0.556 
24:1n 9  0.59 ± 0.56  0.13 ± 0.25  0.44 ± 0.20  0.41 ± 0.48  0.48 ± 0.40  0.38 ± 0.26  0.657 
Total MUFA  15.85 ± 5.02  13.27 ± 2.39  11.57 ± 1.92  16.36 ± 9.93  16.44 ± 6.28  12.70 ± 4.44  0.708 
18:2n 6  6.45 ± 2.34  11.36 ± 0.84  10.82 ± 1.74  11.35 ± 1.30  10.82 ± 4.06  9.10 ± 4.14  0.052 
18:3n 6  0.79 ± 1.50  0.17 ± 0.33  0.47 ± 0.38  0.50 ± 1.00  1.85 ± 2.43  0.16 ± 0.27  0.403 
20:2n 6  0.67 ± 0.54  1.01 ± 0.69  0.57 ± 0.66  0.30 ± 0.42  1.04 ± 1.06  0.81 ± 0.20  0.525 
20:3n 6  1.40 ± 1.19  1.34 ± 1.04  1.05 ± 0.55  1.19 ± 0.44  1.59 ± 1.21  1.79 ± 1.17  0.907 
20:4n 6  3.11 ± 1.10  4.80 ± 3.41  2.53 ± 0.65  2.72 ± 0.62  3.11 ± 1.62  4.63 ± 2.64  0.340 
22:5n 6  1.66 ± 3.04  0.09 ± 0.19  0.50 ± 0.33  0.58 ± 0.95  1.21 ± 1.85  0.62 ± 0.14  0.739 
Total n 6 PUFA  14.07 ± 4.52  18.78 ± 4.18  15.94 ± 2.96  16.64 ± 3.19  19.63 ± 3.99  17.10 ± 7.48  0.394 
18:3n 3  0.29 ± 0.53  0.34 ± 0.12  0.62 ± 0.26  0.10 ± 0.23  0.26 ± 0.35  0.30 ± 0.14  0.385 
20:4n 3  ND 
a  0.48 ± 0.55  0.10 ± 0.12  0.72 ± 0.41 
b  0.22 ± 0.26  0.27 ± 0.35  0.033 
20:5n 3  0.87 ± 0.51  0.60 ± 0.75  0.62 ± 0.20  0.91 ± 0.36  0.59 ± 0.32  0.95 ± 0.46  0.666 
22:5n 3  0.16 ± 0.39  ND  0.21 ± 0.25  0.42 ± 0.61  0.73 ± 1.78  0.20 ± 0.39  0.829 
22:6n 3  1.06 ± 0.75  1.58 ± 0.68  0.41 ± 0.32  1.39 ± 0.59  0.73 ± 0.44  1.07 ± 0.89  0.125 
Total n 3 PUFA  2.43 ± 1.45  3.00 ± 0.30  1.96 ± 0.70  3.54 ± 1.40  2.53 ± 1.35  2.78 ± 1.30  0.497 
ND   negligible detected (mean <0.1% total fatty acid content)    
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have different superscripts   262 
 Table 6.20: Fatty acid composition of PBMC PE in pregnant rats fed experimental diets (% total fatty acids, mean ± standard deviation) 
 
  LF Soyabean 
(n = 5) 
HF Soyabean 
(n = 5) 
HF Linseed 
(n = 6) 
HF Salmon 
(n = 5) 
HF Sunflower 
(n = 6) 
HF Beef tallow 
(n = 5) 
ANOVA  
p value 
14:0  1.00 ± 0.31  0.70 ± 0.64  1.02 ± 0.72  1.25 ± 0.26  1.13 ± 0.56  1.08 ± 0.39  0.679 
16:0  25.31 ± 1.69  26.30 ± 4.26  21.83 ± 4.30  24.34 ± 3.39  27.43 ± 3.65  24.71 ± 2.59  0.155 
18:0  20.18 ± 4.59  23.30 ± 3.82  19.30 ± 4.35  17.04 ± 3.02  20.32 ± 3.62  20.98 ± 6.14  0.372 
20:0  0.44 ± 0.21  0.68 ± 0.23 
a  0.31 ± 0.26  0.13 ± 0.19 
b  0.51 ± 0.21  0.33 ± 0.22  0.010 
22:0  0.25 ± 0.09  0.36 ± 0.21
 b  0.36 ± 0.18 
b  ND 
a  0.36 ± 0.07 
b  0.33 ± 0.11  0.011 
Total saturates  47.18 ± 6.41  51.35 ± 4.81  42.80 ± 8.79  42.81 ± 6.33  49.75 ± 7.64  47.44 ± 9.18  0.331 
16:1n 7  1.18 ± 0.16  1.19 ± 1.74  0.79 ± 0.98  1.25 ± 0.25  0.52 ± 0.35  0.68 ± 0.28  0.606 
18:1n 9  15.61 ± 3.99  16.26 ± 0.80  16.81 ± 1.72  16.17 ± 4.36  15.08 ± 2.92  18.52 ± 2.74  0.529 
20:1n 9  0.55 ± 0.36  0.43 ± 0.43  0.54 ± 0.90  3.00 ± 2.37 *  0.67 ± 0.24  0.55 ± 0.54  0.004 
24:1n 9  0.65 ± 0.39  0.35 ± 0.38  0.31 ± 0.30  0.17 ± 0.24  0.54 ± 0.32  0.41 ± 0.08  0.167 
Total MUFA  17.98 ± 4.16  18.22 ± 2.21  18.45 ± 1.67  20.60 ± 6.11  16.82 ± 3.56  20.16 ± 3.29  0.573 
18:2n 6  12.53 ± 1.79 
b  17.61 ± 4.46  15.74 ± 2.70  15.44 ± 2.31  18.82 ± 3.14 
a  11.92 ± 2.25 
b  0.004 
18:3n 6  0.20 ± 0.20  0.25 ± 0.23  0.79 ± 0.93  1.75 ± 1.97  0.18 ± 0.22  0.52 ± 0.52  0.080 
20:2n 6  0.80 ± 0.47  1.08 ± 0.27  0.63 ± 0.53  0.35 ± 0.48  0.91 ± 0.75  1.11 ± 0.57  0.237 
20:3n 6  1.47 ± 1.00  1.60 ± 0.84  1.30 ± 1.14  1.06 ± 0.32  1.17 ± 0.61  1.10 ± 0.44  0.859 
20:4n 6  15.95 ± 7.81  5.56 ± 1.62   10.07 ± 5.21  7.82 ± 3.94  9.28 ± 7.40  14.28 ± 7.72  0.099 
22:5n 6  1.08 ± 0.94  0.48 ± 0.85  0.98 ± 1.05  0.59 ± 1.11  0.91 ± 0.77  1.04 ± 0.56  0.853 
Total n 6 PUFA  32.02 ± 9.41  26.58 ± 2.39  29.50 ± 6.97  27.02 ± 5.21  31.27 ± 10.07  29.97 ± 9.93  0.845 
18:3n 3  0.55 ± 0.24  1.32 ± 0.76  4.86 ± 2.50 *  0.34 ± 0.34  0.49 ± 0.20  0.36 ± 0.25  < 0.001 
20:4n 3  ND  0.16 ± 0.37  0.34 ± 0.38  1.15 ± 0.76 *  ND  0.14 ± 0.22  0.001 
20:5n 3  0.39 ± 0.23  0.52 ± 0.10  0.98 ± 0.62  3.13 ± 1.59 *  0.53 ± 0.12  0.53 ± 0.17  < 0.001 
22:5n 3  0.37 ± 0.54 
b  0.17 ± 0.37 
b  1.22 ± 0.85  2.12 ± 1.59 
a  0.14 ± 0.35 
b  0.26 ± 0.25 
b  0.002 
22:6n 3  1.42 ± 0.52  1.68 ± 0.71  1.84 ± 0.76  2.83 ± 1.15 
a  0.95 ± 0.41 
b  1.14 ± 0.49 
b  0.004 
Total n 3 PUFA  2.82 ± 0.55 
b  3.85 ± 1.67 
b  9.24 ± 3.74 
a  9.58 ± 3.32 
a  2.16 ± 0.77 
b  2.44 ± 0.76 
b  < 0.001 
ND   negligible detected (mean <0.1% total fatty acid content)  *  significantly different (p < 0.05) from all other groups 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have different superscripts  263 
Table 6.21: Fatty acid composition of spleen PC in pregnant rats fed experimental diets (% total fatty acids, mean ± standard deviation) 
 
  LF Soyabean 
(n=6) 
HF Soyabean 
(n=6) 
HF Linseed 
(n=4) 
HF Salmon 
(n=6) 
HF Sunflower 
(n=5) 
HF Beef tallow 
(n=6) 
ANOVA  
p value 
14:0  0.19 ± 0.30  0.26 ± 0.28  0.38 ± 0.27  1.59 ± 0.19 *  0.30 ± 0.28  0.59 ± 0.46  < 0.001 
16:0  58.73 ± 3.19  53.43 ± 2.21  52.95 ± 0.68  58.06 ± 3.22  55.60 ± 1.96  50.66 ± 2.34  < 0.001 
18:0  11.55 ± 0.92  13.38 ± 2.91  11.86 ± 2.09  9.44 ± 1.24  13.15 ± 2.65  14.11 ± 2.56  0.014 
20:0  ND  ND  0.11 ± 0.21  ND  ND  ND  0.342 
22:0  ND  0.13 ± 0.14  0.15 ± 0.10  ND  0.23 ± 0.21  ND  0.079 
Total saturates  70.51 ± 3.68  67.23 ± 3.10  65.45 ± 2.11  69.20 ± 3.67  69.28 ± 1.84  65.42 ± 3.85  0.067 
16:1n 7  0.21 ± 0.33  0.24 ± 0.29  0.27 ± 0.20  0.82 ± 0.26  0.12 ± 0.17  0.90 ± 1.42  0.206 
18:1n 9  8.74 ± 2.60  8.39 ± 2.71  9.70 ± 0.43  8.45 ± 0.46  8.79 ± 2.12  10.34 ± 1.03  0.448 
20:1n 9  0.75 ± 0.90  0.56 ± 0.48  1.26 ± 0.61  1.78 ± 0.56  0.55 ± 0.50  0.85 ± 0.59  0.018 
24:1n 9  0.35 ± 0.21  0.28 ± 0.15  0.30 ± 0.04  0.47 ± 0.24  0.30 ± 0.19  0.33 ± 0.08  0.482 
Total MUFA  10.06 ± 1.88  9.47 ± 2.18  11.53 ± 0.73  11.52 ± 0.85  9.75 ± 1.67  12.43 ± 1.28  0.018 
18:2n 6  7.92 ± 0.76  12.27 ± 1.49  12.96 ± 0.88  10.07 ± 1.21 *  12.14 ± 0.67  8.00 ± 0.45  < 0.001 
18:3n 6  0.26 ± 0.46  ND  ND  0.29 ± 0.27  ND  0.39 ± 0.92  0.571 
20:2n 6  1.00 ± 0.38  2.14 ± 0.94  1.44 ± 0.33  0.79 ± 0.15  2.65 ± 0.68  0.91 ± 0.21  < 0.001 
20:3n 6  0.56 ± 0.29  1.24 ± 1.44  0.55 ± 0.10  0.46 ± 0.12  0.66 ± 0.28  0.95 ± 0.80  0.457 
20:4n 6  7.78 ± 2.44  5.92 ± 2.01  4.14 ± 0.27  2.97 ± 0.71  4.38 ± 1.47  9.20 ± 1.72  < 0.001 
22:5n 6  0.63 ± 0.16  0.50 ± 0.22  0.33 ± 0.07  ND  0.70 ± 0.09  0.61 ± 0.20  < 0.001 
Total n 6 PUFA  18.16 ± 3.36  22.08 ± 2.87  19.41 ± 1.32  14.65 ± 2.23  20.53 ± 2.57  20.05 ± 2.35  0.001 
18:3n 3  ND  0.14 ± 0.11  1.53 ± 0.35 *  ND  ND  ND  < 0.001 
20:4n 3  ND  ND  0.31 ± 0.07  0.73 ± 0.54  0.14 ± 0.19  0.13 ± 0.20  0.001 
20:5n 3  0.21 ± 0.51  ND  0.35 ± 0.07  1.00 ± 0.35  ND  0.51 ± 0.88  0.015 
22:5n 3  0.38 ± 0.42  0.30 ± 0.18  0.68 ± 0.12  1.19 ± 0.32  ND  0.63 ± 0.47  < 0.001 
22:6n 3  0.61 ± 0.38  0.67 ± 0.22  0.74 ± 0.09  1.62 ± 0.48 *  0.17 ± 0.19  0.81 ± 0.22  < 0.001 
Total n 3 PUFA  1.27 ± 1.21  1.23 ± 0.53  3.61 ± 0.42  4.63 ± 1.14  0.44 ± 0.38  2.10 ± 1.22  < 0.001 
 
ND   negligible detected (mean <0.1% total fatty acid content)    *  Significantly different (p <0.05) from all other groups    264 
 
Table 6.22: Fatty acid composition of spleen PE in pregnant rats fed experimental diets (% total fatty acid, mean ± standard deviation) 
 
  LF Soyabean 
(n=5) 
HF Soyabean 
(n=6) 
HF Linseed 
(n=5) 
HF Salmon 
(n=6) 
HF Sunflower 
(n=6) 
HF Beef tallow 
(n=6) 
ANOVA  
p value 
14:0  ND  ND  ND  0.52 ± 0.31 *  ND  0.16 ± 0.18  < 0.001 
16:0  18.07 ± 3.91  17.52 ± 5.81  12.78 ± 1.11  16.35 ± 2.62  19.54 ± 5.92  15.39 ± 3.29  0.173 
18:0  21.74 ± 1.55  21.26 ± 1.43  21.16 ± 2.93  17.66 ± 2.79  22.26 ± 2.52  22.48 ± 1.75  0.011 
Total saturates  39.83 ± 2.67  38.78 ± 6.57  33.99 ± 3.70  34.55 ± 3.64  41.85 ± 8.24  36.82 ± 3.61  0.129 
16:1n 7  0.20 ± 0.28  0.14 ± 0.33  0.26 ± 0.16  0.97 ± 0.47  0.43 ± 1.04  0.37 ± 0.39  0.138 
18:1n 9  13.10 ± 5.18  14.98 ± 5.33  13.65 ± 2.25  12.20 ± 3.63  15.58 ± 5.33  17.42 ± 4.57  0.432 
20:1n 9  0.43 ± 0.27  0.26 ± 0.40  0.70 ± 0.32  1.80 ± 0.83 *  0.28 ± 0.44  0.74 ± 0.48  < 0.001 
Total MUFA  13.73 ± 4.71  15.38 ± 4.98  14.62 ± 2.48  15.00 ± 3.53  16.34 ± 4.58  17.05 ± 1.79  0.791 
18:2n 6  10.97 ± 1.97  20.03 ± 4.08  15.80 ± 1.12  12.95 ± 2.69  19.26 ± 1.98  9.89 ± 1.39  < 0.001 
18:3n 6  ND  ND  ND  0.47 ± 0.51  0.97 ± 1.85  0.16 ± 0.26  0.359 
20:2n 6  1.33 ± 0.27  2.23 ± 0.63  1.41 ± 0.18  0.91 ± 0.27  2.90 ± 0.54  0.88 ± 0.17  < 0.001 
20:3n 6  1.32 ± 0.23  1.26 ± 0.52  1.16 ± 0.14  1.04 ± 0.14  1.01 ± 0.55  1.86 ± 1.93  0.604 
20:4n 6  25.83 ± 6.47  17.90 ± 10.45  19.32 ± 3.87  12.69 ± 2.89  13.76 ± 9.05  24.15 ± 7.28  0.027 † 
22:5n 6  1.91 ± 0.64  0.55 ± 0.43  0.10 ± 0.11  0.17 ± 0.16  1.57 ± 0.89  1.61 ± 0.52  < 0.001 
Total n 6 PUFA  41.44 ± 5.26  42.06 ± 9.80  37.80 ± 3.53  28.22 ± 1.86  39.47 ± 10.76  40.84 ± 4.49  0.021 
18:3n 3  ND  0.52 ± 0.36  3.14 ± 0.69 *  0.30 ± 0.25  ND  0.16 ± 0.14  < 0.001 
20:4n 3  ND  ND  0.18 ± 0.13  1.60 ± 0.54 *  0.34 ± 0.73  0.20 ± 0.26  < 0.001 
20:5n 3  ND  0.18 ± 0.32  1.46 ± 0.47  4.54 ± 1.11 *  0.39 ± 0.97  0.69 ± 1.51  < 0.001 
22:5n 3  2.05 ± 1.01  1.20 ± 1.13  4.96 ± 1.28  7.23 ± 2.26  0.79 ± 1.01  1.13 ± 0.70  < 0.001 
22:6n 3  2.79 ± 0.99  1.84 ± 1.79  3.84 ± 0.65  8.55 ± 2.10 *  0.75 ± 0.58  2.63 ± 0.97  < 0.001 
Total n 3 PUFA  5.01 ± 2.03  3.79 ± 3.10  13.59 ± 2.06 *  22.22 ± 4.45 *  2.34 ± 1.92  5.29 ± 1.26  < 0.001 
 
ND   negligible detected (mean <0.1% total fatty acid content) 
*  Significantly different (p <0.05) from all other groups  
†  no significant differences between groups when Bonferroni post hoc test applied   265 
Table 6.23: Fatty acid composition of thymus PC in pregnant rats fed experimental diets (% total fatty acids, mean ± standard deviation) 
 
  LF Soyabean 
(n=5) 
HF Soyabean 
(n=6) 
HF Linseed 
(n=6) 
HF Salmon 
(n=6) 
HF Sunflower 
(n=4) 
HF Beef tallow 
(n=4) 
ANOVA 
p value 
14:0  0.33 ± 0.45  ND 
b  ND 
b  0.86 ± 0.70 
a  0.10 ± 0.21  0.11 ± 0.22  0.018 
16:0  43.15 ± 8.96  47.76 ± 4.41   44.70 ± 5.81  39.51 ± 7.45  38.74 ± 8.26  39.15 ± 7.17  0.244 
18:0  14.99 ± 4.12  11.64 ± 2.12  12.99 ± 4.26  16.27 ± 6.23  19.45 ± 9.14  15.29 ± 3.47  0.272 
20:0  0.31 ± 0.45  ND  0.62 ± 1.04  0.56 ± 0.55  0.35 ± 0.71  0.15 ± 0.30  0.536 
22:0  0.13 ± 0.18  ND  ND  ND  ND  ND  0.087 
Total saturates  58.90 ± 6.09  59.48 ± 2.48  58.42 ± 3.75  57.20 ± 4.85  58.65 ± 4.09  54.70 ± 4.52  0.626 
16:1n 7  1.02 ± 0.24  0.51 ± 0.41 
b  0.72 ± 0.44 
b  1.78 ± 0.63
 a  1.01 ± 0.29  1.01 ± 0.40  0.001 
18:1n 9  13.81 ± 3.72  11.49 ± 0.44  11.83 ± 1.33  16.65 ± 5.38  13.04 ± 1.96  14.48 ± 0.58  0.067 
20:1n 9  0.60 ± 0.94  2.10 ± 0.37 
b  1.67 ± 0.54  0.30 ± 0.74 
a  1.54 ± 1.06  2.40 ± 1.61 
b  0.004 
24:1n 9  0.50 ± 0.35  ND  0.41 ± 0.51  0.48 ± 0.27  0.37 ± 0.27  0.56 ± 0.08  0.236 
Total MUFA  15.92 ± 3.16  14.19 ± 0.75  14.62 ± 2.07  19.22 ± 6.20  15.97 ± 1.50  18.44 ± 1.35  0.095 
18:2n 6  8.07 ± 1.45  10.15 ± 1.00 
b  10.72 ± 1.87 
b  8.99 ± 1.49  10.45 ± 2.16 
b  6.80 ± 1.04 
a  0.004 
18:3n 6  ND  0.32 ± 0.79  0.47 ± 0.64  0.11 ± 0.27  ND  ND  0.448 
20:2n 6  1.11 ± 1.10  3.49 ± 0.58  2.55 ± 0.87  1.86 ± 1.29  2.10 ± 2.48  2.17 ± 0.37  0.075 
20:3n 6  1.53 ± 0.83  0.97 ± 0.83  1.35 ± 0.70  1.58 ± 0.54  0.81 ± 0.63  1.26 ± 0.19  0.423 
20:4n 6  11.76 ± 4.31  10.39 ± 0.76  7.93 ± 2.21 
b  7.76 ± 1.84 
b  9.01 ± 2.52  14.46 ± 1.85 
a  0.002 
22:5n 6  0.67 ± 0.58  0.35 ± 0.47  0.14 ± 0.16  0.11 ± 0.19  0.67 ± 0.52  0.68 ± 0.18  0.052 
Total n 6 PUFA  23.14 ± 6.25  25.68 ± 1.68  23.16 ± 2.79  20.40 ± 1.62  23.04 ± 5.19  25.37 ± 3.06  0.215 
18:3n 3  0.13 ± 0.21  ND  1.53 ± 0.27 *  0.10 ± 0.17  0.11 ± 0.21  ND  < 0.001 
20:4n 3  0.71 ± 0.55  0.11 ± 0.17  0.14 ± 0.24  0.37 ± 0.66  0.34 ± 0.26  0.65 ± 0.18  0.122 
20:5n 3  0.10 ± 0.21  0.32 ± 0.41  0.79 ± 0.54  1.51 ± 1.45  0.42 ± 0.44  ND  0.028 † 
22:5n 3  0.33 ± 0.46  ND  0.93 ± 0.82  0.23 ± 0.38  0.71 ± 0.95  0.17 ± 0.24  0.116 
22:6n 3  0.77 ± 0.71  0.10 ± 0.24  0.39 ± 0.35  0.98 ± 0.58  0.77 ± 0.67  0.56 ± 0.21  0.069 
Total n 3 PUFA  2.03 ± 1.57  0.65 ± 0.54 
a  3.79 ± 1.22 
b  3.18 ± 2.21  2.35 ± 1.83  1.48 ± 0.46  0.016 
ND   negligible detected (mean <0.1% total fatty acid content)   *  Significantly different (p <0.05) from all other groups  
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have different superscripts   
† no significant differences between groups when Bonferroni post hoc test applied    266 
Table 6.24: Fatty acid composition of thymus PE in pregnant rats fed experimental diets (% total fatty acids, mean ± standard deviation) 
 
  LF Soyabean 
  (n=4)   
HF Soyabean 
(n=5) 
HF Linseed 
(n=5) 
HF Salmon 
(n=3) 
HF Sunflower 
(n=2) 
HF Beef tallow 
(n=3) 
ANOVA  
p value 
14:0  0.59 ± 0.46  ND  0.12 ± 0.26  ND  0.52 ± 0.17  0.73 ± 0.57  0.019 † 
16:0  16.45 ± 5.99  11.49 ± 3.25  10.47 ± 1.81  11.62 ± 2.27  11.29 ± 0.26  17.43 ± 8.25  0.200 
18:0  20.89 ± 5.22  22.36 ± 2.16  21.77 ± 1.60  19.02 ± 2.76  22.18 ± 2.08  15.00 ± 13.85  0.564 
20:0  ND  0.18 ± 0.40  ND  ND  ND  0.12 ± 0.20  0.808 
Total saturates  38.01 ± 7.33  34.02 ± 5.62  32.36 ± 3.33  30.64 ± 1.96  34.05 ± 2.43  33.28 ± 6.97  0.558 
16:1n 7  0.74 ± 0.29  0.90 ± 1.30  0.18 ± 0.40  1.05 ± 0.91  0.46 ± 0.02  0.29 ± 0.50  0.585 
18:1n 9  16.76 ± 4.47  14.08 ± 2.34  14.31 ± 1.22  16.95 ± 3.16  10.68 ± 1.31  21.02 ± 2.44  0.010 
20:1n 9  1.52 ± 0.83  2.40 ± 2.48  1.85 ± 0.66  2.21 ± 0.38  1.67 ± 0.39  1.99 ± 1.84  0.960 
24:1n 9  0.31 ± 0.23  ND  ND  ND  0.19 ± 0.05  0.18 ± 0.16  0.110 
Total MUFA  19.33 ± 4.15  17.45 ± 4.26  16.38 ± 1.67  20.21 ± 4.25  13.00 ± 1.74  23.49 ± 3.15  0.049 † 
18:2n 6  9.38 ± 2.88  10.32 ± 1.44  10.75 ± 1.58  10.13 ± 2.65  10.62 ± 2.51  8.96 ± 2.34  0.855 
18:3n 6  0.10 ± 0.12  ND  ND  ND  ND  ND  0.074 
20:2n 6  1.19 ± 0.63  2.24 ± 1.33  1.96 ± 0.43  1.11 ± 0.17  3.86 ± 0.88  1.51 ± 0.12  0.014 
20:3n 6  1.11 ± 0.18  1.75 ± 1.02  1.28 ± 0.16  1.51 ± 0.20  1.20 ± 0.11  2.79 ± 3.03  0.526 
20:4n 6  27.71 ± 10.28  30.95 ± 7.21  30.25 ± 4.98  28.54 ± 6.58  33.74 ± 1.90  25.67 ± 1.53  0.783 
22:5n 6  0.94 ± 0.27  0.59 ± 0.08  ND  ND  1.74 ± 0.19 *  1.07 ± 0.25  < 0.001 
Total n 6 PUFA  40.43 ± 8.93  45.85 ± 7.79  44.29 ± 4.98  41.29 ± 4.13  51.16 ± 1.18  40.00 ± 4.20  0.369 
18:3n 3  0.12 ± 0.18  0.14 ± 0.31  1.66 ± 0.79 *  ND  ND  ND  < 0.001 
20:4n 3  0.19 ± 0.22  0.28 ± 0.49  0.14 ± 0.20  0.32 ± 0.28  0.30 ± 0.02  0.34 ± 0.04  0.923 
20:5n 3  0.14 ± 0.24  0.64 ± 0.89  1.77 ± 0.68  2.98 ± 0.49  0.13 ± 0.19  1.38 ± 2.28  0.017 
22:5n 3  0.55 ± 0.12  0.45 ± 0.29  1.98 ± 0.67  1.84 ± 0.41  0.46 ± 0.16  0.33 ± 0.31  < 0.001 
22:6n 3  1.24 ± 0.12  1.16 ± 0.29  1.42 ± 0.25  2.73 ± 0.16 *  0.83 ± 0.25  1.10 ± 0.18  < 0.001 
Total n 3 PUFA  2.24 ± 0.31  2.67 ± 1.45  6.98 ± 0.96  7.86 ± 0.59  1.79 ± 0.49  3.23 ± 2.64  < 0.001 
 
ND   negligible detected (mean <0.1% total fatty acid content)  *  Significantly different (p <0.05) from all other groups 
†   no significant differences between groups when Bonferroni post hoc test applied  267 
6.3.9 Placenta fatty acid composition 
The fatty acid compositions of placenta PC, PE, TAG and CE were assessed by gas 
chromatography (see table 6.25 to 6.28).  The placenta is a tissue which is synthesised 
de novo during pregnancy, and so should provide a good indication of how readily 
maternal dietary fatty acids are incorporated into new tissues during pregnancy.  
Changes in the fatty acid composition of the placenta may affect the functioning of 
membrane bound proteins by inducing changes in membrane fluidity.  This may 
therefore affect the transport of nutrients across the placenta to the developing fetus. 
 
All placenta lipid fractions were significantly affected by maternal diet during 
pregnancy.  The HF linseed oil group had the highest levels of placenta ALNA, with 
particular accumulation of this fatty acid in placenta TAG and CE.  The HF linseed oil 
group also resulted in high levels of EPA and DPA, but not DHA, within placenta 
lipids, though levels were not as high as those achieved with salmon oil feeding.  Levels 
of AA in placenta PC were significantly lower than in other dietary groups, but again 
did not reach the low levels induced by salmon oil diets. 
 
All LC n 3 PUFA were at the highest levels in placenta lipids from the HF salmon oil 
group.  This was associated with the lowest levels of the LC n 6 PUFA AA across all 
placenta lipids. 
 
The HF sunflower oil group did not have the highest levels of LA within placenta lipids, 
but did have significantly higher 22:5n 6 content in PC, PE and TAG than any other 
dietary group.  This diet was also associated with the lowest levels of LC n 3 PUFA 
such as DPA and DHA across all placenta lipid fractions. 
 
The HF beef tallow diet resulted in the highest OA content of placenta lipids, in keeping 
with the high dietary content of this fatty acid.  
 
These data indicate that the fatty acid composition of the developing placenta during 
pregnancy is strongly influenced by the dietary availability of fatty acids. 
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Table 6.25: Fatty acid composition of placenta PC in pregnant rats fed experimental diets (% total fatty acids, mean ± standard deviation, n=6 per group) 
 
Fatty acid  LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef tallow  ANOVA 
p value 
14:0  0.40 ± 0.02  0.36 ± 0.06  0.40 ± 0.09  0.66 ± 0.06 *  0.44 ± 0.09  0.50 ± 0.14  < 0.001 
16:0  34.14 ± 1.59  29.56 ± 1.24  29.29 ± 1.09  32.77 ± 0.79  30.08 ± 1.21  30.12 ± 1.58  < 0.001 
18:0  16.97 ± 1.19  19.86 ± 0.75  19.35 ± 0.66  17.05 ± 0.36  19.84 ± 0.94  18.80 ± 1.32  < 0.001 
20:0  0.18 ± 0.04  0.23 ± 0.06  0.23 ± 0.04  0.23 ± 0.11  0.23 ± 0.05  0.21 ± 0.02  0.631 
22:0  0.14 ± 0.07  0.17 ± 0.04  0.22 ± 0.03  0.10 ± 0.05  0.19 ± 0.02  0.18 ± 0.02  0.001 
Total saturates  51.82 ± 0.50  50.18 ± 0.93  49.49 ± 0.96  50.82 ± 0.68  50.77 ± 0.97  49.82 ± 0.79  < 0.001 
16:1n 7  1.25 ± 0.08  0.59 ± 0.15  0.77 ± 0.27  1.27 ± 0.17  0.55 ± 0.11  0.89 ± 0.30  < 0.001 
18:1n 9  7.34 ± 0.26  5.85 ± 0.34  7.30 ± 1.52  7.28 ± 0.76  5.66 ± 0.56  9.91 ± 1.75 *  < 0.001 
20:1n 9  0.17 ± 0.07  0.18 ± 0.05  0.20 ± 0.04  0.71 ± 0.08 *  0.19 ± 0.04  0.22 ± 0.09  < 0.001 
24:1n 9  ND  ND  0.11 ± 0.02  0.24 ± 0.04 *  ND  0.10 ± 0.05  < 0.001 
Total MUFA  8.79 ± 0.25  6.65 ± 0.46  8.38 ± 1.74  9.49 ± 0.84  6.45 ± 0.67  11.11 ± 2.11  < 0.001 
18:2n 6  14.78 ± 0.69  19.90 ± 1.49  20.76 ± 1.33  18.54 ± 0.92  20.32 ± 1.02  15.08 ± 0.75  < 0.001 
18:3n 6  0.21 ± 0.14  0.29 ± 0.23  0.28 ± 0.23  0.31± 0.26  0.28 ± 0.15  0.22 ± 0.10  0.937 
20:2n 6  0.39 ± 0.04  0.67 ± 0.11  0.50 ± 0.09  0.41 ± 0.10  0.74 ± 0.07  0.39 ± 0.10  < 0.001 
20:3n 6  0.71 ± 0.09  0.79 ± 0.06  0.93 ± 0.13  0.98 ± 0.07  0.73 ± 0.12  0.77 ± 0.07  < 0.001 
20:4n 6  15.56 ± 0.83  14.87 ± 0.61  10.61 ± 1.19 *  7.35 ± 0.17 *  14.08 ± 0.89  15.94 ± 0.78  < 0.001 
22:5n 6  3.20 ± 0.56  1.52 ± 0.62  0.70 ± 0.15  0.52 ± 0.05  4.57 ± 0.69 *  2.85 ± 0.69  < 0.001 
Total n 6 PUFA  34.87 ± 0.56  38.04 ± 1.07 *  33.78 ± 0.92  28.12 ± 0.97 *  40.72 ± 1.16 *  35.25 ± 1.80  < 0.001 
18:3n 3  0.10 ± 0.10  0.15 ± 0.07  0.75 ± 0.07 *  0.17 ± 0.08  ND  ND  < 0.001 
20:4n 3  ND  ND  0.12 ± 0.02 *  0.24 ± 0.02 *  ND  ND  < 0.001 
20:5n 3  ND  ND  1.02 ± 0.14 *  2.09 ± 0.17 *  ND  0.12 ± 0.15  < 0.001 
22:5n 3  0.61 ± 0.12  0.61 ± 0.11  1.53 ± 0.17 *  1.90 ± 0.13 *  0.17 ± 0.09 *  0.44 ± 0.11  < 0.001 
22:6n 3  3.76 ± 0.53  4.30 ± 0.67  4.93 ± 0.86  7.17 ± 0.45 *  1.69 ± 0.12 *  3.20 ± 0.54  < 0.001 
Total n 3 PUFA  4.52 ± 0.50  5.14 ± 0.80  8.35 ± 0.91 *  11.57 ± 0.54 *  2.06 ± 0.23 *  3.82 ± 0.56  < 0.001 
 
ND   negligible detected (mean <0.1% total fatty acid content)     *  Significantly different (p <0.05) from all other groups   269 
Table 6.26: Fatty acid composition of placenta PE in pregnant rats fed experimental diets (% total fatty acids, mean ± standard deviation, n=6 per 
group) 
 
Fatty acid  LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef tallow  ANOVA 
p value 
14:0  0.14 ± 0.09  0.08 ± 0.15  0.25 ± 0.39  0.15 ± 0.09  0.13 ± 0.07  0.15 ± 0.08  0.697 
16:0  10.41 ± 0.93  9.45 ± 0.62  10.25 ± 3.30  10.78 ± 0.90  9.41 ± 1.15  9.26 ± 0.81  0.457 
18:0  18.48 ± 1.68  21.06 ± 0.60  19.77 ± 2.82  17.91 ± 1.36  21.26 ± 1.29  19.82 ± 1.30  0.007 
20:0  0.66 ± 0.27  0.46 ± 0.29  0.51 ± 0.18  0.56 ± 0.23  0.32 ± 0.21  0.42 ± 0.23  0.239 
22:0  0.10 ± 0.16  ND  0.15 ± 0.07  0.15 ± 0.18  ND  ND  0.329 
Total saturates  29.78 ± 1.24  31.09 ± 0.80  30.95 ± 1.49  29.55 ± 0.90  31.19 ± 1.96  29.68 ± 1.73  0.141 
16:1n 7  1.71 ± 1.89  0.44 ± 0.30  0.70 ± 0.61  0.94 ± 0.32  0.70 ± 0.83  0.58 ± 0.14  0.209 
18:1n 9  10.68 ± 0.89  8.66 ± 0.70  10.81 ± 2.55  9.66 ± 1.47  8.50 ± 0.69  11.72 ± 0.75  0.001 
20:1n 9  0.30 ± 0.09  0.28 ± 0.11  0.50 ± 0.41  1.20 ± 0.15 *  0.24 ± 0.04  0.41 ± 0.09  < 0.001 
Total MUFA  12.76 ± 2.12  9.39 ± 0.67  12.01 ± 3.56  11.87 ± 1.62  9.43 ± 1.12  12.71 ± 0.71  0.007 
18:2n 6  7.74 ± 1.62  10.92 ± 1.19  12.06 ± 2.35  9.67 ± 1.96  10.96 ± 1.31  7.80 ± 0.78  < 0.001 
18:3n 6  0.35 ± 0.13  0.62 ± 0.51  0.34 ± 0.28  0.80 ± 0.91  0.38 ± 0.33  0.55 ± 0.64  0.622 
20:2n 6  8.94 ± 3.22  9.01 ± 2.60  6.67 ± 2.13  7.59 ± 1.69  8.98 ± 2.47  10.17 ± 2.35  0.213 
20:3n 6  0.72 ± 0.09  0.86 ± 0.10  0.94 ± 0.16  0.94 ± 0.22  0.78 ± 0.12  0.80 ± 0.08  0.054 
20:4n 6  22.87 ± 2.67  23.40 ± 2.11  18.68 ± 3.66  13.88 ± 1.36 *  22.17 ± 1.11  23.11 ± 0.99  < 0.001 
22:5n 6  6.87 ± 1.14  3.16 ± 0.44 *  0.32 ± 0.06  0.44 ± 0.07  10.67 ± 1.44 *  5.78 ± 1.07  < 0.001 
Total n 6 PUFA  47.50 ± 2.23  47.97 ± 0.93  39.01 ± 2.52 *  33.32 ± 1.64 *  53.94 ± 1.81 *  48.21 ± 2.38  < 0.001 
18:3n 3  0.37 ± 0.43  0.19 ± 0.13  0.78 ± 0.16 *  0.24 ± 0.16  0.15 ± 0.15  0.16 ± 0.15  < 0.001 
20:4n 3  ND  0.11 ± 0.21  0.17 ± 0.04  0.33 ± 0.04  ND  0.12 ± 0.13  < 0.001 
20:5n 3  0.23 ± 0.18  0.29 ± 0.37  1.39 ± 0.13 *  2.97 ± 0.50 *  0.40 ± 0.63  0.44 ± 0.80  < 0.001 
22:5n 3  1.52 ± 0.25  1.56 ± 0.32  4.78 ± 0.64 *  5.58 ± 0.56 *  0.63 ± 0.13  1.29 ± 0.16  < 0.001 
22:6n 3  7.84 ± 0.59  9.40 ± 1.06  10.91 ± 2.03  16.14 ± 1.49 *  4.25 ± 0.34 *  7.39 ± 0.43  < 0.001 
Total n 3 PUFA  9.97 ± 0.39  11.55 ± 0.79  18.03 ± 2.39 *  25.26 ± 2.16 *  5.43 ± 0.90 *  9.40 ± 1.29  < 0.001 
 
ND   negligible detected (mean <0.1% total fatty acid content)    *  Significantly different (p <0.05) from all other groups   270 
Table 6.27: Fatty acid composition of placenta TAG in pregnant rats fed experimental diets (% total fatty acids, mean ± standard deviation, n=6 per 
group) 
 
Fatty acid  LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef tallow  ANOVA 
p value 
14:0  0.66 ± 0.11  0.40 ± 0.07  0.65 ± 0.13  1.14 ± 0.16 *  0.49 ± 0.11  0.83 ± 0.07  < 0.001 
16:0  26.53 ± 1.65  19.73 ± 0.84  20.86 ± 1.04  26.41 ± 2.31   19.16 ± 1.18  23.64 ± 1.29 *  < 0.001 
18:0  13.89 ± 2.00  16.16 ± 1.88  15.42 ± 2.17  16.74 ± 3.10  16.77 ± 1.74  18.62 ± 2.21  0.027 
20:0  0.65 ± 0.10  0.77 ± 0.11  0.70 ± 0.12  0.88 ± 0.15  0.81 ± 0.10  0.87 ± 0.07  0.005 
22:0  0.25 ± 0.03  0.29 ± 0.04  0.19 ± 0.15  0.26 ± 0.17  0.32 ± 0.04  0.28 ± 0.03  0.329 
Total saturates  41.98 ± 3.12  37.36 ± 1.39  37.83 ± 2.76  45.43 ± 5.23  37.56 ± 2.30  44.24 ± 2.01  < 0.001 
16:1n 7  1.84 ± 0.28  0.55 ± 0.21  0.85 ± 0.24  1.62 ± 0.31  0.54 ± 0.11  1.04 ± 0.17  < 0.001 
18:1n 9  16.98 ± 0.44  12.85 ± 1.66  16.08 ± 1.83  14.90 ± 1.93  12.80 ± 1.05  20.75 ± 1.18 *  < 0.001 
20:1n 9  0.39 ± 0.11  0.33 ± 0.04  0.29 ± 0.15  2.28 ± 0.33 *  0.37 ± 0.07  0.50 ± 0.08  < 0.001 
24:1n 9  0.19 ± 0.06  0.12 ± 0.04  ND  0.51 ± 0.41  ND  0.16 ± 0.03  0.003 
Total MUFA  19.40 ± 0.66  13.86 ± 1.85  17.29 ± 2.08  19.31 ± 2.43  13.78 ± 1.08  22.45 ± 1.23  < 0.001 
18:2n 6  21.96 ± 1.72  34.17 ± 0.82  25.68 ± 3.48  18.85 ± 2.86  34.05 ± 1.97  19.96 ± 1.45  < 0.001 
18:3n 6  0.59 ± 0.25  0.78 ± 0.32  0.48 ± 0.27  0.60 ± 0.26  0.62 ± 0.18  0.59 ± 0.24  0.562 
20:2n 6  0.59 ± 0.03  0.83 ± 0.12  0.54 ± 0.07  0.62 ± 0.17  1.00 ± 0.22  0.60 ± 0.14  < 0.001 
20:3n 6  1.09 ± 0.17  0.96 ± 0.09  0.79 ± 0.19  0.77 ± 0.19  1.09 ± 0.17  0.93 ± 0.16  0.005 
20:4n 6  7.79 ± 1.23  5.83 ± 0.80  3.33 ± 1.24  2.22 ± 0.53  6.65 ± 0.78  6.34 ± 0.88  < 0.001 
22:5n 6  2.37 ± 0.37  1.42 ± 0.34  0.86 ± 0.15  0.82 ± 0.16  3.49 ± 0.55 *  1.87 ± 0.26  < 0.001 
Total n 6 PUFA  34.39 ± 2.16  44.00 ± 1.35  31.70 ± 3.04  23.89 ± 3.61 *  46.90 ± 1.97  30.29 ± 1.90  < 0.001 
18:3n 3  0.97 ± 0.55  1.76 ± 0.56  7.74 ± 1.07 *  1.03 ± 0.28  0.53 ± 0.14  0.81 ± 0.32  < 0.001 
20:4n 3  ND  ND  0.21 ± 0.18  0.59 ± 0.07 *  ND  0.10 ± 0.09  < 0.001 
20:5n 3  0.33 ± 0.21  0.43 ± 0.26  1.15 ± 0.20 *  1.97 ± 0.15 *  ND  0.24 ± 0.16  < 0.001 
22:5n 3  0.77 ± 0.15  0.58 ± 0.13  1.61 ± 0.37 *  2.40 ± 0.16 *  0.20 ± 0.11  0.44 ± 0.13  < 0.001 
22:6n 3  2.11 ± 0.18  1.99 ± 0.30  2.47 ± 0.68  5.39 ± 0.29 *  0.93 ± 0.18  1.43 ± 0.24  < 0.001 
Total n 3 PUFA  4.23 ± 0.91  4.79 ± 0.39  13.19 ± 1.92 *  11.37 ± 0.23 *  1.76 ± 0.46  3.02 ± 0.56  < 0.001 
ND   negligible detected (mean <0.1% total fatty acid content)     *  Significantly different (p <0.05) from all other groups   271 
Table 6.28: Fatty acid composition of placenta CE in pregnant rats fed experimental diets (% total fatty acids, mean ± standard deviation, n=6 per 
group) 
 
Fatty acid  LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef tallow  ANOVA 
p value 
14:0  0.89 ± 0.17  0.79 ± 0.15  0.68 ± 0.24  1.00 ± 0.28  0.73 ± 0.20  0.95 ± 0.33  0.172 
16:0  23.84 ± 2.70  19.34 ± 2.83  18.66 ± 1.58  21.58 ± 0.75  18.99 ± 1.32  20.75 ± 3.91  0.010 
18:0  15.48 ± 2.72  15.49 ± 1.72  17.59 ± 3.89  16.25 ± 2.78  17.80 ± 4.30  19.61 ± 4.49  0.319 
20:0  0.90 ± 0.13  0.96 ± 0.21  0.84 ± 0.10  0.88 ± 0.15  0.99 ± 0.16  0.98 ± 0.30  0.690 
22:0  0.17 ± 0.26  0.34 ± 0.21  0.37 ± 0.23  0.29 ± 0.16  0.30 ± 0.20  0.31 ± 0.16  0.625 
Total saturates  41.28 ± 4.70  36.92 ± 3.21  38.14 ± 5.07  40.00 ± 3.42  38.81 ± 3.71  42.60 ± 2.30  0.181 
16:1n 7  2.03 ± 0.28  1.22 ± 0.36  1.11 ± 0.18  1.75 ± 0.18  1.16 ± 0.43  1.61 ± 0.97  0.017 
18:1n 9  14.38 ± 1.11  13.65 ± 3.04  13.88 ± 2.08  13.38 ± 2.07  12.74 ± 2.82  18.15 ± 7.35  0.200 
20:1n 9  0.93 ± 0.14  0.86 ± 0.26  0.89 ± 0.45  2.17 ± 0.30 *  0.86 ± 0.21  0.96 ± 0.30  < 0.001 
24:1n 9  1.97 ± 0.70  1.46 ± 0.62  1.93 ± 1.65  3.72 ± 1.50  1.28 ± 0.58  1.22 ± 0.54  0.004 
Total MUFA  19.32 ± 1.77  17.18 ± 3.26  17.80 ± 4.10  21.02 ± 3.41  16.04 ± 3.41  21.95 ± 7.83  0.228 
18:2n 6  10.60 ± 1.09  18.22 ± 3.25  14.79 ± 2.51  10.18 ± 0.84  17.72 ± 2.34  11.78 ± 1.06  < 0.001 
18:3n 6  0.39 ± 0.06  0.37 ± 0.08  0.21 ± 0.16  0.18 ± 0.09  0.42 ± 0.09  0.26 ± 0.05  < 0.001 
20:2n 6  1.55 ± 0.32  2.69 ± 0.68  1.90 ± 0.52  1.45 ± 0.21  2.86 ± 0.67  1.52 ± 0.76  < 0.001 
20:3n 6  1.59 ± 0.42  1.84 ± 0.36  1.49 ± 0.25  1.32 ± 0.10  1.98 ± 0.36  1.71 ± 0.79  0.178 
20:4n 6  18.78 ± 4.27  16.08 ± 3.53  11.11 ± 1.76  5.87 ± 0.90 *  17.61 ± 3.46  15.38 ± 4.17  < 0.001 
22:5n 6  1.14 ± 0.69  0.53 ± 0.36  0.52 ± 0.46  0.49 ± 0.41  1.12 ± 1.49  0.42 ± 0.16  0.316 
Total n 6 PUFA  34.05 ± 4.23  39.74 ± 3.35  30.02 ± 3.60  19.48 ± 1.15  41.71 ± 3.03  31.08 ± 5.82  < 0.001 
18:3n 3  0.34 ± 0.05  0.67 ± 0.18  2.94 ± 0.28 *  0.33 ± 0.17  0.26 ± 0.40  0.30 ± 0.09  < 0.001 
20:4n 3  0.41 ± 0.32  1.18 ± 1.73  0.47 ± 0.27  2.43 ± 0.67  1.11 ± 1.33  0.98 ± 1.09  0.021 
20:5n 3  0.11 ± 0.19  0.17 ± 0.16  3.36 ± 1.30 *  6.15 ± 1.41 *  0.00 ± 0.00  0.09 ± 0.10  < 0.001 
22:5n 3  0.51 ± 0.41  0.57 ± 0.39  2.65 ± 1.34  3.33 ± 1.18  0.06 ± 0.14  0.47 ± 0.27  < 0.001 
22:6n 3  3.98 ± 0.37  3.58 ± 0.52  4.62 ± 0.91  7.27 ± 0.71 *  2.00 ± 0.20 *  2.54 ± 0.92  < 0.001 
Total n 3 PUFA  5.35 ± 1.10  6.17 ± 1.88  14.04 ± 2.26 *  19.50 ± 1.48 *  3.44 ± 1.52  4.37 ± 1.90  < 0.001 
ND   negligible detected (mean <0.1% total fatty acid content)    *  Significantly different (p <0.05) from all other groups   272 
6.3.10 Fetal plasma glucose and lipid concentrations 
No significant effects of maternal diet were observed upon fetal plasma total 
cholesterol, TAG or glucose concentrations (see table 6.29), indicating that the 
quantitative supply of lipids and glucose to the fetus is well preserved in the face of 
changes which were observed in maternal lipid concentrations (see table 6.5).  There 
was a significant correlation and concentration gradient between maternal and fetal 
plasma glucose concentrations (see figure 6.8).   
 
Figure 6.8: Graph to illustrate the correlation between maternal and fetal plasma glucose 
concentrations 
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6.3.11 Fetal plasma fatty acid composition  
 
Fetal plasma PC, TAG, CE and NEFA fatty acid compositions were assessed by gas 
chromatography (see tables 6.30 to 6.33).  Significant effects of maternal diet were 
observed across all fetal plasma lipid fractions, indicating that the maternal diet has the 
capacity to significantly alter the circulating fatty acids available to the fetus. 
r = 0.648 
p < 0.001   273 
 
 
 
 
 
Table 6.29: Fetal plasma lipid and glucose concentrations (mean ± standard deviation, n=6 per group) 
 
   LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef tallow  ANOVA 
p value 
Total cholesterol (mM)  0.8 ± 0.3  0.8 ± 0.1  0.9 ± 0.4  1.1 ± 0.9  0.8 ± 0.1  0.9 ± 0.2  0.709 
Glucose (mM)  1.5 ± 1.4  1.9 ± 1.0  1.7 ± 0.8  1.5 ± 0.2  1.6 ± 0.7  1.6 ± 0.9  0.955 
NEFA  ( M)  226.7 ± 104.7  302.7 ± 260.6  94.3 ± 62.3  212.8 ± 175.5  102.6 ± 70.2  301.4 ± 223.3  0.153 
TAG (mM)  0.4 ± 0.2  0.4 ± 0.1  0.5 ± 0.2  0.4 ± 0.1  0.5 ± 0.1  0.5 ± 0.1  0.540 
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Table 6.30: Fetal plasma PC fatty acid composition (% total fatty acids, mean ± standard deviation, n=6 per group) 
 
Fatty acid   LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef tallow  ANOVA 
p value 
14:0  0.84 ± 0.16  0.85 ± 0.10  0.78 ± 0.14  1.04 ± 0.07  0.81 ± 0.17  0.91 ± 0.14  0.028 
16:0  27.09± 1.02  25.98 ± 1.96  25.84 ± 1.33  28.82 ± 1.87  27.19 ± 1.79  25.59 ± 1.32  0.013 
18:0  18.14 ± 1.27  19.06 ± 1.27  19.61 ± 2.45  16.74 ± 0.68  18.82 ± 0.86  16.62 ± 1.31  0.003 
20:0  0.41 ± 0.26  0.54 ± 0.31  0.52 ± 0.18  0.63 ± 0.37  0.52 ± 0.22  0.75 ± 0.38  0.462 
22:0  0.52 ± 0.68  0.32 ± 0.28  0.38 ± 0.24  0.23 ± 0.20  0.21 ± 0.23  0.50 ± 0.21  0.525 
Total saturates  47.00 ± 2.01  46.75 ± 2.00  47.12 ± 3.16  47.46 ± 2.09  47.54 ± 2.36  44.38 ± 2.11  0.206 
16:1n 7  2.20 ± 0.19  1.60 ± 0.33  1.76 ± 0.39  2.30 ± 0.19  1.71 ± 0.35  2.61 ± 0.70  0.001 
18:1n 9  10.28 ± 0.95  8.66 ± 0.74  9.66 ± 0.95  11.68 ± 0.46  8.18 ± 2.53  12.92 ± 0.86  < 0.001 
20:1n 9  0.62 ± 0.49  0.67 ± 0.50  0.75 ± 0.47  0.62 ± 0.20  0.64 ± 0.56  1.10 ± 0.43  0.438 
24:1n 9  ND  ND  ND  0.12 ± 0.15  ND  0.10 ± 0.17  0.083 
Total MUFA  13.10 ± 1.04  10.93 ± 1.24  12.17 ± 1.22  14.72 ± 0.86  10.53 ± 2.78  16.73 ± 1.06  < 0.001 
18:2n 6  12.36 ± 1.13  16.02 ± 2.52  16.28 ± 1.51  12.78 ± 0.83  15.95 ± 1.66  11.12 ± 1.20  < 0.001 
18:3n 6  1.08 ± 0.91  1.35 ± 1.08  1.41 ± 0.88  1.63 ± 1.25  1.12 ± 0.95  2.93 ± 1.28  0.054 
20:2n 6  0.37 ± 0.05  0.81 ± 0.80  0.38 ± 0.06  0.43 ± 0.09  0.47 ± 0.12  0.39 ± 0.07  0.229 
20:3n 6  1.47 ± 0.48  1.42 ± 0.40  1.47 ± 0.27  1.50 ± 0.48  1.28 ± 0.30  2.08 ± 1.00  0.206 
20:4n 6  14.57 ± 1.71  13.36 ± 0.28  7.76 ± 1.06 *  4.40 ± 0.45 *  15.42 ± 0.92  12.73 ± 1.82  < 0.001 
22:5n 6  1.85 ± 0.43  0.81 ± 0.09 *  0.12 ± 0.14  0.12 ± 0.14  3.26 ± 0.66 *  1.58 ± 0.36  < 0.001 
Total n 6 PUFA  31.71 ± 1.45  33.77 ± 1.95  27.43 ± 2.38 *  20.86 ± 1.23 *  37.49 ± 1.68 *  30.82 ± 0.74  < 0.001 
18:3n 3  ND  0.13 ± 0.15  0.81 ± 0.22 *  ND  ND  ND  < 0.001 
20:4n 3  ND  ND  0.18 ± 0.10  0.10 ± 0.12  ND  ND  < 0.001 
20:5n 3  0.99 ± 0.80  0.81 ± 0.61  3.30 ± 0.47  4.75 ± 0.92  0.48 ± 0.29  1.90 ± 1.30  < 0.001 
22:5n 3  0.38 ± 0.08  0.32 ± 0.12  1.01 ± 0.13  0.92 ± 0.11  ND  0.22 ± 0.08  < 0.001 
22:6n 3  6.83 ± 0.49  7.29 ± 1.09  7.98 ± 0.45  11.16 ± 0.73 *  3.86 ± 0.48 *  5.94 ± 0.71  < 0.001 
Total n 3 PUFA  8.20 ± 0.80  8.55 ± 1.24  13.28 ± 0.77 *  16.96 ± 1.24 *  4.43 ± 0.40 *  8.07 ± 1.85  < 0.001 
 
ND   negligible detected (mean <0.1% total fatty acid content)     *  Significantly different (p <0.05) from all other groups   275 
Table 6.31: Fetal plasma TAG fatty acid composition (% of total fatty acids, mean ± standard deviation) 
 
Fatty acid  LF Soyabean 
(n=5) 
HF Soyabean 
(n=6) 
HF Linseed 
(n=6) 
HF Salmon 
(n=6) 
HF Sunflower 
(n=6) 
HF Beef tallow 
(n=6) 
ANOVA 
p value 
14:0  0.79 ± 0.31  0.87 ± 0.41  0.52 ± 0.29  1.11 ± 0.57  0.89 ± 0.29  0.72 ± 0.41  0.226 
16:0  24.89 ± 1.52  24.62 ± 1.90  23.81 ± 3.76  26.19 ± 2.53  25.27 ± 3.09  25.80 ± 1.07  0.636 
18:0  10.28 ± 2.93  8.46 ± 0.65  8.73 ± 1.75  12.25 ± 3.39  8.79 ± 1.76  9.88 ± 1.22  0.042 † 
20:0  0.46 ± 0.54  0.41 ± 0.22  0.48 ± 0.27  0.36 ± 0.38  0.31 ± 0.29  0.31 ± 0.28  0.919 
22:0  0.39 ± 0.36  0.12 ± 0.29  0.22 ± 0.19  0.23 ± 0.42  0.47 ± 0.27  0.30 ± 0.29  0.463 
Total saturates  36.80 ± 2.68  34.49 ± 2.04  33.76 ± 5.21  40.16 ± 6.58  35.73 ± 4.66  37.01 ± 1.04  0.159 
16:1n 7  4.26 ± 0.71  2.87 ± 0.76  2.28 ± 0.37  3.21 ± 0.48  2.84 ± 0.33  3.41 ± 0.97  0.001 
18:1n 9  25.95 ± 1.69  22.30 ± 1.57  21.01 ± 1.06  23.96 ± 2.80  22.99 ± 1.61  33.13 ± 1.46 *  < 0.001 
20:1n 9  0.60 ± 0.72  0.54 ± 0.47  1.58 ± 1.64  0.85 ± 0.74  1.49 ± 1.80  0.51 ± 0.46  0.382 
24:1n 9  ND  ND  ND  0.12 ± 0.18  ND  ND  0.146 
Total MUFA  30.82 ± 1.49  25.74 ± 1.72  24.87 ± 2.18  28.14 ± 2.12  27.32 ± 1.15  37.05 ± 1.55 *  < 0.001 
18:2n 6  14.47 ± 1.36  20.30 ± 1.94  13.36 ± 1.89  7.53 ± 0.97 *  19.45 ± 3.10  11.93 ± 1.51  < 0.001 
18:3n 6  1.98 ± 0.66  1.56 ± 0.42  1.66 ± 1.35  1.05 ± 0.83  2.05 ± 0.62  1.31 ± 0.39  0.257 
20:2n 6  0.44 ± 0.10  0.50 ± 0.11  0.41 ± 0.20  0.23 ± 0.13  0.51 ± 0.11  0.29 ± 0.15  0.006 
20:3n 6  0.71 ± 0.48  0.90 ± 0.46  1.50 ± 1.65  0.49 ± 0.38  1.46 ± 1.04  0.95 ± 0.60  0.341 
20:4n 6  4.49 ± 0.64  4.89 ± 0.94  2.20 ± 0.47  1.01 ± 0.20  5.40 ± 0.96  3.58 ± 0.52  < 0.001 
22:5n 6  2.69 ± 0.89  1.71 ± 0.39  ND  ND  4.57 ± 0.55 *  2.55 ± 0.56  < 0.001 
Total n 6 PUFA  24.78 ± 2.45  29.87 ± 2.21  19.13 ± 1.87  10.34 ± 0.48 *  33.44 ± 4.33  20.60 ± 0.99  < 0.001 
18:3n 3  0.76 ± 0.27  1.21 ± 0.26  6.30 ± 1.78 *  0.59 ± 0.11  0.23 ± 0.13  0.50 ± 0.13  < 0.001 
20:4n 3  ND  ND  0.23 ± 0.12  0.20 ± 0.23  ND  ND  < 0.001 
20:5n 3  1.67 ± 1.12  1.14 ± 0.84  3.44 ± 0.60  3.26 ± 0.44  1.55 ± 1.17  0.95 ± 0.42  < 0.001 
22:5n 3  0.58 ± 0.12  0.62 ± 0.20  2.29 ± 0.58  2.29 ± 0.50  0.17 ± 0.13  0.32 ± 0.08  < 0.001 
22:6n 3  4.59 ± 0.45  6.93 ± 2.14  9.97 ± 1.85  15.03 ± 3.61 *  1.57 ± 0.29  3.57 ± 0.65  < 0.001 
Total n 3 PUFA  7.60 ± 1.20  9.90 ± 2.04  22.24 ± 3.18  21.36 ± 4.11  3.51 ± 1.38  5.35 ± 0.79  < 0.001 
 
ND   negligible detected (mean <0.1% total fatty acid content)     *  Significantly different (p <0.05) from all other groups     
†   no significant differences between groups when Bonferroni post hoc test applied  276 
Table 6.32: Fetal plasma CE fatty acid composition (% total fatty acids, mean ± standard deviation, n=6 per group) 
 
Fatty acid   LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef tallow  ANOVA 
p value 
14:0  1.13 ± 0.53  1.18 ± 0.42  1.35 ± 0.22  1.58 ± 0.63  1.23 ± 0.54  1.19 ± 1.01  0.811 
16:0  18.13 ± 3.22  20.25 ± 1.62  20.09 ± 2.50  22.28 ± 3.14  20.93 ± 2.00  19.00 ± 3.48  0.170 
18:0  9.18 ± 1.21  13.16 ± 4.17  10.66 ± 3.49  14.33 ± 3.85  12.60 ± 1.58  11.66 ± 2.46  0.075 
20:0  0.22 ± 0.13  0.32 ± 0.05  0.32 ± 0.08  0.38 ± 0.05  0.30 ± 0.06  0.35 ± 0.11  0.039 
22:0  ND  ND  0.32 ± 0.16 *  ND  ND  ND  < 0.001 
Total saturates  28.65 ± 3.00  34.91 ± 4.79  32.74 ± 5.82  38.57 ± 6.44  35.06 ± 2.54  32.20 ± 2.32  0.016 
16:1n 7  6.20 ± 0.73  3.66 ± 0.50  4.01 ± 0.42  5.14 ± 0.80  4.21 ± 0.46  4.80 ± 1.24  < 0.001 
18:1n 9  22.88 ± 3.65  19.11 ± 2.32  18.76 ± 1.91  20.62 ± 1.77  20.49 ± 2.29  26.19 ± 2.79  < 0.001 
20:1n 9  0.23 ± 0.13  0.21 ± 0.11  0.28 ± 0.08  0.40 ± 0.09  0.18 ± 0.10  0.31 ± 0.17  0.048 † 
24:1n 9  0.28 ± 0.16  0.18 ± 0.14  ND  0.42 ± 0.21  ND  0.21 ± 0.18  < 0.001 
Total MUFA  29.60 ± 3.91  23.15 ± 2.26  23.08 ± 2.16  26.58 ± 2.30  24.88 ± 2.33  31.51 ± 3.17  < 0.001 
18:2n 6  10.65 ± 0.48  13.52 ± 2.45  12.57 ± 1.69  8.17 ± 0.72  13.39 ± 1.26  9.12 ± 1.53  < 0.001 
18:3n 6  0.98 ± 0.09  0.90 ± 0.10  0.73 ± 0.10  0.68 ± 0.11  1.16 ± 0.10  0.96 ± 0.11  < 0.001 
20:2n 6  0.28 ± 0.23  0.46 ± 0.24  ND  ND  0.65 ± 0.18  0.15 ± 0.18  < 0.001 
20:3n 6  1.07 ± 0.12  1.29 ± 0.28  0.75 ± 0.15  0.39 ± 0.21  1.35 ± 0.25  0.81 ± 0.14  < 0.001 
20:4n 6  23.15 ± 1.75  18.88 ± 3.58  11.29 ± 1.60 *  5.99 ± 0.86 *  20.06 ± 0.71  20.25 ± 1.75  < 0.001 
22:5n 6  1.28 ± 0.21  0.78 ± 0.19  ND  ND  2.00 ± 0.26 *  1.11 ± 0.27  < 0.001 
Total n 6 PUFA  37.40 ± 1.76  35.84 ± 6.20  25.40 ± 3.42 *  15.27 ± 1.82 *  38.61 ± 1.55  32.40 ± 2.92  < 0.001 
18:3n 3  0.37 ± 0.19  0.60 ± 0.11  3.69 ± 0.53 *  0.30 ± 0.08  ND  0.23 ± 0.40  < 0.001 
20:4n 3  0.27 ± 0.67  0.97 ± 1.09  1.53 ± 2.14  0.34 ± 0.29  0.16 ± 0.13  0.87 ± 1.25  0.300 
20:5n 3  0.58 ± 0.04  0.64 ± 0.08  6.58 ± 0.92 *  9.22 ± 1.53 *  ND  0.36 ± 0.24  < 0.001 
22:5n 3  0.36 ± 0.07  0.40 ± 0.10  1.66 ± 0.30  1.80 ± 0.45  ND  0.19 ± 0.16  < 0.001 
22:6n 3  2.75 ± 0.31  3.48 ± 0.56  5.31 ± 0.65 *  7.92 ± 1.55 *  1.21 ± 0.21  2.23 ± 0.31  < 0.001 
Total n 3 PUFA  4.34 ± 0.68  6.09 ± 1.01  18.78 ± 2.52  19.58 ± 3.57  1.46 ± 0.16  3.88 ± 1.68  < 0.001 
 
ND   negligible detected (mean <0.1% total fatty acid content)    *  Significantly different (p <0.05) from all other groups  
†   no significant differences between groups when Bonferroni post hoc test applied   277 
Table 6.33: Fetal plasma NEFA fatty acid composition (% of total fatty acids, mean ± standard deviation, n=6 per group) 
 
Fatty acid  LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef tallow  ANOVA 
p value 
12:0  0.18 ± 0.17  0.12 ± 0.13  0.11 ± 0.09  ND  0.10 ± 0.13  ND  0.821 
14:0  1.61 ± 0.57  1.23 ± 0.38  1.29 ± 0.54  1.63 ± 0.30  1.45 ± 0.39  1.49 ± 0.56  0.608 
16:0  24.84 ± 7.35  24.07 ± 0.70  21.83 ± 6.42  25.93 ± 0.96  25.56 ± 2.17  26.09 ± 3.94  0.564 
18:0  23.67 ± 6.64  22.88 ± 4.80  20.20 ± 5.45  23.83 ± 2.77  28.13 ± 8.42  26.29 ± 4.48  0.253 
20:0  0.20 ± 0.50  ND  ND  ND  0.48 ± 0.59  ND  0.114 
22:0  1.24 ± 1.46  0.76 ± 1.01  1.16 ± 0.61  0.63 ± 0.87  0.85 ± 0.95  0.76 ± 0.57  0.851 
Total saturates  51.74 ± 14.67  49.12 ± 3.73  44.63 ± 11.85  52.12 ± 3.21  56.57 ± 9.56  54.71 ± 8.13  0.335 
18:1n 9  16.28 ± 7.28  14.15 ± 2.10  15.89 ± 2.77  13.08 ± 2.38  14.60 ± 2.96  17.74 ± 4.09  0.409 
20:1n 9  1.24 ± 3.05  ND  0.66 ± 1.62  ND  ND  ND  0.552 
24:1n 9  ND  ND  0.12 ± 0.30  ND  ND  0.29 ± 0.27  0.158 
Total MUFA  17.61 ± 6.86  14.21 ± 2.16  16.68 ± 2.07  13.08 ± 2.38  14.73 ± 3.05  18.03 ± 3.92  0.172 
18:2n 6  10.57 ± 4.45 
b  18.34 ± 3.10 
a  12.20 ± 4.09  10.78 ± 2.96 
b  15.11 ± 5.78  10.00 ± 3.14 
b  0.008 
20:2n 6  2.37 ± 1.46  1.34 ± 1.37  1.86 ± 0.97  1.24 ± 1.03  1.47 ± 1.16  2.05 ± 1.53  0.605 
20:3n 6  0.17 ± 0.41  0.12 ± 0.29  ND  ND  ND  ND  0.781 
20:4n 6  4.58 ± 1.97  5.07 ± 1.75  2.89 ± 0.43  2.88 ± 1.64  4.83 ± 1.05  4.80 ± 1.44  0.032 † 
22:5n 6  1.63 ± 2.03  0.71 ± 0.30  0.15 ± 0.24  0.43 ± 0.90  1.81 ± 1.09  1.05 ± 0.94  0.081 
Total n 6 PUFA  19.32 ± 7.96  25.58 ± 2.90 
a  17.10 ± 3.62  15.32 ± 4.14 
b  23.31 ± 7.07  17.96 ± 4.59  0.020 
18:3n 3  0.77 ± 0.23  1.68 ± 0.58  7.69 ± 3.29 *  0.99 ± 0.39  0.55 ± 0.22  0.89 ± 0.15  < 0.001 
20:4n 3  ND  ND  ND  0.32 ± 0.48  ND  0.13 ± 0.21  0.252 
20:5n 3  1.11 ± 1.67  0.33 ± 0.38  2.20 ± 1.88  1.90 ± 1.89  0.99 ± 0.91  0.33 ± 0.47  0.114 
22:5n 3  0.47 ± 0.37 
b  0.43 ± 0.16 
b  1.35 ± 0.60 
a  1.64 ± 0.47 
a  ND 
b  0.28 ± 0.14 
b  < 0.001 
22:6n 3  8.91 ± 2.59 
bc  8.65 ± 2.64 
bc  10.27 ± 3.27 
ac  14.63 ± 5.02 
a  3.86 ± 0.90 
b  7.67 ± 1.95 
bc  < 0.001 
Total n 3 PUFA  11.34 ± 4.20 
b  11.09 ± 2.27 
b  21.60 ± 6.60 
a  19.47 ± 4.85 
a  5.40 ± 1.67 
b  9.30 ± 1.68 
b  < 0.001 
 
ND   negligible detected (mean <0.1% total fatty acid content)       *  Significantly different (p <0.05) from all other groups    
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have different superscripts  
†   no significant differences between groups when Bonferroni post hoc test applied    278 
The HF linseed oil group had the highest ALNA content within all fetal plasma lipid 
fractions.  This diet was associated with higher LC n 3 PUFA and lower AA content 
than all other dietary groups (except HF salmon oil). 
 
The HF salmon oil group had the highest LC n 3 PUFA content within fetal plasma 
lipids.  This was associated with the lowest levels of n 6 PUFA (both LA and AA). 
 
Although the HF sunflower oil diet contained the highest dietary level of LA, this group 
did not demonstrate the highest LA content in fetal plasma.  This group demonstrated 
the highest 22:5n 6 content and the lowest LC n 3 PUFA content of all dietary groups.   
 
The HF beef tallow group exhibited the highest OA content within fetal plasma lipids, 
but 16:0 and 18:0 contents were not significantly different from other dietary groups, 
despite this diet having the highest content of these fatty acids.  
 
Maternal TAG and NEFA are transported across the placenta, and the fatty acids 
released into the fetal circulation as NEFA(153).  Data were therefore assessed for 
correlations between fatty acid compositions of maternal plasma TAG and NEFA and 
fetal plasma NEFA (see table 6.34). 
 
Significant correlations between fatty acids in maternal and fetal plasma lipids were 
observed, particularly within n 6 and n 3 PUFA.  When plotted, there was evidence of 
biomagnification of DHA (see figure 6.9) and AA (see figure 6.10) when fetal plasma 
NEFA was compared to maternal plasma NEFA.  The EFA LA and ALNA 
demonstrated the opposite relationship, with maternal plasma content being 
significantly greater than fetal plasma (see figure 6.11).  The relationship between fetal 
plasma NEFA and maternal plasma TAG was less clear, with diet having a significant 
effect upon the relationships observed.  
 
The ratios of LC PUFA to EFA (e.g. AA to LA ratio) have been reported to be higher in 
fetal than maternal serum(17).  These ratios were calculated (see table 6.35), and this 
feature was also apparent in the current data.  This indicates that there is preferential 
transfer of LC PUFA to the fetus.  The high variation in these ratios reflects the effect of 
maternal diet upon EFA composition.  The preferential transfer of LC PUFA rather than   279 
their EFA precursors also indicates that the capacity of the fetus to endogenously 
synthesise these LC PUFA may be limited. 
 
Table 6.34: Correlations observed between the fatty acid composition of maternal and 
fetal plasma lipids (Pearsons R values unless otherwise indicated) 
 
  Maternal plasma TAG 
vs. fetal plasma NEFA 
(n = 36) 
Maternal plasma NEFA 
vs. fetal plasma NEFA 
(n = 36) 
12:0       0.035†   
14:0  0.132†    0.193   
16:0  0.119    0.108   
18:0  0.136†    0.242   
20:0   0.369†  *  0.083†   
22:0  0.377†  *  0.376  * 
Total saturates  0.145    0.151   
18:1n 9  0.516†  **  0.201†   
20:1n 9   0.230†     0.121†   
24:1n 9  †    0.090†   
Total MUFA  0.330  *  0.279   
18:2n 6  0.451†  **  0.532  ** 
20:2n 6   0.231     0.056   
20:3n 6  0.372†  *  0.114†   
20:4n 6  0.434†  **  0.673  *** 
22:5n 6  0.572  ***  0.496  ** 
Total n 6 PUFA  0.506  **  0.558  *** 
18:3n 3  0.842†  ***  0.721†  *** 
20:4n 3  0.308†    0.479†  ** 
20:5n 3  0.246†    0.424†  * 
22:5n 3  0.812  ***  0.821  *** 
22:6n 3  0.672†  ***  0.445†  ** 
Total n 3 PUFA  0.813†  ***  0.832†  *** 
 
† Spearman’s R value   * p < 0.05, ** p < 0.01, *** p < 0.001 
 
 
Table 6.35: The ratio of LC PUFA to EFA within maternal and fetal plasma lipids 
(mean ± standard deviation) 
 
  Maternal plasma  
TAG 
Maternal plasma  
NEFA 
Fetal plasma 
 NEFA 
AA:LA ratio  0.11 ± 0.11  0.11 ± 0.06  0.35 ± 0.14 
DHA:ALNA ratio  1.36 ± 1.81  1.40 ± 1.04  9.05 ± 7.01 
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Figure 6.9: Graph to illustrate the correlation 
observed between the DHA content (% total 
fatty acids) of maternal and fetal plasma 
NEFA 
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Figure 6.10: Graph to illustrate the 
correlation observed between the AA content 
(% total fatty acids) of maternal and fetal 
plasma NEFA   
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Figure 6.11: Graph to illustrate the 
correlation observed between the LA content 
(% total fatty acids) of maternal and fetal 
plasma NEFA   
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p = 0.001   281 
6.3.12 Fetal liver size and composition 
 
Fetal liver weight was significantly affected by maternal diet during pregnancy 
(ANOVA p = 0.016), but post hoc comparisons lost statistical significance when 
Bonferroni correction was applied.  Maternal diet during pregnancy did not significantly 
affect fetal liver size as a % body weight, or fetal liver lipid or glycogen content (see 
table 6.36).  There was a significant effect of maternal diet upon fetal liver dry weight.  
This may indicate an effect of maternal diet upon the protein content of the fetal liver, 
but this was not assessed. 
 
When fetal liver size and composition data were compared to those of the maternal liver 
(see table 6.10), several differences were identified.  The liver was a greater proportion 
of body weight in the fetus than in pregnant female rats.  The fetal liver also had a lower 
dry weight and lipid content than observed in maternal liver, but the two had 
comparable glycogen content. 
6.3.13 Fetal liver fatty acid composition 
 
Fatty acid compositions of fetal liver PC, PE, TAG and CE were assessed by gas 
chromatography (see table 6.37 to 6.40).  The data demonstrate that maternal diet has 
the capacity to significantly alter fetal liver lipid fatty acid composition. 
 
The trends observed in the fetal liver were comparable to those exhibited in fetal 
plasma.  The HF linseed oil group had the highest ALNA content within all fetal liver 
lipid fractions.  This was associated with higher LC n 3 PUFA and lower AA content 
than all other dietary groups (except HF salmon oil).  The HF salmon oil group had the 
highest LC n 3 PUFA content within fetal liver lipids.  This was associated with low 
levels of n 6 PUFA (both LA and AA).   
 
Although the HF sunflower oil diet contained the highest dietary level of LA, this group 
did not demonstrate the highest LA content in fetal liver.  The AA content of fetal liver 
lipids was highest in the sunflower oil group, a feature which was not apparent in the 
maternal liver.  In the fetal liver, 22:5n 6 was only detectable in fetal liver CE, where 
the sunflower oil group demonstrated a significantly higher content than any other 
dietary group.  The sunflower oil group demonstrated the lowest LC n 3 PUFA content 
of all dietary groups.     282 
 
The HF beef tallow group exhibited the highest OA content within fetal liver lipids, but 
the 16:0 and 18:0 contents were not significantly different from other dietary groups, 
despite this diet having the highest content of these fatty acids. 
 
As was observed in maternal liver lipids, the LC n 6 PUFA 22:5n 6 was almost 
undetectable in all lipid fractions (with the exception of CE), despite making a 
significant contribution to fetal plasma fatty acid composition.  This may suggest that 
22:5n 6 is specifically accumulated within fetal tissues other than the liver.   283 
 
 
 
 
Table 6.36: Fetal liver weight, lipid and glycogen content (mean ± standard deviation, n=6) 
 
 
   LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef tallow  ANOVA 
p value 
Liver weight (mg)  156.1 ± 28.4  179.8 ± 24.3  197.6 ± 42.9  156.6 ± 16.6  206.4 ± 35.3  163.8 ± 15.4  0.016 † 
Liver wet weight (% body weight)  6.8 ± 0.6  7.4 ± 0.9  7.7 ± 0.1  7.6 ± 1.2  8.1 ± 1.1  7.5 ± 1.0  0.315 
Liver dry weight (% of wet weight)  20.8 ± 0.7  21.0 ± 0.8  20.7 ± 0.6  19.9 ± 0.4 
a  21.2 ± 0.7 
b  20.5 ± 0.9  0.047 
Liver lipid (g/100 g liver)  2.4 ± 0.3  2.3 ± 0.2  2.4 ± 0.3  2.1 ± 0.2  2.2 ± 0.4  2.6 ± 0.4  0.160 
Liver glycogen (g/100 g liver)  2.1 ± 1.1  2.8 ± 1.2  3.0 ± 1.7  1.5 ± 0.4  2.5 ± 1.5  2.3 ± 2.2  0.559 
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have different superscripts  
†   no significant differences between groups when Bonferroni post hoc test applied 
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Table 6.37: Fetal liver PC fatty acid composition (% total fatty acids, mean ± standard deviation, n=6 per group) 
 
Fatty acid  LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef 
tallow 
ANOVA 
p value 
14:0  1.18 ± 0.11  1.16 ± 0.10  1.07 ± 0.17  1.25 ± 0.22  1.12 ± 0.14  1.23 ± 0.15  0.316 
16:0  31.62 ± 0.47  30.46 ± 1.31  29.73 ± 0.63  32.66 ± 0.99  32.18 ± 0.83  31.69 ± 1.07  < 0.001 
18:0  12.23 ± 0.42  12.78 ± 0.23  13.30 ± 0.46  12.40 ± 0.65  12.64 ± 0.57  12.27 ± 0.44  0.005 
20:0  ND  0.10 ± 0.16  ND  ND  ND  ND  0.454 
22:0  0.45 ± 0.27  0.52 ± 0.12  0.33 ± 0.27  0.31 ± 0.17  0.37 ± 0.16  0.62 ± 0.31  0.190 
Total saturates  45.49 ± 0.93  45.03 ± 0.96  44.47 ± 0.88  46.72 ± 0.88  46.31 ± 0.73  45.86 ± 0.53  < 0.001 
16:1n 7  3.57 ± 0.27 *  2.31 ± 0.19  2.29 ± 0.28  2.90 ± 0.15  2.47 ± 0.33  3.05 ± 0.32  < 0.001 
18:1n 9  12.56 ± 1.05  10.92 ± 0.84  11.38 ± 1.08  13.37 ± 0.91  11.76 ± 0.73  15.78 ± 1.10 *  < 0.001 
24:1n 9  0.44 ± 0.34  0.28 ± 0.22  ND  0.20 ± 0.16  ND  0.40 ± 0.21  0.011 † 
Total MUFA  16.66 ± 1.10  13.53 ± 0.98  13.77 ± 1.25  16.56 ± 1.03  14.30 ± 0.98  19.31 ± 1.03 *  < 0.001 
18:2n 6  12.59 ± 1.08 *  15.39 ± 1.16  15.06 ± 0.45  10.62 ± 0.63  15.20 ± 1.26  10.33 ± 0.67  < 0.001 
18:3n 6  0.63 ± 0.16  0.62 ± 0.07  0.57 ± 0.18  0.37 ± 0.07  0.88 ± 0.24  0.72 ± 0.25  0.001 
20:2n 6  0.34 ± 0.05  0.41 ± 0.06  0.35 ± 0.05  0.23 ± 0.10  0.45 ± 0.07  0.33 ± 0.08  < 0.001 
20:3n 6  1.16 ± 0.10  1.30 ± 0.09  1.28 ± 0.14  1.10 ± 0.13  1.33 ± 0.23  1.23 ± 0.19  0.109 
20:4n 6  14.46 ± 0.60  14.69 ± 1.09  8.56 ± 0.98 *  5.14 ± 0.36 *  16.80 ± 1.03 *  14.45 ± 1.36  < 0.001 
22:5n 6  0.19 ± 0.31  0.25 ± 0.39  ND  ND  ND  0.35 ± 0.40  0.182 
Total n 6 PUFA  29.37 ± 1.72  32.65 ± 0.96  25.83 ± 1.47  17.46 ± 1.09 *  34.74 ± 1.12  27.41 ± 1.28  < 0.001 
18:3n 3  0.34 ± 0.11  0.40 ± 0.12  1.67 ± 0.16 *  0.25 ± 0.04  0.15 ± 0.13  0.14 ± 0.12  < 0.001 
20:4n 3  ND  ND  0.37 ± 0.07 *  0.18 ± 0.15 *  ND  ND  < 0.001 
20:5n 3  0.55 ± 0.11  0.61 ± 0.16  4.71 ± 0.53 *  6.11 ± 0.58 *  0.14 ± 0.15  0.45 ± 0.27  < 0.001 
22:5n 3  0.54 ± 0.32  0.50 ± 0.12  0.91 ± 0.07  1.05 ± 0.13  ND  0.39 ± 0.20  < 0.001 
22:6n 3  7.06 ± 0.35  7.27 ± 0.62  8.26 ± 0.94  11.68 ± 0.48 *  4.29 ± 0.15 *  6.41 ± 0.45  < 0.001 
Total n 3 PUFA  8.49 ± 0.72  8.79 ± 0.75  15.93 ± 1.13 *  19.27 ± 0.72 *  4.65 ± 0.37 *  7.41 ± 0.64  < 0.001 
 
ND   negligible detected (mean <0.1% total fatty acid content)       *  Significantly different (p <0.05) from all other groups 
†   no significant differences between groups when Bonferroni post hoc test applied    285 
Table 6.38: Fetal liver PE fatty acid composition (% total fatty acids, mean ± standard deviation, n=6 per group) 
 
Fatty acid  LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef tallow  ANOVA 
p value 
14:0  0.15 ± 0.09  0.16 ± 0.08  0.15 ± 0.08  0.17 ± 0.02  0.16 ± 0.08  0.18 ± 0.03  0.990 
16:0  17.46 ± 0.80  16.95 ± 0.38  16.79 ± 0.90  17.82 ± 1.48  17.97 ± 0.66  17.49 ± 0.53  0.155 
18:0  20.97 ± 0.60  21.59 ± 0.92  21.63 ± 1.17  19.42 ± 0.43 *  23.19 ± 0.57 *  20.99 ± 1.05  < 0.001 
20:0  0.13 ± 0.15  0.14 ± 0.12  0.02 ± 0.05  0.14 ± 0.13  0.09 ± 0.14  0.11 ± 0.09  0.484 
22:0  0.13 ± 0.11  0.17 ± 0.19  0.21 ± 0.04  0.20 ± 0.18  0.10 ± 0.17  0.13 ± 0.11  0.760 
Total saturates  38.83 ± 1.23  39.00 ± 1.03  38.80 ± 0.83  37.75 ± 1.40  41.52 ± 0.94 *  38.91 ± 0.88  < 0.001 
16:1n 7  0.91 ± 0.13  0.61 ± 0.07  0.63 ± 0.15  0.76 ± 0.09  0.81 ± 0.09  0.82 ± 0.09  < 0.001 
18:1n 9  6.93 ± 0.32  6.36 ± 0.78  6.17 ± 0.73  6.57 ± 0.54  7.21 ± 0.68  8.32 ± 0.51  < 0.001 
Total MUFA  7.89 ± 0.45  6.99 ± 0.86  6.80 ± 0.86  7.36 ± 0.57  8.05 ± 0.72  9.16 ± 0.62  < 0.001 
18:2n 6  4.33 ± 0.49  5.04 ± 0.39  5.31 ± 0.32  4.03 ± 0.17  5.63 ± 0.36  4.10 ± 0.40  < 0.001 
18:3n 6  0.17 ± 0.04  0.20 ± 0.03  0.11 ± 0.09  0.11 ± 0.06  0.23 ± 0.04  0.19 ± 0.03  0.002 
20:2n 6  0.55 ± 0.50  0.23 ± 0.04  0.17 ± 0.02  0.27 ± 0.20  0.27 ± 0.04  0.53 ± 0.31  0.058 
20:3n 6  0.75 ± 0.10  0.82 ± 0.10  0.87 ± 0.12  0.70 ± 0.12  0.89 ± 0.10  0.76 ± 0.11  0.026 
20:4n 6  25.40 ± 0.67  25.27 ± 0.88  17.59 ± 1.15 *  11.66 ± 0.52 *  28.74 ± 0.66 *  26.63 ± 0.76  < 0.001 
Total n 6 PUFA  31.20 ± 1.08  31.56 ± 0.97  24.05 ± 1.15 *  16.76 ± 0.47 *  35.76 ± 0.57 *  32.22 ± 0.79  < 0.001 
18:3n 3  0.25 ± 0.10  0.22 ± 0.07  0.71 ± 0.06 *  0.18 ± 0.04  0.19 ± 0.16  0.15 ± 0.07  < 0.001 
20:4n 3  ND  ND  0.16 ± 0.09  0.10 ± 0.08  ND  ND  < 0.001 
20:5n 3  0.43 ± 0.11  0.52 ± 0.11  5.44 ± 0.64 *  8.13 ± 0.61 *  0.11 ± 0.13  0.34 ± 0.12  < 0.001 
22:5n 3  0.78 ± 0.16  0.79 ± 0.06  2.60 ± 0.26  2.72 ± 0.24  0.48 ± 0.11  0.61 ± 0.07  < 0.001 
22:6n 3  20.63 ± 0.98  20.92 ± 0.91  21.46 ± 1.59   27.00 ± 0.96 *   13.89 ± 0.79 *   18.61 ± 0.42 *  < 0.001 
Total n 3 PUFA  22.08 ± 1.11  22.45 ± 1.06  30.36 ± 1.28 *  38.13 ± 1.02 *  14.67 ± 0.75 *  19.71 ± 0.49 *  < 0.001 
 
 
ND   negligible detected (mean <0.1% total fatty acid content)  
*  Significantly different (p <0.05) from all other groups   286 
Table 6.39: Fetal liver TAG fatty acid composition (% total fatty acids, mean ± standard deviation, n=6 per group) 
 
Fatty acid  LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef tallow  ANOVA 
p value 
14:0  2.28 ± 0.29  1.91 ± 0.35  1.64 ± 0.12  1.76 ± 0.30  1.97 ± 0.20  2.05 ± 0.28  0.005 
16:0  24.28 ± 1.20  21.69 ± 2.32  19.04 ± 0.93  21.49 ± 1.15  23.19 ± 1.26  23.66 ± 1.51  < 0.001 
18:0  6.55 ± 1.11  7.09 ± 0.94  6.07 ± 1.15  7.48 ± 0.46  7.21 ± 0.66  7.46 ± 0.90  0.071 
20:0  0.26 ± 0.09  0.26 ± 0.05  0.76 ± 0.15 *  0.25 ± 0.04  0.24 ± 0.09  0.40 ± 0.14  < 0.001 
22:0  ND  ND  0.14 ± 0.12  ND  ND  ND  0.055 
Total saturates  33.44 ± 2.14  30.98 ± 3.26  27.65 ± 1.92  30.98 ± 1.51  32.61 ± 1.44  33.57 ± 2.32  < 0.001 
16:1n 7  5.63 ± 0.20 *  2.95 ± 0.64  2.39 ± 0.25  3.07 ± 0.22  3.02 ± 0.38  3.79 ± 0.73  < 0.001 
18:1n 9  28.97 ± 2.71  25.35 ± 5.05  20.89 ± 2.23  24.24 ± 1.67  26.61 ± 1.46  33.25 ± 5.35  < 0.001 
20:1n 9  0.26 ± 0.03  0.21 ± 0.03  0.15 ± 0.17  0.27 ± 0.02  0.23 ± 0.13  0.30 ± 0.07  0.169 
Total MUFA  34.86 ± 2.88  28.52 ± 5.64  23.44 ± 2.36  28.52 ± 5.64  29.86 ± 1.79  37.40 ± 6.02  < 0.001 
18:2n 6  17.80 ± 2.66  20.91 ± 6.17  18.39 ± 1.12  13.84 ± 4.53  26.03 ± 1.48  16.78 ± 4.51  < 0.001 
18:3n 6  1.00 ± 0.16  1.11 ± 0.43  0.69 ± 0.11  0.51 ± 0.28  1.61 ± 0.22 *  1.03 ± 0.12  < 0.001 
20:2n 6  0.28 ± 0.06  0.35 ± 0.12  0.29 ± 0.04  0.15 ± 0.13  0.47 ± 0.04  0.29 ± 0.11  < 0.001 
20:3n 6  0.49 ± 0.09  0.54 ± 0.21  0.39 ± 0.08  0.34 ± 0.15  0.66 ± 0.10  0.44 ± 0.15  0.006 
20:4n 6  3.44 ± 0.57  3.74 ± 1.65  1.56 ± 0.14  1.25 ± 0.94  5.56 ± 1.30  3.20 ± 0.81  < 0.001 
Total n 6 PUFA  23.01 ± 3.19  26.64 ± 8.42  21.32 ± 1.35  16.09 ± 5.98  34.33 ± 2.75  21.73 ± 5.47  < 0.001 
18:3n 3  1.11 ± 0.17  1.24 ± 0.48  8.39 ± 0.91 *  1.04 ± 0.32  0.40 ± 0.08  0.68 ± 0.30  < 0.001 
20:4n 3  ND  ND  0.36 ± 0.04 *  ND  ND  ND  < 0.001 
20:5n 3  0.33 ± 0.12  0.66 ± 0.72  2.05 ± 0.29  2.01 ± 0.69  ND  0.10 ± 0.15  < 0.001 
22:5n 3  0.55 ± 0.16  0.97 ± 0.74  2.42 ± 0.18  2.33 ± 0.81  0.33 ± 0.20  1.45 ± 2.61  0.013 † 
22:6n 3  6.71 ± 1.60  10.98 ± 4.37  14.37 ± 1.83  19.95 ± 4.15 *  2.45 ± 0.37  5.02 ± 3.42  < 0.001 
Total n 3 PUFA  8.70 ± 1.94  13.86 ± 5.83  27.59 ± 3.04  25.35 ± 5.42  3.20 ± 0.41  7.29 ± 2.91  < 0.001 
 
 
ND   negligible detected (mean <0.1% total fatty acid content)     *  Significantly different (p <0.05) from all other groups 
†   no significant differences between groups when Bonferroni post hoc test applied   287 
Table 6.40: Fetal liver CE fatty acid composition (% total fatty acids, mean ± standard deviation, n=6 per group) 
 
Fatty acid  LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef tallow  ANOVA 
p value 
14:0  1.00 ± 0.28  0.95 ± 0.32  0.81 ± 0.53  0.99 ± 0.30  1.05 ± 0.31  1.33 ± 0.35  0.267 
16:0  30.03 ± 1.73  27.98 ± 3.31  27.08 ± 4.71  31.46 ± 2.47  29.39 ± 1.43  31.21 ± 1.80  0.069 
18:0  20.09 ± 5.12  22.07 ± 4.21  22.65 ± 5.81  24.46 ± 2.10  21.09 ± 4.15  21.28 ± 2.74  0.577 
20:0  0.11 ± 0.12  0.25 ± 0.05  0.12 ± 0.14  ND  0.16 ± 0.13  0.25 ± 0.13  0.095 
22:0  ND  ND  0.11 ± 0.15 *  ND  ND  ND  0.015 
Total saturates  51.23 ± 5.88  51.26 ± 7.14  50.77 ± 9.50  57.00 ± 2.44  51.69 ± 4.85  54.07 ± 3.78  0.457 
16:1n 7  6.78 ± 1.27  3.37 ± 0.40  3.00 ± 0.59  3.50 ± 0.49  4.34 ± 0.90  5.26 ± 0.96  < 0.001 
18:1n 9  21.51 ± 2.52  18.58 ± 2.76  17.48 ± 2.92  16.77 ± 2.49  21.55 ± 1.98  24.79 ± 3.65  < 0.001 
20:1n 9  0.11 ± 0.12  0.14 ± 0.11  0.21 ± 0.18  ND  ND  0.15 ± 0.17  0.165 
Total MUFA  28.39 ± 3.66  22.12 ± 2.94  20.69 ± 3.08  20.31 ± 2.54  25.92 ± 2.87  30.22 ± 4.49  < 0.001 
18:2n 6  9.19 ± 1.68  13.08 ± 4.47  9.98 ± 3.02  6.19 ± 0.35  12.04 ± 1.42  6.50 ± 0.84  < 0.001 
18:3n 6  0.13 ± 0.15  0.25 ± 0.13  ND  ND  0.30 ± 0.15  0.14 ± 0.11  0.001 
20:2n 6  0.31 ± 0.22  0.30 ± 0.16  0.13 ± 0.23  0.13 ± 0.33  0.30 ± 0.25  0.44 ± 0.21  0.244 
20:3n 6  0.33 ± 0.17  0.74 ± 0.13  0.33 ± 0.29  0.31 ± 0.49  0.67 ± 0.21  0.28 ± 0.22  0.018 † 
20:4n 6  4.52 ± 0.56  4.25 ± 0.58  2.39 ± 0.65  1.69 ± 0.23  5.07 ± 1.05  3.86 ± 0.42  < 0.001 
22:5n 6  1.25 ± 0.26  0.91 ± 0.29  ND  ND  2.47 ± 0.90 *  1.27 ± 0.42  < 0.001 
Total n 6 PUFA  15.74 ± 1.78  19.53 ± 4.88  12.90 ± 3.84  8.33 ± 0.65  20.85 ± 3.05  12.49 ± 1.36  < 0.001 
18:3n 3  0.68 ± 0.17  0.99 ± 0.39  5.44 ± 1.43 *  0.56 ± 0.47  0.15 ± 0.17  0.12 ± 0.14  < 0.001 
20:4n 3  0.51 ± 0.53  0.26 ± 0.35  0.54 ± 0.66  0.36 ± 0.61  ND  0.30 ± 0.37  0.425 
20:5n 3  0.12 ± 0.14  0.20 ± 0.16  1.93 ± 0.40 *  2.81 ± 0.17 *  ND  ND  < 0.001 
22:5n 3  0.20 ± 0.17  0.44 ± 0.12  1.27 ± 0.25  1.43 ± 0.22  ND  ND  < 0.001 
22:6n 3  3.14 ± 1.42  5.20 ± 1.92  6.45 ± 2.26  9.19 ± 2.49  1.39 ± 0.49  2.70 ± 0.79  < 0.001 
Total n 3 PUFA  4.64 ± 1.80  7.09 ± 1.62  15.63 ± 3.64  14.36 ± 2.54  1.55 ± 0.42  3.22 ± 0.88  < 0.001 
 
ND   negligible detected (mean <0.1% total fatty acid content)         *  Significantly different (p <0.05) from all other groups 
†   no significant differences between groups when Bonferroni post hoc test applied   288 
6.3.14 Fetal brain weight and fatty acid composition 
The fatty acid composition of the fetal brain was analysed in order to determine whether 
there was tissue specific accumulation of maternal dietary fatty acids, particularly as 
brain function has been demonstrated to be affected by maternal diet during pregnancy.  
For example, animals fed n 3 PUFA deficient diets during pregnancy have 
demonstrated impaired cognitive function among their offspring(56).  This indicates the 
importance of accumulation of LC n 3 PUFA in the fetal brain during development. 
 
Maternal diet did not significantly affect fetal brain weight when expressed as either 
absolute weight or weight as a % body weight (see table 6.41).  The fatty acid 
compositions of fetal brain phospholipids (PC and PE) were assessed by gas 
chromatography (see table 6.42 and 6.43).  Fetal brain PC demonstrated fewer 
significant changes in fatty acid composition in response to the maternal diet than was 
observed in the PE fraction.  The PC fraction was saturate rich, and so may more 
closely reflect the endogenous production of these fatty acids, rather than the dietary 
availability of EFA and LC PUFA.  This saturate rich membrane is also suggestive of a 
lipid raft membrane domain, so it is possible that the regulation of fetal brain PC is 
maintained to ensure the formation of lipid rafts.  There were some significant effects of 
maternal diet upon fetal brain PC, particularly upon LC n 6 and n 3 PUFA.  Those in 
the linseed oil and salmon oil dietary groups had the highest EPA and DPA content of 
brain PC, and were significantly different from all other dietary groups.  Those on the 
salmon oil diet had the lowest AA content of brain PC.  The linseed oil and salmon oil 
groups had the lowest 22:5n 6 content in brain PC.  With regard to EPA and DPA 
content (both n 6 and n 3) of fetal brain PC, there was no significant difference between 
the linseed oil and salmon oil groups. 
 
In fetal brain PE, all LC n 6 and n 3 PUFA were significantly affected by maternal diet.  
EPA, DPA and DHA contents were highest in the linseed oil and salmon oil groups.  
22:5n 6 content was significantly higher in the sunflower oil group than in any other 
dietary groups, and lowest in the linseed oil and salmon oil groups.  The AA content of 
fetal brain PE was lowest in the HF salmon oil group, but in the linseed oil group AA 
was retained at levels comparable to those seen in the other dietary groups. 
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These data indicate that the linseed oil and salmon oil diet were equally effective at 
inducing high fetal brain LC n 3 PUFA content when compared to other maternal diets.  
This suggests that either the products of endogenous synthesis of LC n 3 PUFA are 
effectively targeted to the fetal brain, or that endogenous synthesis of LC n 3 PUFA 
from ALNA occurs within the fetal brain.  The lack of any detectable ALNA or 20:4n 3 
in the fetal brain suggests that there is little endogenous synthesis occurring within the 
fetal brain.  Further studies, perhaps using isotope labelled ALNA, would be required to 
fully investigate the source of the LC n 3 PUFA which are incorporated into the fetal 
brain in the linseed oil group, with possible sources including the products of 
endogenous synthesis within the maternal or fetal liver.  
 
 
Table 6.41: Absolute and relative fetal brain weight (mean ± standard deviation) 
 
  Brain weight (mg) 
Brain weight  
(% body weight) 
LF Soyabean  115.4 + 26.1  5.2 + 1.5 
HF Soyabean  118.5 + 26.9  4.8 + 0.8 
HF Linseed  130.1 + 26.1  4.9 + 0.2 
HF Salmon  107.8 + 6.4  5.2 + 0.6 
HF Sunflower  129.7 + 21.6  4.9 + 1.1 
HF Beef tallow  108.8 + 13.7  5.0 + 1.1 
ANOVA p value  0.319  0.982 
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Table 6.42: Fetal brain PC fatty acid composition (% total fatty acid, mean ± standard deviation, n=6 per group) 
 
Fatty acid  LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef tallow  ANOVA 
p value 
14:0  3.37 ± 0.34  3.23 ± 0.25  3.27 ± 0.38  3.41 ± 0.33  3.13 ± 0.52  3.31 ± 0.49  0.856 
16:0  52.73 ± 2.54  51.21 ± 3.48  50.35 ± 5.16  50.64 ± 3.72  50.17 ± 3.73  50.32 ± 6.19  0.906 
18:0  8.75 ± 0.88  9.81 ± 1.53  9.94 ± 1.97  9.45 ± 1.68  10.04 ± 1.82  9.37 ± 2.57  0.834 
Total saturates  64.86 ± 1.79  64.25 ± 2.27  63.57 ± 3.75  63.50 ± 2.38  63.33 ± 2.41  62.99 ± 4.50  0.903 
16:1n 7  3.28 ± 0.13  2.91 ± 0.23  3.05 ± 0.25  3.34 ± 0.23  2.90 ± 0.39  2.93 ± 0.31  0.021 † 
18:1n 9  18.90 ± 0.57  17.84 ± 0.59  18.13 ± 1.03  19.57 ± 1.09  17.64 ± 1.02  19.06 ± 2.74  0.134 
20:1n 9  0.38 ± 0.05  0.35 ± 0.06  0.53 ± 0.56  0.32 ± 0.16  0.27 ± 0.14  0.36 ± 0.04  0.561 
Total MUFA  22.56 ± 0.64  21.10 ± 0.79  21.71 ± 1.35  23.23 ± 1.23  20.81 ± 1.31  22.35 ± 2.96  0.097 
18:2n 6  1.13 ± 0.17  1.44 ± 0.25  1.78 ± 0.63  1.65 ± 0.35  1.42 ± 0.10  1.44 ± 1.05  0.415 
18:3n 6  ND  ND  ND  ND  0.11 ± 0.12 *  ND  0.002 
20:2n 6  ND  ND  ND  ND  0.18 ± 0.14  ND  0.350 
20:3n 6  0.23 ± 0.19  0.43 ± 0.07  0.38 ± 0.19  0.44 ± 0.04  0.34 ± 0.17  0.27 ± 0.14  0.084 
20:4n 6  6.97 ± 0.76  7.66 ± 1.12  6.93 ± 1.96  5.30 ± 1.14 
a  8.41 ± 1.68 
b  7.77 ± 2.06  0.028 
22:5n 6  1.45 ± 0.45 
bd  1.58 ± 0.62 
bcd  0.61 ± 0.51 
ad  0.17 ± 0.21 
ad  2.76 ± 1.07 
bc  1.69 ± 0.80 
bcd  < 0.001 
Total n 6 PUFA  9.81 ± 1.38  11.19 ± 1.66  9.78 ± 2.26  7.65 ± 1.29 
a  13.21 ± 2.73 
b  11.20 ± 2.96  0.003 
18:3n 3  ND  ND  ND  ND  ND  0.10 ± 0.16  0.165 
20:5n 3  ND 
b  ND
 b  0.12 ± 0.19 
a  0.29 ± 0.16 
a  ND 
b  ND 
b  < 0.001 
22:5n 3  ND 
b  ND
 b  0.37 ± 0.32 
a  0.43 ± 0.26 
a  ND 
b  ND 
b  < 0.001 
22:6n 3  2.77 ± 0.56  3.46 ± 1.17  4.40 ± 2.31  4.90 ± 2.00  2.65 ± 0.92  3.36 ± 1.97  0.138 
Total n 3 PUFA  2.77 ± 0.56  3.46 ± 1.17  4.94 ± 2.73  5.62 ± 2.24  2.65 ± 0.92  3.46 ± 1.90  0.034 † 
 
ND   negligible detected (mean <0.1% total fatty acid content)   *  Significantly different (p <0.05) from all other groups     
†   no significant differences between groups when Bonferroni post hoc test applied      
a, b, c, d   groups which differ significantly from each other (Bonferroni p < 0.05) have different superscripts 
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Table 6.43: Fetal brain PE fatty acid composition (% total fatty acid, mean ± standard deviation, n=6 per group) 
 
Fatty acid  LF Soyabean  HF Soyabean  HF Linseed  HF Salmon  HF Sunflower  HF Beef tallow  ANOVA 
p value 
14:0  0.64 ± 0.30  0.81 ± 0.31  0.53 ± 0.09  0.78 ± 0.36  0.64 ± 0.17  0.69 ± 0.38  0.572 
16:0  18.78 ± 2.93  20.68 ± 4.26  18.13 ± 2.85  20.13 ± 4.44  17.09 ± 1.60  19.13 ± 3.91  0.520 
18:0  24.22 ± 1.09  24.11 ± 2.05  24.39 ± 1.39  22.66 ± 1.48  25.96 ± 2.16  22.90 ± 0.95  0.021 
Total saturates  43.63 ± 2.18  45.60 ± 2.97  43.07 ± 2.38  43.57 ± 4.27  43.69 ± 2.34  42.72 ± 3.85  0.694 
16:1n 7  1.27 ± 0.42  1.44 ± 0.35  1.08 ± 0.23  1.73 ± 0.78  1.44 ± 0.53  1.23 ± 0.57  0.355 
18:1n 9  11.04 ± 1.39  11.98 ± 2.35  11.18 ± 2.11  13.57 ± 2.91  10.09 ± 1.18  11.64 ± 2.98  0.182 
20:1n 9  0.30 ± 0.09  0.31 ± 0.08  0.29 ± 0.13  0.30 ± 0.17  0.14 ± 0.11  0.12 ± 0.18  0.046 † 
Total MUFA  12.61 ± 1.59  13.73 ± 2.69  12.55 ± 2.34  15.60 ± 3.63  11.66 ± 1.65  12.99 ± 3.56  0.206 
18:2n 6  0.98 ± 0.36  2.08 ± 1.48  1.25 ± 0.48  1.94 ± 1.08  1.49 ± 0.64  1.38 ± 1.15  0.349 
20:2n 6  0.45 ± 0.03  0.19 ± 0.18  0.32 ± 0.05  0.59 ± 0.13  0.26 ± 0.16  0.44 ± 0.05  < 0.001 
20:3n 6  0.43 ± 0.10  0.54 ± 0.06  0.60 ± 0.08  0.74 ± 0.13  0.53 ± 0.12  0.42 ± 0.13  < 0.001 
20:4n 6  19.87 ± 1.93  19.17 ± 3.21  19.22 ± 1.23  15.06 ± 2.44  21.89 ± 1.51  20.26 ± 3.07  0.001 
22:5n 6  6.82 ± 1.20  5.20 ± 0.81  2.77 ± 0.22  1.07 ± 0.13  11.01 ± 2.29 *  7.23 ± 1.87  < 0.001 
Total n 6 PUFA  28.56 ± 2.38  27.19 ± 3.13  24.23 ± 1.45  19.40 ± 1.47 *  35.19 ± 2.64 *  29.73 ± 3.83  < 0.001 
18:3n 3  ND  ND  ND  ND  ND  0.31 ± 0.48  0.068 
20:5n 3  ND  ND  0.34 ± 0.13  0.64 ± 0.35  0.17 ± 0.32  ND  < 0.001 
22:5n 3  0.33 ± 0.06  0.38 ± 0.09  1.31 ± 0.22  1.58 ± 0.48  0.15 ± 0.16  0.19 ± 0.18  < 0.001 
22:6n 3  14.87 ± 2.27  13.10 ± 2.50  18.48 ± 3.23  19.22 ± 6.07  9.10 ± 1.80  14.02 ± 3.10  < 0.001 
Total n 3 PUFA  15.19 ± 2.33  13.48 ± 2.53  20.15 ± 3.49  21.43 ± 6.67  9.46 ± 1.78  14.56 ± 3.49  < 0.001 
 
ND   negligible detected (mean <0.1% total fatty acid content) 
*  Significantly different (p <0.05) from all other groups 
†   no significant differences between groups when Bonferroni post hoc test applied   292 
Potential predictors of fetal brain DHA status  
 
It would not be possible to design a human study in which maternal dietary fatty acids 
are manipulated during pregnancy, and then samples of the fetal/neonatal brain taken to 
assess how DHA status was affected.  It would be possible to undertake a retrospective 
analysis of fetal brain fatty acid composition from aborted fetuses, infants which were 
stillborn or those who died during infancy, but this would likely be subject to limited 
subject numbers and the findings would be confounded by many factors such as social 
or health variables.  Studies of this type have been undertaken, such as one study which 
examined the fatty acid composition of brain cortex samples collected from term infants 
at post mortem(242).  This study identified that breast fed infants had significantly 
more DHA and significantly less AA and 22:5n 6 in brain cortex when compared to 
bottle fed infants. 
 
In this study using a rat model, samples which could feasibly be taken from human 
subjects were therefore assessed for their suitability as a predictor for fetal brain fatty 
acid status.  Maternal plasma, maternal subcutaneous adipose tissue, fetal plasma and 
placenta were assessed by stepwise multiple regression analysis to determine how their 
n 3 fatty acid content (expressed as ALNA, 20:4n 3, EPA, DPA, DHA or total n 3 fatty 
acid content) could be used to predict fetal brain phospholipid DHA content.  78 
potential predictive variables were assessed and the model R
2 values and predictor 
variables used displayed below (table 6.44).  
 
The adjusted R
2 value achieved for fetal brain PE status was stronger than that achieved 
for PC status.  This implies that fetal brain PC DHA content is regulated by a more 
complex mechanism than by the simple availability of n 3 fatty acids.  The relationship 
between the variables with the greatest Beta value (fetal plasma PC total n 3 content and 
fetal brain PE DHA status) is illustrated in figure 6.12.  
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Table 6.44: Stepwise multiple regression analysis results for samples which could 
feasibly be obtained in a human study which predict fetal brain DHA status 
 
Fetal brain PC DHA content  
Adjusted R
2 = 0.555, p < 0.001 
Fetal brain PE DHA content  
Adjusted R
2 = 0.884, p < 0.001 
Predictor variable  Beta  p  Predictor variable  Beta  p 
Fetal plasma NEFA  
22:5n 3 
0.753  0.001  Placenta CE  
total n 3 content 
0.782  <0.001 
Placenta CE  
22:5n 3 
 0.798  <0.001  Placenta PC  
20:4n 3 
 0.321  0.017 
Fetal plasma PC  
20:4n 3 
0.512  0.003  Maternal plasma CE  
22:5n 3 
0.724  <0.001 
Fetal plasma NEFA  
20:4n 3 
0.346  0.035  Maternal plasma NEFA  
20:4n 3 
 0.848  <0.001 
      Fetal plasma PC  
total n 3 content 
1.0009  <0.001 
      Fetal plasma TAG  
22:6n 3 
 0.618  0.001 
      Fetal plasma PC  
20:4n 3 
 0.283  0.006 
      Maternal plasma PC  
22:5n 3 
0.286  0.016 
 
 
 
Figure 6.12: Graph to illustrate the correlation observed between fetal plasma PC total 
n 3 content and fetal brain PE DHA content (95% confidence interval displayed) 
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6.3.15 Fetal immune cell and tissue fatty acid composition 
The fatty acid compositions of phospholipids in fetal immune tissues were assessed to 
determine whether maternal diet during pregnancy could significantly affect fatty acid 
composition, particularly the AA and EPA content of tissues as these fatty acids are 
precursors for immune signalling molecules such as eicosanoids.   
 
Within fetal thymus PC (see table 6.45), maternal diet had a significant effect upon n 6 
fatty acid composition (including AA), and EPA status.  Within fetal thymus PE (see 
table 6.46), maternal diet did not significantly affect n 6 fatty acid status, but had 
significant effects upon LC n 3 PUFA status, including EPA.  Fetal PBMC PC (see 
table 6.47) demonstrated significant effects of maternal diet, including significant 
effects upon AA and EPA content. 
 
The HF linseed oil and salmon oil diets were associated with the lowest AA content in 
fetal thymus and PBMC PC (see figure 6.13), and the highest EPA status across all fetal 
immune tissues assessed (see figure 6.14).  The HF linseed oil diet was therefore as 
effective as the HF salmon oil diet at affecting the EPA content of fetal immune tissues, 
but without lowering the AA content to the low levels observed in the salmon oil group. 
 
 
Figure 6.13: The AA content (% total fatty acids) of fetal thymus and PBMC 
phosphatidylcholine (mean ± standard deviation) 
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Figure 6.14: The EPA content (% total fatty acids) of fetal thymus and PBMC 
phospholipids (mean ± standard deviation) 
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Table 6.45: Fetal thymus PC fatty acid composition (% total fatty acids, mean ± standard deviation) 
 
Fatty acid 
HF Soyabean 
(n=4) 
HF Soyabean 
(n = 3) 
HF Linseed 
(n = 3) 
HF Salmon 
(n = 6) 
HF Sunflower 
(n = 4) 
Beef tallow 
(n=5) 
ANOVA  
p value 
14:0  ND  0.73 ± 1.26  1.99 ± 0.73  0.30 ± 0.75  1.12 ± 1.38  0.68 ± 0.95  0.124 
16:0  44.41 ± 2.96  41.06 ± 3.63  40.02 ± 3.31  36.33 ± 6.02  38.31 ± 5.09  36.37 ± 4.97  0.148 
18:0  16.48 ± 2.18  16.28 ± 4.18  13.43 ± 2.07  21.10 ± 10.10  17.75 ± 5.89  20.43 ± 9.38  0.686 
20:0  0.19 ± 0.22  0.23 ± 0.25  ND  0.34 ± 0.40  0.21 ± 0.43  ND  0.793 
Total saturates  61.07 ± 2.75  58.30 ± 1.68  55.51 ± 3.29  58.07 ± 7.65  57.39 ± 2.62  57.58 ± 4.07  0.757 
16:1n 7  1.46 ± 1.08  1.65 ± 0.29  2.40 ± 0.32  2.10 ± 0.78  1.58 ± 0.64  1.20 ± 1.12  0.368 
18:1n 9  16.22 ± 1.06  13.28 ± 0.64  15.20 ± 0.60  18.30 ± 3.82  13.40 ± 2.79  15.88 ± 3.14  0.097 
20:1n 9  1.79 ± 0.49  1.63 ± 0.22  0.89 ± 0.53  1.68 ± 1.44  1.79 ± 1.49  1.10 ± 0.82  0.763 
24:1n 9  ND  0.82 ± 0.97  0.23 ± 0.39  0.20 ± 0.16  0.69 ± 1.38  0.94 ± 1.96  0.795 
Total MUFA  19.56 ± 2.31  17.37 ± 1.02  18.71 ± 0.59  22.28 ± 5.61  17.47 ± 3.41  19.12 ± 2.58  0.320 
18:2n 6  6.17 ± 0.76  8.72 ± 0.64  12.20 ± 1.49 *  7.76 ± 1.42  8.15 ± 1.05  5.97 ± 1.53  < 0.001 
20:2n 6  0.58 ± 0.06  1.52 ± 0.30  0.45 ± 0.66  0.27 ± 0.21  1.25 ± 0.81  0.38 ± 0.42  0.005 
20:3n 6  1.79 ± 0.34  0.93 ± 0.81  1.87 ± 0.33  2.63 ± 0.48  2.12 ± 0.90  1.37 ± 0.86  0.022 
20:4n 6  8.49 ± 0.91  10.51 ± 2.10  7.13 ± 1.12  4.28 ± 1.00  11.23 ± 1.39  11.10 ± 1.74  < 0.001 
22:5n 6  0.30 ± 0.23  0.31 ± 0.05  0.27 ± 0.24  ND  0.70 ± 0.31  0.50 ± 0.36  0.006 
Total n 6 PUFA  17.34 ± 1.42  22.03 ± 3.47  21.99 ± 2.11  14.94 ± 1.91  23.50 ± 2.43  19.36 ± 4.04  0.001 
18:3n 3  ND  0.46 ± 0.63  0.39 ± 0.34  0.43 ± 0.66  0.36 ± 0.73  0.52 ± 1.00  0.906 
20:4n 3  0.48 ± 0.31  0.51 ± 0.20  0.30 ± 0.28  0.40 ± 0.55  0.17 ± 0.34  0.80 ± 0.55  0.409 
20:5n 3  ND  ND  1.37 ± 0.45  1.30 ± 0.37  ND  0.20 ± 0.34  < 0.001 
22:5n 3  ND  0.24 ± 0.41  0.65 ± 0.22  0.46 ± 0.26  0.24 ± 0.40  0.32 ± 0.54  0.271 
22:6n 3  1.55 ± 0.50  1.07 ± 0.19  1.08 ± 0.12  2.11± 0.79  0.87 ± 0.37  2.10 ± 1.52  0.157 
Total n 3 PUFA  2.03 ± 0.67  2.31 ± 1.35  3.78 ± 0.73  4.71 ± 1.14  1.65 ± 1.22  3.93 ± 2.59  0.036 † 
 
ND   negligible detected (mean <0.1% total fatty acid content) 
†   no significant differences between groups when Bonferroni post hoc test applied      
*  Significantly different (p <0.05) from all other groups   297 
Table 6.46: Fetal thymus PE fatty acid composition (% total fatty acids, mean ± standard deviation) 
 
Fatty acid 
HF Soyabean  
(n = 4) 
HF Soyabean  
(n = 6) 
HF Linseed  
(n = 4) 
HF Salmon  
(n = 5) 
HF Sunflower 
(n = 5) 
HF Beef tallow 
(n = 4) 
ANOVA 
p value 
14:0  ND  0.43 ± 0.68  ND  ND  0.29 ± 0.70  0.59 ± 0.71  0.400 
16:0  22.47 ± 3.03  24.65 ± 5.38  15.87 ± 3.49  20.41 ± 3.48  20.19 ± 8.66  19.44 ± 3.71  0.254 
18:0  37.03 ± 8.70  36.99 ± 7.31  27.13 ± 6.00  27.16 ± 5.36  32.26 ± 7.68  30.91 ± 8.47  0.163 
20:0  0.18 ± 0.36  0.63 ± 0.24  ND  0.30 ± 0.29  0.35 ± 0.33  0.47 ± 0.51  0.139 
Total saturates  59.68 ± 10.62  62.75 ± 12.56  43.13 ± 8.62  47.95 ± 6.75  55.72 ± 16.76  51.42 ± 10.83  0.149 
16:1n 7  0.59 ± 0.48  0.80 ± 0.46  0.93 ± 0.13  1.49 ± 0.41  0.74 ± 0.15  1.00 ± 0.56  0.028 
18:1n 9  10.82 ± 6.53  9.80 ± 2.29  13.42 ± 2.30  15.87 ± 2.79  10.47 ± 2.17  12.17 ± 4.09  0.088 
20:1n 9  1.04 ± 0.57  0.45 ± 0.42  0.67 ± 0.47  1.20 ± 0.39  0.84 ± 0.53  1.31 ± 0.51  0.080 
Total MUFA  12.46 ± 6.74  11.05 ± 2.96  15.11 ± 2.46  18.57 ± 3.10  11.65 ± 2.80  14.48 ± 4.59  0.049 † 
18:2n 6  4.62 ± 0.91  5.46 ± 1.26  7.76 ± 0.65  9.02 ± 4.70  5.57 ± 0.62  5.85 ± 2.71  0.067 
20:2n 6  0.19 ± 0.22  0.48 ± 0.51  0.53 ± 0.31  0.28 ± 0.16  0.53 ± 0.45  0.43 ± 0.26  0.628 
20:3n 6  0.94 ± 1.09  1.04 ± 0.89  1.55 ± 0.51  1.17 ± 1.28  1.76 ± 0.48  1.35 ± 1.10  0.710 
20:4n 6  18.24 ± 4.27  14.40 ± 8.90  22.56 ± 4.01  11.95 ± 1.75  22.47 ± 13.57  18.57 ± 8.99  0.308 
22:5n 6  0.78 ± 0.53  1.00 ± 1.03  0.55 ± 0.45  0.52 ± 0.63  1.92 ± 1.15  1.59 ± 1.03  0.098 
Total n 6 PUFA  24.77 ± 5.80  22.39 ± 10.24  32.95 ± 4.78  22.94 ± 6.67  29.88 ± 15.27  27.84 ± 8.60  0.372 
18:3n 3  0.21 ± 0.43  1.09 ± 1.21  0.69 ± 0.80  1.70 ± 2.74  0.77 ± 1.35  2.11 ± 3.26  0.706 
20:4n 3  0.29 ± 0.22  0.35 ± 0.32  0.19 ± 0.23  0.15 ± 0.22  0.19 ± 0.23  0.40 ± 0.36  0.677 
20:5n 3  0.13 ± 0.16  0.13 ± 0.23  3.41 ± 1.72  4.02 ± 1.24  ND  0.53 ± 0.43  < 0.001 
22:5n 3  0.16 ± 0.33  0.39 ± 0.09  1.22 ± 0.17  0.96 ± 0.38  0.23 ± 0.31  0.20 ± 0.28  < 0.001 
22:6n 3  2.30 ± 0.87  1.86 ± 0.66  3.29 ± 0.51  3.71 ± 0.64  1.36 ± 0.22  3.03 ± 0.68  < 0.001 
Total n 3 PUFA  3.09 ± 1.17  3.81 ± 1.90  8.80 ± 2.14  10.54 ± 2.43  2.75 ± 1.62  6.26 ± 3.09  < 0.001 
 
ND   negligible detected (mean <0.1% total fatty acid content) 
†   no significant differences between groups when Bonferroni post hoc test applied     298 
Table 6.47: Fetal PBMC PC fatty acid composition (% total fatty acids, mean ± standard deviation) 
 
  LF Soyabean 
(n=3) 
HF Soyabean 
(n=5) 
HF Linseed 
(n=5) 
HF Salmon 
(n=5) 
HF Sunflower  
(n=3) 
HF Beef tallow 
(n=3) 
ANOVA  
p value 
14:0  0.94 ± 1.03  0.78 ± 0.45  0.54 ± 0.52  0.83 ± 0.53  1.12 ± 0.34  1.19 ± 0.19  0.610 
16:0  50.97 ± 3.00  50.64 ± 3.10  47.60 ± 5.17  47.15 ± 5.47  50.59 ± 4.02  44.57 ± 3.63  0.350 
18:0  19.03 ± 5.06  11.77 ± 4.11  19.96 ± 9.94  13.74 ± 4.23  11.61 ± 1.97  13.51 ± 2.04  0.202 
20:0  0.32 ± 0.25  0.17 ± 0.12  0.27 ± 0.30  0.29 ± 0.22  0.16 ± 0.14  0.44 ± 0.20  0.578 
22:0  0.27 ± 0.15  0.13 ± 0.12  0.42 ± 0.16  0.28 ± 0.23  ND  0.21 ± 0.26  0.146 
Total saturates  71.54 ± 1.43  63.49 ± 2.85  68.80 ± 5.52  62.30 ± 2.24  63.57 ± 4.21  59.93 ± 1.48  0.003 
16:1n 7  1.85 ± 0.61  1.66 ± 0.30  0.86 ± 0.83  1.97 ± 0.26  2.09 ± 0.74  2.06 ± 0.18  0.029 † 
18:1n 9  14.45 ± 2.47  12.96 ± 1.31  12.59 ± 1.22  17.54 ± 2.75  14.49 ± 1.47  20.74 ± 1.86  < 0.001 
20:1n 9  ND  0.23 ± 0.22  0.40 ± 0.56  0.46 ± 0.45  0.14 ± 0.25  ND  0.434 
24:1n 9  0.39 ± 0.10  0.17 ± 0.17  0.38 ± 0.27  0.43 ± 0.26  0.22 ± 0.02  0.22 ± 0.21  0.365 
Total MUFA  16.70 ± 3.02  15.01 ± 1.21  14.24 ± 1.80  20.39 ± 2.44  16.94 ± 1.83  23.09 ± 1.75  < 0.001 
18:2n 6  5.31 ± 1.63  9.86 ± 0.48  7.68 ± 2.66  8.75 ± 1.24  8.94 ± 1.68  6.46 ± 1.43  0.017 
18:3n 6  0.24 ± 0.42  0.31 ± 0.20  0.19 ± 0.31  ND  0.27 ± 0.26  0.10 ± 0.17  0.699 
20:2n 6  0.16 ± 0.27  0.29 ± 0.27  0.54 ± 0.73  0.64 ± 0.24  0.38 ± 0.28  1.09 ± 1.05  0.333 
20:3n 6  0.28 ± 0.26  1.28 ± 0.72  1.42 ± 0.93  1.70 ± 1.40  0.62 ± 0.54  0.21 ± 0.36  0.146 
20:4n 6  3.82 ± 1.34  7.54 ± 2.89  3.44 ± 2.45  2.11 ± 0.87  7.34 ± 2.73  5.50 ± 1.69  0.007 
22:5n 6  0.91 ± 0.15  0.88 ± 0.29  0.63 ± 0.44  0.96 ± 0.30  1.16 ± 0.26  2.52 ± 2.49  0.135 
Total n 6 PUFA  10.72 ± 2.16  20.17 ± 3.07  13.89 ± 4.22  14.25 ± 2.77  18.71 ± 5.54  15.89 ± 0.84  0.015 
18:3n 3  ND  0.23 ± 0.14  0.61 ± 0.36  0.23 ± 0.21  ND  0.51 ± 0.89  0.246 
20:4n 3  ND  0.10 ± 0.13  ND  0.49 ± 0.45  ND  ND  0.032 
20:5n 3  0.23 ± 0.39  0.13 ± 0.13  1.24 ± 0.43  1.56 ± 0.87  ND  ND  < 0.001 
22:5n 3  0.19 ± 0.17  ND  0.47 ± 0.32  ND  0.22 ± 0.25  ND  0.016 
22:6n 3  0.53 ± 0.32  0.79 ± 0.47  0.74 ± 0.40  0.75 ± 0.41  0.34 ± 0.20  0.48 ± 0.42  0.594 
Total n 3 PUFA  1.05 ± 0.42  1.33 ± 0.57  3.07 ± 0.85  3.06 ± 1.02  0.78 ± 0.58  1.10 ± 1.14  0.001 
 
ND   negligible detected (mean <0.1% total fatty acid content)     
†   no significant differences between groups when Bonferroni post hoc test applied     299 
Potential predictors of fetal immune tissue EPA status 
 
Maternal plasma, maternal subcutaneous adipose tissue, fetal plasma and placenta were 
assessed by stepwise multiple regression analysis to determine how their n 3 fatty acid 
content (expressed as ALNA, 20:4n 3, EPA, DPA, DHA or total n 3 fatty acid content) 
could be used to predict fetal immune tissue EPA content.  78 potential predictive 
variables were assessed and the model R
2 values and predictor variables used are 
detailed in table 6.48.  
 
Although significant relationships between the variables were apparent, the distributions 
were bimodal, with EPA often only detectable in the immune tissue of animals 
receiving n 3 PUFA rich diets (linseed and salmon oil).  These correlations indicate that 
the placenta is one of the best predictors of fetal immune tissue EPA status.  The 
relationship between the variable with the greatest Beta value (placenta PE 22:5n 3 
content and fetal thymus PC EPA status) is illustrated in figure 6.15.  
 
Figure 6.15: Graph to illustrate the correlation observed between placenta PE 22:5n 3 
and fetal thymus PC EPA content (95% confidence interval displayed) 
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Table 6.48: Stepwise multiple regression analysis results for samples which could feasibly be obtained in a human study which predict fetal immune 
tissue EPA status 
 
Fetal thymus PC EPA content  
Adjusted R
2 = 0.895, p < 0.001 
Fetal thymus PE EPA content  
Adjusted R
2 = 0.971, p < 0.001 
Fetal PBMC PC EPA content  
Adjusted R
2 = 0.902, p < 0.001 
Predictor variable  Beta  p  Predictor variable  Beta  p  Predictor variable  Beta  p 
Placenta PE  
22:5n 3 
0.916  <0.001  Maternal subcut. adipose 
20:5n 3 
0.439  0.001  Maternal subcut. adipose 
20:5n 3 
0.769  0.001 
Fetal plasma NEFA  
22:6n 3 
 0.494  <0.001  Fetal plasma NEFA  
18:3n 3 
0.341  0.001  Fetal plasma NEFA  
22:6n 3 
 0.558  <0.001 
Maternal plasma  
PC 22:5n 3 
0.397  0.016  Maternal plasma CE  
22:5n 3 
0.304  <0.001  Placenta PE  
total n 3 content 
0.495  0.018 
      Placenta CE  
18:3n 3 
 0.300  0.001       
      Placenta TAG  
22:5n 3 
0.739  0.001       
      Placenta TAG  
22:6n 3 
 0.500  0.006       
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6.4 Discussion 
This chapter had set out to addresses the following hypotheses: 
 
a)  that a change in maternal dietary fatty acid intake during pregnancy will alter 
maternal plasma fatty acid composition, thereby altering the supply of fatty 
acids to the developing fetus, including the availability of LC n 3 PUFA. 
b)  that the changes to maternal dietary fatty acid intake during pregnancy will 
significantly affect maternal tissue composition, including the maternal liver, 
adipose tissue and immune tissues.  
c)  that a change in the supply of fatty acids to the developing fetus will alter the 
fatty acid composition of fetal plasma and developing fetal tissues such as the 
liver, brain and immune tissues. 
 
The data collected fully support these hypotheses, and in addition generated data which 
identified novel observations of the effect of maternal diet upon specific incorporation 
of EPA into immune tissues and DHA/22:5n 6 with the fetal brain, and a significant 
effect of an ALNA rich diet during pregnancy upon DHA status. 
   
The data from this study supports that of other authors, with maternal plasma, liver and 
adipose tissues demonstrating a significant effect of maternal diet during pregnancy 
upon fatty acid composition.  As well as increasing the tissue content of fatty acids 
which were direct components of the experimental diets, there was evidence of maternal 
endogenous synthesis of LC PUFA from their EFA precursors, particularly within the 
HF linseed oil group, where higher LC n 3 PUFA contents were observed in the 
absence of any dietary source of these fatty acids.  Clear lipid fraction specificity of 
EPA incorporation with provision of an ALNA rich diet was again observed, as was the 
case in data from chapter 3.  EPA is significantly enriched within CE fractions 
following the provision of an ALNA rich diet, and is incorporated to a much greater 
extent than is observed in phospholipids or TAG.  This feature was pronounced within 
maternal plasma, placenta and fetal plasma, but was not as marked within maternal and 
fetal liver, suggesting a level of tissue specificity for lipid fraction incorporation. 
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The fatty acid composition of maternal plasma demonstrated a close relationship with 
liver lipids, with statistically significant correlations observed between plasma and liver 
saturates, MUFA and PUFA.  The relationship between maternal adipose tissue 
composition and plasma NEFA was strongest for the EFA, indicating that EFA are 
readily incorporated into and mobilised from adipose tissue.  This study could not 
provide information upon total fat mass, only upon the relative proportions of fatty 
acids within maternal fat depots.  It would be of interest to investigate whether the 
experimental diets had a significant effect upon maternal adiposity, as data indicate that 
the rate of weight gain during pregnancy is greatest upon the HF beef tallow and salmon 
oil diet, but without a significant effect of these diets upon litter size.  Experimental 
diets which result in increased maternal body fat might have a greater potential to 
continue to exert an influence on neonatal tissue fatty acid composition by significantly 
affecting the fatty acid composition of maternal milk. 
 
Of particular interest to this study was the potential that maternal diet during pregnancy 
had to alter the fatty acid composition of maternal and fetal immune tissues.  EPA and 
AA are fatty acids with the potential to significantly alter immune function due to their 
role as substrates for eicosanoid production.  The EPA and AA content of both maternal 
and fetal immune tissues were significantly affected by maternal diet, with the effect of 
maternal diet tissue and lipid fraction specific.  For example, the maternal spleen 
demonstrated a greater responsiveness to maternal diet in comparison to maternal 
thymus or PBMC.  This may reflect differences in cellular turnover between immune 
tissue types.  Across all immune tissues it was the PE fraction which was more 
significantly altered by maternal diet than the PC fraction.  These differences between 
the phospholipid classes are likely to be a function of their different cellular locations, 
and therefore different functional roles.  PC tends to be localised on the outer leaflet of 
plasma membranes, whereas PE is found on the inner leaflet and intracellular 
membranes.  The enzyme which hydrolyses fatty acids from cell membranes for 
eicosanoid synthesis is phospholipase A2, an intracellular enzyme.  The location of the 
fatty acid substrates for this enzyme (EPA and AA) within the intracellular environment 
would therefore alter the availability of substrate to this enzyme.  Investigation of both 
maternal and fetal immune function will be undertaken to assess whether these 
biochemical changes induced via maternal diet have the capacity to exert functional 
effects upon the maternal and fetal immune system (see chapter 7).   
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As would be anticipated, the significant differences observed in maternal plasma and 
tissue fatty acids were mirrored by changes to the fatty acid composition of fetal 
plasma, liver, brain and immune tissue.  When maternal and fetal plasma fatty acid 
composition data were compared, it was clear that biomagnification of LC PUFA was 
occurring.  Biomagnification is a term which is used to describe the relationship 
between maternal and fetal plasma fatty acid status, where the LC PUFA such as AA 
and DHA form a higher proportion of the total fatty acids in the fetal circulation 
compared to the maternal circulation, which implies a selective transfer of these fatty 
acids(168).   
 
There was evidence that certain fatty acids, particularly LC n 3 PUFA, are selectively 
incorporated into specific fetal tissues.  A good illustration of this is found by 
comparing the HF linseed oil and HF salmon oil groups.  The HF linseed oil group 
contains no direct source of LC n 3 PUFA, but these fatty acids can be endogenously 
synthesised under the action of desaturase and elongase enzymes within the maternal 
liver.  Despite this, the levels of LC n 3 PUFA within maternal plasma, liver, or adipose 
tissue or within the fetal plasma and liver of the HF linseed oil group were never as high 
as those within the HF salmon oil group, where dietary LC n 3 PUFA were directly 
consumed.  This would seem to indicate that it is preferable to consume preformed LC 
n 3 PUFA.  However, this was not the case within every fetal tissue assessed.  The HF 
linseed oil and salmon oil diets were equally effective at maximising the DHA content 
of fetal brain phospholipids and the EPA content of fetal immune tissue phospholipids.  
This indicates that there is a significant role of maternal and possibly fetal LC n 3 
PUFA synthesis in determining fetal tissue LC n 3 PUFA status, with tissue specific 
incorporation of these fatty acids.   
 
In chapter 4 it was identified that in addition to effects of pregnancy upon in increasing 
DHA status, there was a significantly higher content of 22:5n 6 among pregnant rats at 
day 20 of gestation compared to virgin females, indicating that the effects of pregnancy 
upon LC PUFA synthesis are not limited to LC n 3 PUFA.  Data from this chapter also 
indicated that the effects of pregnancy on 22:5n 6 content were tissue specific with this 
fatty acid found at high levels in maternal plasma lipids at day 20 of pregnancy, but at 
much lower levels within maternal liver lipids and adipose tissue, giving an indication 
that this fatty acid may be preferentially mobilised into the maternal plasma in order to 
be available to the developing fetus.  When data from the current study is assessed, the   304 
22:5n 6 content of tissues was significantly affected by maternal diet, with this fatty 
acid often undetectable in tissues collected from those on n 3 rich diets (HF linseed and 
salmon oil) but at much higher levels among the n 6 or saturate rich diets (HF sunflower 
and beef tallow).  The contribution of 22:5n 6 to fetal fatty acid composition was 
greatest within the fetal plasma and brain, indicating that the brain in particular may 
have a requirement for these highly unsaturated fatty acids (HUFA).  The relationship 
observed between 22:5n 6 and DHA in fetal brain PE (see figure 6.16) seems to indicate 
that there is a minimum requirement for the tissue content of HUFA, which will be met 
by 22:5n 6 in the event of inadequate 22:6n 3 content.  For example, there was no 
significant effect of diet upon fetal brain PE total HUFA content (22:6n 3 + 22:5n 6 as 
% total fatty acids, one way ANOVA p = 0.769), though the individual contribution of 
these fatty acids to fetal brain PE content was significantly influenced by maternal diet.  
These data also imply that maternal plasma 22:5n 6 content may be a simple and useful 
marker of fetal brain DHA status among pregnant women, with the detection of any 
22:5n 6 used as a marker of inadequate dietary n 3 PUFA status. 
 
 
 
Figure 6.16:  Graph to illustrate the relationship between 22:5n 6 and 22:6n 3 within 
fetal brain PE.  Data is mean for each fatty acid ± standard deviation of total HUFA 
content. 
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The effects observed upon fetal brain composition could be further investigated to 
determine whether any behavioural or cognitive changes can be detected in the 
offspring.  Studies undertaken using rat models have demonstrated that n 3 PUFA 
deficient diets post weaning resulted in a significant increase in the 22:5n 6 content of 
brain lipids, and significantly affect behavioural markers, including depression and 
aggression(243).  Whether the same behavioural changes could be induced by less 
intensive dietary n 3 restriction during pregnancy (e.g. HF sunflower oil group), which 
also led to increased 22:5n 6 content could be investigated.  It would also be of interest 
to compare the behavioural effects of the HF linseed oil and HF salmon oil diets.  Both 
these groups achieved equivalent DHA content of fetal brain phospholipids, but the HF 
linseed oil group achieved this without the reductions in AA content which were a 
feature of the HF salmon oil group.  The reductions in AA content which associated 
with the HF salmon oil diet may be due to inhibition of  6 desaturase activity by dietary 
fish oil, which has been identified in murine models(244).  In this respect, the HF 
linseed oil diet may be advantageous over the HF salmon oil diet.   
 
When data from this study are compared with the earlier data from chapter 3, where 
virgin females received the same HF linseed oil and HF soyabean oil diet over the same 
time period (20 days), it is clear that the ALNA rich linseed oil diet has a greater effect 
upon DHA status during pregnancy than was observed among virgin females (see figure 
6.17).  This suggests that a maternal diet rich in ALNA can further promote the 
increases in plasma and tissue DHA status which are a feature of pregnancy.  This 
potential for diet to interact with pregnancy is of relevance to human health, as this 
could confer the benefits associated with higher DHA status during pregnancy in the 
absence of direct consumption of LC n 3 PUFA from products such as oily fish. 
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Figure 6.17: Comparison of the plasma lipid DHA content of virgin females and day 20 
gestation females when fed the HF soyabean oil or HF linseed oil diet for 20 days 
(mean ± standard deviation, effect of diet determined by T test) 
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The longevity of the effects of maternal diet upon maternal and fetal tissue composition, 
and therefore their programming potential, could not be assessed within this study 
design.  However, the significant effects of diet upon maternal weight gain and adipose 
tissue composition suggest that the maternal diet during pregnancy may continue to 
significantly affect offspring fatty acid composition (and perhaps tissue function) if the 
accumulated adipose tissue fatty acids are incorporated in maternal milk.  The effects 
that these maternal diets during pregnancy have upon the maternal and fetal immune 
system are investigated in chapter 7. 
 NS 
 NS 
p = 0.04 
p = 0.007   307 
 
 
 
 
 
 
 
Chapter 7:  The effect of maternal diet 
during pregnancy upon 
immune function 
   308 
7.1 Introduction 
7.1.1 Aims and hypothesis of current study 
This study aims to investigate the effect of maternal dietary fatty acids, particularly n 3 
fatty acids, during pregnancy upon maternal and fetal immune function.  Data have 
already demonstrated that pregnancy is associated with alterations in the maternal 
immune system of the Wistar rat (see chapter 5).  The observed effects of pregnancy 
upon the maternal immune system included thymic involution, reduced lymphoid organ 
cellularity, an increased proportion of CD8
+ cells in blood, reduced expression of 
CD161 on NK cells in blood and the spleen, and an increased Th1:Th2 ratio of cytokine 
production by maternal thymocytes.   
 
In chapter 6 it was demonstrated that altering the maternal diet during pregnancy 
significantly affected both maternal and fetal immune organ fatty acid composition, 
including the content of EPA and AA, fatty acids which are substrates for eicosanoid 
production.  This chapter therefore sets out to addresses the hypothesis that the type of 
dietary fatty acids consumed during pregnancy will significantly alter markers of both 
the maternal and fetal immune function, and these effects correspond to observed 
changes within the fatty acid composition of immune tissues. 
 
The markers of immune function to be assessed include immune organ weight and 
cellularity, cell subsets within immune tissues, lymphocyte proliferation, and cytokine 
and eicosanoid production.  Changes observed in immune function will be correlated 
with the fatty acid composition data obtained from the cohort studied in chapter 6 to 
determine whether functional changes occur as a direct effect of altered fatty acid 
composition, and in particular of n 3 PUFA content.   
7.1.2 Fatty acids and immune function 
Numerous animal studies have been undertaken which have provided various dietary 
fatty acids and assessed their effects upon immune function.  The effects of fatty acids 
upon lymphocyte functions in vitro and ex vivo have been reviewed in detail 
elsewhere(245).   
 
Studies using mouse models which have provided n 3 PUFA rich diets have identified 
that diets containing EPA or DHA reduced proliferation of splenic T helper cells, and   309 
production of interferon (IFN) γ(246).  Studies have also indicated that the effects of 
dietary n 3 fatty acids upon immune tissues are organ specific.  For example, a murine 
study demonstrated that a diet with high DHA content resulted in lower expression of 
CD4 and CD8 on splenocytes, but did not affect thymocytes.  Analysis of the fatty acid 
composition of these cells indicated that DHA was more readily incorporated into 
splenocytes than thymocytes(247).  Reduced CD4 and CD8 expression on T cells in 
response to dietary DHA has also been observed in murine PBMC(248).  Dietary fatty 
acids have also demonstrated significant effects upon cytokine production, with diets 
rich in safflower oil (linoleic acid rich) or fish oil (LC n 3 PUFA rich) resulting in 
significantly lower splenocyte IFN γ production in comparison to LF or saturate rich 
diets(98).  The potential consequences of these dietary effects during pregnancy have 
not yet been evaluated. 
 
Studies using rat models have illustrated that the rat and the mouse differ in some of 
their immune responses to the type of dietary fat provided.  In contrast to the 
observations with mouse models, the quantity and type of dietary fat given to male rats 
(provided over a 10 week feeding period) did not significantly affect the lymphocyte 
cell subsets within the spleen or thymus(249).  Common between species is the effect of 
dietary fats upon lymphocyte proliferation.  For example, reduced lymph node 
lymphocyte proliferation was observed in olive oil (monounsaturated rich), evening 
primrose oil (contains γ linolenic acid) and menhaden oil (LC n 3 PUFA rich) fed rats 
when compared to other dietary fats (hydrogenated coconut oil, safflower oil) or low fat 
feeding(249) but without any significant effect of the diet upon thymus lymphocyte 
proliferation.  This indicates that dietary fatty acids significantly affect lymphocyte 
function in the rat, but in a tissue specific manner.  Similar results were obtained from a 
study of male rats which investigated the effect of various PUFA incorporated into high 
fat (17.8% w/w) diets(250).  This study also identified that there was no significant 
effect of diet upon rat spleen lymphocyte subsets, but did observe lower proliferative 
responses and PGE2 production in animals receiving EPA  or DHA rich diets. 
7.1.3 Fatty acids and immune function during pregnancy 
 
The immune system adapts during pregnancy in order to prevent rejection of the fetus 
via a maternal response to paternal antigens.  It is possible that changes to the maternal 
diet during pregnancy may affect these normal maternal adaptations, or affect the 
developing fetal immune system, with the potential to affect health and disease risk.    310 
Animal studies to date which have investigated the effect of dietary fatty acids upon 
immune function during pregnancy have tended to focus upon offspring immune 
function, and have often also incorporated a period of neonatal feeding, or collected 
samples after weaning. 
One method of assessing immune function in offspring is to assess the incidence of 
infection, or survival following pathogen challenge.  A study which provided rats 
during pregnancy with a diet rich in either corn oil (linoleic acid rich) or menhaden fish 
oil(204) identified that when pups were exposed to streptococcal sepsis at age 7 days, 
survival was significantly better in the fish oil fed group; this was associated with 
reduced PGE2 production.  This indicates that the fatty acid composition of the pre  and 
postnatal diet can beneficially affect the response to neonatal immune challenge. 
Rat studies have also identified that the maternal diet during pregnancy has the capacity 
to significantly affect neonatal thymus and spleen weight (both absolute and as a % 
body weight) and spleen lymphocyte proliferation.  Lymphocyte proliferation was 
higher in the offspring of animals receiving a saturate rich diet (coconut oil based) than 
a linoleic acid (LA) rich diet (corn oil) during pregnancy.  The LA rich diet group also 
demonstrated significantly higher neonatal thymus and spleen weight (both absolute and 
as a % body weight)(205). 
 
Following on from observations in epidemiological studies that a high intake of n 6 
fatty acids increases the risk of atopic disease in childhood and that n 3 fatty acid intake 
may be protective(94;95), human studies have been carried out which provide pregnant 
women or infants with additional dietary n 3 PUFA in an attempt to modulate the 
infant’s susceptibility to atopic diseases such as asthma.  Full details of the findings of 
these studies to date are described in the introduction (see section 1.9.3).  In brief, these 
studies have suggested that providing additional fish oil to pregnant women can alter 
markers of immune function assessed in cord blood samples, with a tendency for those 
infants in the fish oil supplemented group to demonstrate lower levels of Th2 type 
cytokines such as IL 13(209) and IL 4(251).  Lower Th2 cytokine levels could reflect a 
change in the Th1/Th2 balance towards the Th1 phenotype with potential benefits to the 
infant in the prevention of atopy.  Few data are available on the effect that 
supplementation during pregnancy has upon maternal immune function.     311 
7.2 Methods 
The effect of maternal dietary fatty acids upon the maternal and fetal immune system 
will be assessed by monitoring immune organ weight and cellularity, immune cell 
subset phenotyping by flow cytometry, lymphocyte proliferation and the production of 
cytokines and prostaglandins by cultured blood and immune organ mononuclear cells. 
 
All animal work was carried out in accordance with the Home Office Animals 
(Scientific Procedures) Act (1986); for pregnant females, mating was carried out by 
monogamous breeding (see section 2.1).  Animals received experimental diets over a 20 
day period from the time of conception.  Six diets were used, a low fat (LF) soyabean 
oil diet, and five high fat (HF) diets: soyabean oil, linseed oil, salmon oil, sunflower oil, 
beef tallow.  The fatty acid composition of these diets is as described in Chapter 6 (see 
table 6.1).  Maternal and fetal tissues were collected on day 20 of gestation.  Immune 
cell phenotypes were identified by flow cytometry of lysed whole blood or immune 
organ mononuclear cell preparations (see section 2.11.1).  Ex vivo culture was 
performed to assess lymphocyte proliferation (see section 2.11.2) and the production of 
IFN γ, IL 4 and PGE2 in response to concanavalin A (see section 2.11.3).   
 
The effect of maternal diet upon the variables of interest was determined by one way 
ANOVA with Bonferroni post hoc correction for multiple comparisons.  Correlation 
coefficients were calculated using Pearson or Spearman test as appropriate after data 
were assessed for normality.  The effect of pregnancy upon the sensitivity of 
lymphocytes to concanavalin A (Con A) stimulation was assessed by Kruskal Wallis 
test.   
7.3 Results 
7.3.1 Maternal immune organ weights and cellularity 
The effects of diet during pregnancy upon maternal immune organ weight and 
cellularity (see table 7.1) were assessed using tissues from the cohort used in chapter 6, 
in order that samples of immune tissues from the current cohort could be reserved for 
histological and gene expression assessment as part of a collaboration with researchers 
at the University of Utrecht, The Netherlands.    
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Table 7.1: Immune organ size and cellularity in pregnant rats fed experimental diets (n=6 per group) 
 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil  HF Sunflower oil  HF Beef tallow  ANOVA  
p value 
SPLEEN               
Weight (g)  0.52 ± 0.11 
a  0.73 ± 0.08  0.71 ± 0.07
  0.86 ± 0.13 
b  0.65 ± 0.12
  0.75 ± 0.19 
b  0.002 
% body weight  0.19 ± 0.02 
a  0.24 ± 0.03
  0.22 ± 0.01
  0.27 ± 0.02 
b  0.21 ± 0.04
  0.23 ± 0.04
  0.003 
Total mononuclear cells 
(x 10
 6)  44.3 ± 46.5  52.9 ± 42.8  47.37 ± 30.56  113.39 ± 43.03  33.20 ± 33.44  70.85 ± 52.32  0.042 † 
Mononuclear cells per 
mg (x 10
 3)  75.52 ± 68.85  75.10 ± 70.36  81.66 ± 35.16  137.86 ± 67.47  54.85 ± 43.69  97.18 ± 60.71  0.274 
THYMUS               
Weight (g)  0.30 ± 0.07  0.37 ± 0.04
  0.34 ± 0.16
  0.40 ± 0.08
  0.35 ± 0.06
  0.41 ± 0.07
  0.317 
% body weight  0.11 ± 0.02
  0.12 ± 0.01
  0.11 ± 0.05
  0.13 ± 0.02
  0.12 ± 0.02
  0.13 ± 0.01
  0.787 
Total mononuclear cells 
(x 10
 6)  63.96 ± 111.24  69.51 ± 39.30  61.25 ± 36.01  72.01 ± 75.04  38.75 ± 50.74  62.13 ± 96.23  0.977 
Mononuclear cells per 
mg (x 10
 3)  182.41 ± 291.57  183.50 ± 89.63  422.10 ± 657.93  186.63 ± 186.19  109.17 ± 134.73  150.37 ± 209.70  0.627 
LYMPH NODES               
Weight (g)  0.11 ± 0.05  0.09 ± 0.02
  0.11 ± 0.01
  0.11 ± 0.04
  0.08 ± 0.03
  0.11 ± 0.05
  0.626 
% body weight  0.04 ± 0.01  0.03 ± 0.01
  0.03 ± 0.00
  0.04 ± 0.02
  0.03 ± 0.01
  0.03 ± 0.01
  0.444 
Total mononuclear cells 
(x 10
 6)  1.14 ± 0.60  3.02 ± 3.15  1.69 ± 0.41  2.62 ± 1.18  0.96 ± 0.73  3.31 ± 3.15  0.190 
Mononuclear cells per 
mg(x 10
 3)  10.33 ± 4.65  28.71 ± 21.60  15.84 ± 4.90  25.28 ± 14.09  12.07 ± 8.21  27.13 ± 24.24  0.158 
 
 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have different superscripts   
†  no significant differences between groups when Bonferroni applied   313 
Maternal diet was found to have a significant effect upon maternal spleen weight (both 
absolute and relative); with dams on the HF salmon oil and HF beef tallow diets having 
significantly higher spleen weights that those on the LF soyabean oil diet.  This higher 
spleen weight was associated with higher number of total mononuclear cells recovered 
from the maternal spleen, though the proportion of mononuclear cells per mg of 
immune organ tissue was not significantly affected by maternal diet during pregnancy.  
The reductions in maternal mandibular lymph node cellularity which were observed to 
occur during pregnancy (see table 5.3), were not significantly affected by the type of 
fatty acids within the maternal diet during pregnancy.  
7.3.2 Maternal immune cell phenotyping by flow cytometry 
Maternal immune tissues were analysed by flow cytometry to determine whether dietary 
fatty acids during pregnancy could alter the relative proportions of immune cells.   
 
There was no significant effect of maternal dietary fatty acids upon the percentage 
content of total T cells, T helper cells, cytotoxic T cells, NK cells, B cells or 
macrophages within mononuclear cells isolated from the maternal spleen (see table 7.2).  
This indicates that the significant effect of diet observed upon spleen size was not the 
result of an effect upon a particular lymphocyte subset, as the cell types identified 
maintain their relative contribution to tissue content.  There was a significant effect of 
maternal diet upon the mean fluorescence intensity (MFI) of cytotoxic T cell surface 
markers, with dams on the HF linseed oil diet (ALNA rich) demonstrating the highest 
expression of both CD3 and CD8 on their cell surface.  This higher expression of these 
cell surface markers suggests that the sensitivity of cytotoxic T cells to antigen 
presentation may be greatest in the HF linseed oil group.  Effects of n 3 fatty acids upon 
CD8 expression have been observed upon murine splenocytes, where the expression of 
some CD8 epitopes was found to be higher when diets containing fish oil are 
provided(252). 
 
The relative proportions of total T cells, T helper cells, cytotoxic T cells, CD161
+ cells 
(“NK” cells) or B cells within mononuclear cells isolated from the maternal thymus 
were not affected by maternal dietary fatty acids during pregnancy (see table 7.3).  
There was a significant effect of maternal diet upon the expression of CD8 on cytotoxic 
T cells, with the HF linseed oil diet group again demonstrating the highest mean 
expression of this cell surface marker.   314 
 
The relative proportions of total T cells, T helper cells, cytotoxic T cells, NK cells or B 
cells within maternal lysed whole blood were not affected by maternal diet during 
pregnancy (see table 7.4).  There was a significant effect of maternal dietary fatty acids 
upon the number of CD8
+ cells.  It was observed in an earlier study that pregnant 
animals at day 20 gestation have higher proportions of CD8
+ PBMC when compared to 
mid gestation females (See chapter 5, table 5.4).  The data from the current cohort 
indicates that maternal diet exerts a significant effect upon CD8
+ cells within maternal 
PBMC, so it is possible that maternal diet during pregnancy interacts with this 
adaptation to pregnancy. 
 
Mononuclear cells isolated from maternal lymph nodes demonstrated significant effects 
of maternal dietary fatty acids during pregnancy upon the relative proportions of 
cytotoxic T cells and T helper cells (see table 7.5).  There was a trend for the n 3 PUFA 
rich diets (HF linseed and HF salmon oil) to have the highest proportion of cytotoxic T 
cells.  The LF soyabean oil diet had a lower proportion of T helper cells than the HF 
dietary groups.  An effect of maternal diet was again observed upon the expression of 
cell surface markers upon cytotoxic T cells, with the expression of CD3 and CD8 on 
cytotoxic T cells highest in the HF salmon oil diet group (LC n 3 PUFA rich). 
 
Pregnancy was demonstrated in an earlier study (see chapter 5) to lead to significantly 
lower expression of CD161 expression on NK cells within lysed whole blood and 
mononuclear cells isolated from the maternal spleen (see table 5.4 and 5.5).  No 
significant effect of maternal dietary fatty acids was observed upon the expression of 
this cell surface marker on maternal NK cells in this cohort, indicating that maternal diet 
does not interact with this adaptation to pregnancy in the Wistar rat. 
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Table 7.2: Immune cell phenotypes identified within the spleen of pregnant rats fed experimental diets  
(% within lymphocyte gate, MFI, mean ± standard deviation) 
   
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil  HF Sunflower oil  HF Beef tallow  ANOVA 
  (n = 6)  (n = 5)  (n = 5)  (n = 5)  (n = 6)  (n = 6)  p value 
CD3
+ (%)  52.8 ± 9.7  56.7 ± 10.6  63.2 ± 10.2  60.5 ± 10.0  59.6 ± 8.9  62.3 ± 6.7  0.453 
CD8
+ (%)  28.9 ± 5.8  26.8 ± 6.7  32.3 ± 6.4  27.9 ± 6.5  26.7 ± 2.9  30.0 ± 5.7  0.613 
CD4
+ (%)  49.0 ± 6.7  47.8 ± 9.1  50.2 ± 4.0  47.3 ± 7.2  52.6 ± 10.9  49.8 ± 6.7  0.893 
               
CD3
+CD8
+ (%)  
(Cytotoxic T cells)   14.5 ± 4.6  14.5 ± 2.8  17.5 ± 3.7  17.3 ± 3.3  14.7 ± 1.6  18.9 ± 6.9  0.369 
   mean CD3 intensity  21.2 ± 2.9 
b  29.4 ± 4.1  31.7 ± 6.4 
a  30.0 ± 10.4  24.2 ± 3.0  20.2 ± 2.7 
b  0.004 
   mean CD8 intensity  25.2 ± 5.5 
b  37.6 ± 8.0  42.9 ± 12.9 
a  40.2 ± 9.7  27.9 ± 3.4  25.5 ± 7.2 
b  0.002 
               
CD3
+CD4
+ (%) 
(T helper cells)   39.8 ± 7.4  42.7 ± 8.2  45.2 ± 5.5  42.6 ± 7.6  45.8 ± 10.3  43.3 ± 5.6  0.805 
   mean CD3 intensity  33.4 ± 6.9  34.0 ± 7.4  40.3 ± 10.8  40.0 ± 6.7  40.7 ± 6.8  34.7 ± 5.0  0.316 
   mean CD4 intensity  439.1 ± 10.2  472.9 ± 28.0  470.0 ± 25.7  472.6 ± 37.5  465.3 ± 24.7  446.6 ± 39.1  0.245 
               
CD161
+ (%) 
(NK cells)   13.1 ± 4.0  16.6 ± 11.1  10.9 ± 2.1  11.7 ± 4.0  12.1 ± 2.3  11.8 ± 3.3  0.581 
   mean CD161 intensity  69.2 ± 25.3  54.5 ± 8.0  52.8 ± 17.8  49.8 ± 6.3  67.2 ± 20.4  53.9 ± 16.5  0.323 
               
CD3
 CD45
+ (%) 
(B cells)  34.0 ± 7.4  32.4 ± 10.7  23.2 ± 14.4  25.6 ± 10.2  28.3 ± 10.8  27.7 ± 8.1  0.562 
   mean CD45 intensity  125.2 ± 22.0  118.5 ± 14.1  138.9 ± 27.4  150.3 ± 45.6  118.8 ± 30.7  145.0 ± 29.5  0.353 
               
Macrophages (%)  26.7 ± 7.0  23.1 ± 8.1  19.3 ± 13.4  24.4 ± 2.9  22.4 ± 5.3  23.9 ± 7.3  0.763 
   mean CD163 intensity  42.0 ± 11.2  31.6 ± 4.1  44.8 ± 15.6  37.4 ± 8.4  41.5 ± 10.6  43.8 ± 7.6  0.337 
               
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have different superscripts   316 
Table 7.3: Immune cell phenotypes identified within the thymus of pregnant rats fed experimental diets  
(% total cells, MFI, mean ± standard deviation) 
 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil  HF Sunflower oil  HF Beef tallow  ANOVA 
  (n = 6)  (n = 5)  (n = 5)  (n = 5)  (n = 6)  (n = 6)  p value 
CD3
+ (%)  30.7 ± 6.9  34.1 ± 10.2  31.0 ± 4.7  32.0 ± 6.2  33.4 ± 7.7  31.4 ± 5.9  0.956 
CD8
+ (%)  72.0 ± 4.6  73.2 ± 6.7  78.7 ± 6.1  75.2 ± 1.1  70.7 ± 8.1  76.5 ± 3.7  0.205 
CD4
+ (%)  84.4 ± 2.3  83.9 ± 3.6  83.7 ± 4.4  84.5 ± 2.4  82.3 ± 5.9  85.2 ± 3.2  0.865 
               
CD3
+CD8
+ (%)  
(Cytotoxic T cells)   12.6 ± 2.3  16.2 ± 3.3  17.9 ± 4.7  16.5 ± 5.0  14.4 ± 4.0  14.7 ± 3.3  0.286 
   mean CD3 intensity  46.6 ± 2.9  62.9 ± 20.8  56.6 ± 14.0  63.4 ± 15.0  53.2 ± 13.7  46.3 ± 6.4  0.140 
   mean CD8 intensity  37.9 ± 5.8  60.0 ± 28.2  67.4 ± 33.4  61.7 ± 15.3  39.0 ± 6.1  41.1 ± 8.3  0.038 † 
               
CD3
+CD4
+ (%) 
(T helper cells)   28.1 ± 6.5  29.9 ± 8.8  27.4 ± 4.0  28.7 ± 4.9  29.4 ± 5.5  28.2 ± 3.6  0.983 
   mean CD3 intensity  54.8 ± 9.9  53.0 ± 16.6  59.6 ± 9.9  62.8 ± 3.7  57.9 ± 9.3  58.4 ± 4.5  0.663 
   mean CD4 intensity  348.4 ± 53.0  365.7 ± 16.6  419.4 ± 82.9  378.6 ± 34.9  339.1 ± 22.7  367.9 ± 45.1  0.128 
               
CD161
+ (%) 
(NK cells)†  5.5 ± 2.2  4.9 ± 2.2  4.9 ± 2.2  5.6 ± 1.4  6.6 ± 2.2  4.5 ± 1.9  0.612 
   mean CD161 intensity  79.2 ± 13.5  78.7 ± 15.5  96.9 ± 32.5  84.7 ± 22.8  82.3 ± 23.4  94.8 ± 16.6  0.598 
               
CD3
 CD45
+ (%) 
(B cells)  2.7 ± 0.9  2.2 ± 0.7  2.0 ± 0.6  2.4 ± 0.4  3.3 ± 1.1  2.5 ± 1.7  0.404 
   mean CD45 intensity  82.1 ± 13.3  93.3 ± 24.8  102.1 ± 44.1  88.2 ± 9.1  102.3 ± 29.2  98.6 ± 29.6  0.771 
               
 
†  no significant differences between groups when Bonferroni applied 
†These are not likely to be NK cells, but to be another cell type bearing CD161 on the surface   317 
Table 7.4: Immune cell phenotypes identified within in the peripheral blood of pregnant rats fed experimental diets  
(% within lymphocyte gate, MFI, mean ± standard deviation) 
  
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil  HF Sunflower oil  HF Beef tallow  ANOVA 
  (n = 6)  (n = 5)  (n = 4)  (n = 3)  (n = 5)  (n = 6)  p value 
CD3
+ (%)  45.5 ± 7.0  46.3 ± 5.1  51.8 ± 11.5  45.1 ± 9.9  43.7 ± 10.4  48.0 ± 10.5  0.832 
CD8
+ (%)  33.1 ± 3.5  26.5 ± 3.6  28.1 ± 5.4  29.6 ± 2.1  32.0 ± 1.9  33.5 ± 4.1  0.032 † 
CD4
+ (%)  45.1 ± 7.2  50.6 ± 4.3  51.3 ± 5.4  51.0 ± 6.2  50.3 ± 6.1  50.1 ± 8.4  0.643 
               
CD3
+CD8
+ (%)  
(Cytotoxic T cells)   14.2 ± 2.0  12.6 ± 1.5  15.2 ± 4.3  14.3 ± 4.2  13.9 ± 4.4  17.9 ± 4.3  0.303 
   mean CD3 intensity  33.4 ± 5.8  34.8 ± 15.7  40.3 ± 19.8  33.3 ± 17.3  29.9 ± 7.3  27.5 ± 4.5  0.706 
   mean CD8 intensity  54.3 ± 14.9  72.4 ± 23.7  70.8 ± 7.1  65.6 ± 16.6  50.2 ± 10.9  49.6 ± 15.9  0.116 
               
CD3
+CD4
+ (%) 
(T helper cells)   31.1 ± 6.7  34.5 ± 4.0  38.4 ± 8.2  31.8 ± 7.8  31.1 ± 9.9  32.3 ± 7.1  0.680 
   mean CD3 intensity  41.2 ± 9.8  27.4 ± 14.6  43.1 ± 10.7  40.4 ± 8.5  39.6 ± 9.5  42.9 ± 9.5  0.220 
   mean CD4 intensity  590.7 ± 28.0  631.0 ± 44.0  624.8 ± 32.8  614.6 ± 40.0  612.2 ± 40.0  610.7 ± 37.7  0.527 
               
CD161
+ (%) 
(NK cells)   21.4 ± 2.7  18.1 ± 5.3  16.8 ± 3.2  24.9 ± 4.5  21.8 ± 5.6  22.3 ± 4.3  0.147 
   mean CD161 intensity  247.9 ± 37.9  257.7 ± 66.3  273.2 ± 64.2  251.3 ± 68.3  222.8 ± 42.5  238.5 ± 81.7  0.873 
               
CD3
 CD45
+ (%) 
(B cells)  23.3 ± 6.4  21.4 ± 5.1  17.2 ± 3.4  19.4 ± 5.8  19.7 ± 4.4  18.2 ± 6.4  0.550 
   mean CD45 intensity  292.6 ± 35.5  273.3 ± 87.1  331.2 ± 48.4  313.6 ± 83.6  298.5 ± 35.1  245.6 ± 51.4  0.285 
               
 
†  no significant differences between groups when Bonferroni applied    318 
Table 7.5: Immune cell phenotypes identified within the mandibular lymph nodes of pregnant rats fed experimental diets  
(% within lymphocyte gate, MFI, mean ± standard deviation) 
  
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil  HF Sunflower oil  HF Beef tallow  ANOVA 
  (n = 6)  (n = 2)  (n = 3)  (n = 5)  (n = 3)  (n = 4)  p value 
CD3
+ (%)  52.9 ± 10.1  71.5 ± 22.0  69.8 ± 10.7  69.0 ± 7.1  64.1 ± 4.0  57.5 ± 2.9  0.054 
CD8
+ (%)  13.8 ± 2.7  20.6 ± 6.8  21.7 ± 5.1  22.5 ± 5.8  17.1 ± 4.9  17.1 ± 1.6  0.050 
CD4
+ (%)  56.3 ± 2.7  63.7 ± 11.0  61.2 ± 4.9  58.4 ± 8.5  65.0 ± 4.2  56.3 ± 2.7  0.363 
               
CD3
+CD8
+ (%)  
(Cytotoxic T cells)   9.5 ± 3.6  16.3 ± 7.6  18.5 ± 6.1  18.0 ± 4.2  11.4 ± 3.8  12.0 ± 2.0  0.028 † 
   mean CD3 intensity  15.6 ± 1.9 
b  23.1 ± 2.8  18.7 ± 3.1  30.4 ± 11.2 
a  19.0 ± 4.7  15.7 ± 1.8 
b  0.011 
   mean CD8 intensity  17.3 ± 0.7 
b  28.3 ± 5.1  24.5 ± 8.0  36.1 ± 7.6 
a  20.5 ± 4.0 
b  19.9 ± 1.4 
b  < 0.001 
               
CD3
+CD4
+ (%) 
(T helper cells)   43.8 ± 6.6  56.9 ± 14.3  54.7 ± 6.2  53.8 ± 4.7  54.6 ± 2.6  47.3 ± 3.3  0.044 † 
   mean CD3 intensity  24.6 ± 4.8  27.2 ± 15.8  29.5 ± 12.0  33.9 ± 9.7  29.4 ± 6.6  31.2 ± 7.5  0.634 
   mean CD4 intensity  399.4 ± 49.0  422.8 ± 163.5  457.5 ± 77.0  439.9 ± 43.3  426.9 ± 31.4  453.2 ± 35.2  0.725 
               
CD161
+ (%) 
(NK cells)   8.8 ± 2.8  7.3 ± 1.7  8.6 ± 1.6  8.8 ± 2.4  8.2 ± 0.5  8.7 ± 3.8  0.981 
   mean CD161 intensity  41.5 ± 8.0  55.3 ± 1.3  32.1 ± 23.0  53.9 ± 16.6  51.3 ± 16.6  36.9 ± 2.1  0.143 
               
CD3
 CD45
+ (%) 
(B cells)  32.2 ± 5.6  21.7 ± 21.7  23.4 ± 10.8  23.4 ± 6.2  24.6 ± 6.7  32.5 ± 5.1  0.303 
   mean CD45 intensity  102.2 ± 18.7  128.8 ± 8.0  116.6 ± 45.7  145.3 ± 12.4  119.0 ± 22.7  142.1 ± 51.3  0.253 
               
 
†  no significant differences between groups when Bonferroni applied   319 
7.3.3 Maternal lymphocyte proliferation 
 
Lymphocyte proliferation in response to Con A (stimulation index, adjusted for CD3
+ 
cells) was assessed in mononuclear cell suspensions derived from the maternal spleen 
and thymus.  Proliferative responses were assessed by calculation of area under the 
curve (AUC) of the Con A dose response (see figures 7.1 and 7.2, table 7.6).  There was 
little indication of any significant effect of maternal dietary fatty acids upon maternal 
lymphocyte proliferation.  
 
Figure 7.1: Mean proliferation of spleen lymphocytes from pregnant rats fed different 
diets (stimulation index, adjusted for CD3
+ cell numbers) 
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Figure 7.2: Mean proliferation of thymic lymphocytes from pregnant rats fed different 
diets (stimulation index, adjusted for CD3
+ cell numbers) 
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Table 7.6: Proliferative responses of lymphocytes from pregnant rats fed different diets   
(AUC, adjusted for CD3
+ cell numbers, mean ± standard deviation) 
 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil  HF Sunflower oil  HF Beef Tallow 
ANOVA 
p value 
  (n=3)  (n=4)  (n=3)  (n=4)  (n=4)  (n=6)   
Spleen  10.1 ± 4.0  13.1 ± 5.8  24.0 ± 23.9  12.4 ± 7.5  10.2 ± 3.6  20.7 ± 11.3  0.401 
  (n=5)  (n=4)  (n=5)  (n=5)  (n=3)  (n=6)   
Thymus  37.2 ± 26.8  28.4 ± 13.3  21.2 ± 6.1  28.3 ± 21.6  30.2 ± 17.6  20.4 ± 8.9  0.642 
 
 
  
 
 
    322 
7.3.4 Maternal production of immune signalling molecules 
 
PGE2 
 
PGE2 is a mediator produced by monocytes and macrophages from AA.  Maternal diet 
altered PGE2 production by maternal spleen cells, with the diets containing the most n 3 
PUFA (HF soyabean, linseed and salmon oil) having the lowest PGE2 production.  No 
significant effect of maternal dietary fatty acids during pregnancy was observed upon 
PGE2 concentrations in maternal plasma, or PGE2 produced by maternal PBMC (see 
table 7.7). 
 
IFN γ 
 
IFN γ is a Th1 type cytokine produced by T helper cells, cytotoxic T cells and NK cells.  
Data suggests that maternal dietary fatty acids during pregnancy can alter IFN γ 
production by maternal spleen cells, with dams on the HF Beef tallow diet having the 
highest IFN γ production by spleen lymphocytes (both stimulated with Con A and 
unstimulated).  No significant effect of maternal diet was observed upon IFN γ 
production by the maternal thymus or PBMC (see table 7.8). 
 
IL 4 
IL 4 is a Th 2 type cytokine produced by T helper cells, cytotoxic T cells and NK cells.  
No significant effect of maternal dietary fatty acids during pregnancy was observed 
upon IL 4 production by cells from the maternal spleen, thymus or blood (see table 7.9). 
Th1:Th2 ratio 
An increased maternal Th1:Th2 ratio had been observed within thymocytes of pregnant 
rats when compared to virgin rats (see chapter 5, table 5.12).  No significant effect of 
maternal dietary fatty acids during pregnancy was observed upon the Th1 to Th2 ratio 
of cytokines produced by cells from the maternal spleen, thymus or blood (see table 
7.10).  323 
 
 
 
 
Table 7.7: PGE2 concentration in plasma and PGE2 production by spleen and peripheral blood lymphocytes from pregnant rats fed experimental diets 
(ng/ml; mean ± standard deviation) 
 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil  HF Sunflower 
oil 
HF Beef tallow   ANOVA  
p value 
Plasma  (n=6)  (n=6)  (n=6)  (n=6)  (n=6)  (n=6)   
  33.3 ± 32.0  27.6 ± 19.5  122.5 ± 143.5  34.6 ± 21.1  25.2 ± 6.4  30.7 ± 23.4  0.077 
Spleen  (n=5)  (n=5)  (n=6)  (n=6)  (n=6)  (n=6)   
No Con A  2.2 ± 1.1  1.4 ± 1.0  0.6 ± 0.3  0.9 ± 0.5  1.6 ± 0.6  2.8 ± 2.8  0.104 
5  g/ml Con A  2.5 ± 0.4  0.5 ± 0.6  0.7 ± 0.5  0.9 ± 0.4  1.9 ± 0.9  2.9 ± 2.8  0.043 † 
Mean SI  1.3 ± 0.7  0.4 ± 0.5  1.1 ± 0.9  1.0 ± 0.4  1.4 ± 0.9  1.2 ± 0.5  0.327 
PBMC  (n=5)  (n=4)  (n=6)  (n=4)  (n=6)  (n=4)   
No Con A  3.4 ± 2.7  24.1 ± 43.9  1.5 ± 0.8  21.7 ± 37.6  35.8 ± 79.5  3.7 ± 3.3  0.704 
5  g/ml Con A  11.3 ± 5.9  44.9 ± 73.7  3.7 ± 4.2  23.3 ± 40.3  37.0 ± 71.0  9.8 ± 7.0  0.709 
Mean SI  4.5 ± 3.3  1.2 ± 0.2  2.3 ± 1.8  1.3 ± 0.6  2.9 ± 2.3  3.9 ± 3.4  0.304 
 
SI   stimulation index  
†  no significant differences between groups when Bonferroni applied    324 
 
 
Table 7.8: IFN γ production by spleen, thymus and peripheral blood lymphocytes from pregnant rats fed experimental diets (mean ± standard 
deviation) 
 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil  HF Sunflower 
oil 
HF Beef tallow   ANOVA  
p value 
Spleen  (n=5)  (n=6)  (n=6)  (n=5)  (n=6)  (n=6)   
No Con A (pg/ml)  ND  4.4 ± 3.8  3.0 ± 2.8  31.6 ± 62.9  34.5 ± 23.1  50.4 ± 25.3  0.020 † 
5  g/ml Con A (ng/ml)  38.7 ± 30.9  9.7 ± 10.1 
b  14.5 ± 12.6 
b  44.3 ± 25.7  23.9 ± 15.6 
b  80.7 ± 47.8 
a  0.006 
Mean SI (x 10
 3)  38.7 ± 30.9  7.0 ± 11.4  10.1 ± 15.5  35.8 ± 32.9  0.8 ± 0.3  1.8 ± 1.1  0.010 † 
Thymus  (n=5)  (n=5)  (n=6)  (n=6)  (n=6)  (n=6)   
No Con A (pg/ml)  39.5 ± 54.0  15.5 ± 26.4  3.5 ± 3.0  48.5 ± 94.7  7.1 ± 7.3  1.6 ± 2.4  0.393 
5  g/ml Con A (ng/ml)  15.1 ± 8.0  7.1 ± 6.2  7.3 ± 4.7  28.9 ± 21.5  24.3 ± 18.3  27.3 ± 35.4  0.421 
Mean SI (x 10
 3)  5.2 ± 4.6  1.5 ± 1.2  3.5 ± 4.6  8.0 ± 13.4  6.2 ± 5.1  12.7 ± 8.1  0.272 
PBMC  (n=5)  (n=4)  (n=4)  (n=5)  (n=6)  (n=4)   
No Con A (pg/ml)  47.3 ± 31.4  85.0 ± 126.5  23.7 ± 38.0  115.6 ± 163.5  50.9 ± 109.5  246.4 ± 432.1  0.581 
5  g/ml Con A (ng/ml)  26.1 ± 25.3  2.5 ± 2.2  12.0 ± 13.9  6.9 ± 6.4  8.8 ± 8.7  16.2 ± 3.1  0.207 
Mean SI (x 10
 2)  5.0 ± 2.6  1.1 ± 0.6  3.8 ± 1.5  37.1 ± 56.6  49.8 ± 77.3  45.1 ± 84.1  0.692 
 
SI   stimulation index 
†  no significant differences between groups when Bonferroni applied  
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have different superscripts 
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Table 7.9: IL 4 production by spleen, thymus and peripheral blood lymphocytes from pregnant rats fed experimental diets (mean ± standard deviation) 
 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil  HF Sunflower 
oil 
HF Beef tallow   ANOVA  
p value 
Spleen  (n=5)  (n=6)  (n=6)  (n=6)  (n=6)  (n=6)   
No Con A (pg/ml)  11.9 ± 9.1  17.3 ± 7.1  17.9 ± 10.0  17.0 ± 8.6  21.1 ± 3.8  22.2 ± 10.3  0.430 
5  g/ml Con A (ng/ml)  7.5 ± 5.3  14.8 ± 5.2  21.8 ± 12.8  14.4 ± 12.4  18.5 ± 13.2  19.2 ± 13.4  0.463 
Thymus  (n=5)  (n=5)  (n=6)  (n=6)  (n=6)  (n=6)   
No Con A (pg/ml)  16.3 ± 12.9  17.8 ± 7.9  14.5 ± 11.5  13.1 ± 11.7  13.1 ± 5.1  20.0 ± 6.4  0.784 
5  g/ml Con A (ng/ml)  6.7 ± 9.0  14.5 ± 12.7  12.6 ± 8.9  14.3 ± 11.8  18.1 ± 11.6  15.6 ± 8.2  0.621 
PBMC  (n=5)  (n=4)  (n=4)  (n=5)  (n=6)  (n=4)   
No Con A (pg/ml)  6.6 ± 3.2  7.9 ± 13.2  13.3 ± 6.5  11.0 ± 15.1  9.7 ± 9.7  10.0 ± 5.5  0.937 
5  g/ml Con A (ng/ml)  5.3 ± 4.6  18.8 ± 9.1  14.6 ± 9.8  17.4 ± 18.1  11.9 ± 9.8  9.0 ± 3.5  0.425 
 
 
Table 7.10: IFNγ:IL 4 ratios produced by Con A stimulated spleen, thymus and peripheral blood lymphocytes from virgin and pregnant rats (mean ± 
standard deviation) 
 
  LF Soyabean 
oil 
HF Soyabean 
oil 
HF Linseed oil  HF Salmon oil  HF Sunflower 
oil 
HF Beef tallow   ANOVA  
p value 
  (n=5)  (n=4)  (n=4)  (n=5)  (n=6)  (n=6)   
Spleen IFNγ:IL 4 x 10
 3  6.1 ± 4.0  1.0 ± 1.3  0.9 ± 0.9  9.1 ± 10.2  35.5 ± 83.6  6.0 ± 4.0  0.675 
  (n=3)  (n=3)  (n=3)  (n=4)  (n=4)  (n=6)   
Thymus IFNγ:IL 4 x 10
 3  5.4 ± 7.0  0.3 ± 0.2  0.3 ± 0.2  2.7 ± 2.2  1.3 ± 1.2  2.1 ± 2.5  0.312 
  (n=4)  (n=3)  (n=2)  (n=3)  (n=5)  (n=4)   
Peripheral blood IFNγ:IL 4 x 10
 3  9.5 ± 10.7  0.2 ± 0.3  1.5 ± 2.0  0.2 ± 0.2  0.7 ± 0.9  2.2 ± 1.5  0.128   326 
7.3.5 Fetal thymus weight and cellularity 
 
The effects of maternal diet during pregnancy upon fetal thymus weight and cellularity 
were assessed in tissues collected from the cohort used in chapter 6, in order that 
samples of immune tissues from this cohort could be reserved for histological and gene 
expression assessment as part of a collaboration with researchers at the University of 
Utrecht, The Netherlands.   
 
No significant effects of maternal diet during pregnancy were observed upon fetal 
thymus weight or cellularity (see table 7.11).  The contribution of the fetal thymus 
towards body weight and its cellularity were comparable to those observed among adult 
virgin females (virgin female thymus: 0.21 ± 0.04% total body weight, 47.0 x 10
4 cells 
per mg, see table 5.3). 
 
7.3.6 Fetal immune cell phenotyping by flow cytometry 
 
Mononuclear cells isolated from the fetal thymus were analysed to determine whether 
maternal dietary fatty acids during pregnancy could alter the proportions of the cell 
types identified.  No significant effects of maternal diet were observed upon the 
proportion of total T cells, cytotoxic T cells or T helper cells within the fetal thymus.  
Maternal diet significantly affected the proportion of CD161
+ cells (“NK” cells).  The 
HF linseed oil group had the highest proportion of these cells, and the HF sunflower oil 
group the lowest (see table 7.12).  This suggests that the balance of n 3 and n 6 fatty 
acids in the maternal diet has the capacity to influence the lineage commitment and 
differentiation of progenitor cells within the thymus.   
 
The expression of CD3 and CD8 upon the cell surface of cytotoxic T cells within the 
fetal thymus was significantly affected by maternal dietary fatty acids during pregnancy.  
The HF salmon oil group had a significantly higher expression of CD3 than any other 
dietary group.  Expression of CD8 tended to be highest among the n 3 PUFA rich diet 
groups (HF linseed and HF salmon oil).  
 
   327 
Table 7.11: Fetal thymus weight and cellularity (mean ± standard deviation, n=6 per group) 
 
 
LF Soyabean 
oil 
HF Soyabean 
oil  HF Linseed oil  HF Salmon oil  HF Sunflower 
oil  HF Beef tallow  ANOVA  
p value 
Thymus weight (mg/pup)  3.52 + 1.61  4.56 + 0.82  4.62 + 1.50  3.73 + 0.78  4.29 + 1.49  4.02 + 0.89  0.565 
Thymus weight (% body weight)  0.15 + 0.06  0.19 + 0.04  0.20 + 0.04  0.18 + 0.04  0.18 + 0.03  0.19 + 0.05  0.598 
Total mononuclear cells from 
whole litter (x 10
 6)  19.25 ± 6.53  15.65 ± 7.15  16.07 ± 10.29  17.42 ± 6.06  23.77 ± 15.43  17.42 ± 8.93  0.718 
Mononuclear cells per mg 
thymus (x 10
 4)  97.46 ± 153.33  32.19 ± 19.30  36.28 ± 35.29  37.21 ± 21.02  47.45 ± 18.71  33.90 ± 19.33  0.518 
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Table 7.12: Immune cell phenotypes identified within the fetal thymus (% within lymphocyte gate, MFI, mean ± standard deviation) 
 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil  HF Sunflower oil  HF Beef tallow  ANOVA 
  (n=5)  (n=5)  (n=5)  (n=5)  (n=6)  (n=6)  p value 
CD3
+ (%)  15.5 ± 5.5  16.3 ± 2.8  16.5 ± 4.3  15.1 ± 3.0  13.7 ± 5.4  17.5 ± 5.1  0.789 
CD8
+ (%)  77.4 ± 9.3  84.8 ± 7.9  84.5 ± 8.3  86.8 ± 2.8  84.1 ± 4.5  73.1 ± 13.3  0.089 
CD4
+ (%)  82.4 ± 2.4  80.4 ± 7.5  75.7 ± 7.0  78.5 ± 3.8  80.7 ± 5.4  76.7 ± 5.4  0.371 
               
CD3
+CD8
+ (%)  
(Cytotoxic T cells)   10.6 ± 4.6  14.8 ± 3.4  16.2 ± 4.3  14.1 ± 2.8  10.9 ± 5.2  11.7 ± 5.1  0.247 
   mean CD3 intensity  46.5 ± 8.4  54.9 ± 12.7  50.4 ± 10.6  78.1 ± 9.9 *  55.7 ± 12.5  46.3 ± 11.6  0.001 
   mean CD8 intensity  146.2 ± 73.6  198.0 ± 99.0  283.7 ± 80.4  257.0 ± 64.7  164.3 ± 35.8  167.0 ± 93.4  0.042 † 
               
CD3
+CD4
+ (%) 
(T helper cells)   16.7 ± 7.1  14.6 ± 3.7  15.3 ± 5.2  15.2 ± 3.5  14.8 ± 5.9  18.5 ± 6.0  0.816 
   mean CD3 intensity  58.0 ± 11.9  70.4 ± 30.1  70.9 ± 18.0  76.1 ± 25.5  67.1 ± 34.4  49.1 ± 8.0  0.444 
   mean CD4 intensity  477.4 ± 74.9  477.6 ± 120.1  739.5 ± 210.8  664.7 ± 298.0  499.3 ± 109.3  522.6 ± 144.8  0.097 
               
CD161
+ (%) 
(NK cells) †  5.5 ± 1.5  5.3 ± 2.7  9.8 ± 2.7
 a  7.7 ± 2.4  5.1 ± 2.1
 b  6.6 ± 2.4  0.024 
   mean CD161 intensity  147.0 ± 53.7  133.9 ± 13.3  101.9 ± 15.7  146.1 ± 32.4  149.5 ± 42.3  139.0 ± 19.1  0.225 
               
 
†  no significant differences between groups when Bonferroni applied 
a, b  groups which differ significantly from each other (Bonferroni p < 0.05) have different superscripts 
*  significantly different from all other groups (Bonferroni p < 0.05) 
†These are not likely to be NK cells, but to be another cell type bearing CD161 on the surface   329 
7.3.7 Fetal thymocyte proliferation 
 
Proliferation of mononuclear cell isolated from the fetal thymus in response to Con A 
(stimulation index, adjusted for CD3
+ cells) was assessed for the effect of maternal 
dietary fatty acids during pregnancy by analysis of area under the curve.  There was a 
significant effect of maternal diet during pregnancy upon fetal thymus proliferation, 
with the n 3 PUFA rich dietary groups (HF soyabean, linseed and salmon oil) tending to 
have the lowest proliferative responses (see figure 7.3, table 7.13).  It should be noted 
that the data available for fetal thymus proliferation was severely limited by small 
sample size, due to difficulties in obtaining sufficient cell numbers to perform the 
analysis. 
 
 
Figure 7.3: Mean proliferation of fetal thymic lymphocytes (stimulation index, adjusted 
for CD3
+ cell numbers) 
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Error bars omitted for clarity   330 
 
 
 
 
 
 
 
Table 7.13: Proliferative responses of fetal thymic lymphocytes (AUC*, adjusted for CD3
+ cell numbers, mean ± standard deviation) 
 
  LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil  HF Sunflower oil  HF Beef Tallow 
ANOVA 
p value 
  (n=2)  (n=2)  (n=2)  (n=1)  (n=2)  (n=2)   
Fetal thymus  7.0 ± 1.1  2.6 ± 0.8  1.6 ± 0.8  2.63  6.1 ± 0.5  5.8 ± 2.3  0.004 
 
* AUC calculated using data points from 1 7.5 g/ml ConA. 
NB   Bonferroni not possible as n = 1 in HF salmon oil group.   331 
7.3.8 Fetal production of immune signalling molecules 
 
PGE2 
 
There was a significant effect of maternal dietary fatty acids upon PGE2 production by 
fetal PBMC, with production of PGE2 being highest in the HF soyabean and HF beef 
tallow dietary groups.  No significant effect of maternal diet was observed upon PGE2 
concentrations in fetal plasma (see table 7.14). 
 
IFN γ 
 
Fetal immune cells were less responsive to Con A stimulation than was observed in 
maternal immune cells.  No significant effect of maternal dietary fatty acids during 
pregnancy was observed upon fetal IFN γ production by thymocytes or PBMC (see 
table 7.15). 
 
IL 4 
Maternal diet during pregnancy exerted a significant effect upon IL 4 production by 
fetal thymus cells with production being highest in dietary groups rich in n 3 PUFA (see 
table 7.16). 
Th1:Th2 ratio 
No significant effect of maternal diet was observed upon the ratio of Th1 to Th2 
cytokines produced by fetal thymus cells or PBMC (see table 7.17).  332 
   
Table 7.14: PGE2 concentration in fetal plasma and PGE2 production by fetal peripheral blood lymphocytes (ng/ml; mean ± standard deviation) 
 
 
LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil 
HF Sunflower 
oil  HF Beef tallow 
ANOVA  
p value 
Plasma  (n=6)  (n=6)  (n=6)  (n=6)  (n=6)  (n=6)   
  16.1 ± 7.2  17.8 ± 4.2  14.6 ± 3.8  13.6 ± 4.9  13.3 ± 1.5  13.9 ± 2.7  0.478 
PBMC  (n=4)  (n=3)  (n=4)  (n=4)  (n=4)  (n=5)   
No Con A  1.1 ± 0.5  1.2 ± 1.4  1.1 ± 0.9  1.0 ± 0.1  1.1 ± 0.4  1.5 ± 1.3  0.970 
5 g/ml Con A  1.0 ± 0.4  5.1 ± 3.9  1.8 ± 0.7  1.0 ± 0.2  0.8 ± 0.3  2.7 ± 2.7  0.084 
Mean SI  0.9 ± 0.1  2.7 ± 0.2  1.4 ± 0.7  1.0 ± 0.1  0.9 ± 0.3  1.8 ± 1.2  0.035 † 
 
†  no significant differences between groups when Bonferroni applied 
 
 
Table 7.15: IFN γ production by fetal thymus and peripheral blood lymphocytes (pg/ml; mean ± standard deviation) 
 
 
LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil 
HF Sunflower 
oil  HF Beef tallow 
ANOVA  
p value 
Thymus  (n=5)  (n=5)  (n=4)  (n=6)  (n=4)  (n=5)   
No Con A  25.9 ± 5.2  3.0 ± 3.0  2.9 ± 3.7  1.6 ± 3.9  0.6 ± 1.1  10.5 ± 23.6  0.636 
5 g/ml Con A  45.8 ± 82.0  5.6 ± 2.4  257.6 ± 500.3  15.3 ± 17.1  15.2 ± 15.7  200.3 ± 390.2  0.604 
Mean SI  45.6 ± 82.1  4.2 ± 2.9  83.4 ± 154.4  24.9 ± 17.0  15.2 ± 15.7  184.7 ± 397.7  0.746 
PBMC  (n=4)  (n=3)  (n=4)  (n=5)  (n=4)  (n=5)   
No Con A  10.4 ± 20.1  4.1 ± 0.5  1.5 ± 1.1  1.9 ± 4.2  32.8 ± 62.6  6.6 ± 9.7  0.557 
5 g/ml Con A  6.9 ± 6.0  5.2 ± 2.8  93.6 ± 161.4  197.7 ± 197.5  201.1 ± 219.7  452.4 ± 467.7  0.231 
Mean SI  5.5 ± 6.9  1.2 ± 0.6  93.5 ± 161.6  197.7 ± 197.5  91.6 ± 125.6  182.4 ± 232.3  0.485 
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Table 7.16 IL 4 production by fetal peripheral blood lymphocytes (pg/ml; mean ± standard deviation) 
 
 
LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil  HF Sunflower oil  HF Beef tallow 
ANOVA 
p value 
Thymus  (n=5)  (n=5)  (n=4)  (n=6)  (n=4)  (n=5)   
No Con A  3.5 ± 6.4 
b  18.5 ± 8.0  22.2 ± 6.2 
a  15.4 ± 12.0  9.0 ± 7.3  3.4 ± 4.5 
b  0.005 
5  g/ml Con A  6.0 ± 5.6  18.0 ± 13.0  24.2 ± 7.7  14.6 ± 13.2  6.7 ± 3.1  12.7 ± 5.5  0.081 
PBMC  (n=4)  (n=3)  (n=5)  (n=5)  (n=4)  (n=5)   
No Con A  8.0 ± 5.9  8.3 ± 7.3  18.8 ± 20.7  15.4 ± 7.1  13.6 ± 7.1  11.9 ± 7.1  0.705 
5  g/ml Con A  7.0 ± 4.7  4.8 ± 6.7  19.9 ± 11.4  13.5 ± 7.6  7.3 ± 5.5  7.7 ± 1.9  0.081 
 
 
 
 
Table 7.17: IFN γ:IL 4 ratios produced by Con A stimulated thymus and peripheral blood lymphocytes (mean ± standard deviation) 
 
LF Soyabean oil  HF Soyabean oil  HF Linseed oil  HF Salmon oil  HF Sunflower oil  HF Beef tallow 
ANOVA  
p value 
  (n=3)  (n=4)  (n=4)  (n=5)  (n=3)  (n=5)   
THYMUS IFN γ:IL 4  1.1 ± 1.3  0.8 ± 1.0  19.6 ± 38.6  21.2 ± 30.4  2.7 ± 2.4  15.4 ± 30.0  0.732 
  (n=5)  (n=1)  (n=3)  (n=4)  (n=3)  (n=5)   
PBMC IFN γ:IL 4  4.1 ± 7.4  0.3  7.9 ± 13.7  21.9 ± 21.5  30.0 ± 44.3  69.1 ± 71.1  0.290 
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7.3.9 Correlations between markers of immune function and tissue 
fatty acid composition 
Maternal and fetal immune tissues from the cohort used in chapter 6 were assessed for 
fatty acid composition (see tables 6.19 to 6.24; 6.45 to 6.47).  These data were 
correlated with the markers of immune function studied in the current cohort to identify 
possible relationships between tissue fatty acid composition and function.   
Correlations between PGE2 and fatty acid composition of tissues 
 
PGE2 is an eicosanoid mediator which is generated from AA.  Other authors have 
demonstrated that human immune cells with the greatest AA content produce the most 
PGE2(96).  A study which used a rat model identified that feeding n 3 rich diets resulted 
in significant reductions in PGE2 production(250).  It is hypothesised that by increasing 
the EPA content of cell membranes the production of PGE2 is reduced, by either 
reducing the substrate available for PGE2 synthesis, or by competitive inhibition of 
cyclooxygenase by EPA.  The current dataset was therefore assessed for correlations 
between AA or EPA content and PGE2 production.   
 
A significant positive correlation between the maternal spleen basal PGE2 production 
and AA content of the maternal spleen phospholipid PC, but not PE, was observed (see 
table 7.18, figure 7.4).  This suggests that n 3 PUFA rich maternal diets (HF linseed and 
salmon oil) which are associated with the lowest AA content of spleen phospholipids, 
will have a direct functional effect on PGE2 production.  Similar but non significant 
correlations were also observed between the AA content of spleen PC and Con A 
stimulated PGE2 production (see figure 7.5).  No significant correlations were observed 
between the AA content of maternal or fetal PBMC with the PGE2 produced by these 
tissues in culture.  
 
There was a clear trend for inverse relationships between the EPA content of tissues and 
the PGE2 production by cells from these tissues, though this did not reach statistical 
significance (see table 7.19, figure 7.6).   
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Table 7.18: Correlations observed between mean maternal spleen PGE2 production and 
phospholipid AA content (% total fatty acids) (n = 6, Pearson R values) 
 
AA as % total fatty acids in  Tissue PGE2 production  
  No Con A  5  g/ml Con A 
Maternal Spleen PC  0.916*  0.759 
Maternal Spleen PE  0.672  0.618 
Maternal PBMC PC  0.048  0.385 
Maternal PBMC PE   0.676   0.717 
Fetal PBMC PC  0.441  0.540 
 
* p = 0.01 
 
 
 
Figure 7.4: Graph to illustrate the correlation between maternal spleen cell basal PGE2 
production and spleen cell PC AA content (% total fatty acids) (mean ± standard 
deviation) 
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r = 0.916 
P = 0.010   336 
Figure 7.5: Graph to illustrate the correlation between maternal spleen Con A 
stimulated PGE2 production and spleen PC AA content (% total fatty acids) (mean ± 
standard deviation) 
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Table 7.19: Correlations observed between maternal spleen PGE2 production and 
phospholipid EPA content (% total fatty acids) groups (n = 6, Pearson R values) 
 
EPA as % total fatty acids in  Tissue PGE2 production 
  No Con A  5  g/ml Con A 
Maternal Spleen PC   0.180   0.049 
Maternal Spleen PE   0.534   0.398 
Maternal PBMC PC   0.458   0.498 
Maternal PBMC PE  0.171   0.030 
Fetal PBMC PC   0.586   0.325 
 
 
r = 0.759 
P = 0.080 
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Figure 7.6: Graph to illustrate the correlation between fetal PBMC basal PGE2 
production and fetal PBMC PC EPA content (% total fatty acids) (mean ± standard 
deviation) 
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Correlations between immune tissue fatty acid composition and cytotoxic T cell 
surface marker expression 
 
Flow cytometry data identified a clear interaction between maternal diet during 
pregnancy and the expression of cytotoxic T cell surface markers in both maternal and 
fetal immune tissues.  Studies have demonstrated a significant effect of DHA (when 
provided in vitro or in murine dietary studies) upon the expression of CD8 on cytotoxic 
T cells(252).  It is possible that this is the mechanism responsible for the significantly 
different CD8 expression of the salmon oil group within lymph nodes (see table 7.5), 
but does not adequately explain the effects upon CD8 expression observed within the 
HF linseed oil group in the maternal spleen (see table 7.2).  Data were therefore 
assessed to determine whether the expression of CD3 or CD8 within maternal or fetal 
immune tissues correlates to the n 3 or n 6 fatty acid composition of the tissues 
collected from a parallel cohort. 
r =  0.586 
 p =  0.222 
EPA content of fetal PMBC PC (% total fatty acids)   338 
 
Within the fetal thymus there were positive correlations between LC n 3 PUFA content 
and CD8 expression (see table 7.20, figure 7.7).  No significant correlations between 
fetal thymus CD3 expression and n 3 PUFA content were observed.  The n 6 PUFA 
content of the fetal thymus was not correlated to the expression of CD3 or CD8 (data 
not shown).   
 
Within maternal immune tissues inverse correlations were observed between the n 6 
PUFA content (particularly 22:5n 6) of immune tissues and the expression of CD3 and 
CD8 upon cytotoxic T cells (see figure 7.8, table 7.21).  No relationships were observed 
between maternal immune tissue n 3 PUFA composition and the expression of CD3 and 
CD8 upon cytotoxic T cells (data not shown). 
 
 
 
Table 7.20: Correlations observed between the n 3 PUFA content (% total fatty acids) 
of fetal thymus phospholipids and the MFI of cytotoxic T cell surface marker 
expression (Pearson r values) 
 
  CD3  CD8 
  PC  PE  PC  PE 
18:3n 3   0.219  0.345   0.299  0.135 
20:4n 3   0.311   0.630   0.311   0.575 
20:5n 3  0.556  0.635  0.986  0.916* 
22:5n 3  0.119  0.471  0.909*  0.990** 
22:6n 3  0.311  0.383  0.007  0.673 
N 3 PUFA  0.480  0.588  0.678  0.849* 
 
 
 
* p < 0.05, ** p < 0.01 
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Figure 7.7: Graph to illustrate the correlation observed between the DPA content (% 
total fatty acids) of fetal thymus PE and the MFI of CD8 on cytotoxic T cells in the fetal 
thymus (mean ± standard deviation) 
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Figure 7.8: Graph to illustrate the correlation between the 22:5n 6 content (% total fatty 
acids) of maternal spleen PE and the MFI of CD8 on cytotoxic T cells in the maternal 
spleen (mean ± standard deviation) 
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Table 7.21: Correlations observed between the n 6 PUFA content (% total fatty acids) of maternal immune tissue phospholipids and cytotoxic T cell 
surface marker MFI (Pearson r values) 
 
  Maternal PBMC PC  Maternal thymus PC   Maternal spleen PC  Maternal spleen PE 
  CD3  CD8  CD3  CD8  CD3  CD8  CD3  CD8 
18:2n 6  0.234  0.552  0.624  0.537  0.772  0.676  0.527  0.383 
18:3n 6   0.231   0.497   0.851  0.667   0.384   0.280  0.280  0.018 
20:2n 6   0.360   0.289  0.589  0.565  0.149   0.010  0.073   0.098 
20:3n 6   0.928**   0.836*   0.080  0.205   0.097   0.114   0.628   0.511 
20:4n 6   0.469   0.086   0.727   0.645   0.808   0.742   0.616   0.533 
22:5n 6   0.279   0.696   0.818*   0.965**   0.828   0.916*   0.961**   0.991** 
Total n 6 PUFA   0.332   0.015   0.302   0.216   0.152   0.222   0.492   0.536 
 
* p < 0.05, ** p < 0.01 
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7.4 Discussion 
 
This chapter set out to address the hypothesis that the type of dietary fatty acids 
consumed during pregnancy will significantly alter markers of both maternal and fetal 
immune function, and these effects correspond to changes in the fatty acid composition 
of immune tissues.  The data collected supports this hypothesis, with significant effects 
of maternal diet observed upon both maternal and fetal cytotoxic T cell surface marker 
expression across a range of immune tissues which in turn demonstrate significant 
correlations to the n 6 and n 3 content of these immune tissues.  In addition, significant 
effects of maternal diet were observed upon the proportion of CD161
+ cells within the 
fetal thymus.   
 
It was identified in an earlier chapter that the female rat undergoes immune adaptations 
in response to pregnancy (see chapter 5).  The adaptations which had been observed to 
occur in response to pregnancy were an increased proportion of CD8
+ cells in the blood 
lymphocyte population, reduced expression of CD161 on NK cells in the blood 
lymphocyte population and in the spleen, and an increased ratio of Th1:Th2 cytokine 
production by thymocytes.  Of these changes associated with pregnancy, maternal diet 
was found to have a significant effect upon the proportion of CD8
+ cells in maternal 
blood lymphocytes.  The diets containing the highest n 3 fatty acid content (HF 
soyabean, linseed and salmon oil) had the lowest proportion of CD8
+ cells.  This 
suggests that maternal diet during pregnancy may exert a significant effect upon 
maternal immune adaptations to pregnancy.  The potential impact of these dietary 
effects could be further studied by assessment of any changes in the absolute number of 
CD8+ cells, data which was not collected in this study, or by assessment of the 
activation or cytotoxic functions of either cytotoxic T cells or NK cells, both of which 
express CD8. 
 
Additional effects of maternal diet during pregnancy were observed upon markers of 
maternal immune function, particularly within the spleen.  Maternal diets rich in n 3 
fatty acids were found to significantly affect spleen weight (highest in HF salmon oil) 
and expression of CD3 and CD8 on cytotoxic T cells (highest in HF linseed oil group).  
This suggests that the sensitivity to activation of maternal cytotoxic T cells may be 
significantly increased by the HF linseed oil diet.  This feature could be further assessed   342 
by assays of T cell activation, such as investigating whether there are changes in the 
expression of activation markers such as CD69 and CD25 upon these cells in response 
to Con A stimulation.  Statistically significant inverse correlations were observed 
between maternal spleen LC n 6 PUFA content and cytotoxic T cell marker expression, 
which suggests that the expression of these cell surface markers has a significant 
relationship with membrane fatty acid composition.  While, the data used for this 
correlation was limited to use of the means for each dietary group as these two variables 
were assessed in two distinct cohorts, available literature from murine in vitro studies 
does support a causal relationship between fatty acid composition and the expression of 
CD8(252). 
 
Significant effects of a maternal diet rich in n 3 fatty acids were not limited to the 
maternal spleen, with significant effects also observed upon expression of cell surface 
markers of cytotoxic T cells within the maternal thymus and within maternal lymph 
nodes, which again demonstrated statistically significant inverse relationship with the 
LC n 6 PUFA content of immune tissue phospholipids.  The consistent effects of a n 3 
rich maternal diet upon maternal cytotoxic T cells warrants further investigation into the 
role of cytotoxic T cells within rat pregnancy, their absolute circulating and tissue 
numbers, sensitivity to activation and markers of cytotoxic function.    
 
Maternal dietary fatty acid intake during pregnancy was also found to significantly 
affect fetal cytotoxic T cells, with these cells within the fetal thymus having the highest 
expression of CD3 on their surface within the HF salmon oil group, and the highest 
expression of CD8 with both the n 3 PUFA rich groups (HF linseed oil, salmon oil).  In 
contrast to the observations where an inverse relationship was observed between CD8 
expression and n 6 PUFA, within the fetal thymus there were statistically significant 
positive correlations between LC n 3 PUFA content of the fetal thymus and CD8 
expression, and no significant inverse relationship with n 6 fatty acid content.  Taken 
together both maternal and fetal data provides strong evidence for a significant effect of 
the n 3 content of the maternal diet during pregnancy upon cytotoxic T cell function.  
Cytotoxic T cells have important roles in detection of viral infection, and may also have 
a role in auto immune disease.  Further useful data may therefore be obtained from 
animal studies among both pregnant and adult animals with auto immune disease to 
assess the potential effect of diet upon disregulated cytotoxic immune disease, or upon 
animal survival in response to viral infection.   343 
In addition to the effects observed upon cytotoxic T cells, a significant effect of 
maternal diet was observed upon the proportion of CD161
+ cells within the fetal 
thymus, with the highest proportion of these cells observed in the HF linseed oil group.  
This change to the proportion of cell types within the fetal thymus suggests that the 
maternal diet has the capacity to influence the lineage and differentiation of cells within 
the fetal thymus, and is indicative of a potential programming effect of maternal dietary 
fatty acids during pregnancy.  For a true programming effect to be confirmed, data 
would be required upon the longevity and functional impact of these changes to fetal 
thymus immune cells, data which was not obtained in this study.   
 
CD161 is typically used as a marker for NK cells since it is a NK cell receptor known as 
NKR P1.  However, CD161 is also found on other cell types, such as thymus dendritic 
cells(253) and some T cell subsets.  In the fetal mouse, thymic NK cells derive from 
TNK cells, a progenitor of both T and NK cells(254).  It is therefore possible that the 
maternal diet interacts with a transcription factor which is involved in the divergence of 
T and NK cells in the thymus.  The major sites of NK cell development have not been 
identified, but the thymus is a known to be a source of NK cells in both the mouse and 
human fetus.  Other potential sources of NK cells include the bone marrow and the 
liver(255).  NK cells were identified in this study using CD161 in a single staining 
protocol.  It is therefore possible that a subset of the cells identified as NK cells may in 
fact be NKT cells, i.e.  T cells which also express the NK cell surface marker, or 
dendritic cells.  Flow cytometry staining protocols could be developed further in order 
to categorise more clearly the cells identified within the fetal thymus as NK cells.  For 
example, dual staining of CD161 with CD3, CD4 or CD8 could be used to try and 
identify the proportion of CD161
+ cells which are in fact NKT cells.  The samples of 
immune tissues from this cohort which were reserved for histological and gene 
expression assessment as part of a collaboration with researchers at the University of 
Utrecht, The Netherlands, may provide further information on the identity of the cells 
expressing CD161 within the fetal thymus, and in addition provide an indication of 
whether the effects of maternal diet during pregnancy result in changes to the structural 
organisation of the fetal thymus.   
 
NK cells have important roles within innate immunity, and an adequate innate immune 
response will be essential in neonatal life in response to the antigen exposure which will 
follow delivery.  The work in this thesis could therefore be developed further using   344 
animal models to assess whether the maternal diet during pregnancy can significantly 
affect neonatal survival of viral infection, or to directly assess fetal NK cell activation 
and cytotoxic mechanisms. 
 
IL 4 is a cytokine produced by NKT cells(256), and it was observed that the within the 
HF linseed oil dietary group there was both the highest proportion of CD161
+ cells, and 
the highest basal IL 4 production.  Indeed, a significant positive correlation between the 
proportion of CD161
+ cells in the fetal thymus cell population and IL 4 production by 
those cells was observed (see figure 7.9).   
 
Figure 7.9: Graph to illustrate the correlation between the proportion of fetal thymus 
CD161
+ cells and basal IL 4 production by cultured fetal thymus lymphocytes  
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IL 4 is a cytokine associated with Th2 immune responses, and excessive Th2 responses 
are a feature of atopic disease.  However, this association should be investigated further 
before a causal relationship between maternal diet and the risk of later offspring atopic 
disease is postulated.  The cells obtained in this study were from fetal immune tissues, 
and whether the immune cells of neonatal or weanling rats which have been exposed to 
environmental antigens would express this same cytokine profile is unclear, and 
Pearson r = 0.429 
p = 0.032   345 
requires further detailed investigation.  The use of ELISAs to assess cytokine 
production limited the number of cytokines which could be assessed within the sample 
quantity which was available.  Use of a multiplex kit which enables the simultaneous 
analysis of a wider panel of cytokines from a much smaller sample volume would allow 
further insight into the effect of maternal diet upon fetal thymus cytokine production, 
and in particular allow assessment of whether the changes observed reflect a change in 
the overall capacity for cytokine production, or a true Th2 skewed response.   
The longevity of the observed effects of maternal dietary fatty acids upon both maternal 
and fetal immune function is of interest, and studies could be undertaken to determine 
whether there is altered susceptibility of both the mother and the offspring to infectious 
disease, or to development of immune disorders such as atopic responses.   
 
The data obtained in this thesis therefore indicate that maternal diet can exert a 
significant effect upon markers of both the maternal and fetal immune system, 
particularly upon cytotoxic T cells, and that the cells types within the fetal thymus can 
also be significantly affected by maternal diet.  A limitation of the data collected in this 
thesis is the lack of clear functional or clinically relevant effects of the maternal diet 
upon the fetal immune system.  To gain information into the potential translational 
value of these data it will be necessary to conduct further detailed studies into the 
functional effects which are observed in neonatal or early life.  This could be achieved 
by a combination of measurements of alternative markers of immune function such as 
cytotoxic assays, the use of disease or allergic sensitisation models, or the exposure of 
neonates to pathogens.  Though these investigations are beyond the scope of the current 
thesis, the data obtained here indicates a strong potential for maternal diet during 
pregnancy to influence these outcomes, possibly via programming effects.      346 
 
 
 
 
 
 
 
Chapter 8:  Final Discussion and 
Conclusions   347 
8.1 The effect of gender, pregnancy and diet during pregnancy 
upon tissue fatty acid composition 
8.1.1 Gender 
 
Human studies have demonstrated that gender has a significant effect upon plasma fatty 
acid composition, with females having significantly higher plasma status of the longer 
chain n 3 polyunsaturated fatty acid (LC n 3 PUFA) docosahexaenoic acid (DHA) 
compared to males(132 135) which is independent of dietary intakes of n 3 fatty acids.  
Studies which have used isotope labelled fatty acids have identified that this gender 
difference is likely to be mediated by an increased capacity for LC n 3 PUFA synthesis 
among women(130;131).  Data which was lacking from human studies included the 
effect of additional dietary α linolenic acid (ALNA) on LC n 3 PUFA status in women, 
whether the differences seen in plasma fatty acid composition are also apparent within 
metabolically relevant organs, and to date have provided little information into the 
mechanisms which mediate the gender differences in LC PUFA synthesis.  While data 
from human studies which have investigated the effect of oral contraceptives, hormone 
replacement therapy or sex hormone administration to transsexual subjects suggest that 
sex hormones are likely to be involved in the gender differences in LC n 3 PUFA 
synthesis and plasma status(133;135;147;148), no human studies have yet been 
conducted to investigate whether there are associations between plasma fatty acid 
composition and hormone status.  Animal studies of the effect of sex hormones upon the 
activity of fatty acid desaturase enzymes in the liver(150 152) have not identified 
whether these effects are also apparent within the normal physiological range of sex 
hormone concentrations. 
 
The studies described in this thesis were therefore conducted to address whether the rat 
is a suitable model for an investigation of the effects of gender upon plasma fatty acid 
composition, and whether sex hormone status or the expression of fatty acid desaturase 
and elongase genes in the liver are mechanisms which mediate the gender differences in 
fatty acid status.  The data collected in this study confirmed the suitability of the rat as a 
model of gender differences in fatty acid composition, and expanded upon data 
currently available from human studies by demonstrating that these differences are also 
apparent within the liver and adipose tissue.   
   348 
This study did not identify any significant relationships between circulating sex 
hormone status and plasma DHA content, or the mRNA expression of elongase or 
desaturase enzymes within the liver.  The use of mRNA expression as a marker of 
enzyme activity is limited by the lack of insight it allows into the numerous other 
processes which affect enzyme activity, such as efficiency of translation, post 
translational modifications, influence of inhibitors or activators or negative feedback 
mechanisms.  However, data did provide evidence of an influence of sex hormones 
upon the activity of desaturase and elongase enzymes within the liver when activity was 
assessed by the substrate:product ratio of fatty acids within liver lipids.  While use of 
this substrate:product ratio is a crude marker of enzyme activity, as it does not allow 
any insight into other processes which are involved in the maintenance of membrane 
composition such as enzyme specificity during lipid assembly, this approach has been 
demonstrated to be consistent with variations in  6 desaturase and  5 desaturase 
activity(257) as assessed by liver microsome experiments.  There were clear and strong 
relationships apparent between this marker and both gender and sex hormone 
concentrations, including a statistically significant inverse relationship between this 
marker of  6 desaturase activity and testosterone status, and a positive relationship with 
oestradiol status.  It is possible that this effect of sex hormones upon  6 desaturase 
activity may account for the higher plasma content of 18:3n 6 and DHA observed in 
females compared to males, particularly given that  6 desaturase is the rate limiting 
enzyme in LC PUFA synthesis.  Further investigations will be required to establish with 
confidence the causal nature of these relationships.  
 
The use of three dietary groups in this study exerted some confounding effects, 
particularly due to the relationship between dietary fat intake and sex hormone status 
that was observed.  However, use of these dietary groups also identified some novel 
features of the effect of diet upon LC n 3 PUFA synthesis.  A significant effect of diet 
was observed upon  6 desaturase gene expression, with both male and female rats fed a 
diet high in ALNA having the highest mRNA expression of this enzyme.  This supports 
the observations of other authors that dietary fatty acids can influence transcription 
factors such as SREPB 1 and PPAR α(258) which are involved in the regulation of 
desaturase gene expression(259 262).  These data also have important translational 
value to human health due to the importance of DHA in the development of fetal visual 
and neural tissues(56;57) and their benefits upon cardiovascular and inflammatory 
disease among adults.  If an increasing dietary intake of ALNA increases the expression   349 
of hepatic  6 desaturase in humans, this may have the potential to significantly alter LC 
n 3 PUFA status in humans by improving access to this rate limiting enzyme, and due 
to its substrate specificity for ALNA. 
 
This study therefore addressed several of the research questions which had been 
unanswered by human and animal studies conducted to date, and indicated clearly that 
the effect of gender upon fatty acid status is likely to be mediated by an effect of sex 
hormones upon fatty acid desaturase enzyme activity rather than gene expression.  This 
study provides some direction for future research in this area, particularly into the 
potential interactions between dietary ALNA and  6 desaturase expression.  Further 
research will be required to establish if there is a true causal relationship between sex 
hormone status and fatty acid desaturase activity, perhaps by either the assessment of 
hormone status within a human study providing stable isotope fatty acid substrates, or 
by in vitro assessment of enzyme activity in response to physiological concentrations of 
sex hormones.   
8.1.2 Pregnancy 
 
Existing data indicates that the fatty acid composition of human plasma lipids is 
significantly altered during pregnancy(162 166).  However, the effects observed to date 
are mixed, and may be complicated by dietary variation between subjects and the lack 
of pre pregnancy data in longitudinal studies.  Animal models, which enable complete 
dietary control and collection of comparable data in the non pregnant state, have 
identified that there are significant effects of pregnancy upon plasma and liver fatty acid 
composition, including increases in DHA status(167 170).  The mechanisms which may 
be responsible for the effects of pregnancy have not been investigated in studies to date, 
and so this study investigated whether sex hormones or fatty acid desaturase and 
elongase gene expression in the liver are involved.   
 
This study confirmed that pregnancy significantly alters plasma and tissue fatty acid 
composition, particularly for DHA and AA content, as has been described in previous 
rat studies.  An additional novel observation was that there are marked increases in the 
22:5n 6 content of tissues in pregnancy, which indicates that maternal LC n 6 PUFA 
synthesis is also significantly affected by pregnancy, and may in fact account for the 
reductions observed in AA content.  The effect of pregnancy upon 22:5n 6 status was   350 
tissue specific, and indicates that this fatty acid may be preferentially mobilised into the 
maternal plasma in order to be available to the fetus.   
 
There was no significant association between the status of the three sex hormones 
measured during pregnancy and plasma DHA content.  However, it is possible that any 
potential effect of sex hormone status was obscured by maternal transfer of DHA to the 
fetus, which could not be quantified in this study.  It would be possible to investigate 
this further in future studies by using isotope labelled fatty acids provided to animals, 
and tissue analysis to determine the extent of transfer to the fetus.   
 
A significant positive correlation was observed between circulating progesterone 
concentrations and  6 desaturase mRNA expression in the liver.  This indicates that the 
increasing progesterone concentrations which are a feature of pregnancy associate with 
an availability of  6 desaturase to metabolise essential fatty acids, a finding of 
particular importance given that the activity of  6 desaturase is the rate limiting step in 
the synthesis of LC PUFA.  However, the lack of this same relationship among non 
pregnancy females studied in chapter 3 indicates that further studies will be required to 
establish whether this relationship is directly causal, or instead under the influence of an 
additional variable which is associated with changes to progesterone status during 
pregnancy.   
 
The substrate:product ratio of fatty acids within liver lipids was used as a crude marker 
of desaturase and elongase activities.  The effects of pregnancy upon this index were 
complex, and did not demonstrate a significant relationship with sex hormone status.  
There are two possible explanations for this lack of association: it is possible that other 
hormones which alter during pregnancy (e.g. relaxin, oxytocin) which were not assessed 
in this study may have been involved in the effects observed; or alternatively that the 
three timepoints assessed were insufficient to gain an insight into the nature of the 
changes which occur during pregnancy.  The complex pattern of differences in fatty 
acid composition during pregnancy would support the latter, with the day 12 gestation 
group demonstrating dramatic differences in fatty acid composition from both virgin 
and day 20 pregnant females.  This indicates that the changes in fatty acid composition 
during pregnancy and the mechanisms which maintain them are non linear, and would 
require the study of numerous additional timepoints, preferably using a longitudinal 
study design, to evaluate fully.  351 
8.1.3 Diet during pregnancy 
 
Animal studies have demonstrated that the maternal diet during pregnancy has the 
capacity to significantly alter fetal tissue fatty acid composition, including that of the 
liver(228) and brain(263).  This study set out to investigate whether maternal diet 
during pregnancy could also significantly alter maternal and fetal immune tissue 
composition, in order that the potential effect that this may have upon immune function 
could be investigated.  The diets used in this study were chosen to reflect the standard 
low fat diet of the laboratory rat (LF soyabean, 3% w/w), and higher fat diets (13% 
w/w) used to represent human intakes of fat as a proportion of dietary energy.  These 
high fat diets either contained a balance of n 6 and n 3 PUFA representative of that 
consumed in Western populations (HF soyabean), or were rich in ALNA (HF linseed), 
LC n 3 PUFA (HF salmon), n 6 PUFA (HF sunflower) or saturates and MUFA (HF 
beef tallow). 
 
The effect of maternal diet during pregnancy upon maternal and fetal tissue fatty acid 
composition was studied in detail, in order that any variations in response to diet could 
later be assessed for their relationship with changes in immune function.  This study 
therefore provided extensive information about the effects of maternal diet during 
pregnancy upon a wide range of tissues, and demonstrated that maternal diet 
significantly affects the fatty acid composition of maternal plasma, liver, adipose tissue 
and immune tissues, placenta and fetal plasma, liver, brain and immune tissues. 
 
It had been anticipated that the HF salmon oil diet would demonstrate the most 
pronounced effects upon LC n 3 PUFA status, as this diet contains these fatty acids 
preformed, and would therefore not be subject to the potential limitations of maternal or 
fetal LC n 3 PUFA synthesis from ALNA.  However, it was observed that the HF 
linseed oil diet resulted in equivalent EPA status in fetal immune tissues and equivalent 
DHA status in the fetal brain to that achieved within the HF salmon oil diet group.  This 
finding was particularly unexpected as this feature of dietary ALNA was not observed 
within any other maternal or fetal tissue assessed, and indicates that maternal dietary 
ALNA during pregnancy may be as effective as preformed LC n 3 PUFA at maximising 
the DHA content of the fetal brain and EPA status of the fetal immune tissues.  
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It is well established that sufficient DHA status is required for optimal brain and visual 
development(56;57).  Thus there may be physiological mechanisms that operate to 
ensure that the brain acquires DHA irrespective of its status in other tissues and that 
these mechanisms are efficient when DHA is either provided preformed (e.g. in the HF 
salmon oil group) or is synthesised endogenously when the precursor (ALNA) is 
abundant (e.g. in the HF linseed oil group).  A relationship was also observed between 
maternal diet and the 22:5n 6 content of the fetal brain.  This n 6 highly unsaturated 
fatty acid (HUFA) is generated from LA by the action of the same sequence of enzymes 
which generate DHA from ALNA.  It was identified that the total HUFA content of the 
fetal brain was not significantly affected by maternal diet, and was maintained by either 
DHA or 22:5n 6 depending upon the dietary availability of fatty acid substrates (see 
figure 6.16).  Whether the balance of DHA and 22:5n 6 in maintaining this HUFA 
status has functional consequences could potentially be assessed in future studies which 
include neurological assessments such as effects upon offspring behaviour or memory. 
 
The observation that fetal immune tissues achieve a similar EPA status when the 
maternal diet is salmon oil or linseed oil rich diet suggests that the immune system may 
have an optimal EPA requirement for development and that physiological mechanisms 
operate to achieve this irrespective of the status of other tissues.  If so, this is a highly 
novel observation that is of significant importance in the human context.  Thus far the 
interest in providing LC n 3 PUFA to pregnant and lactating women and to infants in 
their formula has been driven by a desire to optimise brain and visual function through 
providing DHA.  If the immune system also has a high requirement of LC n 3 PUFA, 
particularly EPA, then there may be immunologic advantages to those strategies that 
have been promoted to enhance intake of these fatty acids in women such as 
consumption of oily fish.  Human studies could be feasibly undertaken to determine the 
effect of dietary ALNA during pregnancy upon the fatty acid composition of neonatal 
PBMC and any associated changes in disease risk or atopic symptoms. 
 
When data from the HF linseed oil group from this study of diet during pregnancy were 
compared with the virgin female HF linseed oil group from the gender study conducted 
in chapter 3, there was a clear indication of a diet pregnancy interaction, with the 
production of DHA from ALNA significantly up regulated during pregnancy when an 
ALNA rich diet is provided (see figure 6.17).  Studies of the mRNA expression of fatty 
acid desaturase and elongase genes among a cohort of HF linseed fed rats during   353 
pregnancy would therefore be of interest, based upon the observations among non 
pregnant rats that dietary ALNA is associated with significant increases in  6 
desaturase expression.  The effect of an ALNA rich diet upon DHA status during 
pregnancy also has significant implications for human health, and may be of particular 
relevance among vegetarian or vegan populations to ensure adequate DHA status of the 
fetus when little LC n 3 PUFA are consumed.  It would be possible to assess within 
human studies the potential effect of dietary ALNA during pregnancy upon markers of 
cognitive or visual function in infants, particularly those which have been demonstrated 
to be significantly affected by inclusion of DHA in infant formula(58). 
8.2 The effect of pregnancy and diet during pregnancy upon 
immune function 
8.2.1 The effect of pregnancy upon immune function in the rat 
 
The effect of pregnancy upon rat immune function was assessed as available literature 
had reported conflicting findings(179 181).  In order that the effect of maternal diet 
during pregnancy upon maternal and fetal immune function could be assessed in a later 
cohort it was important to clearly characterise the effects of pregnancy upon maternal 
immune function.  This study demonstrated that rat pregnancy is associated with 
significant alterations in immune function.  Some of these changes were in agreement 
with those observed in human and murine studies.  For example, thymic involution and 
reduced lymphoid organ cellularity were observed.  These adaptations to pregnancy 
may reflect a reduction in production of novel T cells within the thymus which may 
recognise paternal antigens and result in fetal rejection.  Other features of rat immune 
function during pregnancy were in contrast to those described in human and murine 
studies.  While human pregnancy has been demonstrated to involve a Th2 switch, where 
the maternal immune system produces more Th2 type cytokines(172), in this study the 
maternal rat demonstrated an increased Th1:Th2 cytokine ratio during pregnancy.  
These contrasts between human and rat immune adaptations to pregnancy may indicate 
that the rat is of limited suitability as a model for human pregnancy. 
 
Novel features of rat pregnancy were also identified in this study, such as the lower 
expression of CD161 upon the cell surface of NK cells within the mononuclear cell 
populations isolated from maternal blood and spleen, indicating that the responsiveness 
of NK cells may be reduced during pregnancy.  This could be an adaptation to   354 
pregnancy that reduces the risk of fetal rejection, though further information upon the 
absolute numbers of NK cells and functional assays of activation or cytotoxicity would 
be useful to confirm this hypothesis.  There was an increased proportion of CD8
+ cells 
within the maternal blood lymphocyte population during pregnancy, indicating that 
cytotoxic immune responses may also be affected by pregnancy.  It is possible that this 
adaptation is in response to the potentially diminished activity of NK cells, and occurs 
in order maintain maternal resistance to viruses, though further studies would be 
required to demonstrate that this indeed reflects a change in cytotoxic function.  
8.2.2 Maternal diet during pregnancy and maternal and fetal immune 
function 
 
Provision of diets which varied in the quantity and quality of fatty acids during 
pregnancy were demonstrated to significantly affect markers of both maternal and fetal 
immune function.  The principal effects observed were changes to the expression of cell 
surface markers upon both maternal and fetal cytotoxic T cells across a range of tissues 
including the maternal spleen, PBMCs, lymph nodes, thymus and the fetal thymus.  A 
change in the proportion of CD161
+ cells (putative NK cells) within the fetal thymus 
was also observed, with an association between the proportion of these cells and the 
production of IL 4, a Th2 cytokine.  These effects of maternal diet were pronounced 
within the n 3 PUFA rich HF linseed and HF salmon oil dietary groups, and were 
identified to significantly correlate to tissue fatty acid composition.  These data indicate 
that changes to the n 3 and n 6 content of the maternal diet therefore have the capacity 
to significantly alter both maternal and fetal immune function, which may have 
significant implications for maternal and fetal resistance to infection, alter the risk of 
immune dysfunction among offspring, or potentially exert longer term programming 
effects upon fetal health if the functional effects are maintained.   
 
While the data obtained in this study informs future research of the potential that 
maternal diet during pregnancy may have upon both the maternal and fetal immune 
system, it is not possible to say with certainty what the longer term or potential 
programming effects of these changes to markers of the fetal immune system might be.  
Studies which could take these findings forward could include more detailed assessment 
of the functional impact of the changes observed within fetal cytotoxic T cells and NK 
cells, such as assessment of the activation status and cytotoxic activities of these cell 
types at the same timepoint, or the inclusion of timepoints after delivery to assess the   355 
longevity and influence of environmental antigens upon these processes.  Animal 
studies would be of use to determine whether there are associated changes to neonatal 
survival following pathogen challenge.  Animal models of disease, particularly auto 
immune disease and atopic disease models would be of use to determine whether 
maternal diet may prevent the development, or reduce the severity of these diseases 
which are associated with immune dysfunction.   
 
Data collected in this study could also inform potential human research.  Numerous 
studies have been undertaken to date where women are provided with addition LC n 3 
PUFA supplements or oily fish during pregnancy.  Data from my research can be used 
as a starting point to investigate the potential effect of these interventions upon both 
maternal and fetal cytotoxic and NK cell activity, and also suggests that maternal 
dietary ALNA supplementation may significantly alter markers of both the maternal and 
fetal immune system.  
8.3 Future research considerations 
 
The data generated over the course of this study have provided novel information about 
the mechanisms involved in the maintenance of the gender differences and effects of 
pregnancy upon fatty acid composition.  Data have also been generated which suggest 
that dietary ALNA may exert stronger effects upon tissue LC n 3 PUFA status in 
women than has been inferred from human studies of dietary ALNA provision, and may 
be of particular public health relevance among women and during pregnancy. 
 
The work undertaken to assess the effect of dietary fatty acids during pregnancy has 
demonstrated that maternal diet has the potential to significantly affect maternal and 
fetal immune tissue fatty acid composition, and that these changes are associated with 
significant alterations in markers of both maternal and fetal immune function.  These 
data also demonstrate that maternal dietary fatty acids during pregnancy have the 
potential to alter other maternal and fetal systems, such as fetal brain development, 
placental function, and numerous other organ systems which were not directly assessed 
in this study such as the pancreas and cardiovascular systems.   
 
Data suggest that maternal diet has the capacity to significantly affect fetal immune 
function, and may therefore exert programming effects.  Programming cannot be 
confirmed in this study, as offspring were not followed beyond day 20 of gestation.  It is   356 
possible that the observed effects may only be apparent during either direct dietary 
intervention, or as a result of indirect fatty acid transfer during lactation, and further 
detailed studies will be required to investigate whether the significant effects observed 
have longevity into adulthood.  The potential effects that dietary interventions, 
particularly an increasing intake of n 3 fatty acids during pregnancy may exert upon the 
fetal immune system, warrant further investigation, particularly against a background of 
increasing atopic disease prevalence in Western populations.  
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